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Abstract: Eine der wichtigsten post-transkriptionellen Protein-Modifikationen ist die reversible Phosphorylier-
ung. Katalysiert durch Kinasen und Phosphatasen spielt die Phosphorylierung bzw. Dephosphorylier-
ung von Proteinen eine bedeutende Rolle in der Regulation verschiedenster zellulärer Prozesse, wie z.B.
in der Regulation des Zell-Zykluses, bei der Wachstumskontrolle, der Apoptose und in der Steuerung
von Signalwegen. Eine abnormale Proteinphosphorylierung kann Ursache vieler verschiedener men-
schlicher Krankheiten sein, weshalb ein Verständnis dieser Modifikation von wichtiger Bedeutung ist.
Der stark konservierte EGFR/RAS/MAPK Signalweg ist der vermutlich am besten untersuchte Signal-
transduktionsweg in der Zellbiologie. Er spielt eine bedeutende Rolle in verschiedensten Vorgängen der
Entwicklung sowie bei der Entstehung von Krebs. Seine Aktivität wird durch Proteinphosphorylierung
moduliert und durch ein komplexes Netzwerk negativer Regulatoren kontrolliert. Einer dieser Regula-
toren ist die Protein Tyrosin Phosphatase DEP-1, welche den EGF Rezeptor und andere Rezeptor Tyro-
sin Kinasen dephosphoryliert. DEP-1 gehört somit zu den Tumorsuppressoren und ist in zahlreichen
menschlichen Tumoren mutiert, wie z.B. in Schilddrüsen-, Darm-, Lungen-, Prostata- und Brustkrebs.
Das Ziel dieser Arbeit war, neue Interaktionspartner von DEP-1 im Nematoden C. elegans zu finden.
Hierzu reinigte ich verschieden Varianten von markiertem DEP-1 aus C. elegans oder E. coli auf, und
identifizierte mittels Massenspektrometrie die Proteine, welche an DEP-1 binden. Dabei entdeckte ich
die ￿-Integrin Untereinheit PAT-3 als neues Substrat von DEP-1. Integrine sind heterodimere Membran-
proteine bestehend aus nicht-kovalent verbundenen ￿ und ￿ Untereinheiten, welche unter anderem für die
Interaktion von Zellen mit der extrazellulären Matrix sowie für die Aktivierung zahlreicher Signal- wege
bedeutsam sind. Sie spielen eine Schlüsselrolle während der Entwicklung, der Immunabwehr, Blut- stil-
lung und der Krebsentstehung, und können somit Ursache vieler menschlicher Krankheiten sein. Anhand
verschiedener biochemischer Experimente konnte ich zeigen dass DEP-1 ein konserviertes NPxY Motiv
von PAT-3 dephosphoryliert. DEP-1 hat somit eine regulatorische Rolle in der Integrin Aktivierung.
Ausserdem untersuchte ich die Interaktion von DEP-1 und PAT-3 in vivo während der Entwicklung der
Vulva von C. elegans. Die Vulva ist ein 22-zelliges Organ, durch das der Hermaphrodit seine Eier ablegt.
Sie wird von drei Vulvavorläuferzellen gebildet, deren Differenzierungen durch ein Zusammenspiel vom
EGFR/RAS/MAPK, DELTA/NOTCH sowie dem WNT Signalweg gesteuert werden. Meine genetischen
Experimente zeigten, dass DEP-1 das NPxY Motiv von PAT-3 dephosphoryliert, um die Integrine zu ak-
tivieren. Als Folge davon inhibieren aktivierte Integrine den RAS/MAPK Signalweg in den sekundären
Vulvavorläuferzellen. Diese Ergebnisse zeigen eine bisher unbekannte Rolle von DEP-1 und den Integri-
nen in der Regulation des EGFR/RAS/MAPK Signalwegs, und tragen zu einem besseren Verständnis
der Funktion und Regu- lierung der Integrine in vivo bei. Reversible protein phosphorylation is one of
the most important and well-studied post-translational modifications. Catalyzed by protein kinases and
protein phosphatases, phosphorylation and dephos- phorylation play a critical role in the regulation of
many cellular processes, such as cell cycle, cell growth, apoptosis and signal transduction pathways. Ab-
normal protein phosphorylation can be a cause of human diseases, for which reason an understanding of
this modification is of major importance. The highly conserved EGFR/RAS/MAPK signaling pathway
is probably the best characterized signal transduction pathway in cell biology and plays a crucial role in
many developmental processes and can- cer formation. Its activity is regulated through protein phospho-
rylation and controlled by a broad nega- tive regulatory network that attenuates the different components
of the EGFR/RAS/MAPK pathway. A member of this network is the density enhanced phosphatase
DEP-1, which belongs to the receptor protein tyrosine phosphatases. It inhibits EGFR/RAS/MAPK
signaling through dephosphorylation of the EGF receptor and thereby acts as a tumor suppressor. It has
been found that DEP-1 is frequently de- leted and mutated in various human cancers such as thyroid,
colon, lung, pancreatic, and breast cancer. In order to identify novel physiological substrates of DEP-1
in the nematode C. elegans, I performed affinity purifications of differently tagged versions of DEP-1
that were expressed in C. elegans or E. coli. Proteins that bound to DEP-1 were then identified by mass
spectrometry. Thereby, the ￿-integrin subunit PAT-3 was found as a novel substrate of DEP-1. Inte-
grins are non-covalently associated ￿/￿ heterodimers that mediate cell adhesions, make transmembrane
connections to the cytoskeleton and activate many intracellular signaling pathways. Playing key roles
in development, immune response, hemostasis and cancer formation, Integrins are at the heart of many
human diseases. By performing several biochemical experiments, I could show that DEP-1 binds to the
evolutionary conserved NPXY motif of the PAT-3 cytoplasmic tail, the phosphorylation of which plays a
regulatory role in integrin activation. Furthermore, I investigated the interaction of DEP-1 and PAT-3 in
vivo during development of the C. elegans hermaphrodite vulva. This simple egg-laying organ is formed
by 22 cells and originates from three vulval precursor cells (VPCs), whose cell-fates are determined by the
interplay of the EGFR/RAS/ MAPK, DELTA/NOTCH, and WNT signaling pathways. My genetic ex-
periments could show that DEP-1 dephosphorylates the NPXY motif of PAT-3 to promote its activation.
As a consequence, activated integrins inhibit the RAS/MAPK signaling pathway in the secondary VPCs.
Together, my results demonstrate a novel role of DEP-1 and the integrins during vulval development and
give further insights into integrin regulation in vivo.
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Für Ärnschtu und Dädät

Eine der wichtigsten post-transkriptionellen Protein-Modifikationen ist die reversible Phosphorylier-
ung. Katalysiert durch Kinasen und Phosphatasen spielt die Phosphorylierung bzw. Dephosphorylier-
ung von Proteinen eine bedeutende Rolle in der Regulation verschiedenster zellulärer Prozesse, wie z.B. 
in der Regulation des Zell-Zykluses, bei der Wachstumskontrolle, der Apoptose und in der Steuerung 
von Signalwegen. Eine abnormale Proteinphosphorylierung kann Ursache vieler verschiedener men-
schlicher Krankheiten sein, weshalb ein Verständnis dieser Modifikation von wichtiger Bedeutung ist. 
Der stark konservierte EGFR/RAS/MAPK Signalweg ist der vermutlich am besten untersuchte Signal-
transduktionsweg in der Zellbiologie. Er spielt eine bedeutende Rolle in verschiedensten Vorgängen der 
Entwicklung sowie bei der Entstehung von Krebs. Seine Aktivität wird durch Proteinphosphorylierung 
moduliert und durch ein komplexes Netzwerk negativer Regulatoren kontrolliert. Einer dieser Regula-
toren ist die Protein Tyrosin Phosphatase DEP-1, welche den EGF Rezeptor und andere Rezeptor Tyro-
sin Kinasen dephosphoryliert. DEP-1 gehört somit zu den Tumorsuppressoren und ist in zahlreichen 
menschlichen Tumoren mutiert, wie z.B. in Schilddrüsen-, Darm-, Lungen-, Prostata- und Brustkrebs.
Das Ziel dieser Arbeit war, neue Interaktionspartner von DEP-1 im Nematoden C. elegans zu finden. 
Hierzu reinigte ich verschieden Varianten von markiertem DEP-1 aus C. elegans oder E. coli auf, und 
identifizierte mittels Massenspektrometrie die Proteine, welche an DEP-1 binden. Dabei entdeckte ich 
die β-Integrin Untereinheit PAT-3 als neues Substrat von DEP-1. Integrine sind heterodimere Membran-
proteine bestehend aus nicht-kovalent verbundenen α und β Untereinheiten, welche unter anderem für 
die Interaktion von Zellen mit der extrazellulären Matrix sowie für die Aktivierung zahlreicher Signal-
wege bedeutsam sind. Sie spielen eine Schlüsselrolle während der Entwicklung, der Immunabwehr, Blut-
stillung und der Krebsentstehung, und können somit Ursache vieler menschlicher Krankheiten sein.
Anhand verschiedener biochemischer Experimente konnte ich zeigen dass DEP-1 ein konserviertes 
NPxY Motiv von PAT-3 dephosphoryliert. DEP-1 hat somit eine regulatorische Rolle in der Integrin 
Aktivierung. 
Ausserdem untersuchte ich die Interaktion von DEP-1 und PAT-3 in vivo während der Entwicklung der 
Vulva von C. elegans. Die Vulva ist ein 22-zelliges Organ, durch das der Hermaphrodit seine Eier ablegt. 
Sie wird von drei Vulvavorläuferzellen gebildet, deren Differenzierungen durch ein Zusammenspiel vom 
EGFR/RAS/MAPK, DELTA/NOTCH sowie dem WNT Signalweg gesteuert werden. Meine genetischen 
Experimente zeigten, dass DEP-1 das NPxY Motiv von PAT-3 dephosphoryliert, um die Integrine zu ak-
tivieren. Als Folge davon inhibieren aktivierte Integrine den RAS/MAPK Signalweg in den sekundären 
Vulvavorläuferzellen. 
Diese Ergebnisse zeigen eine bisher unbekannte Rolle von DEP-1 und den Integrinen in der Regulation 
des EGFR/RAS/MAPK Signalwegs, und tragen zu einem besseren Verständnis der Funktion und Regu-
lierung der Integrine in vivo bei.
Zusammenfassung
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Reversible protein phosphorylation is one of the most important and well-studied post-translational 
modifications. Catalyzed by protein kinases and protein phosphatases, phosphorylation and dephos-
phorylation play a critical role in the regulation of many cellular processes, such as cell cycle, cell 
growth, apoptosis and signal transduction pathways. Abnormal protein phosphorylation can be a cause 
of human diseases, for which reason an understanding of this modification is of major importance.
The highly conserved EGFR/RAS/MAPK signaling pathway is probably the best characterized signal 
transduction pathway in cell biology and plays a crucial role in many developmental processes and can-
cer formation. Its activity is regulated through protein phosphorylation and controlled by a broad nega-
tive regulatory network that attenuates the different components of the EGFR/RAS/MAPK pathway. 
A member of this network is the density enhanced phosphatase DEP-1, which belongs to the receptor 
protein tyrosine phosphatases. It inhibits EGFR/RAS/MAPK signaling through dephosphorylation of 
the EGF receptor and thereby acts as a tumor suppressor. It has been found that DEP-1 is frequently de-
leted and mutated in various human cancers such as thyroid, colon, lung, pancreatic, and breast cancer.
In order to identify novel physiological substrates of DEP-1 in the nematode C. elegans, I performed 
affinity purifications of differently tagged versions of DEP-1 that were expressed in C. elegans or 
E. coli. Proteins that bound to DEP-1 were then identified by mass spectrometry. Thereby, the β-integrin 
subunit PAT-3 was found as a novel substrate of DEP-1. Integrins are non-covalently associated α/β 
heterodimers that mediate cell adhesions, make transmembrane connections to the cytoskeleton and 
activate many intracellular signaling pathways. Playing key roles in development, immune response, 
hemostasis and cancer formation, Integrins are at the heart of many human diseases.
By performing several biochemical experiments, I could show that DEP-1 binds to the evolutionary 
conserved NPXY motif of the PAT-3 cytoplasmic tail, the phosphorylation of which plays a regulatory 
role in integrin activation.
Furthermore, I investigated the interaction of DEP-1 and PAT-3 in vivo during development of the 
C. elegans hermaphrodite vulva. This simple egg-laying organ is formed by 22 cells and originates from 
three vulval precursor cells (VPCs), whose cell-fates are determined by the interplay of the EGFR/RAS/
MAPK, DELTA/NOTCH, and WNT signaling pathways. 
My genetic experiments could show that DEP-1 dephosphorylates the NPXY motif of PAT-3 to promote 
its activation. As a consequence, activated integrins inhibit the RAS/MAPK signaling pathway in the 
secondary VPCs. 
Together, my results demonstrate a novel role of DEP-1 and the integrins during vulval development and 
give further insights into integrin regulation in vivo. 
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The model organism C. elegans
Caenorhabditis elegans is a small, free-living, non-parasitic nematode that lives in nutrient- and micro-
organism-rich habitats such as compost, mushroom beds and garden soil where it feeds on bacteria and 
probably on other microorganisms (Wood, 1988). In Latin, the name of this approximately 1.3 mm-long 
roundworm means “recent” (caeno), “rod-like” (rhabditis) and “nice” (elegans): a newly discovered rod-
like animal, which elegantly moves forward and backward in sinoidal waves.
In the early 70s, Sydney Brenner established C. elegans as a model organism to study various aspects 
of cell biology, developmental biology and behavior (Brenner, 1974). Nowadays, it is one of the most 
popular model organisms due to several attractive features, such as its short generation time, small size, 
cheap and space-saving maintenance, transparent body, the capability of keeping it frozen in -80°C in-
definitely, and an invariant cell lineage. 
The wild-type strain, named N2, was originally collected from compost near Bristol, England and de-
fined as wild-type in the year 1965 (Wood, 1988). In the laboratory, the worms grow on agar plates 
seeded with genetically modified E. coli as food supply. The E. coli strain OP50 is more translucent than 
standard laboratory strains, facilitating the investigation of the worms under the microscope.
C. elegans has a short generation time, requiring 3.5 days going from the single-celled egg to adulthood 
(Fig. 1.1). After the embryo has hatched, the larva goes through four stages (L1 to L4) before becoming 
a mature adult. In response to overcrowding and in the absence of adequate food supply, C. elegans can 
undergo an alternative L3 stage, called dauer larva. This dauer larva can remain viable for as long as 
three months while it roams around in search of food. 
In C. elegans there are two sexes, males and hermaphrodites (Fig. 1.2). The predominant sexual form is 
the hermaphrodite, which produces both sperm and eggs and has thus the ability of self-fertilization. 
Thus, in nature consist most populations of clones, meaning that the animals are the offspring of a 
single hermaphrodite. C. elegans is extremely fecund; one hermaphrodite can produce about 300 to 350 
offspring by self-fertilization and even more if it mates with a male. These traits make it easy to produce 
numerous genotypes and phenotypes for genetic research (Ferguson and Horvitz, 1985; Tax et al., 1997).
1. Introduction
1.1 The model organism C. elegans
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The roundworm has five pairs of autosomes and one pair of sex chromosomes. In 1998 its genome was 
the first animal genome to be sequenced and comprises about 19’000 genes (C. elegans Sequencing Con-
sortium, 1998). Approximately 35% of the C. elegans genes are closely related to human genes. 
The gender of C. elegans is defined by the ratio of autosomal to sex-chromosomes: Hermaphrodites have 
two X-chromosomes, but can spontaneously generate X0 males by nondisjunction of the X-chromo-
some, which happens at a frequency of 0.1% (wormbook.org). 
In 2002, Sydney Brenner (GB), H. Robert Horvitz (USA) and John E. Sulston (GB) received the Nobel 
Prize for Physiology and Medicine for their research in “genetic regulation of organ development and 
programmed cell death” in C. elegans.
Figure 1.1 Life cycle of C. elegans.
After cleavage and embryogenesis there are four larval stages (L1 - L4) before the sexually mature adult is developped. Under 
crowded conditions and with limited food, the L1 larvae can enter an alternative developmental program called the dauer 
stage. (From www.wormatlas.org).
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Figure 1.2 Sexes of C. elegans.
(A) Nomarski image of an adult hermaphrodite and (B) schematic drawing of its anatomical structures. (C) Nomarski 
image of an adult male and (D) schematic drawing of its anatomical structures, left lateral side. Scale bar represents 0.1 mm. 
(Adapted from www.wormatlas.org).
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1.2.1 The vulval precursor cells
During the first larval stage, six equipotent vulval precursor cells (VPCs), termed P3.p through P8.p, are 
selected from 12 epithelial Pn.p cells, which are positioned along the ventral midline of the developing 
larva (Sulston and Horvitz, 1977). As a result of two signaling events, the VPCs adopt one of three dif-
ferent vulval fates at the early L3 stage (Fig. 1.3 A; Félix, 2012). The VPC fates differ in the cell lineage 
they produce: P6.p adopts a primary cell fate (1°) and divides three times to produce eight progeny cells 
that will form the inner part of the vulva. P5.p and P7.p adopt a secondary cell fate (2°) and undergo 
three rounds of cell divisions to produce seven progeny cells each, which will form the outer part of the 
vulva (Schindler and Sherwood, 2013; Sternberg and Horvitz, 1986; Sulston and White, 1980). The 1° 
and 2° fates are collectively referred to as vulval fates since only cells, which adopt a 1° or 2° fate con-
tribute to the mature vulva. The other VPCs (P3.p, P4.p and P8.p) adopt a tertiary non-vulval cell fate 
(3°) and undergo one round of cell division before they fuse with the hyp7, the hypodermal syncytial cell 
that surrounds the VPCs. 
In the late L3 and L4 stages, the descendants of the 1° and 2° cells undergo morphogenic movements and 
cell fusions to form a tube, consisting of seven toroidal rings that form the mature vulva (Schindler and 
Sherwood, 2013; Sharma-Kishore et al., 1999). During morphogenesis, the vulval cells also attach to the 
vulval muscles that control egg laying by regulating the opening of the vulva.
The vulva of the hermaphrodite C.elegans is located on the ventral side of the mid section of the body, 
and consists of 22 cells forming a passage, through which sperm from males can enter and fertilized 
eggs can be laid (Fig. 1.2, 1.4 I). Vulval development occurs over a period of 20 hours and is one of the 
best-studied processes in animal development. The cells that form the vulva adopt an invariant pattern 
of cell fates, and disruption of this pattern by the creation of mutations within genes involved in vulval 
formation leads to the development of malformed vulvae. Vulval development is genetically amenable 
because mutations that affect vulval development are often viable and the corresponding phenotypes 
are easily discernable under the microscope making it a practical model to study organogenesis.
Since several evolutionary conserved signaling pathways such as the EGFR/RAS/MAPK, DELTA/
NOTCH and Wnt pathways are involved, vulval development provides a simple model for the genetic 
and molecular analysis of pattern formation and organ morphogenesis during metazoan development 
(Horvitz and Sternberg, 1991). 
Several human genes that play a key role in diseases such as Cancer or Alzheimer’s have their C.elegans 
counterparts that control vulval development. Thus, the investigation of vulval development may lead 
to new effective therapeutic approaches for treating these diseases. 
1.2 The vulva of C. elegans 
1.2.2 The inductive signal
At the beginning of the third larval stage (L3), the anchor cell (AC), a specialized cell in the somatic 
gonad, induces the underlying VPCs by secreting the epidermal growth factor (EGF) like ligand LIN-3 
in a graded fashion (Fig. 1.3 B; Kornfeld, 1997; Sternberg and Han, 1998). All VPCs are equally com-
petent to respond to the AC signal, but P6.p is closest to the AC. Therefore, P6.p receives the highest 
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Figure 1.3 Vulval development.
(A) After the inductive signal (IS) is secreted by the anchor cell (AC), P6.p adopts the 1° Cell fate and divides three times to 
produce eight progeny cells. The lateral signal (LS) causes P5.p and P7.p to adopt the 2° Cell fate. They divide symmetrically 
twice, and once asymmetrically, to produce seven progeny cells. The other VPCs (P3.p, P4.p and P8.p) adopt the 3° Cell fate 
and fuse with the hypodermis (hyp7). (B) The AC triggers the evolutionarily conserved EGFR/RAS/MAPK pathway to spe-
cify the 1° Cell fate in P6.p. In addition, activation of LET-23/EGFR in P6.p also results in the production of a lateral signal 
via LIN-12/NOTCH that induces the adjacent VPCs (P5.p and P7.p) to adopt the 2° Cell fate. DEP-1 and LIP-1 block the 
transduction of the inductive AC signal in P5.p and P7.p.
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1.2.4 The inhibitory signals
1.2.3 The lateral signal
In addition to the inductive and the lateral signal, other signaling events impact on VPC fates. The 
synMuv (synthetic Multivulva) genes ensure that the distal VPCs P3.p, P4.p and P8.p adopt the tertiary 
(3°) non-vulval fate (Fig. 1.3 A; Fay and Yochem, 2007). They are grouped into three classes: synMuvA, 
synMuvB, and synMuvC. Most mutants of single synMuv genes do not exhibit defects during vulval 
development. However, a loss-of-function combination of synMuv class A with synMuv class B leads to 
a highly penetrant synthetic Muv phenotype (Fay and Yochem, 2007). Class C synMuv mutants elicit a 
Muv phenotype only in combination with a mutant of either class A or class B (Fay and Yochem, 2007). 
The synMuv genes repress lin-39 in the distal VPCs that promotes their fusion to the hypodermal hyp7 
syncytium (Chen and Han, 2001). hyp7 in turn represses the transcription of lin-3 to prevent the VPCs 
from adopting a vulval cell fates (Cui et al., 2006). 
After P6.p has received the instructive signal from the AC, the lateral signal from P6.p activates the 
highly conserved LIN-12/NOTCH signaling pathway in the adjacent cells P5.p and P7.p to specify the 
2°-1°-2° pattern of vulval cell fates (Sternberg, 1988; Wang and Sternberg, 2001; Yochem et al., 1988).
The high level of EGFR/RAS/MAPK signaling in P6.p down-regulates the LIN-12/NOTCH receptor via 
SUR-2, and reliefs the VPC-wide repression of LAG-2 by LIN-1 phosphorylation (Fig. 1.3 B; Shaye and 
Greenwald, 2002; Zhang et al., 2005). These ligands bind to the LIN-12/NOTCH receptor in P5.p and 
P7.p and activate the LIN-12/NOTCH pathway. 
LIN-12/NOTCH signaling antagonizes the EGFR/RAS/MAPK activity by stimulating the transcription 
of various negative regulators such as lip-1 and lst-1 – lst-4 (Berset et al., 2001; Yoo et al., 2004). The out-
come of this is a feedback loop where low EGFR/RAS/MAPK releases the LIN-12/NOTCH suppression 
by SUR-2. Beside this inhibition of the 1° cell fate in P5.p and P7.p, it has been suggested that LIN-12/
NOTCH also plays an instructive role in specifying the 2° fate in these cells (Ambros, 1999; Sternberg 
and Horvitz, 1989).
possible level of inductive signal and thus adopts the 1° cell fate. P5.p and P7.p being further away from 
the AC receive lower levels and thereby adopt the 2° fate. P3.p, P4.p, and P8.p receive even less (or no) 
inductive signal, which results in the non-vulval 3° fate. 
LIN-3/EGF binds to the EGF receptor tyrosine kinase (EGFR) homolog LET-23, which is initially ex-
pressed in all VPCs and activates the highly conserved EGFR/RAS/MAPK-pathway (Fig. 1.3 B; Stern-
berg and Han, 1998). LIN-1, an ETS domain containing transcription factor, is a crucial target of the 
EGFR/RAS/MAPK signaling pathway and acts as an inhibitor of vulval induction (Beitel et al., 1995). In 
the absence of the inductive signal, LIN-1 forms a hetero-dimer with LIN-31, a forkhead transcription 
factor, resulting in the inhibition of a vulval cell fate (Miller et al., 1993; Tan et al., 1998).
During vulval induction, LIN-1 and LIN-31 are both phosphorylated by MPK-1 in P6.p, leading to a 
disruption of the heterodimeric complex (Fig. 1.3 B). Thereafter, LIN-31 is able to induce the transcrip-
tion of genes specific for 1° cell fate adoption, while LIN-1 is able to relief the VPC-wide lag-2 repres-
sion in P6.p (Zhang and Greenwald, 2011). In P5.p and P6.p, the inhibitory effect of the hetero-dimer is 
overcome by the activation of several 2° cell fate specific target genes via the lateral signal (Félix, 2012). 
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1.3 Vulval induction index - a readout for RAS/MAPK signaling
1.4 Negative regulators of the EGFR/RAS/MAPK signaling pathway 
1.4.1 Lateral signal induced phosphatase LIP-1
1.4.2 Density enhanced phosphatase DEP-1
One of the target genes of the LIN-12/NOTCH pathway is the Lateral signal Induced Phosphatase-1 
(LIP-1), a dual-specific phosphatase that inactivates the MAP kinase MPK-1 by dephosphorylation to 
inhibit 1° fate specification in P5.p and P7.p (Berset et al., 2001). lip-1(lf) animals contain higher levels of 
MAP kinase enzymatic activity, increasing the sensitivity of the VPCs toward the inductive signal. Since 
lip-1(lf) does not cause other defects in a wild-type background (Fig. 1.4 C), it is assumed that there are 
multiple LIN-12 target genes that act in a redundant manner (Berset et al., 2001). 
All six VPCs have the equal developing potential to adopt one of the three vulval cell fates, and in wild-
type animals, three out of the six VPCs are induced (vulval induction index = 3). However, in mutants 
where EGFR/RAS/MAPK signaling is elevated, e.g. in let-60(gf) animals, more than three VPCs are 
induced (vulval induction index of >3), resulting in a “multivulva” (Muv) phenotype (Félix, 2012).
Vice versa, when fewer than three cells are induced, the animals have a vulval induction index <3 and 
exhibit a “vulvaless” (Vul) phenotype. In these mutants, the progeny hatches and grows inside the her-
maphrodite’s body which is not able to lay eggs (Sternberg and Horvitz, 1986).
Hence, by counting the induced VPCs and by calculating the vulval induction index, it is possible 
to draw conclusions about the activity of EGFR/RAS/MAPK signaling in the different mutant back-
grounds. This makes vulval development an excellent tool to study activities of signaling pathways.
In a screen done in a sensitized lip-1(lf) background for genes that regulate the 1° versus 2° cell fate 
decision during vulval development, the receptor-type protein tyrosine phosphatase (R-PTP) DEP-1 
was found (Berset, 2005). Further analyses have shown that DEP-1 negatively regulates LET-23 EGFR 
signaling in the vulva. 
DEP-1::GFP is expressed at equal levels in P5.p, P6.p, and P7.p at the time of vulval induction. However, 
after the first round of cell division, DEP-1::GFP is down-regulated in the 1° lineage, but its expression 
persists in the 2° vulval cells until the L4 stage (Berset, 2005).
As in lip-1(lf) animals, vulval development appears normal in dep-1(lf) single mutants (Fig. 1.4 B). In 
contrast, dep-1(lf);lip-1(lf) double mutants show an adjacent primary fate (APF) phenotype, in which 
P5.p and P7.p descendants adopt a hybrid cell fate with 2° and 1° characteristics (Fig. 1.4 D, F, and H). In 
addition, dep-1(lf);lip-1(lf) animals exhibit a weak multivulva (Muv) phenotype due to an ectopic induc-
tion of P3.p, P4.p, or P8.p (Berset, 2005). 
The transformation of cell fate can be visualized by analyzing the expression pattern of the 2° cell specific 
marker LIN-11::GFP, whose expression is absent or strongly reduced in most 2° cells of dep-1(lf);lip-1(lf) 
animals (Fig. 1.3 E and F).
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DEP-1 (also known as PTPRJ, PTP-η or CD148) encodes a protein of 1367 amino acids and belongs to 
the class III R-PTP family (Hertog et al., 1999). Its expression is directly related to cell density – hence 
the name Density-Enhanced Phosphatase 1 (Östman et al., 1994). 
Among the 100 PTPs encoded in the human genome 21 are R-PTPs, four of which are classified as class 
III. Characteristic for class III R-PTP, DEP-1 contains an intracellular catalytic tyrosine phosphatase 
domain, a single transmembrane domain, and multiple extracellular fibronectin type III repeats (Fig. 
1.5 B). Furthermore, DEP-1 is highly glycosylated and contains multiple N-glycosylation sites in the ex-
tracellular region (Krueger et al., 1990; Matozaki et al., 1994; Thomas et al., 1994; Tonks, 2006). 
The specificity for particular substrates of PTPs is a result of the configuration of the PTP active 
site. A characteristic of all members of the PTP family is the presence of a signature motif, [I/V]
HCXXGXXR[S/T] (Fig. 1.5 C [1]), where the cysteine residue is essential for catalysis (Tonks, 2003). 
In the intracellular COOH-terminal region, vertebrate PTPs share a common YxNΦ motif. The tyro-
sine of this motif can be phosphorylated to promote binding of Src-family kinases (Murata et al., 2010). 
Additionally, the phosphyorylated YxNΦ motifs serve as binding sites for the Src homology (SH) 2 do-
mains. “Substrate-trapping” mutants of R-PTPs form stable complexes with receptor tyrosine kinases 
(RTKs), suggesting that RTKs are direct targets for R-PTP enzymatic activity (Flint et al., 1997; Jeon et 
al., 2012). However, this YxNΦ motif is not present in C. elegans DEP-1.
wild-type
wild-type
Plin-11::GFP Plin-11::GFP
wild-type dep-1(lf); lip-1(lf)
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Figure 1.4 dep-1(lf);lip-1(lf) double mutants exhibit an adjacent primary fate phenotype.
Nomarski images of (A) wild-type, (B) dep-1(lf);lip-1(lf), (C) dep-1(lf), and (D) lip-1(lf) vulvae in L4 larvae. (B) In the 
dep-1(lf);lip-1(lf) mutant, the descendants of P7.p have detached from the cuticula and moved inward. (E) Plin-11::GFP 
expression in the P5.p and P7.p descendants of wild-type L4 larva and in dep-1(lf);lip-1(lf) mutants (F), in which 
Plin-11::GFP expression is strongly reduced. Adult vulvae of wild-type (G) and dep-1(lf);lip-1(lf) animals (H), exhibiting a 
protrusion of the vulva tissue, due to a mixed 1°/2° Cell fate of the P5.p and P7.p descendants. (I) Scanning electron micro-
graphs of an adult vulva in a wild-type and (K) a dep-1(lf);lip-1(lf) double mutant. Arrows point to the Plin-11::GFP expres-
sing vulval cells. AC: Anchor cell. Scale bars represent 10 µm. 
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DEP-1 tends to be expressed specifically at the apical surface of polarized cells, and it is most abundant 
in endothelial cells and various types of hematopoietic cells, but also in epithelial cells and fibroblasts 
(Autschbach et al., 1999; Borges et al., 1996; la Fuente-García et al., 1998; Östman et al., 1994; Tangye 
et al., 1998). 
DEP-1 was found to be frequently deleted and mutated in various human cancers such as thyroid, colon, 
lung, pancreatic, and breast cancer (Iuliano et al., 2003; Ruivenkamp et al., 2002; Tonks, 2006; Trapasso 
et al., 2004). Furthermore, the mouse PTPRJ was found as the colon cancer susceptibility locus Scc1 
(Ruivenkamp et al., 2002), and it exhibits tumor-suppressor activity when ectopically overexpressed 
(Iuliano et al., 2003; Keane et al., 1996; Trapasso et al., 2000). 
This growth inhibitory function of DEP-1 is consistent with the nature of some of its reported substrates 
(Fig. 1.5 D), namely a variety of growth factor receptors such as the epidermal growth factor receptor 
EGFR, the platelet-derived growth factor receptor (PDGFR), the vascular-endothelial growth factor re-
ceptor VEGFR, and the colony stimulating factor-1 receptor (MET), as well as Src family kinases (SFKs), 
ERK-1/2, and the p85 subunit of PI3K (Arora et al., 2011; Berset, 2005; Chabot et al., 2009; Grazia Lam-
pugnani et al., 2003; Kappert et al., 2007; Palka, 2002; Sacco et al., 2009; Tarcic et al., 2009; Tsuboi et al., 
2008; Zhu et al., 2008). Aberrations in their regulation is accountable for self-sufficiency cell growth, the 
first hallmark of cancer (Hanahan and Weinberg, 2011). 
Known as other substrates of DEP-1 are proteins from the cell-cell junctional complexes including 
p120ctn, β-catenin and γ-catenin, occludin, and ZO-1, which might impact biological functions depen-
dent on the loosening/strengthening of intercellular contacts (Holsinger et al., 2002; Palka, 2002; Sallee 
and Burridge, 2009). Finally, it has been reported that DEP-1 serves as a positive regulator of B-cell and 
macrophage immunoreceptor signaling and thrombocyte activation (Senis et al., 2009; Zhu et al., 2008).
Together, these findings make DEP-1 a fascinating candidate for the development of innovative thera-
peutic strategies. For example, Takahashi et al. were able to induce ERK-1/2 dephosphorylation and 
inhibition of both in vitro cell growth and in vivo angiogenesis by using a monoclonal PTPRJ antibody 
(Takahashi, 2006).
The regulatory mechanisms controlling DEP-1 activity are largely unknown. However, two lingands 
have been identified in human cell culture experiments, namely thrombospondin 1 and syndecan-2 
(Takahashi et al., 2012; Whiteford et al., 2011). Thrombospondin 1 is a trimeric glycoprotein that binds 
with high affinity to the extracellular part of DEP-1, resulting in increased catalytic activity of DEP-1 
and thereby in inhibition of cell growth (Takahashi et al., 2012). Similarly, the heparan sulfat proteogly-
can syndecan-2 binds to the extracellular part of DEP-1 to promote DEP-1 activity, which results in the 
stimulation of cell proliferation and cell growth (Whiteford et al., 2011). 
1.4.3 The substrate trapping mutation D1241A
An essential step towards a complete understanding of the physiological function of the PTPs is the 
identification of their physiological substrates (Flint et al., 1997). Since the interaction between PTPs 
and their substrates are too weak to permit isolation of these complexes, the affinity for substrates has 
to be increased. By mutating the aspartic acid 1241 to an uncharged alanine (Fig. 1.5 C [2]), a decrease 
in negative charge at this position, as well as a conformation change forming a hydrophobic pocket 
that buries the pTyr of the substrate is induced (Jia et al., 1995), such that DEP-1 can covalently bind to 
its physiological substrates, but is unable to dephosphorylate the target efficiently. By this “substrate-
trapping”, the mutant DEP-1 and its substrate become locked in a stable “dead-end” complex.
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Figure 1.5 Density enhanced phosphatase DEP-1.
(A) Intron-exon structure of C. elegans dep-1. Asterisks indicates the stop mutation zh34 and hash key indicates the substrate 
trapping mutation D1241A. (B) Domain structures of C. elegans DEP-1. (C) Protein sequence of C. elegans DEP-1. Fibronectin 
repeats, transmembrane-domain and catalytic domains are colour coded as in (B). The conserved [I/V]HCXXGXXR[S/T] 
motif is highlited and indicated with [1], the substrate trapping mutation D1241A with [2], and the stop mutation zh34 with 
[3]. (D) Overview of the so far known substrates of DEP-1/PTPRJ/CD148. Scale bar represents 500 bp.
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1.5 Integrins
The integrins, which are found on nearly all nucleated cells of multicellular animals, are a large family 
of cell adhesion molecules that form non-covalently associated α/β heterodimers (Hynes, 2002). The 
first integrin was identified 1986, and was named so because integrins serve to integrate the extracellu-
lar and intracellular environments. They do so by binding to ligands in the extra cellular matrix (ECM), 
such as fibronectin, vitronectin and collagen, and to cytoskeletal components and signaling molecules 
inside the cell (Hynes, 1992; Pytela et al., 1985; Springer, 1994; Tamkun et al., 1986; White et al., 2004). 
Integrins are especially important in areas that involve tissue growth or areas, in which cell attachment 
is necessary for proper function. Thus, embryonic development, angiogenesis and the immune system 
are critically dependent on integrins (Silva et al., 2008; Smith-Garvin et al., 2009; Spencer et al., 2004). 
Integrins are known to be involved in various disorders such as thrombosis, immune system disorders, 
infections, osteoporosis, and have been associated with a number of metastatic cancers (Coller and 
Shattil, 2008; Evans et al., 2009; Felding-Habermann, 2003; Hood and Cheresh, 2002; Lee et al., 2007; 
Stewart and Nemerow, 2007)
In vertebrates, at least 24 distinct α/β heterodimer combinations are formed by 18 α-subunits and 8 
β-subunits, each of which can bind to a specific repertoire of cell-surface, ECM or soluble protein 
ligands (Fig. 1.6 A). Both α- and β-subunits are type I transmembrane glycoproteins with a large mul-
tidomain extracellular portion (>700 residues) and single spanning transmembrane domains. The 
α-chain is composed of a short cytoplasmic domain and a long extracellular domain composed of two 
calf domains followed by a thigh domain, and seven repeats constituting the β-propeller (Fig. 1.6 B). 
The β-chain has a longer cytoplasmic domain, four extracellular integrin epidermal growth factor-like 
domains (I-EGF), and an I-like domain inserted into the hybrid domain (Cox et al., 2010). 
Integrins appear in three distinct conformations: a resting, closed conformation, an intermediate par-
tially activated state, and a fully activated open, ligand-binding conformation (Fig. 1.6 C and D; Takagi 
et al., 2002; Xiao et al., 2004; Xiong et al., 2001). The regulation of integrin function occurs under 
tight spatial and temporal control of integrin affinity to extracellular ligands and is achieved by rapid, 
reversible changes in the confirmation of the extracellular domains of the integrin heterodimer, 
so-called “integrin activation” (Sims et al., 1991; Woodside et al., 2001).
Originally, it was thought that integrins are simply adhesion molecules and not true receptors because 
they have no homology to other known receptors and no evidence of intracellular signaling motifs (Cox 
et al., 2010). However, it has been found that signal transduction through the integrins can be conducted 
in either direction, which is referred to as either “inside-out” or “outside-in” signaling. 
During “inside-out” signaling, intracellular activators, such as talin or kindlins, bind to the β-integrin 
cytoplasmic tail and cause a conformational change in the extracellular part of the integrins (Fig. 1.6 C)
(Coller and Shattil, 2008). This results in increased affinity for extracellular ligands (integrin “acti-
vation”) and controls adhesion strength and enables strong interactions between integrins and ECM 
proteins. 
When integrins behave like traditional signaling receptors in transmitting information into cells by 
“outside-in” signaling, extracellular ligands bind to the α-I and β-I domains on the extracellular part 
of the integrins, resulting in conformation changes of the integrins (Fig. 1.6 D). Because many of the 
ligands are multivalent, this contributes additionally to integrin clustering. 
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Figure 1.6 Integrins.
(A) Integrins are heterodimers comprising an α- and β-subunit. In vertebrates, 18 α-subunits and 10 β-subunits are known, 
in C. elegans two α-subunits and a single β-subunit. (Adapted from Cox et al, 2010). (B) Domain structures of vertebrate α- 
and β-Integrin subunits. (C) Potential mechanism regulating talin-mediated integrin activation. Resting integrins are held 
in a bent-inactive conformation. Talin binding to cytoplasmic integrin β tail induces conformational changes in the extracel-
lular domain to form a high affinity receptor (inside-out signaling). Some of the structural proteins that couple the integrin 
and the actin cytoskeleton are shown. Src mediated tyrosine phosphorylation of integrin NPxY motifs, and competition 
with other β tail-binding proteins (e.g. DOK-1) may prevent integrin-talin interaction, so inhibiting integrin activation. (D) 
Binding of a ligand to activated integrin induces recruitment of additional signaling molecules (SFK and Syk) to the integrin 
tails, to activate downstream responses (e.g. over FAK/PI3K). This process is reffered to as outside-in signaling (Modified 
from Calderwood, 2004 and Lowell et al., 2011). 
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Although the two processes “outside-in” and “inside-out” signaling are separated, they are often closely 
linked. Thus, integrin activation can increase ligand binding, resulting in “outside-in” signaling, and 
conversely, ligand binding can generate signals that cause “inside-out” signaling (Shattil et al., 2010). 
Together, these two events lead to intracellular signals that control cell polarity, cytoskeletal structure, 
gene expression, cell survival and proliferation (Shattil et al., 2010). 
1.5.1 Integrin cytoplasmic tails
The transmembrane helices and short cytoplasmic tails of both integrin subunits play a crucial role in 
coordinating the bidirectional signaling and the activation states of integrins (Liu et al., 2000; Shattil et 
al., 2010). The cytoplasmic tail of the α-subunits are between 15 and 78 amino acids long, and the cyto-
plasmic tails of the β-subunits contain between 46 and 68 amino acids. Since they do not have known 
enzymatic activity, they must interact with cytoplasmic signaling or adaptor proteins – there are at least 
21 proteins known to bind to one or more integrin β tails – to affect or respond to the changing cellular 
activation state (Liu et al., 2000).
Both, the α- and β-cytoplasmic membrane-proximal tails, contain strong evolutionary conserved re-
gions and play crucial roles in integrin activation (Fig. 1.7 A and B). Deletion of the cytoplasmic tail of 
the α-subunit, or of the conserved GFFKR sequence alone results in constitutive activation of the inte-
grins, but a deletion that retains the GFFKR sequence does not (Lu and Springer, 1997; O’Toole et al., 
1995; Ylänne et al., 1993). Similarly, a deletion of the membrane-proximal region of the β-cytoplasmic 
tail, activates integrins, but deletions that are closer to the C-terminal block integrin activation (Crowe 
et al., 1994; Hughes et al., 1995; Lu et al., 2001). Therefore, it is assumed that the membrane-proximal 
regions of the α- and β-cytoplasmic tails play a crucial role in integrin activation, probably by interacting 
with one another to stabilize an inactive conformation. On the one hand, the more distal regions of the 
β-cytoplasmic tails regulate activation through interactions with signaling proteins that might disrupt 
the membrane-proximal interaction, on the other, the membrane-distal α-sequences also regulate β-tail 
conformation and association with activator proteins in a cell-type specific manner (Calderwood, 2004).
Figure 1.7 Integrin cytoplasmic tails.
(A) Alignment of the amino acid sequences of C. elegans PAT-2 and human α6, α7, α3, α5, and α8 cytoplasmic tails. (B) 
Alignment of the amino acid sequences of C. elegans PAT-3 and human β2, β7, β1, β3, and β6 cytoplasmic tails. Conserved 
domains are highlighted in grey and yellow. 
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1.5.2  C. elegans integrins
In contrast to the numerous integrin subunits in vertebrates, C. elegans has only three integrins: Two 
α-subunits (INA-1 and PAT-2) and one β-subunit (PAT-3), providing an excellent model system for ex-
amining integrin function (Girard et al., 2007). Null alleles of pat-2 and pat-3 cause a “Paralyzed and 
Arrested at Two-fold” embryonic lethality phenotype (Pat), loss of ina-1 (INtegrin alpha) results in a 
larval lethal phenotype (Baum and Garriga, 1997; Williams and Waterston, 1994). 
PAT-3 is widely expressed in most tissues throughout development. PAT-3 expression can especially 
be observed in the body wall and sex muscles, along the intestinal tract, in the embryonic pharynx, 
the spermatheca, the uterus, the somatic gonad, the neurons, and the vulva (Gettner et al., 1995). 
Heterodimers of PAT-2/PAT-3 are expressed in many tissues, including the muscles and the somatic go-
nad, whereas INA-1/PAT-3 are localized mainly to migratory cells such as the distal tip cells (DTC) and 
the neurons (Cram et al., 2006; Lee et al., 2001; Meighan and Schwarzbauer, 2007). 
It has been reported, that the integrins are also involved in vulval development: INA-1/PAT-3 play a key 
regulatory function during anchor cell invasion through the basal membrane by targeting the netrin 
receptor UNC-40 to the AC’s plasma membrane (Hagedorn et al., 2009). 
Several pat-3 alleles including a null and a reduction-of-function mutation were found, all of which are 
positioned within the extracellular domain. Unfortunately, this limits the analysis of its intracellular 
function (Gettner et al., 1995). 
A central role for integrin activation is played by the NPxY (Asp-Pro-X-Tyr) motifs, C-terminal to the 
membrane-proximal region of the β-cytoplasmic tail (Fig. 1.7 B). Tyrosine phosphorylation of the NPxY 
motifs by the Src-family kinases reduces cell adhesion, leads to integrin displacement from focal adhe-
sions, and is important in cell migration, hemostasis and transformation – indicating that phosphoryla-
tion of this Tyrosine may serve as an integrin activation “off switch” by interfering with required interac-
tors (Datta et al., 2001; 2002; Johansson et al., 1994; Law et al., 1999; Sakai et al., 2001; 1998). In accordance 
to this, it was observed that when the Tyrosine in the first conserved NPxY motif was mutated to Alanine, 
the activation and structural changes of the integrins was strongly inhibited (Ulmer et al., 2001).
Tyrosine phosphorylation of the NPxY motif regulates the interaction of different phosphotyrosine bind-
ing (PTB) domain-containing proteins, such as the docking protein 1 (DOK1) and talin 1 (Fig 1.6 C)
(Calderwood et al., 2003; Oxley et al., 2008). Talin is a major cytoskeletal actin-binding protein that binds 
with high affinity to the non-phosphorylated NPxY motif and plays a crucial role in integrin activation 
(Critchley, 2000; Tadokoro et al., 2003). On the other hand, DOK1 binds to the phosphorylated NPxY 
motif – further supporting the theory that Tyrosine phosphorylation of NPxY serves as a switch that con-
trols, which of the alternating groups of PTB-containing proteins can bind to the integrins (Calderwood 
et al., 2003; Oxley et al., 2008).
The NPxY motifs are canonical signals for clathrin-mediated endocytosis of various surface receptors 
(Ohno et al., 1995), and several observations suggest that they are also involved in the regulation of integ-
rin endocytosis. First, the β3-endonexin-mediated internalization of ligand-bound integrins is impaired 
when Y is substituted to A in the membrane proximal NPxY motif. Second, F to A substitutions in either 
one of the NPxY motifs of β2 integrins compromises their endocytosis. And third, clathrin-dependent 
integrin endocytosis in fibroblasts is reduced when Y is mutated to F in both NPxY motifs (Pellinen et 
al., 2008). Nevertheless, the exact pathways involved in the endocytosis of integrins are not clearly known 
and seem to vary between integrin heterodimers (Ramsay et al., 2007; Upla et al., 2004).
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1.6 Analyses of protein-protein interactions by mass spectrometry
1.6.1 Protein-protein interactions
Proteins are the workhorses of a cell and facilitate most processes, including gene expression, cell 
growth, proliferation, morphology, motility, nutrient uptake, signal transduction and apoptosis (Gole-
mis and Adams, 2005). Protein expression is a highly dynamic process: Many proteins are expressed in 
a cell type-dependent manner, and cells respond to countless stimuli. Furthermore, a protein may inter-
act only briefly with another protein just to modify it, for example a protein phosphatase that removes a 
phosphate from its target protein, which in turn may change protein-protein interactions. 
This complexity makes it difficult to investigate and understand protein function in the proper biologi-
cal context. However, information about these interactions is essential for a better understanding of the 
principles of cellular organization and diseases, and it is the basis for new therapeutic approaches (Li et 
al., 2012).
Protein-protein interactions can be classified based on their composition, affinity and lifetime as homo- 
and hetero-oligomeric complexes, and transient and permanent complexes, respectively (Ozbabacan et 
al., 2011). 
In contrast to a permanent protein-protein interaction, which is usually very stable and thus only exists 
in its complexed form, a transient protein-protein interaction associates and dissociates in vivo (Nooren 
and Thornton, 2003). Transient interactions are, as the name implies, temporary in nature and typically 
require a set of conditions that promote their interaction. These can be phosphorylation, conforma-
tional changes or localization to discrete areas in the cells. Transient protein interactions are crucial for 
diverse biological processes, especially in the regulation of biochemical pathways and signaling cascades 
in the cells (Ozbabacan et al., 2011).
1.6.2 Identification of protein-protein interactions
One popular technique to determine and discover previously unknown physical interaction between 
two or more proteins is the pull-down assay. In this in vitro method, the target protein is tagged with an 
affinity tag (e.g. HA-, Strep-III-, or GST-tag) and expressed in C. elegans or E. coli. This “bait” is then 
captured by an immobilized affinity ligand specific for the tag, and incubated with a protein source 
that contains putative “prey” proteins, such as a cell lysate. The proteins that bind to the “bait” can then 
be detected by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), Western blot 
analysis, or mass spectrometry. 
61% of the PAT-3 protein sequence harbors similarity to the human β1 integrin, and shares many con-
served motifs (see Fig. 1.7 B), such as the NPxY motifs. Mutations in the tyrosines of the NPxY motifs 
can rescue the embryonic lethality of the pat-3(st564) null allele, but display multiple mutant larval and 
adult phenotypes caused by defective integrin function, such as defects in DTC migration, ovulation, 
and muscle cell function (Lee et al., 2001; Xu et al., 2010).
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Figure 1.8 Protein identification by LC-MS/MS mass spectrometry. 
(A) Workflow of sample preparation for MS analysis, measuring peptides in LTQ-Orbitrap LC-MS/MS, and data analysis by 
different softwares. (B) RP-HPLC (Eksigent 1 plus). (C) Mass spectrometer Thermo Scientific LTQ-Orbitrap. (D) Schematic 
of the LTQ-Orbitrap. Peptides are ionized by ESI [1] and move into the C-trap [3] via a quadrupole linear ion trap (LTQ)
[2]. Ions are then injected into the orbitrap [4| where the m/z of the ions are detected. (E) Electrospray ionisation (ESI) and 
desorption of ions from solution. (F) During MS/MS, a limited m/z range including the precursor ions of interest are iso-
lated by the LTQ [2]. After their fragmentation [3], the following fragment ions move to the C-trap and are analyzed in the 
orbitrap mass analyser. (G) Mass spectrum of a MS scan. 
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1.6.3 Sample preparation for mass spectrometry
Complex protein mixtures derived from pull-down assays present several problems in MS analysis. First, 
the mass spectra from complex mixtures are very difficult to fully analyze because of the overwhelming 
number of components. And second, the proteins are dissolved in buffers that contain chemicals that 
impair the MS results, e.g. detergents. To overcome these problems, the samples have to be prepared for 
their MS analysis by different techniques. 
To reduce the complexity of the protein mixture, the proteins can be separated by SDS-PAGE according 
to their molecular weights and subsequently visualized by Colloidal Coomassie staining. The protein 
bands of interest are then excised and prepared for tryptic in-gel digestion (Fig. 1.8 A). 
In the following preparation steps, the proteins in the gel pieces are de-stained and the disulphide bridg-
es are irreversibly broken up by reduction and alkylation of the cystines and cysteines. The unfolded 
proteins are then cut enzymatically into a limited number of peptides by trypsin, a serine protease that 
cuts the peptide bond specifically at the carboxyl end of the basic amino acids arginine and lysine. After 
finishing the in-gel digestion, the peptides generated in this process are extracted from the gel matrix 
and resolved in an appropriate buffer that does not impact MS results.
Before the samples are ready for MS analysis, the peptide mixtures are desalted, purified and concen-
Tagging of proteins has the advantage that the tag can be systematically applied to any number of pro-
teins. However, the tag modifies the protein, which may alter its activity. Also overexpression of the 
tagged protein might become a problem. 
Another approach is to perform co-immunoprecipitation (Co-IP), where antibodies that bind specifi-
cally to the protein of interest are used to capture protein complexes. However, the main disadvantage is 
thereby, that high-quality antibodies are available only for a limited set of proteins (Mallick and Kuster, 
2010). 
In both approaches there is a high risk of non-specific co-purification. Therefore, it is essential to have 
the appropriate controls, and to further validate an identified interaction by other biochemical and ge-
netic methods.
The characterization of protein-protein interactions by the above described methods helped to achieve 
a better understanding of how proteins function and what their biological function in the cell are. But 
until the late 1990’s, protein function analyses were mainly focused on single proteins, so much, that the 
understanding of their function was fully limited to the knowledge of their interaction partners. 
Thanks to the publication of the human genome and technological developments in mass spectrometry 
(MS) 15 years ago, it became possible to understand how proteins interact with each other and how they 
act in biological networks within the cell (Li et al., 2012). This was the birth of proteomics – the study 
of all proteins in a biological system. Nowadays proteomics spans diverse research topics, ranging from 
protein expression profiling analyzing signaling pathways and to developing protein biomarker assay 
systems (Mallick and Kuster, 2010). 
The identification of protein complexes by proteomics has several advantages. First, interacting pro-
teins can be purified under almost physiological conditions from an endogenous source, which limits 
artifacts. Second, functionally important protein modifications, such as phosphorylation or acetylation, 
can often be determined in the same context. And finally, protein complexes can generally easily be 
identified by mass spectrometry after either a solution digest or a one-dimensional SDS gel.
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1.6.5 RP-HPLC and ESI
In spite of the sample preparation mentioned above, the samples are still too complex for MS analysis 
and have to be further simplified before its introduction into the mass spectrometer. This is achieved 
by using reversed phase high-pressure liquid chromatography (RP-HPLC), where the liquid samples are 
separated according to their polarity, respectively their hydrophobicity (Fig. 1.8 B).
After RP-HPLC separation, the eluents are vaporized and ionized by electrospray ionization (ESI), 
which is especially useful for analyzing large biomolecules such as proteins, peptides and oligonucle-
otides (Chowdhury et al., 1990). The main advantage lies in the fact that ESI produces multiply charged 
ions with little or no fragmentation and it does not require heat or high vacuum.
During ESI, liquid sample is sprayed (nebulized) into a sharply pointed hollow metal tube, such as a 
syringe needle (Fig. 1.8 E). The tube outlet is connected to a high voltage power supply that charges the 
liquid at the needle tip, from which a jet of similarly charged liquid droplets is expelled. The electrostatic 
field causes further dissociation of the liquid droplets in the jet, resulting in a mist of fine droplets that 
evaporate to leave behind the highly charged analyte molecules for analyses. Eventually, the ions are 
ejected into the gas phase and pass through a capillary sampling entrance into the mass spectrometer.
1.6.4 Mass spectrometry
Mass spectrometry (MS) is a sensitive and powerful analytical technique to detect, identify, and quan-
titate molecules based on their mass and charge (m/z). Originally developed almost 100 years ago, mass 
spectrometry was used to measure elemental atomic weights and the natural abundance of specific 
isotopes (Willard, 1988). Over time, a number of methods have been developed such as electrospray 
ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI), which allows the collection 
of protein mass “fingerprints” that can be matched to proteins and peptides in databases to predict the 
identity of unknown proteins (Finehout and Lee, 2004). The sensitivity of current mass spectrometers 
allows one to detect analytes at concentrations in the attomolar range (10-15; Sadiq et al., 2011).
A mass spectrometer consists of three major components (Fig. 1.8 D): First, an ion source produces gas-
eous ions from the studied substrate, second, a mass analyzer resolves the ions into their characteristic 
mass components according to their mass-to-charge (m/z) ratio, and third, a detector system detects the 
ions and records the relative abundance of each of the resolved ionic species. 
trated. This is achieved by C18 ZipTip purification, a process in which the peptides are passed through 
a reverse phase that contains linear aliphatic hydrocarbon of eighteen carbons (C18), and washed with 
aqueous solution. Finally, the purified peptides are solved in proper mobile phases and ion-pairing re-
agents. 
By doing these sample preparation steps, the problems mentioned above are solved: The samples be-
come less complex, chemicals that impair MS analysis are gone, and the mixture contains roughly equal 
amounts of constituents. However, the sample preparation for MS-based analysis is a critical step, be-
cause it significantly impacts the quality and reproducibility of the MS results.
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1.6.6 LTQ Orbitrap LC-MS/MS
The mass spectrometer “LQT Orbitrap LC-MS/MS” (Fig. 1.8 C) consists of three main components: 
A linear ion trap for sample ionization, selection and fragmentation; an intermediate storage device 
(curved linear trap) that is required for short pulse injection; and an Orbitrap analyzer for Fourier trans-
formation based analysis (Fig. 1.8 D). 
After electrospray ionization, the ions first enter into the “linear trap quadrupole” ion trap (LTQ), which 
consists of four parallel rods arranged in a square (quadrupole; Fig. 1.7 D [2]). By applying voltages to the 
rods, electromagnetic fields are generated that determine which mass-to-charge ratio of ions can pass 
through the filter at a given time, and which specific ions are trapped (Fig. 1.8 F).
In the mass spectrometer “LTQ Orbitrap”, the m/z is not only evaluated in the linear ion trap, but also 
in the “Orbitrap” mass analyzer. After passing the LTQ, the ions are stored intermediately in a curved 
linear trap (C-trap). Subsequently they are sent in the “Orbitrap” mass analyzer (Fig. 1.7 D [4]). The Or-
bitrap cell consists of an outer barrel-like electrode and a coaxial inner spindle-like electrode that form 
electrostatic fields. The ions are trapped in circular orbits because their electrostatic attraction to the 
inner electrode is balanced by centrifugal forces – they cycle around the inner electrode on elliptical 
trajectories. Additionally, the ions also move forward and back along the axis of the central electrode 
(z-axis), whereby their trajectories in space look like helices. The frequency of these harmonic oscil-
lations along the z-axis depends only on the ion mass-to-charge ratio. Therefore, by measuring these 
oscillations and by using Fourier transformation, the m/z ratios of the ions can be determined. The en-
tire process has to be performed under an extreme vacuum to remove contaminating non-sample ions, 
which can collide with sample ions and produce non-specific reaction products.
The mass spectrometer is connected to a computer with software that analyze the ion detector data and 
produces graphs that organize the detected ions by their individual m/z and relative abundance (Fig. 
1.8 G). By processing these ions through databases, the identity of the molecule can be predicted, based 
on the m/z ratio. 
The resulting molecular weight of the peptides measured by this described “full MS scan” is very valu-
able, but to identify the exact composition more structural information is needed. A technique that is 
commonly used to sequence proteins and oligonucleotides is multiple-stage MS (MS/MS, also known 
as tandem MS). Hereby, specific “precursor” ions are trapped in the LTQ and fragmented by colliding 
them with a stream of inert gas, a process known as collision induced dissociation (CID; Fig. 1.8 F [3-4]). 
The CID generates “product” ions out of the “precursor” ions, which can be in turn ejected from the 
LTQ, stored intermediately in the C-trap and analyzed in the Orbitrap mass analyzer. 
1.6.7 Data analysis
The most common data representation of the MS analysis is the mass spectrum, which represents in-
tensity vs. the m/z in a histogram (Fig. 1.8 G). These mass spectra are unique for each peptide, but its 
interpretation requires combined use of various procedures. 
First, the mass spectra of the MS and MS/MS scans are compared against a library of mass spectra 
by using the software Mascot, whereby the amino acid sequences of the peptides are determined. In a 
second step, the sequences of the peptides are compared to protein databases (e.g. SwissProt) whereas 
the proteins corresponding to the peptides are identified. Finally, all data from the different MS experi-
ments are compared by proteome software (e.g. Scaffold) and interpreted for their biological relevance.
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2. Aim of this thesis
2
Reversible protein phosphorylation is one of the most important and well-studied post-translational 
modifications. Catalyzed by protein kinases and protein phosphatases, phosphorylation and dephos-
phorylation plays a critical role in the regulation of many cellular processes including cell cycle, growth, 
apoptosis and signal transduction pathway. About 30% of human proteins contain covalently bound 
phosphate, and abnormal protein phosphorylation can be a cause of many human diseases. Thus, it is of 
major importance to understand how phosphorylation regulates the function of proteins.
The physiological substrates of most protein phosphatases have not yet been identified, since the func-
tional activity of phosphatases is complicated by the fact that animals mutant for a single phosphatase 
gene display no obvious phenotype, suggesting that most protein phosphatase act redundantly (Haj et 
al., 2003; Harroch et al., 2000). However, information about these interactions is essential for a better 
understanding of the principles of cellular organization and diseases, and it is the basis for new thera-
peutic approaches (Li et al., 2012). 
The highly conserved EGFR/RAS/MAPK signaling pathway is probably the best characterized signal 
transduction pathway in cell biology and plays a crucial role in many developmental processes. Its dys-
regulation is common in many cancers as Ras is the most frequently mutated oncogene in human cancer 
and cancer formation. 
EGFR/RAS/MAPK activity is regulated through protein phosphorylation and controlled by a broad 
negative regulatory network that attenuates the different components of this signaling pathway. A mem-
ber of this network is the density enhanced phosphatase DEP-1, which belongs to the receptor protein 
tyrosine phosphatases. It inhibits EGFR/RAS/MAPK signaling through dephosphorylation of the EGF 
receptor and thereby acts as a tumor suppressor (Berset, 2005; Jeon and Zinn, 2009; Tarcic et al., 2009). 
In vertebrates, DEP-1 was found as the colon cancer susceptibility locus Scc1 (Ruivenkamp et al., 2002), 
and it has been found that DEP-1 is frequently deleted and mutated in various human cancers such as 
thyroid, colon, lung, pancreatic, and breast cancer (Iuliano et al., 2003; Ruivenkamp et al., 2002; Tonks, 
2006; Trapasso et al., 2004). 
Many experiments were performed in cell culture to identify novel interactors of DEP-1. However, the 
lack of in vivo confirmation makes it difficult to estimate the physiological relevance during cell fate 
specification, pattern formation and tumorigenesis. 
Thus, the specific aim of this thesis was to identify novel interactors of DEP-1 by a mass spectrometry-
based approach, and to further elucidate their role in vivo during development of the C. elegans her-
maphrodite vulva.
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3.1.1 Abstract
3.1.2 Introduction
Reversible protein phosphorylation is one of the most important and well-studied post-translational 
modifications and plays a critical role in the regulation of many cellular processes including cell cycle, 
growth, apoptosis and signal transduction pathway. The receptor protein tyrosine phosphatase DEP-1 
inhibits EGFR/RAS/MAPK signaling through dephosphorylation of the EGF receptor. Moreover, DEP-1 
regulates cell adhesion and motility, suggesting that DEP-1 has numerous physiological substrates.
In order to identify novel substrates of DEP-1, we have performed a mass spectrometry-based approach 
using a substrate-trapping DEP-1 mutant. In this manner, we identified the β-integrin subunit PAT-3 as 
a novel substrate of DEP-1. DEP-1 dephosphorylates one of the evolutionary conserved NPxY motifs of 
the PAT-3 cytoplasmic tail and thereby promotes PAT-3 activation. In the developing vulva, activated 
PAT-3 inhibits the RAS/MAPK signaling pathway in the secondary vulval cells. These results demon-
strate a novel role of DEP-1 and integrins during regulation of RAS/MAPK signaling and give further 
insights into integrin regulation in vivo. 
Phosphorylation of proteins is a reversible post-translational modification and one of the most common 
modes of regulating protein functions (Hunter, 1999). Several components of the epidermal growth fac-
tor receptor (EGFR) signal transduction pathway are phosphorylated and activated when an EGF ligand 
binds to its receptor (Schlessinger, 2000). On the contrary, protein phosphatases attenuate the activity 
of EGFR/RAS/MAPK pathway by being part of a negative regulatory network. The genome of both ver-
tebrates and invertebrates encode a large number of predicted phosphatase genes (Alonso et al., 2004), 
and disruption of their activities may lead to serious diseases and disorders (Kishihara et al., 1993; Li 
and Dixon, 2000; Shultz et al., 1993). The physiological substrates of most protein phosphatases have not 
yet been identified, as many of the experiments addressing this question were performed in vitro or by 
overexpression, which often impairs the substrate specification of phosphatases (Blanchetot et al., 2005; 
Hertog et al., 1999). However, the knowledge about physiological substrates of protein phosphatases is 
essential for a better understanding of the principles of cellular organization and diseases, and it is the 
basis for new therapeutic approaches (Li et al., 2012).
The Density Enhanced Phosphatase DEP-1 (also known as PTPRJ, PTP-η or CD148) belongs to the class 
III Receptor Protein Tyrosine Phosphatase (R-PTP) family (Hertog et al., 1999). As characteristical for 
R-PTP, DEP-1 contains an intracellular catalytic tyrosine phosphatase domain, a single transmembrane 
domain, and multiple extracellular fibronectin type III repeats. The mouse PTPRJ was found as the co-
lon cancer susceptibility locus Scc1 (Ruivenkamp et al., 2002), and it regulates cell motility and exhibits 
tumor-suppressor activity when ectopically overexpressed (Iuliano et al., 2003; Keane et al., 1996; Peter-
mann et al., 2010; Trapasso et al., 2000). Moreover, DEP-1 was found to be frequently deleted and mu-
tated in various human cancers such as thyroid, colon, lung, pancreatic, and breast cancer (Iuliano et al., 
2003; Ruivenkamp et al., 2002; Tonks, 2006; Trapasso et al., 2004). The substrates of DEP-1 identified so 
far, namely a variety of growth factor receptors such as EGFR, PDGFR, VEGFR, MET, SFKs, ERK-1/2 
and the p85 subunit of PI3K, as well as cell-cell junctional complexes including p120ctn, β-catenin and 
γ-catenin, occluding, and ZO-1, were analyzed almost exclusively in cell culture experiments (Arora et 
al., 2011; Berset, 2005; Chabot et al., 2009; Grazia Lampugnani et al., 2003; Kappert et al., 2007; Palka, 
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2002; Sacco et al., 2009; Tarcic et al., 2009; Tsuboi et al., 2008; Zhu et al., 2008). However, the lack of in 
vivo confirmation makes it difficult to estimate the physiological relevance during cell fate specifica-
tion, pattern formation and tumorigenesis.
The development of the C. elegans hermaphrodite vulva serves as an excellent model to study evolu-
tionary conserved signaling pathways like the RAS/MAPK, DELTA/NOTCH, and WNT-pathways and 
is one of the best-characterized models for organogenesis (Sternberg, 2005). In L2 larval stage, vulval 
development is induced when the gonadal anchor cell (AC) secretes the EGF-like growth factor LIN-3 
in a graded fashion to the adjacent vulval precursor cells (VPCs) (Kornfeld, 1997; Sternberg and Han, 
1998). All six VPCs, termed P3.p to P8.p, are equally competent to respond to this inductive AC signal, 
but P6.p is closest to the AC. Hence, P6.p receives the highest possible level of LIN-3 that activates the 
EGF receptor homolog LET-23 and thereby the RAS/MAPK pathway to specify the primary (1°) cell 
fate. Consequently, a lateral signal from P6.p is transduced by the DELTA/NOTCH signaling pathway 
to induce the secondary (2°) fate and to inactivate the EGFR/RAS/MAPK pathway in the neighboring 
VPCs P5.p and P7.p (Ambros, 1999; Berset et al., 2001; Chen and Greenwald, 2004; Yoo et al., 2004). The 
latter is achieved by the transcription of several negative regulators of the EGFR/RAS/MAPK signaling 
pathway in P5.p and P7.p, such as dep-1, lip-1 and the lst genes (Berset, 2005; Berset et al., 2001; Yoo et 
al., 2004). After the vulval cell fates have been specified, the 1° VPC P6.p and the 2° VPCs P5.p and P7.p 
each go through three rounds of cell divisions to generate 22 cells that form the vulva. The remaining 
distal VPCs (P3.p, P4.p and P8.p) adopt the tertiary (3°) non-vulval cell fate, which divide once before 
they fuse with the surrounding hypodermis (hyp7). 
Integrins, which are found on nearly all nucleated cells of multicellular animals, are a large family of cell 
adhesion molecules that form non-covalently associated α/β heterodimers. Both α- and β-subunits are 
type I transmembrane glycoproteins with a large multidomain extracellular portion, single spanning 
transmembrane domains, and short cytoplasmic tails (Hynes, 2002). In mammals, at least 24 distinct 
α/β heterodimer combinations are formed by 18 α-subunits and 8 β-subunits, each of which can bind to 
a specific repertoire of cell-surface, extra cellular matrix (ECM) or soluble protein ligands (Hynes, 1992; 
2002). In addition to the regulation of cell adhesion events, integrins play critical roles in transducing 
signals in either direction, in what is referred to as either “inside-out” or “outside-in” signaling (Liu 
et al., 2000). In coordinating the bidirectional signaling and the activation states of the integrins, the 
transmembrane helices and short cytoplasmic tails of both subunits play a crucial role (Liu et al., 2000; 
Shattil et al., 2010).
Contrary to the numerous integrin subunits in vertebrates, C. elegans has only three integrins: Two 
α-subunits (INA-1 and PAT-2) and one β-subunit (PAT-3), providing an excellent model system for ex-
amining integrin function. Null alleles of pat-2 and pat-3 cause a “Paralyzed and Arrested at Two-fold” 
embryonic lethal phenotype (PAT), and loss of ina-1 (INtegrin Alpha) results in larval lethality (Baum 
and Garriga, 1997; Williams and Waterston, 1994). PAT-3 is widely expressed in most tissues through-
out development, especially in the body wall and sex muscles, along the intestinal tract, in embryonic 
pharynx, spermatheca, uterus, somatic gonad, neurons, and the vulva (Gettner et al., 1995). Further-
more, it has been shown that PAT-3 plays together with INA-1 a key regulatory function during anchor 
cell invasion through the basal membrane by targeting the netrin receptor UNC-40 to the AC’s plasma 
membrane (Hagedorn et al., 2009).
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3.1.3 A mass spectrometry-based approach to find novel substrates of DEP-1
In order to identify novel substrates of C. elegans DEP-1, we performed a mass spectrometry-based ap-
proach in which proteins from pull-down experiments were analyzed by LC-MS/MS. The intracellular 
domain of DEP-1, which carries the substrate trapping mutation D1241A (Palka, 2002), was affinity-
purified from E. coli using GST sepharose and used for pull-down experiments with total protein extract 
from mixed-staged C. elegans N2 (Fig. 3.1 A and B; Berset, 2005). To distinguish between proteins that 
remained bound specifically to the substrate trapping mutation and proteins that are not substrates of 
DEP-1, we also performed pull-down experiments with the wild-type intracellular domain (DEP-1in-
trawt) and with GST only (Fig. 3.1 C). Subsequently, protein complexes were separated by SDS-PAGE 
and stained with Colloidal Coomassie Blue, which led to the identification of three prominent protein 
bands with a molecular weight of 90.1 kD, 135.9 kD, and 174.4 kD, which were exclusively present in the 
DEP-1intraDA pull-downs (Fig. 3.1 D). After fragmentation of the SDS-gel (dotted lines in Fig. 3.1 D), 
proteins were processed for in-gel tryptic digestion and C18 ZipTip purification. Liquid chromatography 
and tandem mass spectrometry (LC-MS/MS) in conjunction with database searching against the C. el-
egans protein database finally led to the identification of 585 proteins, 97 of which were not present in the 
empty GST control (see section 3.1.9). Among the 43 proteins that bound exclusively to DEP-1intraDA, 99 
peptides of the α-integrin subunit PAT-2 (MW=135.9 kD), and 54 peptides of the β-integrin subunit PAT-
3 (MW=90.1 kD) were identified (Fig. 3.1 E), indicating an unambiguous identification of these proteins. 
Since it is unlikely that DEP-1 interacts with both the α and β integrin subunit, and because previously 
reportet data suggest a tyrosine phosphorylation dependent regulatory role of β-integrins (Calderwood, 
2004), we focused our further studies on the examination of the interaction between DEP-1 and PAT-3.
3.1.4 DEP-1 binds to the NPxY motif of its substrate PAT-3
To confirm the binding of DEP-1intraDA to PAT-3, we performed co-immunoprecipitation (Co-IP) 
experiments using GST-purified DEP-1 and total protein extract from worms expressing PAT-3::GFP 
(qyIs43). Western blots against GFP showed a clear interaction between DEP-1intraDA and PAT-3::GFP, 
whereas no binding of DEP-1intrawt to PAT-3 was observed (Fig. 3.2 A). 
Similar to these findings were the results from Co-IP experiments with protein extract from worms ex-
pressing PAT-2::GFP (jeIs2222). PAT-2::GFP clearly interacted with DEP-1intraDA, whereas only a very 
weak interaction with DEP-1intrawt was observed (data not shown). 
To further test if this interaction is phosphorylation dependent, we added the PTP inhibitor sodium 
orthovanadate (Na3VO4; Huyer et al., 1997) to the protein extract that was subsequently used for Co-IP 
experiments. As expected, the interaction of DEP-1intraDA with PAT-3::GFP was completely inhibited 
in presence of sodium orthovanadate (Fig. 3.1 B). Thus, we conclude that the interaction of DEP-1 with 
its substrate PAT-3 is phosphorylation dependent.
In this study, we report the identification of the C. elegans β-integrin subunit PAT-3 in a mass spec-
trometry based approach as a novel substrate of the tyrosine phosphatase DEP-1. Using biochemical and 
genetic epistasis analyses, we found that DEP-1 dephosphorylates the highly conserved NPxY motif of 
the PAT-3 cytoplasmic tail to regulate its activity. Activated PAT-3 acts as a negative regulator of RAS/
MAPK signaling during vulval development, most likely by inhibiting EGFR activation.
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Figure 3.1 Mass spectrometry-based approach to identify novel substrates of DEP-1.
(A) Domain structures of C. elegans DEP-1 and scheme of GST-tagged DEP-1intrawt and DEP-1intraDA fusion proteins. 
Asterisks indicates the substrate trapping mutation D1241A. (B) Workflow of GST purification, pull-down, and subsequent 
analysis by MS/MS. (C) Samples of purified DEP-1intrawt, DEP-1intraDA and GST were loaded on a SDS gel and stai-
ned with Coomassie Blue. (D) Samples after pull-down of N2 wild-type protein extract with purified GST::DEP-1 intrawt, 
GST::DEP-1intraDA, or GST were fractionated by SDS-PAGE and stained with Colloidal Coomassie Blue. Dashed lines 
indicate cutting lines of the SDS gel for subsequent tryptic in-gel digestion. (E) Top-six proteins that were identified by LC-
MS/MS after pull-down experiments. Three independent purifications were analyzed (#1-3). Numbers indicate the quantity 
of identified peptides per protein. All listed proteins were not identified in the controls. PMin protein = 95%; #Min peptides = 
2; PMin peptide = 95%.
3. Projects
40
DE
P-
1 intr
aw
t
To
t E
xtr
ac
t
DE
P-
1 intr
aD
A
GS
T
DE
P-
1 intr
aw
t
DE
P-
1 intr
aD
A
GS
T
- Na3VO4 + Na3VO4
αGFPPAT-3::GFP
DE
P-
1 intr
aw
t
To
t E
xtr
ac
t
PAT-3::GFP
DE
P-
1 intr
aD
A
GS
T
αGFP
αGFP
IP
WB
IP
WB
A
C
D E
B
Input
IP DEP-1DA
IP DEP-1wt
wtPAT-3::GFP Y7
72
A
Y7
92
A
Y8
04
A
Y7
92
A Y
80
4A
TT
T7
96
-79
8A
AA
Relative intensity (%)
Binding of PAT-3::GFP to DEP-1intraDA
wt
0 20 40 60 80 100
Y772A
Y792A
Y804A
Y792A Y804A
TTT796-798AAA
L
L
L
L M I I HD RR E F AK F EK EKM NAKWD T GEN P I Y K SAV T T - -
A I H L SD L R EY RR F EK EK L K SQWNN - DN P L F K SAT T T - -
L SV E I YD RR EY SR F EK EQQQ LNWKQD SN P L Y K SA I T T - -
L I T I HD RK E F AK F E E ERA RAKWD T ANN P L Y K EAT ST F T
L L V S FHD RK EV AK F EA ER S KAKWQT GT N P L Y RG ST ST F K
N P KY EGK - -
N P K F A E S- -
N P R FQ EAD -
N I T Y R- - - -
N V T Y KH R EK
L L T V LHD R S EY AT FNN ER L MAKWD T N EN P I Y KQAT T T F KN P V Y AGKAN
Human Beta-1
Human Beta-2
Human Beta-7
Human Beta-3
Human Beta-6
Consensus
C. elegans PAT-3
792 796-798772 804
***
***
***
**
Figure 3.2 Interaction of PAT-3 with DEP-1 depends on NPxY phosphorylation.
(A) Co-IP confirms binding of DEP-1intraDA to PAT-3::GFP in vitro. (B) Interaction of DEP-1intraDA with PAT-3 is inhi-
bited by the addition of 5 mM sodium orthovanadate (Na3VO4). (C) Alignment of the amino acid sequences of C. elegans 
PAT-3 and human β2, β7, β1, β3, and β6 cytoplasmic tails. Conserved tyrosines are highlited in purple and conserved NPxY 
domains are in grey. (D) Co-IP of DEP-1intra with different versions of PAT-3::GFP containing Tyr to Ala / Thr to Ala 
exchanges in the intracellular domain. (E) Quantification of the Co-IP experiments (relative intensity) that are shown in 
(D). All IPs were done in triplicates and normalized to the control Co-IP with wild-type PAT-3::GFP. Note that disruption 
of the Y792 in the first NPxY motif significantly diminishes binding to DEP-1. ** indicates a p-value≤0.005 and *** a p-
value≤0.0005. Error bars report the standard error of the mean. 
Since the catalytic phosphatase domain of DEP-1 is cytoplasmic, we assumed that the interaction with 
PAT-3 occurs over a cytoplasmic phospho-tyrosine. Thus, we focused our studies on the cytoplasmic tail 
of PAT-3, which contains three highly conserved tyrosines, namely Y772, Y792, and Y804 (Fig. 3.1 C). 
Y792 and Y804 belong to the two evolutionary conserved NPxY (Asp-Pro-X-Tyr) motifs, whose tyrosine 
phosphorylation are thought to activate integrins and to promote interactions with downstream signal-
ing molecules (Calderwood et al., 2002; Chen et al., 1990; Lee et al., 2001). To determine if DEP-1 binds 
to one of these tyrosines, we generated C. elegans strains expressing ectopic PAT-3::GFP, in which the 
cytoplasmic tyrosines Y772, Y792, Y804, as well as the conserved threonins TTT796-798 were replaced 
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3.1.5 PAT-3 is a negative regulator of RAS/MAPK signaling during vulval development
To further investigate the interaction between DEP-1 and PAT-3 in vivo, we examined the role of PAT-3 
during C. elegans vulval development. Mutations in genes encoding components of signaling pathways 
that are involved during vulval development, such RAS/MAPK, NOTCH, and WNT pathways, change 
the patterning of the VPC fates. Mutations that hyperactivate the RAS/MAPK pathway, for example, 
cause the induction of more than three VPCs, resulting in a Multivulva phenotype (Félix, 2012). On the 
other hand, mutations that cause a decrease of RAS/MAPK signaling activity, lead to an induction of 
less than three VPCs and thus to a phenotype called Vulvaless. Thus, vulval induction by RAS/MAPK 
signaling can be quantified by counting the number of induced VPCs (Sternberg and Horvitz, 1986) and 
by determining the vulval index (VI).
dep-1(lf) single mutants develop a wild-type vulva due to redundancy of its phosphatase activity (Fig. 
3.1 A; Berset, 2005). However, in the sensitized let-60(gf) background, in which the RAS/MAPK pathway 
is constitutively active because LET-60/RAS is hyperactivated (Ferguson and Horvitz, 1985), the role of 
DEP-1 as a negative regulator of RAS/MAPK signaling is evident. Compared to let-60(gf) single mutants 
(VI = 3.9), dep-1(lf);let-60(gf) double mutants exhibit highly increased vulval induction (VI = 5.5; Fig. 
3.3 B, C and G; Berset, 2005). Thus, the sensitized let-60(gf) background enables the characterization of 
genes that influence RAS/MAPK signaling, which would otherwise not exhibit a vulval phenotype. 
Loss-off PAT-2 or PAT-3 function results in strong “Paralyzed and Arrested at Two-fold” phenotypes, 
preventing an examination of their role when vulval development takes place. To overcome this prob-
lem, we reduced PAT-2 and PAT-3 function exclusively in the VPCs of let-60(gf) animals using the 
tissue-specific RNAi strain let-60(gf);rde-1(ne219);zhEx418[lin-31::rde-1;myo-2::mCherry] (Master thesis 
Anina Schneider). Compared to empty vector control treated animals, RNAi against both pat-2 and 
pat-3 increased the induction of VPCs significantly (Fig. 3.3 H). Furthermore, L4 larvae of pat-2 and 
pat-3 RNAi treated animals showed a similar adjacent primary fate (APF) phenotype as observed in 
dep-1(lf);let-60(gf) double mutants (Fig. 3.3 C-F; Berset, 2005). 
To further determine the role of PAT-3 during vulval development, we disrupted pat-3 function by a 
previously characterized dominant-negative construct (Lee et al., 2001), which was expressed under 
the vulval specific promoter of lin-31 (Tan et al., 1998) in let-60(n1046) animals. In accordance with 
the RNAi results, animals expressing the dominant-negative PAT-3 showed significantly higher vulval 
induction compared to let-60 animals control animals (Fig. 3.3 I). 
In summary, these morphological changes in cell fate determination suggest that the PAT-2/PAT-3 inte-
grins act as negative regulators of RAS/MAPK signaling during vulval development.
with alanine (Y772A, Y792A, Y792A Y804A, Y804A, and TTT796-798AAA). Co-IP experiments re-
vealed that the interaction of DEP-1intraDA with PAT-3 containing the Y792A mutation (Y792A and 
Y792A Y804A) is significantly reduced (Fig. 3.1D and E). In contrast, the Y804A mutant did not af-
fect the binding of DEP-1intraDA to PAT-3. Surprisingly, also the TTT796-798AAA mutation reduced 
significantly the interaction of PAT-3 with DEP-1intraDA. This might be caused by conformational 
changes that are induced by the replacement of the threonins TTT796-798 with alanines, leading to a 
disturbed interaction of DEP-1 with Y792 of the NPxY motif.
Taken together, our biochemical data indicate that DEP-1 dephosphorylates the tyrosine Y792, which is 
part of the first NPxY motif in the cytoplasmic tail of PAT-3. 
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Figure 3.3  PAT-3 is a negative regulator of RAS/MAPK signaling during vulval development.
(A) Nomarski images of dep-1(lf) and (B) let-60 ras (gf) L4 larva. In let-60(gf) mutants, P5.p and P7.p have adopted the 2° 
fate, and their descendants remain attached to the cuticula, while some descendants of P4.p form an anterior pseudovulva. 
(C) dep-1(lf);let-60(gf) L4 larva exhibits 2° Cell fate transformation of P5.p in addition to the Muv phenotype. (D-F) RNAi 
in let-60(gf);rde-1(ne219);zhEx418[lin-31::rde-1;myo-2::mCherry] L4 larvae against empty vector control (D), pat-2 (E), and 
pat-3 (F). pat-2i and pat-3i cause similar cell fate transformation as in dep-1(lf);let-60(gf) animals. (G) Vulval induction 
is not altered in dep-1(lf) animals. However, dep-1(lf) increases the enhanced vulval induction of let-60(gf) animals in L4 
staged animals. (H) RNAi against pat-2 and pat-3 enhances vulval induction of let-60(gf);rde-1(ne219);zhEx418[lin-31::rde-
1;myo-2::mCherry] L4 larvae. (I) Vulval specific expression of dominant negative PAT-3 also increases vulval induction of 
let-60(gf) animals. (K) Extrachromosomal expression of PAT-3 containing Y792A transition decreases vulval induction of 
let-60(gf);pat-3(lf) animals. In contrast, expression of Y804F mutant PAT-3 does not alter vulval induction of let-60(gf);pat-
3(lf) animals. * indicates a p-value≤0.05, ** a p-value≤0.005, and *** p-value≤0.0005. Error bars report the standard error 
of the mean. Scale bar represents 10 µm.
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3.1.6 The influence of PAT-3 on RAS/MAPK signaling is regulated by the NPxY motif
Phosphorylation of cytoplasmic NPxY motifs is thought to be a switch mechanism for the control of 
integrin receptor activation (Oxley et al., 2008). Since our biochemical data indicated that DEP-1 binds 
to the first NPxY motif, we next investigated if tyrosine phosphorylation of Y792 regulates the inhibi-
tory function of PAT-3 on RAS/MAPK signaling during vulval development. As reported previously, 
animals expressing PAT-3 with mutated NPxY motifs (pat-3Y792F, pat-3Y804F, and pat-3Y792F) rescue 
the embryonic lethality of pat-3(st564) null mutants and generate viable and fertile progeny (Lee et al., 
2001). Thus, we analyzed these pat-3 mutant constructs in the sensitized pat-3(lf);let-60(gf) background 
to examine the level of induced VPCs. As expected, the Y792 mutation causes a significant decrease of 
vulval induction, whereas the Y804 mutation did not show an alteration in induced vulval cells (Fig. 
3.3 K). We therefore conclude that dephosphorylation of Y792 by DEP-1 activates PAT-3 to inhibit RAS/
MAPK signaling during vulval development.
3.1.7 DEP-1 co-localizes with LET-23 and PAT-3 during vulval development
We next examined the expression pattern and subcellular localization of DEP-1, LET-23 and PAT-3 
during vulval development. Therefore, we generated a functional endogenous DEP-1::mCherry reporter 
line by MosTic integration (Robert et al., 2009; see section 3.2.10) that was analyzed by confocal spin-
ning disc microscopy. Expression of DEP-1::mCherry could be observed on the apical plasma membrane 
as well as in intracellular punctae of the VPC at the Pn.px and Pn.pxx larval stages (3.4 A’ and B’). Simi-
lar results were observed with an endogenous DEP-1::GFP reporter line (see section 3.2.11), which was 
able to rescue the adjacent primary fate (APF) phenotype of dep-1(lf);lip-1(lf) animals. DEP-1::mCherry, 
which is slightly enhanced in the 2° lineage, partially co-localized with LET-23::GFP in punctate struc-
ture near the plasma membrane of both Pn.px and Pn.pxx staged animals (Fig. 3.4 A’’ and B’’). 
As reported previously, a translational PAT-3::GFP reporter that is co-expressed with genomic 
INA-1, was expressed during vulval development within the AC, the basolateral side of the VPCs, as 
well as in neighboring somatic gonad (Hagedorn et al., 2009). Further expression studies together with 
DEP-1::mCherry revealed that DEP-1::mCherry partially co-localized with PAT-3::GFP at the basolat-
eral side and in intracellular punctae of 2° VPCs of Pn.px (Fig. 3.4 C’’) and Pn.pxx larvae (Fig. 3.4 D’’). 
In later stages, namely in early L4 (Fig. 3.4 E’’) and late L4 larvae (3.4 F’’), DEP-1::mCherry expression 
and its co-localization with PAT-3::GFP was predominantly observed at the apical side of the 2° VPCs, 
but only rarely in intracellular punctae. 
Finally, we tested if DEP-1 regulates the subcellular localization of PAT-3 and LET-23 in the VPCs. As 
mentioned before, PAT-3::GFP expression is usually seen at the basolateral side of the VPCs, whereas 
expression at the apical side is detected rarely. However, in dep-1(lf) mutants an enhanced apical accu-
mulation of PAT-3::GFP in punctate structure was observed, indicating that DEP-1 might be involved in 
the regulation of integrin trafficking (Fig. 3.4 G and H). In contrast, no misexpression of LET-23::GFP 
could be observed in dep-1(lf) mutants (data not shown). 
Taken together, these results indicate that DEP-1 interacts not only in vitro with its substrates LET-23 
and PAT-3, but also in vivo during vulval development. In addition, our data suggest that DEP-1 might 
have a regulatory function to control endocytosis and trafficking of PAT-3. 
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Figure 3.4 DEP-1 co-localizes with PAT-3 and LET-23 during vulval development.
(A-B) Expression of LET-23::GFP and DEP-1::mCherry at the Pn.px stage (A) and at the Pn.pxx stage (B). (A’’ and B’’) 
Merged images whereas details (dashed squares) are shown in (A’’’ and B’’’). Arrow heads point at intracellular punctae con-
taining both DEP-1::mCherry and LET-23::GFP. (C-F) Expression of PAT-3::GFP and DEP-1::mCherry at the Pn.px stage 
(C), at the Pn.pxx stage (D), after invagination (E) and at L4 christmas tree stage (F). (C’’-F’’) Merged images whereas details 
(dashed squares) are shown in (C’’’) and (D’’’). Arrow heads point at intracellular punctae containing both DEP-1::mCherry 
and PAT-3::GFP. (G and H) Expression of PAT-3::GFP in Pn.pxx stage. (H) In dep-1(lf) mutants, more PAT-3::GFP is ex-
pressed at the apical side, indicated by arrow heads. All images are z-projections (average intensity) of spinning-confocal 
z-stacks. Scale bar represents 10 µm.
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Activated integrins negatively regulate RAS/MAPK signaling during vulval development
Tyrosine phosphorylation by kinases and the subsequent dephosphorylation by phosphatases are 
key mechanisms that regulate intracellular signal transduction required for organogenesis. During 
Caenorhabditits elegans vulval development, the receptor protein tyrosine phosphatase DEP-1 (PTPRJ, 
PTP-η or CD148) inhibits EGFR/RAS/MAPK signaling in the secondary vulval cells through dephos-
phorylation of the EGF receptor. In order to identify novel physiological substrates of DEP-1, we per-
formed pull-down experiments with the intracellular domain of DEP-1 containing the substrate trap-
ping mutation D1241A and whole protein extract of C. elegans. Proteins that bound to DEP-1 were then 
identified by LC-MS/MS mass spectrometry. Among 43 proteins that bound solely to DEP-1intraDA, 
the β-integrin subunit PAT-3 was found. 
PAT-3 binds almost exclusively to DEP-1 containing the substrate-trapping mutation D1241A that al-
lows the catalytically inactive DEP-1 to remain bound to its phosphorylated substrate (Palka, 2002), but 
not to wild-type DEP-1. Together with the observation that the interaction of PAT-3 and DEP-1intraDA 
is completely inhibited in presence of the phosphatase inhibitor sodium orthovanadate, these data sug-
gests that PAT-3 interacts with DEP-1 in a phosphorylation-dependent manner. 
Our further biochemical results give evidence that DEP-1 dephosphorylates the tyrosine Y792 of the 
PAT-3 cytoplasmic tail, which is part of the evolutionary conserved NPxY motif. Phosphorylation of the 
NPxY motifs by Src-family kinases is essential for integrin activation and promotes the interaction with 
competing integrin-binding proteins, such as talin and DOK-1 (Oxley et al., 2008).
Talin, a major cytoskeletal protein that binds with high affinity to non-phosphorylated NPxY, triggers 
integrin activation (Critchley, 2000; Tadokoro et al., 2003). Moreover, it provides a mechanical link 
between integrins and the actin cytoskeleton, and induces conformational changes in the extracellular 
domain of the integrins (Ye et al., 2010). However, phosphorylation of the NPxY motif decreases bind-
ing of talin while increasing binding of DOK-1, which both inhibit integrin activation (Calderwood et 
al., 2003). 
Results from cell culture experiments give evidence for this integrin activation “off switch”, since NPxY 
phosphorylation reduces cell adhesion, leads to integrin displacement from focal adhesions, and affects 
cell migration, hemostasis and transformation (Datta et al., 2001; 2002; Johansson et al., 1994; Law et al., 
1999; Sakai et al., 2001; 1998). Also data from C. elegans integrins highlight the important role of NPxY 
phosphorylation. C. elegans expressing PAT-3 with disrupted NPxY motifs are viable (Lee et al., 2001), 
but they display aberrant distal tip cell migration and ovulation, and defects in muscle cell formation 
and tail morphogenesis (Xu et al., 2010). This further suggests that NPxY motifs play important roles in 
the tissue-specific function of integrins.
Functional studies of NPxY motifs in mice showed that disruption of the NPxY motifs impairs the pro-
liferation and survival of mouse embryonic fibroblasts (Hirsch et al., 2002). Furthermore, other data 
revealed that aberrant NPxY motifs in mouse β1 or β3 integrins affect integrin functions and platelet 
aggregation (Law et al., 1999), or cause bleeding defects and embryonic lethality (Chen et al., 2006).
In summary, numerous data indicate that phosphorylation of the NPxY motifs is crucial for integrin 
regulation, but its importance in vivo remains to be further determined.
3.1.8 Discussion
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Activated integrins negatively regulate RAS/MAPK signaling during vulval development
Vulval development of C. elegans provides a convenient model to study the functions of DEP-1 and 
PAT-3 in vivo. Our data reveal that vulval-specific knockdown of the integrin subunits pat-2 and pat-3 
by RNAi or by expression of a dominant negative form of pat-3 results in the enhancement of the mul-
tivulva phenotype of let-60(gf) animals, suggesting that integrins inhibit RAS/MAPK signaling in the 
secondary VPCs. Additionally, knockdown of pat-2 and pat-3 in let-60(gf) mutants results in a similar 
adjacent primary fate (APF) phenotype as it is observed in dep-1(lf);let-60(gf) double mutants (Berset, 
2005). This transformation of the 2° cell fate into 1° fate with mixed 1° and 2° characteristics in P5.p and 
P7.p descendants further supports a negative regulatory function of the integrins during vulval develop-
ment (Fig. 3.5).
The inhibitory effect of PAT-3 on RAS/MPK signaling can be activated when the tyrosine Y792 is mu-
tated to phenylalanine, which mimics the enhanced dephosphorylation caused by dep-1(gf). Interest-
ingly, this is the same tyrosine being part of the regulatory NPxY motif, which has been identified to 
be the binding site of DEP-1 in our biochemical experiments. Hence, we have both in vitro and in vivo 
evidence that DEP-1 dephosphorylates PAT-3 at the first NPxY motif, which further supports the model 
that phosphorylation of the NPxY motifs plays a regulatory function in integrin activation.
The molecular mechanisms of how PAT-2/PAT-3 negatively inhibits RAS/MAPK signaling are not yet 
known. It also remains to be elucidated if the integrins negatively regulate the activity of the EGF recep-
tor LET-23 themselves, or if the inhibitory effect of integrins concerns more downstream components 
of the RAS/MAPK signaling pathway, such as RAS/LET-60 (Fig. 3.5). 
Since the cytoplasmic tails of integrins have no homology to other intracellular signaling motifs known 
(Cox et al., 2010), it is likely that the inhibitory effect on RAS/MAPK signaling is achieved indirectly 
over one or several of the numerous adaptor proteins that are known to bind to integrin β-tails (Fig. 3.5 
protein “X”; Liu et al., 2000).
One of the most important adaptor protein is talin, which binds with high affinity to the non-phos-
phorylated NPxY motif and plays a crucial role in integrin activation (Critchley, 2000; Tadokoro et al., 
2003). C. elegans talin (TLN-1, UNC-35) co-localizes with PAT-2 and PAT-3 (Moulder et al., 1996) and 
plays a central role in regulating distal tip cell migration. Furthermore, reduction of talin expression 
causes severe defects in gonad formation, disrupted oocyte maturation, and contractile muscle cells 
showed disorganization of the actin cytoskeleton leading to complete paralysis, a phenotype that was 
also observed with depletion of pat-2 and pat-3. (Cram et al., 2003). Thus, it would be conceivable that 
the inhibitory effect of PAT-2/PAT-3 on RAS/MAPK signaling observed in this study might be acting 
indirectly via talin/UNC-35. 
However, there are also other possibilities of how integrins can collaborate with EGFR or other growth 
factor receptors (GFR). First, it has been reported that the signaling function of integrins depends on 
intracellular signal molecules, which are shared with other growth factor signaling pathways, for ex-
ample Shc, Src family kinases, RAS-MAPK, JNK, PKC and PI3K (Clark and Brugge, 1995; Fantl et al., 
1993; Howe et al., 1998; Schlaepfer and Hunter, 1998; Schwartz et al., 1995). Furthermore, focal adhesion 
kinase (FAK) is associated with both, integrin signaling and several different signaling proteins (Mi-
tra and Schlaepfer, 2006). However, loss of kin-32/FAK did not alter the vulval induction of let-60(gf) 
animals (PhD thesis of Itay Naktimon, table 1), indicating that FAK is not involved in regulating RAS/
MAPK signaling during vulval development.
Second, integrins mutually collaborate with GFR to create an environment in which the GFRs can 
properly interact with downstream signaling molecules (Yamada and Even-Ram, 2002). This crosstalk 
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may involve direct induction of EGFR phosphorylation by integrin binding, signal amplification of 
GF-induced receptor activation by integrin-ECM ligation, or physical interaction between the receptors 
(Giancotti and Tarone, 2003). 
Third, integrins mediate direct activation of GFRs, including direct interaction between the receptors. 
αVβ3 and β1 for example associate with EGFR on the membrane, and the clustering of the two recep-
tor types triggers transactivation (Moro, 2001). Forth, many growth factors activate the expression of 
integrins, which in turn may further activate signaling by GFRs, such as the hepatocyte growth factor, 
which increases selectively the expression of α2 and α3 integrins (Chiu et al., 2002). 
In most of these cases, integrins appear to function as positive regulators of GFR signaling. However, 
there are also mechanisms described in which integrins negatively regulate GFR signaling. One example 
is the α1β1 mediated activation of the T cell protein tyrosine phosphatase TCPTP, which induces de-
phosphorylation of EGFR, VEGFR2, and PDGFRβ to attenuate their activity (Mattila et al., 2008; 2010; 
2005). 
X
EGFR/LET-23
RAS/LET-60
ERK/MPK-1
EGF/LIN-3
DEP-1
1° cell fate
Y792βPAT-3
αPAT-2
Y792βPAT-3
αPAT-2
P
Figure 3.5 A model for PAT-3/PAT-2 and DEP-1 function during vulval development.
EGF activates the EGFR/RAS/MPK signaling pathway to induce 1° cell fate specific gene expression. DEP-1 blocks the 
transduction of the inductive signal by dephosphorylating the EGFR LET-23. In addition, DEP-1 dephosphorylates the 
cytoplasmic tail of β integrin PAT-3 (Y702) to activate the integrin heterodimers PAT-2/PAT-3, which in turn negatively 
regulate RAS/MPK signaling.
NPxY motifs are involved in PAT-3 trafficking
The expression pattern of PAT-3::GFP and DEP-1::mCherry give further evidence that DEP-1 and PAT-3 
do not only interact in vitro, but also in vivo during vulval development. Furthermore, co-localization 
of DEP-1 with both LET-23 and PAT-3 is observed in similar subcellular regions, namely in intracellular 
punctae as well as at the membrane, suggesting that all three transmembrane protein might interact 
with each other in a complex inside the cells. However, this hypothesis remains to be elucidated. 
In addition, the examination of the expression pattern of PAT-3::GFP indicates that DEP-1 not only 
activates PAT-3, but also might regulate its subcellular localization. While PAT-3::GFP expression is 
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normaly seen at the basolateral side of the VPCs, loss off dep-1 enhances apical accumulation of PAT-
3::GFP, suggesting induced endocytosis of PAT-3 in dep-1(lf) mutants. We have to admit that these 
changes in subcellular localization are very weak and due to the limits of optical resolution we have not 
yet been able to quantify these changes. 
However, it is known that integrins are constantly internalized and recycled back to the plasma mem-
brane in most cell types (Pellinen, 2006) to control integrin-dependent cell adhesion, spreading and 
migration, as well as cancer cell invasion (Margadant et al., 2011). Both clathrin-mediated endocytosis 
and clathrin-independent internalization of integrins have been demonstrated for integrins. 
The NPxY motifs are canonical signals for clathrin-mediated endocytosis of various surface receptors 
(Ohno et al., 1995), and several observations suggest that they are also involved in the regulation of 
integrin endocytosis. First, the β3-endonexin-mediated internalization of ligand-bound integrins is im-
paired when Y is substituted to A in the membrane proximal NPxY motif. Second, F to A substitutions 
in either one of the NPxY motifs of β2 integrins compromises their endocytosis. And third, clathrin-
dependent integrin endocytosis in fibroblasts is reduced when Y is mutated to F in both NPxY motifs 
(Pellinen et al., 2008). 
Nevertheless, the exact pathways involved in the endocytosis of integrins are not clearly known and 
seem to vary between integrin heterodimers (Ramsay et al., 2007; Upla et al., 2004). Moreover, it re-
mains unclear how the individual NPxY motifs regulate integrin trafficking, and through which pro-
teins this is achieved. 
Several studies based on cell-culture experiments investigated the manifold functions of integrins and 
DEP-1, and showed that both seem to participate in a large number of protein-protein interactions. 
However, only some of these interactions have been observed in vitro, and the lack of in vivo confirma-
tion makes it difficult to estimate the physiological relevance of many observations (Ivaska and Heino, 
2011). 
Our data describe a novel connection between integrins and RAS/MAPK, which both are of central 
importance during developmental processes and cancer formation. Moreover, our results established 
vulval development as a system to study the role of integrin activity during developmental processes, 
and to analyze the connection to the RAS/MAPK signaling pathway in vivo. 
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3.1.9 Proteins identified by GST::DEP-1 pull-down experiments and MS/MS analyses
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pat-2 P34446 Integrin alpha pat-2 (Paralyzed arrest at two-fold protein 2) 4 0 0 43 33 23 0 0 0 58.8
pat-3 Q27874 Integrin beta pat-3 (Paralyzed arrest at two-fold protein 3) 0 0 0 29 18 7 0 0 0 42
nid-1 C7FZU3 Protein F54F3.1b, partially confirmed by transcript evidence 2 2 0 25 16 0 0 0 0 63.8
prp-8 P34369 Pre-mRNA-splicing factor 8 homolog 0 3 0 12 16 0 0 0 0 65.6
rps-6 Q9NEN6 40S ribosomal protein S6 0 10 7 8 15 8 0 0 0 2440
K12D12.1 Q23670 Probable DNA topoisomerase 2 0 2 0 8 9 0 0 0 0 111
puf-12 Q09622 Pumilio domain-containing protein 12 0 0 2 7 5 0 0 0 0 107
vit-4 P18947 Vitellogenin-4 0 0 0 7 4 2 0 0 0 570
apl-1 Q10651 Beta-amyloid-like protein 0 0 0 6 5 0 0 0 0 8.26
F08D12.1 P91240 Signal recognition particle 72 kDa protein homolog 0 0 0 6 0 0 0 0 0 134
rpl-16 Q27389 60S ribosomal protein L13a 9 5 0 5 9 5 0 0 0 2404
eft-1 Q23463 Elongation factor protein 1, confirmed by transcript evidence 0 0 5 5 5 4 0 0 0 70.8
avr-15 Q95PJ6 Protein R11G10.1b, confirmed by transcript evidence 0 0 0 4 2 0 0 0 0 4.21
mcm-5 Q21902 DNA replication licensing factor mcm-5 2 0 2 4 0 3 0 0 0 69.5
C13B9.3 Q09236 Probable coatomer subunit delta (Delta-coat protein) 2 2 0 4 0 0 0 0 0 164
eif-3 O02328 Eukaryotic translation initiation factor 3 subunit C 0 0 0 4 0 0 0 0 0 169
kin-19 P42168 Casein kinase I isoform alpha 0 0 0 4 0 0 0 0 0 160
sym-1 Q93374 Protein C44H4.3 0 0 0 4 0 0 0 0 0 52.2
Q95XR0 Q95XR0 Putative uncharacterized protein 2 0 0 3 5 2 0 0 0 289
pro-3 Q9NEU2 Protein SDA1 homolog 0 0 2 3 3 2 0 0 0 24.6
mrs-1 Q20970 Methionyl-tRNA synthetase, cytoplasmic 0 0 0 3 2 2 0 0 0 120
F58G11.2 P90897 Putative uncharacterized protein F58G11.2 0 0 5 3 0 0 0 0 0 74.9
cnx-1 P34652 Calnexin homolog 0 0 0 3 0 0 0 0 0 72.6
F14B4.3 Q27493 Protein F14B4.3, partially confirmed by transcript evidence 0 0 0 3 0 0 0 0 0 31.7
math-33 O45623 Protein H19N07.2a, confirmed by transcript evidence 0 0 0 3 0 0 0 0 0 71.3
ngp-1 Q56VZ2 Protein T19A6.2c, confirmed by transcript evidence 0 0 0 3 0 0 0 0 0 63.3 
T05E11.3 Q22235 Protein T05E11.3a, confirmed by transcript evidence 0 0 0 3 0 0 0 0 0 448
rpl-11.2 Q19162 Ribosomal protein, large subunit protein 11.2 4 4 5 2 5 3 0 0 0 808
car-1 Q9XW17 Protein Y18D10A.17, confirmed by transcript evidence 3 0 3 2 3 3 0 0 0 524
C18B2.3 Q18074 Putative uncharacterized protein 2 3 0 2 3 2 0 0 0 153
rpt-2 O16368 Probable 26S protease regulatory subunit 4 0 2 0 2 2 0 0 0 0 535
K04C2.2 Q21210 Putative uncharacterized protein 0 0 0 2 2 0 0 0 0 65.5
his-24 P10771 Histone H1.1 0 0 0 2 0 2 0 0 0 596
rsp-1 Q23121 Probable splicing factor, arginine/serine-rich 1 (CeSRp75) (RNA-binding protein srp-5) 0 0 2 2 0 0 0 0 0 199
abcf-3 Q20306 Putative uncharacterized protein 0 0 0 2 0 0 0 0 0 96
ama-1 P16356 DNA-directed RNA polymerase II subunit RPB1 (RNA polymerase II subunit B1) 0 0 0 2 0 0 0 0 0 66.1
npp-13 Q9BKT9 Nuclear pore complex protein protein 13, isoform a 0 0 0 2 0 0 0 0 0 102
nsf-1 Q09EE7 Protein H15N14.2b, confirmed by transcript evidence 0 0 0 2 0 0 0 0 0 90.8
nst-1 Q21086 Guanine nucleotide-binding protein-like 3 homolog (Nucleostemin-1) 0 0 0 2 0 0 0 0 0 108
pgl-1 Q304E5 P granule abnormality protein 1, isoform b 0 0 0 2 0 0 0 0 0 97.2
rpb-2 Q10578 RNA polymerase II subunit B2 0 0 0 2 0 0 0 0 0 59.4
tps-2 O45380 Trehalose-6-phosphate synthase 2 0 0 0 2 0 0 0 0 0 27.2
unc-54 Q09981 UNC-45 0 0 0 2 0 0 0 0 0 2658
ZK550.3 O62512 Protein ZK550.3, partially confirmed by transcript evidence 0 0 0 2 0 0 0 0 0 40
Y37E3.8 Q9BKU5 Putative uncharacterized protein 0 4 3 0 5 0 0 0 0 2162
Y62H9A.6 Q9XWT3 Protein Y62H9A.6, confirmed by transcript evidence 0 0 2 0 3 0 0 0 0 565
Y54G2A.2 Y54G2A.2 Protein Y54G2A 0 0 0 0 3 0 0 0 0
ivd-1 O44446 Isovaleryl-CoA dehydrogenase ivd-1 0 0 0 0 2 2 0 0 0 389
rps-5 P49041 40S ribosomal protein S5 4 4 3 0 2 0 0 0 0 1535
F55A12.5 O01756 Putative uncharacterized protein 3 0 0 0 2 0 0 0 0 28.3
rpl-15 P91374 60S ribosomal protein L15 0 5 0 0 2 0 0 0 0 2131
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F44E5.1 Q9XU97 Protein F44E5.1, confirmed by transcript evidence 0 0 0 0 2 0 0 0 0 709
F45H10.2 O45525 Protein F45H10.2, confirmed by transcript evidence 0 0 0 0 2 0 0 0 0 271
F46F11.1 P91309 Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 0 0 0 0 2 0 0 0 0 18.6
imb-4 Q23089 Importin beta family protein 4, isoform a 0 0 0 0 2 0 0 0 0 46.7
R09F10.8 Q23031 Putative uncharacterized protein 0 0 0 0 2 0 0 0 0 8.03
rpl-38 O17570 60S ribosomal protein L38 0 0 0 0 2 0 0 0 0 1169
plp-1 Q94230 Pur alpha like protein protein 1, confirmed by transcript evidence 0 0 0 0 0 4 0 0 0 468
cey-1 O62213 Protein F33A8.3, confirmed by transcript evidence 0 0 0 0 0 3 0 0 0 1132
K01G5.5 O17919 Putative H/ACA ribonucleoprotein complex subunit 4 0 0 0 0 0 3 0 0 0 245
ret-1 A5JYU4 Protein W06A7.3f 0 0 0 0 0 3 0 0 0 69.1
Y62H9A.3 Q9XWT5 Protein Y62H9A.3, confirmed by transcript evidence 0 0 0 0 0 3 0 0 0 12.9
cdc-48.1 P54811 Transitional endoplasmic reticulum ATPase homolog 1 3 0 3 0 0 2 0 0 0 436
rab-11.1 O01803 Rab family protein 11.1 2 3 0 0 0 2 0 0 0 226
C46G7.2 O02141 Putative uncharacterized protein 0 3 0 0 0 2 0 0 0 211
ran-1 O17915 GTP-binding nuclear protein ran-1 (Ras-related nuclear protein 1) 0 2 0 0 0 2 0 0 0 831
sqd-1 Q8MXR6 Homologous to drosophila sqd (Squid) protein protein 1 0 2 0 0 0 2 0 0 0 1530
C05G5.4 P53596 Succinyl-CoA synthetase subunit alpha 0 0 0 0 0 2 0 0 0 1365
C10G11.7 P91027 Putative uncharacterized protein 0 0 0 0 0 2 0 0 0 547
imp-2 P49049 Intramembrane protease 2 0 0 0 0 0 2 0 0 0 76.7
R04D3.3  Q21713 Protein R04D3.3 , partially confirmed by transcript evidence 0 0 0 0 0 2 0 0 0 1.15
rpt-5 O76371 Proteasome regulatory particle, atpase-like protein 5 0 0 0 0 0 2 0 0 0 834
let-711 Q20937 Lethal protein 711, partially confirmed by transcript evidence 2 2 0 0 0 0 0 0 0 26.9
tag-18 Q22508 Temporarily assigned gene name protein 18 2 2 0 0 0 0 0 0 0 131
asp-1 Q9TVS4 Aspartic protease 1 2 0 0 0 0 0 0 0 0 1290
cey-2 P91306 Y-box protein 2, confirmed by transcript evidence 2 0 0 0 0 0 0 0 0 490
cox-2 P24894 Cytochrome c oxidase subunit 2 2 0 0 0 0 0 0 0 0 74.2
D2045.2 Q18983 Protein D2045.2, partially confirmed by transcript evidence 2 0 0 0 0 0 0 0 0 37.2
npp-8 Q95Y15 Nuclear pore complex protein protein 8, isoform b 2 0 0 0 0 0 0 0 0 21.8
pat-4 Q9TZC4 Paralysed arrest at two-fold protein 4, confirmed by transcript evidence 2 0 0 0 0 0 0 0 0 67
R13H4.2 A5Z2W3 Protein R13H4.2a, confirmed by transcript evidence 2 0 0 0 0 0 0 0 0 35.1
rps-30 Q18231 Ribosomal protein, small subunit protein 30, confirmed by transcript evidence 0 2 2 0 0 0 0 0 0 154
larp-1 D5MCN1 Larp (Rna binding la related protein) homolog protein 1 0 2 0 0 0 0 0 0 0 304
dpy-11 Q9UAV4 Dumpy : shorter than wild-type protein 11 0 2 0 0 0 0 0 0 0 135
F25H2.2 Q93566 Protein F25H2.2, confirmed by transcript evidence 0 2 0 0 0 0 0 0 0 1.91
F55C5.8 Q20822 Probable signal recognition particle 68 kDa protein (SRP68) 0 2 0 0 0 0 0 0 0 106
gfi-1 Q94246 Gei-4(Four) interacting protein protein 1 0 2 0 0 0 0 0 0 0 60.9
his-2 P08898 Histone H3 0 2 0 0 0 0 0 0 0 187
ift-74 Q18106 Ift (Chlamydomonas intraflagellar transport) homolog protein 74 0 2 0 0 0 0 0 0 0
K07H8.10 O45181 Putative uncharacterized protein 0 2 0 0 0 0 0 0 0 230
rop-1 Q27274 60 kDa SS-A/Ro ribonucleoprotein homolog 0 2 0 0 0 0 0 0 0 74.8
dhs-3 A5JYX4 Protein T02E1.5a, confirmed by transcript evidence 0 0 2 0 0 0 0 0 0 104
F23B12.4 A8WHS3 Protein F23B12.4a, confirmed by transcript evidence 0 0 2 0 0 0 0 0 0 10.2
kin-3 P18334 Casein kinase II subunit alpha 0 0 2 0 0 0 0 0 0 220
mcm-7 O16297 Yeast mcm (Licensing factor) related protein 7 0 0 2 0 0 0 0 0 0 39.1
tag-174 Q20779 Probable cytochrome c oxidase subunit 6A 0 0 2 0 0 0 0 0 0 379
tba-4 Q20409 Protein F44F4.11, partially confirmed by transcript evidence 0 0 2 0 0 0 0 0 0 426
ubl-1 P37165 Ubiquitin-like protein 1-40S ribosomal protein S27a 0 0 2 0 0 0 0 0 0 592
atp-3 P91283 Atp synthase subunit protein 3, isoform a, confirmed by transcript evidence 6 6 6 0 2 9 0 0 2 1538
trap-3 Q95XS1 Translocon-associated protein protein 3, confirmed by transcript evidence 0 0 0 0 0 0 0 0 2 295
rpl-10 Q09533 60S ribosomal protein L10 (QM protein homolog) 10 12 9 12 11 9 0 2 0 2038
Y25C1A.5 Q9TYL9 Coatomer subunit beta (Beta-coat protein) 0 0 4 7 3 5 0 2 0 127
eif-3.B Q9XWI6 Eukaryotic translation initiation factor 3 subunit B (eIF3b) 0 0 2 6 0 3 0 2 0 100
egl-45 P34339 Egg-laying defective protein 45 (Eukaryotic translation initiation factor 3 subunit 10) 2 2 0 4 0 3 0 2 0 208
alg-1 B6VQ75 Protein F48F7.1b 0 0 4 3 2 2 0 2 0 72.5
Y59A8A.3 Q9GRZ9 Protein Y59A8A.3, confirmed by transcript evidence 0 0 2 3 0 4 0 2 0 362
rps-24 Q1XFY9 Ribosomal protein, small subunit protein 24 0 3 6 2 4 5 0 2 0 2060
lmp-1 Q11117 LAMP family protein lmp-1 2 2 2 2 0 0 0 2 0 139
imb-5 Q965V4 Importin beta family protein 5 0 0 4 2 0 0 0 2 0 45.7
dnj-29 Q9U1V9 Protein Y63D3A.6b, confirmed by transcript evidence 0 0 0 2 0 0 0 2 0 73.6
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npp-9 Q21021 Protein F59A2.1a, confirmed by transcript evidence 0 0 0 2 0 0 0 2 0 217
rskn-2 Q18846 PRibosomal protein S6 kinase alpha-5 homolog 0 0 0 2 0 0 0 2 0 45.8
spl-1 Q9Y194 Sphingosine-1-phosphate aldolase 0 0 0 2 0 0 0 2 0 95.9
rpl-32 Q22716 Protein T24B8.1a, confirmed by transcript evidence 2 0 2 0 3 3 0 2 0 2363
rps-27 Q9TXP0 40S ribosomal protein S27 0 0 0 0 2 2 0 2 0 191
unc-116 P34540 Kinesin heavy chain (Uncoordinated protein 116) 0 3 2 0 2 0 0 2 0 179
rpl-25.1 P48162 60S ribosomal protein L23a 1 0 0 0 0 2 0 0 2 0 1316
tba-3 P91910 Tubulin alpha-3 chain (Mechanosensory abnormality protein 12) 0 0 0 0 2 0 0 2 0
prmt-1 Q9U2X0 Protein Y113G7B.17, confirmed by transcript evidence 2 0 0 0 0 0 0 2 0 446
Y57G11C O18239 Putative uncharacterized protein Y57G11C.15 2 0 0 0 0 0 0 2 0 190
nuo-1 Q17880 Protein C09H10.3, confirmed by transcript evidence 0 2 2 0 0 0 0 2 0 249
gst-16 Q93698 Protein F37B1.5, partially confirmed by transcript evidence 0 2 0 0 0 0 0 2 0 24.4
rla-2 Q9U1X9 Protein Y62E10A.1, confirmed by transcript evidence 0 0 2 0 0 0 0 2 0 5637
Y67H2A.5 Q95PZ1 Protein Y67H2A.5, confirmed by transcript evidence 0 0 2 0 0 0 0 2 0 670
acdh-11 Q3T978 Protein Y45F3A.3b, confirmed by transcript evidence 0 0 0 0 0 0 0 2 0 68.6
acs-11 Q20264 Fatty acid coa synthetase family protein 11, partially confirmed by transcript evidence 0 0 0 0 0 0 0 2 0 294
acs-5 Q9XWD1 Protein Y76A2B.3, confirmed by transcript evidence 0 0 0 0 0 0 0 2 0 83.7
arp-1 Q9NA98 Protein Y53F4B.22, confirmed by transcript evidence 0 0 0 0 0 0 0 2 0 202
C34F11.3 D7SFL2 Putative uncharacterized protein 0 0 0 0 0 0 0 2 0 170
clp-1 P34308 Calpain clp-1 0 0 0 0 0 0 0 2 0 203
D1005.1 P53585 Probable ATP-citrate synthase 0 0 0 0 0 0 0 2 0 152
dpf-3 O44987 Dipeptidyl peptidase four (Iv) family protein 3 0 0 0 0 0 0 0 2 0 40.1
emb-8 Q09590 NADPH--cytochrome P450 reductase 0 0 0 0 0 0 0 2 0 75.9
F07A11.2 Q19130 Protein F07A11.2a, confirmed by transcript evidence 0 0 0 0 0 0 0 2 0 22.6
gsk-3 Q9U2Q9 Glycogen synthase kinase-3 0 0 0 0 0 0 0 2 0 177
gsnl-1 Q21253 Gelsolin-like protein 1 0 0 0 0 0 0 0 2 0 136
gsp-1 Q27497 Serine/threonine-protein phosphatase PP1-alpha 0 0 0 0 0 0 0 2 0 202
H03A11.2 Q9XTW1 Protein H03A11.2, partially confirmed by transcript evidence 0 0 0 0 0 0 0 2 0 48.1
haf-4 Q9TZD9 Half transporter (Pgp related) protein 4 0 0 0 0 0 0 0 2 0 56.1
hpo-29 Q8WTL6 Putative uncharacterized protein 0 0 0 0 0 0 0 2 0
immt-1 Q22505 Putative uncharacterized protein 0 0 0 0 0 0 0 2 0 294
nduf-5 Q9N3D9 Putative uncharacterized protein 0 0 0 0 0 0 0 2 0 453
npl-4.2 O01894 Putative uncharacterized protein 0 0 0 0 0 0 0 2 0 37.2
pod-2 Q9GZI3 Polarity and osmotic sensitivity defect protein 2, isoform a 0 0 0 0 0 0 0 2 0 57.6
ppw-1 O02095 Paz/piwi domain-containing protein 1 0 0 0 0 0 0 0 2 0 34.9
ppw-2 Q9N585 Paz/piwi domain-containing protein 2 0 0 0 0 0 0 0 2 0 29.4
R02D3.1 O44503 Putative uncharacterized protein R02D3.1 0 0 0 0 0 0 0 2 0 179
ran-3 Q18211 Regulator of chromosome condensation (RCC1 homolog) 0 0 0 0 0 0 0 2 0 182
rpn-5 Q19324 Proteasome regulatory particle, non-atpase-like protein 5 0 0 0 0 0 0 0 2 0 223
tag-320 Q11067 Probable protein disulfide-isomerase A6 0 0 0 0 0 0 0 2 0 415
tba-1 O18688 Protein F26E4.8, confirmed by transcript evidence 0 0 0 0 0 0 0 2 0 573
ttr-2 P34500 Transthyretin-like protein 2 0 0 0 0 0 0 0 2 0 364
ttr-24 Q9XXR4 Protein Y51A2D.9, confirmed by transcript evidence 0 0 0 0 0 0 0 2 0 119
Y71H10B.1 Q86MI3 Putative uncharacterized protein 0 0 0 0 0 0 0 2 0 74
Y71H2AR.1 Q9BL27 Putative uncharacterized protein 0 0 0 0 0 0 0 2 0 184
ZK669.4 Q23571 Protein ZK669.4, confirmed by transcript evidence 0 0 0 0 0 0 0 2 0 174
ZK829.7 Q23624 Protein ZK829.7, confirmed by transcript evidence 0 0 0 0 0 0 0 2 0 175
ZK836.2 Q23629 Probable 2-oxoglutarate dehydrogenase E1 component DHKTD1 homolog 0 0 0 0 0 0 0 2 0 117
cyp-25a5 O44485 Cytochrome p450 family protein 25A5 0 0 0 0 0 0 0 2 0
rps-25 P52821 40S ribosomal protein S25 2 2 6 2 5 6 0 2 2 2175
B0303.3  P34255 Uncharacterized protein B0303.3  0 0 3 2 4 3 0 2 2 426
rpl-31 Q9U332 60S ribosomal protein L31 0 0 3 0 2 2 0 2 2 864
nduf-7 Q94360 NADH-ubiquinone oxidoreductase 20 kDa subunit 0 0 0 0 0 0 0 2 2
Y71F9AL.17 Q9N4H7 Putative uncharacterized protein 4 0 0 10 4 5 0 3 0 145
T22D1.4 Q9GZH4 Putative uncharacterized protein 0 3 2 2 0 0 0 3 0 198
rpl-35 P34662 60S ribosomal protein L35 0 3 3 0 2 2 0 3 0 4176
let-805 Q9UB28 Myotactin form B 0 0 0 0 2 0 0 3 0 87.1
alh-12 Q7Z1Q2 Aldehyde dehydrogenase protein 12, isoform b 0 0 0 0 0 0 0 3 0 391
apb-1 Q9N4F3 APB-1 protein, isoform a 0 0 0 0 0 0 0 3 0 122
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C32F10.8 O01685 Putative uncharacterized protein C32F10.8 0 0 0 0 0 0 0 3 0 417
C41G7.9 B3WFW9 Protein C41G7.9a, confirmed by transcript evidence 0 0 0 0 0 0 0 3 0 277
drp-1 Q8WQC9 Dynamin related protein protein 1, isoform b 0 0 0 0 0 0 0 3 0 76.2
F42G9.1 P49595 Probable protein phosphatase 2C F42G9.1 0 0 0 0 0 0 0 3 0 137
F52E4.5 Q20675 Putative uncharacterized protein 0 0 0 0 0 0 0 3 0 131
glh-1 P34689 ATP-dependent RNA helicase glh-1 0 0 0 0 0 0 0 3 0 119
H19N07.1 O45622 Protein H19N07.1a, confirmed by transcript evidence 0 0 0 0 0 0 0 3 0 176
haf-9 O44897 Half transporter (Pgp related) protein 9, isoform a 0 0 0 0 0 0 0 3 0 74.2
M106.4 Q09580 Glutamine amidotransferase 0 0 0 0 0 0 0 3 0 98.7
mvk-1 Q9N4Z7 Putative uncharacterized protein 0 0 0 0 0 0 0 3 0
oig-2 Q9XWM1 Protein Y38F1A.9, partially confirmed by transcript evidence 0 0 0 0 0 0 0 3 0 179
pdi-3 O17908 CeERp57 0 0 0 0 0 0 0 3 0 1362
R06C7.1 Q21770 Germ cell-expressed protein R06C7.1 0 0 0 0 0 0 0 3 0 42.2
rnr-1 Q03604 Ribonucleotide reductase large subunit 0 0 0 0 0 0 0 3 0 69.1
rps-21 P49197 40S ribosomal protein S21 0 0 0 0 0 0 0 3 0 2616
T20B3.1 Q9XUN8 Protein T20B3.1, confirmed by transcript evidence 0 0 0 0 0 0 0 3 0 49.2
tax-6 Q0G819 Protein C02F4.2c, partially confirmed by transcript evidence 0 0 0 0 0 0 0 3 0 101
Y67D2.3 Q9BKQ9 Putative uncharacterized protein 0 0 0 0 0 0 0 3 0 262
fbp-1 Q9N2M2 Fructose-1,6-biphosphatase protein 1 3 0 4 2 0 3 0 3 2 690
rpn-3 Q04908 26S proteasome regulatory subunit rpn-3 0 0 0 2 0 2 0 3 2 306
F38E11.5 Q20168 Probable coatomer subunit beta’ (Beta’-coat protein)) 2 0 3 6 0 5 0 3 3 217
F59C6.5 Q93831 Protein F59C6.5, confirmed by transcript evidence 0 0 0 0 0 0 0 3 3 405
vit-1 P55155 Vitellogenin-1 7 4 7 39 30 13 0 4 0 715
abcf-2 Q9XTD9 Protein T27E9.7, confirmed by transcript evidence 2 2 0 3 0 0 0 4 0 112
Y46G5A.4 Q9U2G0 Putative U5 small nuclear ribonucleoprotein 200 kDa helicase (EC 3.6.4.13) 0 5 0 2 3 0 0 4 0 56.4
ears-1 Q23315 Protein ZC434.5, confirmed by transcript evidence 2 0 0 2 2 3 0 4 0
pyr-1 Q18990 Protein D2085.1, partially confirmed by transcript evidence 0 2 0 2 0 0 0 4 0 103
crt-1 P27798 Calreticulin 0 2 0 0 2 0 0 4 0 3113
nmt-1 P46548 Myristoyl-CoA:protein N-myristoyltransferase 2 3 0 0 0 0 0 4 0 163
msp-10 P05634 Major sperm protein 10/36/56/76 (MSP) 0 2 2 0 0 0 0 4 0 56.8
rpl-36 P49181 60S ribosomal protein L36 0 0 3 0 0 0 0 4 0 1493
cyn-15 Q9U1Q3 Protein Y87G2A.6, confirmed by transcript evidence 0 0 0 0 0 0 0 4 0 47.1
F55H12.4 P90889 Protein F55H12.4, confirmed by transcript evidence 0 0 0 0 0 0 0 4 0 72.9
iff-2 Q20751 Eukaryotic translation initiation factor 5A-2 0 0 0 0 0 0 0 4 0 643
lrp-1 Q04833 Low-density lipoprotein receptor-related protein (LRP) 0 0 0 0 0 0 0 4 0 16.1
T04A8.7 Q22137 Protein T04A8.7a, confirmed by transcript evidence 0 0 0 0 0 0 0 4 0 143
ZC416.6 O44183 Putative uncharacterized protein ZC416.6 0 0 0 0 0 0 0 4 0 16.5
egl-4 O76360 cGMP-dependent protein kinase egl-4 3 2 3 8 4 2 0 5 0 113
ars-2 O01541 Alanyl-tRNA synthetase, cytoplasmic 2 2 2 5 2 0 0 5 0 292
alh-3 Q19428 Protein F36H1.6, confirmed by transcript evidence 0 0 0 4 0 0 0 5 0 412
R05F9.6 Q21742 Putative uncharacterized protein 4 3 0 3 0 2 0 5 0 378
ddb-1 Q21554 DNA damage-binding protein 1 2 0 0 0 2 0 0 5 0 32.1
grs-1 Q10039 Glycyl-tRNA synthetase 0 2 0 0 0 0 0 5 0 344
fars-1 Q86B36 Phenylalanyl amino-acyl trna synthetase protein 1, isoform b 0 0 0 0 0 0 0 5 0
pars-1 Q22620 Prolyl trna synthetase protein 1, isoform a 0 0 0 0 0 0 0 5 0
spc-1 Q21408 Spectrin protein 1 0 0 0 0 0 0 0 5 0 295
unc-18 P34815 Putative acetylcholine regulator unc-18 0 0 0 0 0 0 0 5 0 65
unc-22 D3YT57 unc-22 0 0 0 0 0 0 0 5 0 132
unc-70 E0AHA7 Uncoordinated protein 70, isoform c 0 0 0 0 0 0 0 5 0 181
unc-89 O01761 Muscle M-line assembly protein unc-89 0 0 0 0 0 0 0 5 0 64.7
W09C5.8 Q9U329 Protein W09C5.8, confirmed by transcript evidence 0 0 2 0 0 0 0 5 2 354
uba-1 C1P636 Protein C47E12.5c, confirmed by transcript evidence 5 5 0 4 0 2 0 6 0 335
eel-1 Q9GUP2 Enhancer of efl-1 mutant phenotype protein 1 0 0 0 0 0 0 0 6 0 42.1
gspd-1 Q27464 Glucose-6-phosphate 1-dehydrogenase 0 0 0 0 0 0 0 6 0 123
vrs-2 Q9U1Q4 Valyl-tRNA synthetase 4 0 3 8 0 2 0 7 0 209
tsn-1 Q19328 Tudor staphylococcal nuclease homolog protein 1 4 0 6 4 2 7 0 7 0 697
gsy-1 Q9U2D9 Probable glycogen [starch] synthase 0 2 0 4 0 0 0 7 0 223
lev-11 Q22866 Tropomyosin isoforms a/b/d/f (Levamisole resistant protein 11) 13 7 0 7 0 4 0 8 8 7575
npp-12 P91495 Nuclear pore complex protein protein 12 2 0 0 0 0 0 0 10 0 51.6
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The C. elegans β-Integrin PAT-3 is a substrate of the tyrosine phosphatase DEP-1 
ketn-1 A7DT47 Kettin (Drosophila actin-binding) homolog protein 1 0 0 0 0 0 0 0 13 0 134
nmy-1 Q20641 Non-muscle myosin protein 1 0 0 0 2 0 0 0 17 2 114
fasn-1 P91871 Protein F32H2.5, partially confirmed by transcript evidence 9 7 0 12 8 0 0 21 0 147
dhc-1 Q19020 Dynein heavy chain, cytoplasmic (Dynein heavy chain, cytosolic) (DYHC) 0 8 0 0 4 0 0 29 0 65.1
gcn-1 B3CJ34 Putative uncharacterized protein 16 14 0 20 21 0 0 42 0 75.2
T08G11.1 Q8T3D2 Protein T08G11.1b, partially confirmed by transcript evidence 0 2 0 0 0 0 0 55 0 69.1
clu-1 P34466 Protein KIAA0664 homolog 2 3 3 7 4 5 2 0 0 116
F54F11.2 B6VQ96 Protein F54F11.2b, partially confirmed by transcript evidence 0 0 0 3 0 0 2 0 0 127
got-2 Q17994 Aspartate aminotransferase 2 0 2 2 0 0 2 0 0
asp-4 Q21966 Protein R12H7.2, confirmed by transcript evidence 2 0 0 2 0 0 2 0 0 588
tag-241 D3KFS7 Protein C34E11.3a 0 0 0 2 0 0 2 0 0
rpl-37a Q9U2A8 60S ribosomal protein L37a 0 0 3 0 3 0 2 0 0 83.8
rpl-26 Q19869 60S ribosomal protein L26 0 5 3 0 2 0 2 0 0 1712
aldo-2 P46563 Fructose-bisphosphate aldolase 2 2 0 0 0 0 2 2 0 0 2697
Y53G8AL.2 Q9N3H3 Putative uncharacterized protein 0 0 0 0 0 2 2 0 0 285
F44G3.2 O45518 Protein F44G3.2, confirmed by transcript evidence 5 0 4 0 0 0 2 0 0 96.6
goa-1 P51875 Guanine nucleotide-binding protein G(o) subunit alpha 2 0 2 0 0 0 2 0 0 115
F23B12.5 Q19749 Pyruvate dehydrogenase complex component E2 2 0 0 0 0 0 2 0 0 593
sdz-8 P90780 Protein C55A6.5, partially confirmed by transcript evidence 2 0 0 0 0 0 2 0 0 144
sod-2 P31161 Superoxide dismutase 0 3 0 0 0 0 2 0 0 210
R09B3.3  O45713 Protein R09B3.3 , confirmed by transcript evidence 0 0 2 0 0 0 2 0 0 5025
bre-1 Q18801 GDP-mannose 4,6 dehydratase 1 0 0 0 0 0 0 2 0 0 2.11
C24A3.2 Q18124 Putative uncharacterized protein 0 0 0 0 0 0 2 0 0 35.1
cyn-7 P52015 Peptidyl-prolyl cis-trans isomerase 7 0 0 0 0 0 0 2 0 0 2407
cyt-1 P41956 Succinate dehydrogenase cytochrome b560 subunit, mitochondrial 0 0 0 0 0 0 2 0 0
eif-3 O61820 Eukaryotic translation initiation factor 3 subunit E 0 0 0 0 0 0 2 0 0 174
F32A7.5 P91859 Protein F32A7.5a, partially confirmed by transcript evidence 0 0 0 0 0 0 2 0 0 229
let-70 P35129 Ubiquitin-conjugating enzyme E2 2 0 0 0 0 0 0 2 0 0 332
lpd-9 D5MCR9 Protein T21C9.5b, confirmed by transcript evidence 0 0 0 0 0 0 2 0 0 123
ndk-1 Q93576 Protein F25H2.5, confirmed by transcript evidence 0 0 0 0 0 0 2 0 0
srs-2 Q18678 Serine--tRNA ligase 0 0 0 0 0 0 2 0 0 300
T08H10.1 Q22352 Putative uncharacterized protein T08H10.1 0 0 0 0 0 0 2 0 0 296
ttr-41 Q86NH9 Putative uncharacterized protein 0 0 0 0 0 0 2 0 0 281
ubc-9 Q95017 Ubiquitin-conjugating enzyme E2 9 0 0 0 0 0 0 2 0 0 142
W09H1.5 O45903 Probable trans-2-enoyl-CoA reductase 1 0 0 0 0 0 0 2 0 0 71
rpl-17 Q9BL19 60S ribosomal protein L17 0 5 4 0 4 7 2 0 2 1932
hpo-18 O16298 Putative uncharacterized protein 0 0 0 0 2 0 2 0 2
pmt-2 Q22993 Putative uncharacterized protein 0 0 0 0 0 0 2 0 2 556
nra-4 Q8ITW0 Putative uncharacterized protein 2 3 0 5 0 2 2 2 0
lrs-1 Q09996 Leucyl-tRNA synthetase 0 3 0 3 0 2 2 2 0 161
csq-1 Q20203 Protein F40E10.3, confirmed by transcript evidence 0 0 0 2 0 0 2 2 0 250
cpl-1 O45734 Protein T03E6.7, confirmed by transcript evidence 2 4 0 0 3 5 2 2 0 589
ril-1 O17694 Protein C53A5.1, confirmed by transcript evidence 0 0 0 0 3 0 2 2 0 437
ZK1073.1 O02485 Uncharacterized protein ZK1073.1 0 0 0 0 0 2 2 2 0 212
his-11 P04255 Histone H2B 1 0 2 0 0 0 0 2 2 0 426
nrs-1 Q19722 Asparaginyl-tRNA synthetase 0 2 0 0 0 0 2 2 0 311
cct-5 P47209 T-complex protein 1 subunit epsilon 0 0 0 0 0 0 2 2 0 723
F45H10.3 O02267 Protein F45H10.3, confirmed by transcript evidence 0 0 0 0 0 0 2 2 0 436
hsp-4 P20163 Heat shock 70 kDa protein D 0 0 0 0 0 0 2 2 0 440
rrt-1 Q19825 Probable arginyl-tRNA synthetase 0 0 0 0 0 0 2 2 0 146
spg-7 Q9N3T5 Spg (Spastic paraplegia) protein 7 0 0 0 0 0 0 2 2 0 115
T20B12.7 P41847 Anamorsin homolog (Fe-S cluster assembly protein DRE2 homolog) 0 0 0 0 0 0 2 2 0 379
Y39B6A.3 A5HWB2 Protein Y39B6A.3b, confirmed by transcript evidence 0 0 0 0 0 0 2 2 0 9.24
T14G10.5 Q22498 Probable coatomer subunit gamma 4 4 2 4 3 4 2 2 2 158
F43E2.7 O02093 Putative uncharacterized protein F43E2.7 2 0 3 0 0 2 2 2 2 255
R53.4 Q22021 Putative ATP synthase subunit f, mitochondrial 0 3 3 0 3 2 2 2 3 386
mmcm-1 Q23381 MethylmalonylCoA mutase homolog 1 0 0 0 3 0 0 2 3 0 205
krs-1 Q22099 Lysyl-tRNA synthetase 0 0 0 2 0 0 2 3 0 280
par-5 P41932 14-3-3-like protein 1 (Partitioning defective protein 5) 3 3 0 0 0 2 2 3 0 1754
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C30F12.7 Q95YD8 Putative uncharacterized protein 3 0 0 0 0 0 2 3 0 175
rpa-2 O01504 60S acidic ribosomal protein P2 2 0 4 0 0 0 2 3 0 138
paa-1 Q09543 Protein phosphatase PP2A regulatory subunit A 0 4 0 0 0 0 2 3 0 432
K02F3.2 Q21153 Probable calcium-binding mitochondrial carrier K02F3.2 0 0 0 0 0 0 2 3 0 138
sqv-4 Q19905 UDP-glucose 6-dehydrogenase (Squashed vulva protein 4) 0 0 0 0 0 0 2 3 0 181
trap-4 Q9U238 Protein Y56A3A.21, confirmed by transcript evidence 0 0 0 0 0 0 2 3 0 360
trs-1 P52709 Threonyl-tRNA synthetase 0 0 0 0 0 0 2 3 0 165
F36A2.7 P90860 Protein F36A2.7, confirmed by transcript evidence 0 0 0 0 2 2 2 3 2 1020
asb-1 Q20053 Protein F35G12.10, confirmed by transcript evidence 0 3 0 0 0 2 2 3 2 138
vit-3 Q9N4J2 Vitellogenin-3 7 3 2 25 17 5 2 4 0 595
K07C5.4 Q21276 Uncharacterized NOP5 family protein K07C5.4 5 5 10 15 12 11 2 4 0 411
alh-13 P54889 Aldehyde dehydrogenase family 13 0 0 3 4 0 0 2 4 0 104
rpl-27 P91914 60S ribosomal protein L27 0 4 8 2 5 5 2 4 0 2873
ads-1 O45218 Alkyldihydroxyacetonephosphate synthase 2 0 2 0 0 0 2 4 0 128
R05H10.5 O62327 Probable glutathione peroxidase 0 0 0 0 0 0 2 4 0 236
hrp-2 Q9NLD1 Protein F58D5.1a, confirmed by transcript evidence 3 5 0 3 0 0 2 4 2 386
pab-1 Q9U302 Protein Y106G6H.2a, confirmed by transcript evidence 13 13 2 13 0 3 2 5 0 840
laf-1 Q4W5R4 Lethal and feminizing protein 1, confirmed by transcript evidence 8 15 2 12 0 4 2 5 0 171
cpt-1 Q9U2F2 Protein Y46G5A.17, confirmed by transcript evidence 0 0 6 6 0 2 2 5 0 51.3
rps-13 P51404 40S ribosomal protein S13 2 6 2 4 6 2 2 5 0 2561
gst-29 Q9NAB1 Protein Y53F4B.32, confirmed by transcript evidence 6 8 2 2 3 2 2 5 0 26.2
F58F9.7 Q20992 Acyl-coenzyme A oxidase 0 0 0 0 0 0 2 5 0 84.2
rps-17 O01692 40S ribosomal protein S17 2 4 4 0 4 3 2 5 2 3320
lec-3 Q09581 32 kDa beta-galactoside-binding lectin lec-3 0 0 0 0 0 0 2 6 0 419
nex-2 Q27512 Protein T07C4.9a, confirmed by transcript evidence 0 0 0 0 0 0 2 6 0 64.8
cgh-1 Q95YF3 ATP-dependent RNA helicase cgh-1 4 6 5 5 3 5 2 6 2 265
ers-1 O62431 Probable glutaminyl-tRNA synthetase 2 2 3 8 4 4 2 7 0 213
nol-5 O45012 Putative uncharacterized protein 2 4 8 5 2 8 2 7 0 353
C14C10.5 Q17971 Protein C14C10.5, partially confirmed by transcript evidence 0 0 0 0 0 0 2 7 0 42.5
cpt-2 Q17831 Protein R07H5.2a, confirmed by transcript evidence 0 0 0 0 0 0 2 7 0 136
pdi-2 Q17770 Protein disulfide-isomerase 2 0 0 0 0 0 0 2 7 0 3642
W06H3.3  Q9XXN1 Protein W06H3.3 , partially confirmed by transcript evidence 0 0 2 3 0 0 2 8 0 119
frs-2 Q19713 Phenylalanyl-tRNA synthetase beta chain 2 2 0 0 0 0 2 8 0 181
F20D6.11 Q19655 Putative uncharacterized protein 0 0 0 0 0 0 2 8 0 130
T23E7.2 O17338 Putative uncharacterized protein 3 4 0 9 4 2 3 0 0 397
cpn-3 O01542 Calponin protein 3 2 2 3 0 2 2 3 0 0 2021
F27D4.1 Q93615 Probable electron transfer flavoprotein subunit alpha 0 0 0 0 0 3 3 0 0 903
B0250.5 Q9XTI0 Probable 3-hydroxyisobutyrate dehydrogenase 0 0 0 0 0 2 3 0 0 262
mdt-28 A8WHP8 Protein W01A8.1c, confirmed by transcript evidence 0 0 2 0 0 0 3 0 0 258
C50F7.4 P53589 Succinyl-CoA synthetase beta chain 0 0 0 0 0 0 3 0 0 246
cpz-1 O01850 Cathepsin Z-like enzyme cpz-1 0 0 0 0 0 0 3 0 0 189
cts-1 P34575 Probable citrate synthase 0 0 0 0 0 0 3 0 0 1582
F32D1.5 O16294 Guanosine 5’-monophosphate oxidoreductase 0 0 0 0 0 0 3 0 0 434
iff-1 P34563 Eukaryotic translation initiation factor 5A-1 0 0 0 0 0 0 3 0 0 882
pfn-1 Q9XW16 Profilin-1 0 0 0 0 0 0 3 0 0 804
vha-14 P34462 V-type proton ATPase subunit D 0 0 0 0 0 0 3 0 0 476
rpl-10a Q9N4I4 60S ribosomal protein L10a 3 4 4 6 4 6 3 0 2 2038
rpl-20 O44480 60S ribosomal protein L18a 0 7 4 4 3 7 3 0 2 2610
acdh-3 O44549 Putative uncharacterized protein 5 2 3 4 0 3 3 2 0 705
his-1 P62784 Histone H4 0 2 3 2 2 0 3 2 0 681
rpt-3 P46502 Probable 26S protease regulatory subunit 6B 0 0 0 2 0 2 3 2 0 370
gst-23 P91505 Glutathione s-transferase protein 23, partially confirmed by transcript evidence 2 2 0 2 0 0 3 2 0 NA
rpl-25 Q20647 60S ribosomal protein L23a 2 0 6 4 0 4 3 3 2 0 2133
rpl-28 Q21930 60S ribosomal protein L28 3 2 3 0 3 2 3 2 0 2695
rps-28 Q95Y04 40S ribosomal protein S28 0 2 0 0 3 0 3 2 0 2729
gst-24 Q93694 Protein F37B1.1, confirmed by transcript evidence 0 4 0 0 2 0 3 2 0 47.2
rpa-1 P91913 60S acidic ribosomal protein P1 (Ribosomal protein large subunit P1) 3 0 0 0 0 3 3 2 0 139
gpdh-2 A7LPE6 Protein K11H3.1d, confirmed by transcript evidence 0 0 0 0 0 3 3 2 0 474
unc-87 P37806 Protein unc-87 (Uncoordinated protein 87) 0 2 0 0 0 2 3 2 0 626
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The C. elegans β-Integrin PAT-3 is a substrate of the tyrosine phosphatase DEP-1 
hgo-1 Q9Y041 Homogentisic acid oxidase 0 0 0 0 0 0 3 2 0 222
T12D8.10 Q69ZI6 Protein T12D8.10, confirmed by transcript evidence 0 0 0 0 0 0 3 2 0 263
gpb-1 P17343 Guanine nucleotide-binding protein subunit beta-1 0 0 0 0 0 2 3 2 2 345
acdh-10 Q22347 Probable medium-chain specific acyl-CoA dehydrogenase 10, 5 0 2 4 0 0 3 2 3 451
rpt-6 Q9XTT9 Protein Y49E10.1, confirmed by transcript evidence 0 0 0 2 2 0 3 3 0 282
R04F11.2 Q21732 Protein R04F11.2, confirmed by transcript evidence 0 0 4 0 2 2 3 3 0 1053
eif-3 Q95QW0 Eukaryotic translation initiation factor 3 subunit L (eIF3l) 2 0 2 0 0 0 3 3 0
rme-1 Q86S80 Receptor mediated endocytosis protein 1, isoform f 2 0 0 0 0 0 3 3 0 182
mbf-1 Q9XTV4 Protein H21P03.1, confirmed by transcript evidence 0 0 0 0 0 0 3 3 0 432
Y38F2AR.9 Q95XS2 Putative uncharacterized protein 0 0 0 0 0 0 3 3 0 53.5
rps-23 Q19877 40S ribosomal protein S23 2 2 4 3 5 4 3 3 2 2491
T09A5.11 P45971 Oligosaccharyl transferase 48 kDa subunit 3 3 4 2 2 3 3 3 2 177
rps-22 O17218 Ribosomal protein, small subunit protein 22, isoform a, 2 4 10 0 6 3 3 3 2 2759
rpl-23 P48158 60S ribosomal protein L23 0 2 6 2 4 4 3 3 3 2135
cand-1 Q9XTJ0 Protein Y102A5A.1, partially confirmed by transcript evidence 5 4 4 5 3 3 3 4 0 123
tag-203 O44985 Temporarily assigned gene name protein 203 0 0 0 3 0 0 3 4 0 75.7
ucr-2.2 Q22370 Protein T10B10.2, confirmed by transcript evidence 0 0 0 0 0 0 3 4 0 472
rpl-13 P91128 60S ribosomal protein L13 8 10 3 4 7 4 3 4 2 2209
rps-10 O01869 Ribosomal protein, small subunit protein 10 4 4 5 2 2 3 3 4 3 2017
alh-8 P52713 Malonate-semialdehyde dehydrogenase 2 4 2 3 2 3 3 5 0 1955
rpl-3 P50880 60S ribosomal protein L3 11 15 5 13 15 4 3 5 2 2393
sip-1 Q20363 Stress-induced protein 1 0 2 0 0 0 3 3 5 3 2326
drs-1 Q03577 Aspartyl-tRNA synthetase 5 0 6 4 2 6 3 6 0 255
cct-4 P47208 T-complex protein 1 subunit delta 0 0 0 0 0 0 3 6 0 857
acs-4 Q20121 Fatty acid coa synthetase family protein 4, confirmed by transcript evidence 4 2 4 9 0 5 3 6 2 148
cct-7 Q9TZS5 Chaperonin containing tcp-1 protein 7, isoform a, confirmed by transcript evidence 2 2 2 0 0 3 3 6 2 476
C28H8.3 Q09475 Uncharacterized helicase C28H8.3 3 2 3 6 0 2 3 7 0 87.2
R12C12.1 Q21962 Putative uncharacterized protein 0 0 3 5 3 2 3 7 0 210
sdhb-1 Q09545 Succinate dehydrogenase 0 3 0 0 0 0 3 7 0 340
R05D3.9 P34542 Uncharacterized protein R05D3.9 0 0 0 0 0 0 3 7 0 52.6
rps-18 O18240 Protein Y57G11C.16, confirmed by transcript evidence 2 7 6 3 6 4 3 7 3 4920
rpl-22 P52819 60S ribosomal protein L22 0 7 13 7 11 8 3 8 2 3299
rpn-1 Q9GZH5 Proteasome regulatory particle, non-atpase-like protein 1 3 2 9 11 5 5 3 9 5 255
nuo-5 Q9N4Y8 Nadh ubiquinone oxidoreductase protein 5, isoform a 2 4 5 10 2 7 3 12 3 540
W07E11.1 Q22275 Protein W07E11.1, partially confirmed by transcript evidence 2 5 0 0 0 0 3 18 2 111
myo-5 Q21‘000 Putative uncharacterized protein 4 3 0 3 0 0 3 19 2 141
vha-8 Q95X44 Vacuolar h atpase protein 8 3 4 0 3 0 3 4 0 0 1473
fmo-2 Q21310 Flavin monooxygenase 2 0 0 2 0 2 4 0 0 3.83
rpn-6 Q20938 Probable 26S proteasome regulatory subunit rpn-6.1 0 0 2 2 0 0 4 0 0 302
rpt-4 O17071 Proteasome regulatory particle ATPase-like protein 4 0 0 2 0 2 0 4 0 0 494
rpt-1 Q18787 Proteasome 26S subunit ATPase 2 0 0 0 0 0 0 4 0 0 322
C04C3.3  O44451 Pyruvate dehydrogenase E1 component subunit beta 3 2 0 4 0 3 4 0 2 499
fib-1 Q22053 rRNA 2’-O-methyltransferase fibrillarin 5 4 3 7 6 6 4 2 0 712
rab-1 Q9UAQ6 Rab family protein 1 4 5 0 3 0 4 4 2 0 758
W08E12.7 Q9N5B3 Putative uncharacterized protein 0 0 0 0 0 0 4 2 0 1063
rps-26 O45499 40S ribosomal protein S26 4 3 3 4 5 3 4 2 2 1335
rpl-19 O02639 60S ribosomal protein L19 9 6 4 4 12 5 4 3 0 3055
tag-210 P91917 Putative GTP-binding protein tag-210 3 0 3 0 0 4 4 3 0 476
rpl-14 Q9XVE9 Protein C04F12.4, confirmed by transcript evidence 0 5 5 4 5 4 4 3 2 3227
cco-2 P55954 Cytochrome c oxidase subunit 5A, mitochondrial (Cytochrome c oxidase polypeptide Va) 0 0 2 0 0 2 4 3 2 916
rps-7 Q23312 40S ribosomal protein S7 2 5 11 8 11 6 4 4 0 2334
tufm-1 Q19072 Elongation factor Tu 4 4 0 6 5 2 4 4 0 330
hsp-12.2 P34328 Heat shock protein Hsp-12.2 0 0 0 0 0 0 4 4 0 412
vig-1 O16646 Vig (Drosophila vasa intronic gene) ortholog protein 1 5 7 7 6 5 4 4 4 2 1843
ldh-1 Q27888 L-lactate dehydrogenase 4 6 0 6 2 6 4 4 2 279
let-767 C1P622 Lethal protein 767, isoform b, confirmed by transcript evidence 2 2 2 2 0 7 4 4 2 184
gst-6 P91252 Probable glutathione S-transferase 6 2 4 0 0 2 0 4 4 2 122
K08E3.5 Q69Z13 Protein K08E3.5f, confirmed by transcript evidence 0 0 0 0 0 0 4 4 2 345
T22F3.3  Q86NC1 Phosphorylase 6 3 3 9 7 2 4 5 0 970
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mca-3 Q95XP6 Putative uncharacterized protein 2 0 0 8 0 0 4 5 0 153
rps-2 P51403 40S ribosomal protein S2 2 9 8 4 7 3 4 5 0 2158
T25B9.9 Q17761 6-phosphogluconate dehydrogenase 0 4 0 2 0 0 4 5 0 557
rpn-2 Q18115 26S proteasome non-ATPase regulatory subunit 1 4 3 3 10 4 5 4 5 2 184
ucr-2.1 Q9BI61 Protein VW06B3R.1b, confirmed by transcript evidence 2 4 4 2 0 0 4 5 2 968
aldo-1 P54216 Fructose-bisphosphate aldolase 1 5 3 4 4 2 2 4 5 3 2067
hel-1 Q18212 Spliceosome RNA helicase DDX39B homolog 0 0 2 0 2 3 4 5 3 337
rpl-24.1 O01868 60S ribosomal protein L24 0 7 0 4 10 8 4 6 0 3526
tcp-1 P41988 T-complex protein 1 subunit alpha 0 4 4 2 2 0 4 6 0 472
rps-8 P48156 40S ribosomal protein S8 6 11 7 11 11 9 4 6 3 2237
rps-19 O18650 40S ribosomal protein S19 4 7 7 0 6 5 4 6 3 2483
F47B10.1 P53588 Succinyl-CoA synthetase beta-A chain 5 4 5 2 5 6 4 7 2 695
irs-1 Q21926 Isoleucyl-tRNA synthetase 4 2 3 9 0 3 4 8 0 122
cat-2 O61235 Catalase-2 0 0 0 0 0 2 4 8 0 3.23
rpl-21 P34334 60S ribosomal protein L21 2 6 3 5 8 5 4 8 3 2356
Y37E3.17 Q6AW03 Putative uncharacterized protein 0 2 0 7 0 0 4 10 3 310
cdc-48 P54812 Transitional endoplasmic reticulum ATPase homolog 2 5 2 5 9 4 6 4 11 2 436
unc-15 P10567 Paramyosin (Uncoordinated protein 15) 3 6 5 12 5 5 4 17 6 2391
F22F7.1 Q9GZE9 Putative uncharacterized protein 0 0 0 0 0 0 5 0 0 201
dim-1 Q18066 Disorganized muscle protein 1 (2D-page protein spot 8) 0 0 0 0 0 4 5 0 2 594
rps-14 P48150 40S ribosomal protein S14 2 4 5 4 6 3 5 3 0 1597
cth-1 O45391 Protein F22B8.6, confirmed by transcript evidence 2 0 0 2 0 0 5 3 0 71.2
rpl-6 P47991 60S ribosomal protein L6 7 11 9 6 8 7 5 3 2 2295
acdh-7 Q22781 Acyl coa dehydrogenase protein 7, confirmed by transcript evidence 5 2 3 3 0 4 5 3 2 600
R05G6.7 Q21752 Probable voltage-dependent anion-selective channel 0 6 2 0 5 8 5 3 2 2361
rpl-8 Q9XVF7 60S ribosomal protein L8 5 10 6 9 5 8 5 3 3 1650
unc-60 Q07750 Actin-depolymerizing factor 1, isoforms a/b (Uncoordinated protein 60) 2 3 0 0 0 0 5 3 3 1788
rps-9 Q20228 40S ribosomal protein S9 0 9 5 4 6 4 5 4 0 2186
glrx-10 Q9N456 Glutaredoxin protein 10 3 4 5 2 5 2 5 4 4 684
F41C3.5 P52717 Uncharacterized serine carboxypeptidase F41C3.5 4 4 3 0 2 3 5 5 0 630
gst-38 O45451 Protein F35E8.8, confirmed by transcript evidence 2 3 0 3 0 0 5 5 2 8.02
asb-2 Q19126 Atp synthase b homolog protein 2 4 6 2 5 0 6 5 5 4 557
phb-1 Q9BKU4 Mitochondrial prohibitin complex protein 1 (Prohibitin-1) 3 2 6 2 3 6 5 5 4 1108
rpl-7 O01802 60S ribosomal protein L7 8 10 6 8 8 13 5 5 5 2403
atp-5 Q17763 Protein C06H2.1, confirmed by transcript evidence 10 8 7 3 2 5 5 5 5 1427
T02G5.7 Q22101 Putative uncharacterized protein 0 0 0 3 0 0 5 6 0 480
glb-1 P30627 Globin-like protein 0 2 2 0 2 0 5 6 0 653
sams-1 O17680 PS-adenosylmethionine synthase 1 2 0 0 0 0 2 5 6 0 672
act-5 O45815 Protein T25C8.2, confirmed by transcript evidence 6 4 3 4 4 2 5 6 5 1298
imb-3 Q9N5V3 Importin beta family protein 3, confirmed by transcript evidence 5 5 7 9 4 9 5 7 0 121
LLC1.3 O17953 Protein LLC1.3a, confirmed by transcript evidence 2 3 0 5 0 0 5 7 0 984
cct-8 Q9N358 T-complex protein 1 subunit theta (TCP-1-theta) (CCT-theta) 4 2 3 2 0 2 5 7 0 473
F53A2.7 O45552 Protein F53A2.7, confirmed by transcript evidence 4 0 3 3 0 3 5 7 2 1165
prdx-2 A8DYR6 Peroxiredoxin protein 2 5 7 5 4 6 2 5 9 2 2916
rps-20 Q8WQA8 Protein Y105E8A.16, confirmed by transcript evidence 3 4 3 0 6 3 5 10 3 3421
vha-15 Q22494 Vacuolar proton pump subunit H 2 5 5 2 7 6 4 5 10 5 416
hsp-60 P50140 Chaperonin homolog Hsp-60, mitochondrial (Heat shock protein 60) 0 0 0 0 0 0 5 11 0 2423
alh-9 P46562 Putative aldehyde dehydrogenase family 7 member A1 homolog 3 3 0 3 2 0 5 11 3 601
cct-6 P46550 T-complex protein 1 subunit zeta 4 6 0 0 0 0 5 12 2 472
T25F10.6 Q23050 Putative uncharacterized protein T25F10.6 6 3 0 9 0 2 5 15 4 1392
T22B11.5 O61199 Alpha-ketoglutarate dehydrogenase 10 7 14 17 8 12 5 16 5 530
rpl-9 Q95Y90 60S ribosomal protein L9 2 10 5 7 9 4 6 2 0 2896
asg-2 Q18803 Probable ATP synthase subunit g 2 7 5 3 0 3 3 6 2 3 481
phb-2 P50093 Mitochondrial prohibitin complex protein 2 (Prohibitin-2) 4 5 4 5 4 5 6 3 5 604
R07H5.8 Q93934 Protein R07H5.8, confirmed by transcript evidence 2 2 0 3 0 2 6 4 2 1017
acp-6 Q9GUF2 Acid phosphatase family protein 6, confirmed by transcript evidence 8 2 3 6 2 5 6 4 3 220
fum-1 O17214 Probable fumarate hydratase 2 2 0 2 0 0 6 5 0 934
D2063.3  Q6EZG4 Putative uncharacterized protein 2 0 0 2 0 0 6 5 0 93.7
rpl-30 Q9XWS4 Protein Y106G6H.3, confirmed by transcript evidence 4 3 5 0 5 2 6 5 0 1099
57
The C. elegans β-Integrin PAT-3 is a substrate of the tyrosine phosphatase DEP-1 
sodh-1 Q17334 Alcohol dehydrogenase 1 (Sorbitol dehydrogenase family protein 1) 3 6 4 4 3 3 6 6 2 1763
rps-15 Q9XVP0 40S ribosomal protein S15 3 7 7 5 8 4 6 6 3 2721
rpl-33 P49180 60S ribosomal protein L35a 2 6 6 0 3 2 6 6 5 2326
C16A3.10 Q18040 Probable ornithine aminotransferase 7 4 3 6 5 3 6 7 3 730
rps-12 P49196 40S ribosomal protein S12 0 3 5 0 2 5 6 8 6 900
rpl-4 O02056 60S ribosomal protein L4 17 18 10 22 19 13 6 9 6 2708
gst-41 Q966G8 Glutathione s-transferase protein 41 5 13 4 3 6 4 6 10 4 29.9
rps-1 P48154 40S ribosomal protein S3a 9 10 12 12 13 7 6 11 2 2661
F57B10.3 O44742 Cofactor-independent phosphoglycerate mutase 0 4 3 2 2 2 6 11 3 705
Y43F4B.5 O45934 Protein Y43F4B.5a, confirmed by transcript evidence 0 0 0 0 0 0 6 11 4 330
cct-2 P47207 T-complex protein 1 subunit beta 2 0 0 2 0 2 6 12 0 444
Y71H10A.1 Q9TZL8 6-phosphofructokinase 3 4 4 11 4 6 6 12 2 280
gdh-1 Q23621 Glutamate dehydrogenase 5 6 5 6 3 6 6 16 7
F17C11.9 P54412 Probable elongation factor 1-gamma (EF-1-gamma) (eEF-1B gamma) 3 0 0 0 0 0 7 3 0 937
rps-11 Q20206 Protein F40F11.1, confirmed by transcript evidence 2 5 8 5 8 6 7 4 3 1776
gpd-1 P04970 Glyceraldehyde-3-phosphate dehydrogenase 1 6 6 2 6 3 6 7 7 0 756
K08D12.3 Q966I7 Putative uncharacterized protein 0 0 0 0 0 0 7 7 2 328
rpa-0 Q93572 60S acidic ribosomal protein P0 8 5 8 6 3 10 7 8 7 2663
C37E2.1 Q93353 Isocitric dehydrogenase subunit beta 5 5 4 3 0 5 7 10 5 338
enol-1 Q27527 2-phospho-D-glycerate hydro-lyase 4 12 3 6 7 2 7 11 0 4422
rpl-7A Q966C6 60S ribosomal protein L7a 8 12 9 12 7 10 7 11 5 2015
vha-12 Q19626 Vacuolar proton pump subunit B 6 6 4 7 5 4 7 12 4 1979
pccb-1 Q20676 Putative uncharacterized protein 5 6 5 9 5 0 7 17 4 846
pam-1 Q20627 Puromycin-sensitive aminopeptidase protein 1, isoform a 6 3 3 7 7 5 7 18 3 418
gei-7 Q10663 Bifunctional glyoxylate cycle protein (Gex-3-interacting protein 7) 19 5 10 23 16 13 7 18 6 777
F58F12.1 Q09544 ATP synthase subunit delta, mitochondrial (F-ATPase delta subunit) 2 3 0 3 0 2 8 3 3 1959
rpl-18 O45946 60S ribosomal protein L18 7 12 6 9 10 9 8 5 0 3797
mdh-1 Q9UAV5 Malate dehydrogenase 5 3 3 4 3 0 8 5 0 2090
rpl-12 P61866 60S ribosomal protein L12 3 5 4 6 4 3 8 6 2 3385
F43G9.1 Q93714 Probable isocitrate dehydrogenase 7 5 6 3 3 6 8 7 0 802
cct-3 Q9N4J8 Putative uncharacterized protein 2 2 0 3 0 3 8 8 0 385
rps-4 Q9N3X2 40S ribosomal protein S4 11 19 16 22 16 19 8 9 2 2657
Y69A2AR Q95XJ0 ATP synthase gamma chain 8 9 8 11 9 7 8 9 4 1322
C44B7.10 Q18599 Putative uncharacterized protein 9 9 8 9 9 7 8 9 5 2154
rps-16 Q22054 40S ribosomal protein S16 9 9 10 8 12 11 8 9 8 2456
acdh-12 Q19057 Acyl coa dehydrogenase protein 12, isoform a 0 2 0 0 0 0 8 10 4 491
T08B2.7 Q9BIC3 Putative uncharacterized protein 3 2 15 14 11 11 8 12 5 479
gst-39 Q9NAB0 Protein Y53F4B.33, confirmed by transcript evidence 16 14 7 9 6 4 8 12 7 109
F49E2.2 A6ZJ46 Protein F49E2.2c, partially confirmed by transcript evidence 5 8 0 7 0 0 8 13 4 58.9
hsp-3 P27420 Heat shock 70 kDa protein C 6 7 0 6 0 3 8 15 4 1510
pyk-1 B7WNA0 Protein F25H5.3e, partially confirmed by transcript evidence 4 4 0 4 0 0 8 16 0 443
W10C8.5 O45011 Putative uncharacterized protein 3 4 3 3 0 0 9 9 3 306
ucr-1 P98080 Ubiquinol-cytochrome-c reductase complex core protein 1 7 10 6 8 7 9 9 11 7 1192
fln-1 D0IMZ5 FLN-1 protein, isoform a, partially confirmed by transcript evidence 7 3 9 17 4 12 9 16 4 343
tct-1 Q93573 Translationally-controlled tumor protein homolog (TCTP) 2 6 5 2 0 2 10 0 2 3680
gst-27 Q9NAB3 Protein Y53F4B.30, confirmed by transcript evidence 15 7 5 8 7 3 10 10 4 355
mlc-1 P19625 Myosin regulatory light chain 1 5 6 6 6 7 5 10 10 6 2151
aco-1 Q23500 Probable cytoplasmic aconitate hydratase (Aconitase) 6 6 6 9 3 4 10 19 5 882
gst-26 Q9NAB4 Protein Y53F4B.29, confirmed by transcript evidence 9 8 6 6 4 4 11 7 5 318
inf-1 P27639 Eukaryotic initiation factor 4A (eIF-4A) 9 7 3 9 6 5 11 10 5 735
F01G4.6 P40614 Phosphate carrier protein, mitochondrial (PTP) 9 7 10 11 8 8 11 12 9 613
rpl-5 P49405 60S ribosomal protein L5 10 15 8 16 12 11 11 13 8 3694
rack-1 Q21215 Guanine nucleotide-binding protein subunit beta-2-like 1 8 10 7 7 7 9 11 14 3 2329
gst-13 Q22814 Protein T26C5.1, confirmed by transcript evidence 16 18 10 7 13 8 11 16 11 136
tkt-1 O17759 Protein F01G10.1, confirmed by transcript evidence 10 4 4 6 0 3 11 19 3 1834
T25G3.4 P90795 Probable glycerol-3-phosphate dehydrogenase 7 5 3 7 0 3 11 20 2 159
F46H5.3 Q10454 Probable arginine kinase F46H5.3 (AK) (EC 2.7.3.3 ) 7 7 6 6 4 5 12 8 4 4094
C08H9.2 Q17832 Protein C08H9.2a, confirmed by transcript evidence 4 5 9 13 6 7 12 11 2 583
rps-0 P46769 40S ribosomal protein SA 10 11 10 11 9 10 12 12 8 2456
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gst-4 Q21355 Glutathione S-transferase 4 11 16 6 6 13 5 12 13 6 83
F45D11.15 Q9N2K4 Putative uncharacterized protein 8 12 7 8 5 4 12 15 0 716
mlc-3 P53014 Myosin, essential light chain (Myosin light chain alkali) 13 12 6 6 7 8 12 16 11 7584
vha-13 Q9XW92 Vacuolar proton pump subunit alpha 7 7 0 5 0 2 12 17 6 2335
aco-2 P34455 Probable aconitate hydratase (Aconitase) 12 8 13 18 10 10 12 19 8 1933
gpd-2 P17329 Glyceraldehyde-3-phosphate dehydrogenase 2 (GAPDH-2) 9 9 6 10 5 4 13 10 6 2973
rps-3 P48152 40S ribosomal protein S3 10 13 11 14 12 12 13 10 8 2815
hsp-6 P11141 Heat shock 70 kDa protein F, mitochondrial 4 5 0 5 0 0 13 14 4 1261
chc-1 P34574 Probable clathrin heavy chain 1 20 11 8 29 16 9 13 15 5 247
5C820 Q9GQ62 5C820 4 8 5 0 5 2 14 14 8 342
gst-28 Q9NAB2 Protein Y53F4B.31, confirmed by transcript evidence 17 12 6 18 12 8 14 16 6 174
sca-1 Q9XU13 Protein K11D9.2b, confirmed by transcript evidence 18 10 8 21 12 9 14 21 4 634
dep-1 Q20120 Protein	F44G4.8a,	partially	confirmed	by	transcript	evidence	 68 55 51 66 42 48 14 23 3 1.16
eat-6 P90735 Protein B0365.3, confirmed by transcript evidence 18 10 11 23 12 13 14 24 5 426
idh-1 Q21032 Isocitrate dehydrogenase 8 9 0 9 6 0 15 10 0 1244
gst-36 Q09607 Probable glutathione S-transferase gst-36 14 16 9 9 8 10 15 11 9 375
mdh-1 O02640 Probable malate dehydrogenase 11 9 7 10 4 8 15 15 7 2090
pcca-1 Q19842 Propionyl-CoA carboxylase alpha chain 16 8 8 26 12 10 15 18 3 902
ahcy-1 P27604 Adenosylhomocysteinase (AdoHcyase) 10 12 8 13 9 8 16 11 6 4696
sdha-1 Q09508 Succinate dehydrogenase 8 10 2 8 0 5 16 16 9 635
tba-2 P34690 Tubulin alpha-2 chain 14 18 12 19 17 15 17 17 5 874
gst-20 O01987 Protein Y48E1B.10 gst-20 16 23 13 12 19 11 17 18 10 266
pyc-1 O17732 Pyruvate carboxylase 1 11 11 8 26 15 10 17 19 2 327
ant-1 O45865 Protein T27E9.1a, confirmed by transcript evidence 12 18 15 16 18 19 18 23 15 819
daf-21 Q18688 Heat shock protein 90 (Abnormal dauer formation protein 21) 20 15 18 30 17 25 19 29 10 1522
hsp-1 P09446 Heat shock 70 kDa protein A 13 16 9 15 2 13 20 28 13 2550
gst-5 Q09596 Probable glutathione S-transferase 5 19 23 14 15 18 15 21 19 14 199
gst-7 P91253 Probable glutathione S-transferase 7 23 23 14 13 18 16 21 24 18 778
W05G11.6 O44906 Putative uncharacterized protein W05G11.6 22 17 13 20 2 12 22 32 6 1439
tbb-2 P52275 Tubulin beta-2 chain (Beta-2-tubulin) 19 24 16 31 21 25 23 21 10 1372
gst-1 P10299 Glutathione S-transferase P 22 24 21 21 17 21 24 23 18 690
eef-2 P29691 Elongation factor 2 (EF-2) 20 6 10 26 19 16 24 34 13 7.81
vit-5 P06125 Vitellogenin-5 69 50 42 167 129 85 24 47 9 750
gst-10 Q9N4X8 Glutathione S-transferase P 10 25 25 17 16 24 20 25 28 20 215
R11A5.4 O02286 Protein R11A5.4a, confirmed by transcript evidence 19 22 14 22 3 13 25 34 19 1849
atp-2 P46561 ATP synthase subunit beta, mitochondrial 26 21 18 29 17 21 26 24 18 6267
eft-3 P53013 Elongation factor 1-alpha (EF-1-alpha) 19 22 21 20 21 16 28 27 15 3510
act-1 P10983 Actin-1/3 25 25 18 29 21 18 29 23 17 2359
H28O16.1 Q9XXK1 ATP synthase subunit alpha, mitochondrial 26 26 24 32 25 18 31 38 25 6282
myo-1 P02567 Myosin-1 (Lethal protein 75) 30 14 7 39 17 11 32 67 27
myo-3 P12844 Myosin-3 (Myosin heavy chain A) 37 10 2 49 8 7 35 44 14 489
vit-2 P05690 Vitellogenin-2 78 54 55 184 123 86 37 55 14 1514
myo-2 P12845 Myosin-2 (Myosin heavy chain C) 33 21 2 50 24 12 39 79 31 570
vit-6 P18948 Vitellogenin-6 102 68 87 227 177 152 56 82 33 1565
myo-4 P02566 Myosin-4 (Myosin heavy chain B) (Uncoordinated protein 54) 130 71 69 162 62 85 126 175 113
Table 1 Proteins that were identified by LC-MS/MS analyses after GST::DEP-1 pull-down experiments.
LC-MS/MS analyses identified 585 proteins. Every pull-down was done in triplicates. The numbers represent the peptides 
that were detected. Min. Protein Probability = 95%; Min. Number of Peptides = 2. Values from „Protein abundance“ corre-
spond to the „C.elegans PaxDB integrated dataset“ (www.pax-db.org).
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3.1.10 Materials and methods
C. elegans methods and strains
The strains used for the experiments and crosses were derivates of Bristol strain N2 of Caenorhabditis 
elegans. The animals were cultivated under standard conditions at 20°C as described in (Brenner, 1974). 
Unless noted otherwise, the mutations used have been described previously and are listed below by 
their linkage group. Standard methods were used to construct double mutants. The vulval index (VI)
was scored at the L4 larval stage using Nomarski optics as described (Berset et al., 2001). For Nomarski 
analysis, animals were mounted on 4% agarose pads in M9 solution containing 20 mM tetramisole hy-
drochloride. 
The alleles used are LGII: dep-1(zh34) (Tarcic et al., 2009), unc-4(e120) (Brenner, 1974), rrf-3(pk1426) 
(Simmer et al., 2002), ttTi25067 (dep-1 transposon insertion) (Université Lyon 1, Villeurbanne, France). 
LGIII: unc-119(e2498) (Maduro and Pilgrim, 1995), unc-119(ed3) (Maduro and Pilgrim, 1995), unc-
119(ed4) (Maduro and Pilgrim, 1995), pat-3(st564) (Williams and Waterston, 1994), glp-1(q339) (Troemel 
et al., 1999). LGIV: lip-1(zh15) (Berset et al., 2001), let-60(n1046) (Ferguson and Horvitz, 1985). LGV: rde-
1(ne219) (Pavelec et al., 2009), nid-1(cg119) (Trzebiatowska et al., 2008), 
The integrated transgenic arrays are: LGII: zhIs70[dep-1::gfp::unc-119(+)],zhIs71[dep-1::mCherry:: 
unc-119(+)]. LGIV: qyIs15[zmp-1>HA-ßtail] (Hagedorn et al., 2009), zhIs038[let-23::GFP; unc-119(+)] 
(Haag et al., unpublished data). LG unknown: qyIs43 [pat-3::GFP + ina-1(genomic) + unc-119(+)] (Hage-
dorn et al., 2009), zhIs020[peft-3::taptag::dep-1 extracellular domain / unc-119(+)],qyIs110(egl-17>dnPat-3) 
(Hagedorn et al., 2009), jeIs2222[pat-2::GFP rol-6(su1006)] (Meighan and Schwarzbauer, 2007).
The transgenic arrays /transgene, cotransformation marker) were: zhEx418[lin-31::rde-1, myo-
2::mCherry], zhEx419[pat-3::gfp Y792A Y804A], zhEx420[pat-3::gfp Y772A], zhEx432[pat-3::gfp Y772A 
Y804A], zhEx456[pat-3::gfp Y792A,], zhEx457[pat-3::gfp Y804A], zhEx458[pat-3::gfp TTT796-798AAA], 
zhEx477[dep-1::mCherry], zhEx524[pat-3::gfp,myo-2::mCherry], zhEx528[pat-3::gfp Y804A, myo-2::mCherry], 
mwEx31[pat-3 Y804F] (Lee et al., 2001), mwEx32[pat3 Y792F Y804F] (Lee et al., 2001).
GST pull-down experiments for LC-MS/MS analyses
The intracellular domain of DEP-1 (wild-type and D1241A) was cloned into the BamHI site of the 
E. coli expression vector pGEX-2TK (Pharmacia) as described by Berset et al. (2005). Recombinant pro-
teins were affinity-purified on glutathione Sepharose according to the manufacturer’s protocol, except 
that protein expression was induced in BL21 bacteria at 18°C, and fusion proteins were washed in 20 
mM NaP pH=8.0, 250 mM NaCl, 1% Triton-X. Approximately 50 µg of each DEP-1 fusion protein (wild-
type/D1241A) and 100 µg of GST as a negative control were used for each binding reaction. To prepare 
N2 worm extract, mixed-stage liquid cultures were cleaned by sucrose f lotation, resuspended in lysis 
buffer (100 mM Tris pH=8.0, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.5% NP-40, 1x protease in-
hibitor cocktail; Roche), shock frozen in liquid nitrogen, and homogenized in a mixer mill (MM300; 
Retsch). Thawed worm extract was then centrifuged for 10 min at 4°C and 10’000g to remove insoluble 
components. About 2.5 mg of total protein extract was used for each reaction. Binding was performed 
at 4°C over night, followed by three washes with lysis buffer. Bound proteins were eluted by boiling the 
beads for 5 min in 30 µl of laemmli buffer and separated on a 4-15% linear gradient SDS-gel (Biorad Nr. 
161-1104), followed by Colloidal Coomassie Blue staining according the manufacturer’s protocol (Roti 
Blue; Roth).
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In-gel digestion and protein identification by LTQ-Orbitrap
Differential protein bands were excised with a scalpel into small pieces and prepared for in-gel tryptic 
digestion. Thereby the gel pieces were washed and dehydrated three times in 50% Acetonitrile and dried 
in speedvac. 10 mM DTT (in 25 mM Ammonium bicarbonate pH=8.0) was added to cover gel pieces 
and incubated for 45 min at 56°C. After DTT was removed, 50 mM IAM (in 25 mM Ammonium bicar-
bonate pH=8.0) was added to cover gel pieces and incubated for 1 hour at room temperature in the dark. 
IAM was removed and gel pieces were washed twice with 50% Acetonitrile before dried in Speed Vac. 
25 mM Ammonium bicarbonate pH=8.0 containing 50 ng trypsin was added to be absorbed by the gel 
pieces and incubated over night at 37°C. To extract the peptides, gel pieces were incubated three times 
for 15 min with 50% Acetonitrile / 5% TFA and once with 100% Acetonitrile. The peptides were speed-
vac dried before resuspended in 5 µl of 3% Acetonitrile/0.1% formic acid. Samples were desalted with 
C18 ZipTip® (Millipore) according to the manufacturer’s protocol before being analyzed on a calibrated 
LTQ-Orbitrap mass spectrometer (Thermo Scientific). Desalted peptides were resovled in 15 µl of 3% 
Acetonitrile/0.2% formic acid and loaded on a 10 cm fused silica column packed with 3 µm 200 Å pore 
size C18 resin. Peptides were eluted from the column via an ACN gradient of 5-45% (v/v) over 80 min 
and 40-80% ACN over the subsequent 15 min in a buffer containing 0.2% formic acid (v/v) at a f low rate 
of 200 nl/min. 
The range of MS scan was m/z 450-1500. LC-MS/MS spectra were exported to the MASCOT generic 
format (mgf) and proteins were identified by searching the MASCOT database search engine version 2.2 
(Perkins et al., 1999). The MASCOT search parameters were as follows: set-off threshold at 0.05 in the 
expectation value cutoff, peptide tolerance at 5 ppm, MS/MS tolerance at 0.8 Da, peptide charge of 2+ or 
3+, trypsin as enzyme allowing up to one missed cleavage, carbamidomethylation on cysteines as a fixed 
modification and oxidation on methionine as a variable modification. Only peptides with a maximum 
of 2 (3 for semi-tryptic digest) missed cleavage sites were allowed in database searches. Further compari-
sons of the proteins were performed using Scaffold 3.0 (Proteome Software).
GST pull-down experiments for Western blot experiments
Approximately 10 µg of purified GST::DEP-1 (wild-type and D1241A) and 40 µg of GST (negative con-
trol) were incubated with ca. 800 µg total worm extract over night at 4°C for each binding reaction. 
Followed by washing with lysis buffer (see above), bound proteins were eluted by boiling the beads for 
5 min in Laemmli buffer. GFP tagged proteins were detected on Western blots of 10% acrylamide gels 
with monoclonal anti-GFP antibody (Roche, Cat. No. 11 814 460 001). For phosphatase inhibitor experi-
ments, 5 mM Na3VO4 was added to the lysis buffer.
Endogenous dep-1::mCherry reporter
An endogenous single copy reporter of dep-1::mCherry was created by MosTIC insertion as reported 
by Robert et al., (2009). The repair templates were cloned by PCR fusion of the last 1.8 kb of the dep-1 
locus to mCherry, followed by 500 bp of the dep-1 3’ UTR, the C. briggsae unc-119 rescue construct, and 
1.9 kb of the genomic dep-1 downstream region. The final construct was subcloned into pGEM®-T Easy 
(Promega) and 50 ng/µl of the created plasmid (pMW28) was micro-injected together with 50 ng of the 
Mos1-transposase pJL43.1, 2.5 ng of myo-2::mCherry, 5 ng of pCFJ104, and 10 ng of pGH8 into the Mos 
insertion line ttTi25067; unc-119(e2498). MosTIC engineered animals were identified by screening the F2 
progeny for crawlers that lost the myo-2::mCherry marker, and confirmed by sequencing.
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RNAi
RNAi was performed by feeding worms with dsRNA-producing E. coli as described by Kamath et al., 
(2001) with the following modifications: The worms were synchronized with hypochloride solution, and 
L1 larvae (P0) were placed on growth media plates and allowed to grow at 20°C. The F2 generation was 
then analyzed. 3 mM IPTG was added to the agar to induce the expression of dsRNA.
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3.2 Additional experiments
3.2.1 Optimizing the preparation of C. elegans protein extract
An efficient and gentle preparation of protein extract is one of the basic steps during biochemical ex-
periments. Several methods are known to extract proteins from a tissue, such as repeated freezing and 
thawing, sonication, mechanical disruption, or permeabilization by organic solvents. The method of 
choice depends on how robust the tissue is and how fragile the proteins are. Since the extraction process 
releases proteases that start digesting the proteins in solution, it is essential to slow down proteolysis by 
adding protease inhibitors and to perform protein extraction under cooled conditions. 
The tough cuticle of C. elegans, which is composed primarily of collagens, highly cross-linked cuticle, 
and surface glycoproteins (Page and Johnstone, 2007), complicates protein extraction. In our labora-
tory, proteins have been so far extracted from worms by dounce homogenization (Fig. 3.6 A). Thereby, 
animals were mechanically disrupted by shear stresses that were generated by up- and down movements 
of a pestle in a glass mortar. However, the yield of protein extract obtained by this method was very low 
because only adult animals are disrupted, whereas the majority of larvae stayed intact (Fig. 3.6 B). In 
addition, the handling of the dounce homogenizer was exhausting and made it impossible to extract 
proteins at constant chilled temperatures. 
To achieve a disruption of worms in all larval stages and to increase the yield of protein extract, we tried 
to grind C. elegans in a MixerMill (Fig. 3.6 C). Thereby, animals were suspended in lysis buffer and drop 
wise shock frozen in liquid nitrogen. The frozen droplets were then transferred to a grinding beaker 
containing a small steel ball (Fig. 3.6 C), which was pre-chilled in liquid nitrogen. By shaking the grind-
ing beaker in a MixerMill with a frequency of 30 Hz, the frozen worms were grinded to a fine powder. 
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Figure 3.6 Preparation of C. elegans protein extract.
(A) Traditional protein extraction was performed by homogenizing worms in a dounce homogenizer. (B) Disruption of 
worms after dounce homogenization (150x up and down). (C) Grinding of frozen worms in a MixerMill (3x 2min at 30 
Hz) results in a much more efficient disruption of worms (D). (E) Protein concentration of total protein extract obtained by 
dounce homogenization or MixerMill grinding. (F) Immunoblot of total protein extract from DEP-1full::HS animals using 
anti-HA antibodies. Protein extract was either obtained by dounce homogenization or MixerMill grinding.
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After slow thawing of the powder at 4°C and subsequent centrifugation in a cool centrifuge, the whole 
worm protein extract was obtained. 
By applying this new method, the efficiency of protein extraction could be improved notably. No intact 
animals could be recognized after MixerMill homogenization (Fig. 3.6 D), and the concentration of 
total protein extract was clearly enhanced (Fig. 3.6 E). Also the yield of membrane-bound DEP-1 was 
increased (Fig. 3.6 F). Furthermore, this method allowed a sample preparation at constant temperatures 
below 4°C, preventing a protein degradation.
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Figure 3.7 StrepTactin-HA affinity-purification of DEP-1.
(A) Domain structures of C. elegans DEP-1 and scheme of Hemaglutinin-StrepTactin-III (HS)-tagged DEP-1fullwt and 
DEP-1intraDA fusion proteins. Asterisks indicates the substrate trapping mutation D1241A. Amino acid sequence of the HS 
tag is indicated. (B) Peft-3::dep-1full::HS was co-injected with sur-5::dsRed in dep-1(lf);lip-1(lf) animals. Two lines of animals 
carring the extrachromosomal arrays rescued the Pvl phenotype. (C) Workflow of StrepTactin-HA double- and HA single 
purification with subsequent analysis by MS/MS. (D) Eluates of the StrepTactin-HA double purification and (E) of HA single 
purification were analyzed on an immunoblot using antiHA antibodies.
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3.2.2 StrepTactin-HA double affinity-purification of DEP-1::HS
To purify DEP-1 together with its physiological interaction partners we initially used the tandem affinity-
purification TAP-tag system (Puig et al., 2001). However, this system was not working in our hands (C. 
Walser, T. Schmid, M. Walser, data not shown) for which reason we decided to use the small double- 
affinity HA-Strep-III-tag (HS) that was recently developed at the ETH (Fig. 3.7 A, Glatter et al., 2009). The 
StrepTactin-haemagglutinin (SH) double purification enables a pure sample preparation with very little 
contaminant protein present, which allows to analyze the entire affinity-purified sample by a reversed-
phase liquid chromatography unit coupled to a mass spectrometer in one single step (Glatter et al., 2009). 
A further advantage of the HS tag is its smaller size of the HS tag (5 kD) compared to the TAP-tag (21 kD). 
In our approach, the HA-Strep-III-tag was cloned to the C-terminus of full-length DEP-1 (DEP-1 
full::HS / pMW4, Fig. 3.7 A) and to the DEP-1 intracellular domain containing the substrate-trapping mu-
tation D1241A in the phosphatase domain (DEP-1intraDA::HS / pMW5), which allows the catalytically 
inactive enzyme to remain bound to its phosphorylated substrate (Palka, 2002). Since DEP-1 is expressed 
only in a few cells and therefore belongs to lower abundant proteins (1.16 ppm; www.pax-db.org), we 
over-expressed DEP-1::HS under the ubiquitous eft-3 promoter. Otherwise, we would not have been able 
to purify an adequate amount of tagged proteins. By integrating the plasmids pMW4 and pMW5 into 
the genome of C. elegans by ballistic transformation, we obtained the two transgenic strains zhIs27[Peft-
3::dep-1full::HS;unc-119(+)] and zhIs28[Peft-3::dep-1intraD1241A::HS;unc-119(+)].
To test the functionality of Peft-3::dep-1full::HS (pMW4), we micro-injected this construct together with 
the co-injection marker sur-5::dsRed into dep-1;lip-1(lf) animals, which show typically a strong Pvl-phe-
notype (Fig. 3.7B). Since Peft-3::dep-1full::HS was able to rescue the Pvl phenotype of dep-1;lip-1(lf) ani-
mals, we concluded that this construct was functional.
For the double affinity-purification of DEP-1::HS, proteins were extracted from zhIs27 and zhIs28 ani-
mals by MixerMill grinding and incubated during a first purification step with StrepTactin-sepharose 
(Fig. 3.7 C). After several washing steps, purified DEP-1::HS was eluted with Biotin and incubated in a 
second purification step with monoclonal anti-HA agarose conjugate. Further washing steps followed 
before the double affinity-purified DEP-1::HS was eluted under acidic conditions. In order to identify 
contaminants that were not eliminated during washing procedures (e.g. proteins that bound to the Strep-
Tactin sepharose and/or to the HA-agarose), we made mock purifications using protein extract of wild-
type N2 animals. 
The progress of the two purification steps was monitored by Western blot analyses, where the eluates of 
the different purification steps were loaded on a SDS-gel and immunoblotted with antibodies against HA 
(Fig. 3.7 D). 
3.2.3 LC-MS/MS analysis of StrepTactin-HA purified DEP-1::HS
Western blot analyses indicated a very low yield of StrepTactin-HA purified DEP-1, especially from DEP-1 
fullwt::HS (Fig. 3.7 D). Thus, we performed the tryptic digestion directly in the sample (in-solution diges-
tion) instead of first separating the proteins by SDS-PAGE and performing an in-gel tryptic digestion (see 
3.1.3). After ZipTip purification, the prepared samples were analyzed by LC-MS/MS. In total, 42 proteins 
were identified (Fig. 3.8 A), of which DEP-1 was the most abundant protein. Thus, we concluded that 
the SH double affinity-purification was working. However, the low yield of SH-purified DEP-1 made it 
impossible to pull-down an adequate amount of interacting proteins that can be detected by LC-MS/MS. 
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3.2.5 HA single purification of DEP-1::HS
3.2.6 LC-MS/MS analysis of HA purified DEP-1::HS 
To increase the yield of purified DEP-1 and thereby the amount of proteins interacting with DEP-1::HS, 
we decided to omit the StrepTactin purification and to perform only a single HA-purification (Fig. 3.7 C, 
dashed arrow). Furthermore, we tested if an increase of total C. elegans protein extract could enlarge 
the yield of purified DEP-1::HS. Thus, we incubated equilibrated monoclonal anti-HA agarose conjugate 
with 35 mg, 70 mg or 100 mg of total extract (Fig. 3.8 E) that derived from zhIs27 and zhIs28 animals. 
After intensive washing steps, purified DEP-1::HS was eluted under acidic conditions and further pro-
cessed for LC-MS/MS analyses.
Western blot analyses of HA-purified DEP-1 revealed that the yield of DEP-1::HS could be increased sig-
nificantly by performing only HA-single purification (Fig. 3.7 E). This enlarged yield of DEP-1 resulted 
in a three-fold increase of proteins that were identified by LC-MS/MS. Among the 332 proteins that were 
identified in two independent LC-MS/MS experiments, 27 proteins were found exclusively in the DEP-
1intraDA::HS fraction (Fig. 3.8 A).
However, not only an omission of the StrepTactin purification could increase the number of identified 
proteins but also the amount of protein extract that was used for the HA-purification, since an enhance-
ment of protein extract from 35 mg to 100 mg resulted in the identification of 1.3 times more proteins 
(Fig. 3.8 E). 
Taken together, these findings indicate that an increase of the yield of purified DEP-1::HS could improve 
the quality of the mass spectrometry results, and that the amount of purified DEP-1 is crucial for the 
successful identification of DEP-1 interactors by LC-MS/MS. 
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dep-1 Q20120 Density enhanced phosphatase 21 15 28 36 0 0 1.16 ppm
vit-1 P55155 Vitellogenin-1 4 2 0 2 0 0 715 ppm
pcca-1 Q19842 Propionyl-CoA carboxylase alpha chain 4 0 3 2 0 0 902 ppm
lact-9 O62481 Protein LACT-9, isoform a 3 0 1 2 0 0 14.3 ppm
rps-12 P49196 40S ribosomal protein S12 3 0 1 0 0 0 900 ppm
chc-1 P34574 Probable clathrin heavy chain 1 3 0 0 0 0 0 247 ppm
sca-1 Q9XTG6 Calcium ATPase 3 0 0 0 0 0 634 ppm
lec-2 Q20684 Protein LEC-2, isoform a 2 6 2 0 0 0 630 ppm
M28.5 Q21568 NHP2-like protein 1 homolog 2 1 1 0 0 0 1259 ppm
ahcy-1 P27604 Adenosylhomocysteinase 2 1 0 2 0 0 4696 ppm
F46H5.3 Q10454 Probable arginine kinase F46H5.3 (AK) (EC 2.7.3.3 ) 2 1 0 0 0 0 4094 ppm
eat-6 P90735 Protein EAT-6 2 0 1 1 0 0 426 ppm
dld-1 O17953 Dihydrolipoyl dehydrogenase 2 0 1 0 0 0
inf-1 P27639 Eukaryotic initiation factor 4A (eIF-4A) 2 0 0 0 0 0 735 ppm
3.2.4 Proteins identified by DEP-1::HS pull-down experiments and MS/MS analyses
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vha-12 Q19626 Probable V-type proton ATPase subunit B 2 0 0 0 0 0 1979 ppm
gdh-1 Q23621 Glutamate dehydrogenase 2 0 0 0 0 0
lys-7 O16202 Protein LYS-7 1 3 0 1 0 0 74.6 ppm
act-5 O45815 Protein ACT-5 1 3 0 1 0 0 1298 ppm
rps-28 Q95Y04 40S ribosomal protein S28 1 2 1 0 0 0 2729 ppm
vit-5 P06125 Vitellogenin-5 1 2 0 0 0 0 750 ppm
phb-1 Q9BKU4 Mitochondrial prohibitin complex protein 1 1 0 2 0 0 0 1108 ppm
lpd-5 Q9N4L8 Protein LPD-5 1 0 1 2 0 0 653 ppm
B0513.4 O45227 Protein B0513.4, isoform a 1 0 0 3 0 0 107 ppm
rpl-15 P91374 60S ribosomal protein L15 1 0 0 2 0 0 2131 ppm
vab-10 O18290 Protein ZK1151.1a 0 15 0 1 0 0 60.1 ppm
Y43F8B.1 B7FAR9 Protein Y43F8B.1, isoform d 0 12 0 0 0 0 82.3 ppm
nmy-2 Q19658 Protein F20G4.3 0 6 0 0 0 0 81.6 ppm
atn-1 Q23158 Protein ATN-1, isoform a 0 6 0 0 0 0 179 ppm
deb-1 P19826 Vinculin (P107B) 0 5 0 0 0 0 200 ppm
C39D10.7 Q18529 Protein C39D10.7 0 5 0 0 0 0 30.0 ppm
gei-15 Q21482  Putative uncharacterized protein 0 5 0 0 0 0 214 ppm
hmg-11 Q22204 High mobility group protein I alpha 0 5 0 0 0 0 895 ppm
lfi-1 Q23081 Lin-5 (Five) interacting protein protein 1 0 5 0 0 0 0 334 ppm
D1086.10 B1Q273 Protein D1086.10, isoform c 0 4 0 0 0 0 129 ppm
grd-5 O16462 Protein GRD-5 0 3 0 2 0 0 728 ppm
C08A9.10 Q27GT6 Protein C08A9.10 0 3 0 1 0 0 7.04 ppm
C14F11.4 B3WFT8 Protein C14F11.4, isoform a 0 3 0 0 0 0 71.2 ppm
hmg-12 O45912 High mobility group protein I beta 0 3 0 0 0 0 358 ppm
fipr-21 Q20277 Protein FIPR-21 0 3 0 0 0 0 168 ppm
W03F8.10 Q7YZM5  Putative uncharacterized protein 0 3 0 0 0 0 256 ppm
W03F11.1 O01780 Protein W03F11.1 0 2 0 1 0 0 21.9 ppm
F19C7.1 Q19591 Protein F19C7.1 0 2 0 1 0 0 88.1 ppm
lam-1 O44565 Protein LAM-1 0 2 0 0 0 0 106 ppm
 ZK484.3 O44895 Protein ZK484.3 0 2 0 0 0 0 228 ppm
ttr-51 O62289 Protein TTR-51 0 2 0 0 0 0 638 ppm
W01F3.2 O62390 Protein W01F3.2 0 2 0 0 0 0 26.2 ppm
emb-9 P17139 Collagen alpha-1(IV) chain 0 2 0 0 0 0 12.4 ppm
ifa-4 P90900 Intermediate filament protein ifa-4 (Cel IF A4) 0 2 0 0 0 0 235 ppm
mlc-4 Q09510 Probable myosin regulatory light chain 0 2 0 0 0 0 268 ppm
C18B2.3 Q18074 Protein C18B2.3 0 2 0 0 0 0 153 ppm
 ZK84.1 Q23635 Protein ZK84.1 0 2 0 0 0 0 82.2 ppm
gfi-1 Q94246 Protein GFI-1 0 2 0 0 0 0 60.9 ppm
unc-95 Q9NEZ5 Protein UNC-95 0 2 0 0 0 0 104 ppm
K07H8.10 O45181 Protein K07H8.10 2 1 2 0 0 1 230 ppm
rpl-17 Q9BL19 60S ribosomal protein L17 2 1 1 1 0 1 1932 ppm
C25A1.6 Q9XVR8 Putative H/ACA ribonucleoprotein complex subunit 3-like protein 2 2 1 1 0 2 379 ppm
W01D2.1 O62388 Ribosomal protein L37 3 1 4 4 0 3 1314 ppm
eef-2 P29691 Elongation factor 2 (EF-2) 5 2 3 4 1 0 7.81 ppm
rps-0 P46769 40S ribosomal protein SA 4 2 2 4 1 0 2456 ppm
gpd-2 P17329 Glyceraldehyde-3-phosphate dehydrogenase 2 3 2 2 2 1 0 2973 ppm
rpl-9 Q95Y90 60S ribosomal protein L9 3 1 1 1 1 0 2896 ppm
alg-2 O16720 Protein ALG-2, isoform a 3 0 1 0 1 0 67.2 ppm
anc-1 Q9N4M4 Nuclear anchorage protein 1 2 6 0 0 1 0 294 ppm
sqd-1 Q8MXR6 Protein SQD-1, isoform a 2 1 3 1 1 0 1530 ppm
aco-2 P34455 Probable aconitate hydratase, mitochondrial 2 1 2 1 1 0 1933 ppm
hil-3 Q19743 Histone H1.3 2 0 2 0 1 0 168 ppm
mdh-1 Q9UAV5 Malate dehydrogenase 2 0 1 0 1 0 2090 ppm
hsp-3 P27420 Heat shock 70 kDa protein C 2 0 0 0 1 0 1510 ppm
ucr-2.2 Q22370 Protein UCR-2.2 2 0 0 0 1 0 472 ppm
T23E7.2 O17338 Putative uncharacterized protein 1 4 4 0 1 0 397 ppm
rps-20 Q8WQA8 Protein RPS-20 1 3 1 2 1 0 3421 ppm
ZC373.2 Q23258 Protein ZC373.2 1 2 0 0 1 0 230 ppm
sdha-1 Q09508 Succinate dehydrogenase 1 1 2 0 1 0 635 ppm
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W09D12.1 Q23227 Protein W09D12.1 1 1 2 0 1 0 22.8 ppm
D1054.11 Q18947 Protein D1054.11 1 1 0 3 1 0 186 ppm
dlst-1 O45148 Protein DLST-1 1 0 1 2 1 0
rack-1 Q21215 Guanine nucleotide-binding protein subunit beta-2-like 1 1 0 1 2 1 0 2329 ppm
ifb-1 Q19289 Intermediate filament protein ifb-1 0 16 0 0 1 0 1291 ppm
ifa-1 D2Y8W0 Protein F38B2.1d 0 13 0 0 1 0 413 ppm
hpo-34 Q6A2D2 Protein HPO-34 0 12 0 0 1 0
hil-4 O17536 Histone H1.4 (Histone H1-like protein 4) 0 5 0 0 1 0 122 ppm
ZK1321.4 Q9XTP9 Protein ZK1321.4a 0 4 0 0 1 0 207 ppm
lam-2 Q18823 Laminin-like protein lam-2 0 3 0 0 1 0 152 ppm
mlc-5 Q9XVI9 Protein MLC-5 0 3 0 0 1 0
tag-18 Q22508 Protein TAG-18 0 2 0 0 1 0 131 ppm
ifd-1 Q86DC6 Intermediate filament protein ifd-1 0 2 0 0 1 0 66.2 ppm
H03A11.2 Q9XTW1 Protein H03A11.2 0 2 0 0 1 0 48.1 ppm
K07C5.4 Q21276 Uncharacterized NOP5 family protein K07C5.4 5 0 4 2 1 1 411 ppm
K06G5.1B Q5WRM0 Protein K06G5.1 4 3 3 2 1 1 320 ppm
rps-1 P48154 40S ribosomal protein S3a 4 1 3 4 1 1 2661 ppm
asp-6 O01530 Aspartic protease 6 (EC 3.4.23.-) 3 4 5 1 1 1 961 ppm
rpl-11.2 Q19162 Protein RPL-11.2 3 2 1 1 1 1 808 ppm
hil-2 P15796 Histone H1.2 (Histone H1-like protein 2) 2 4 2 1 1 1 275 ppm
isp-1 O44512 Cytochrome b-c1 complex subunit Rieske, mitochondrial (EC 1.10.2.2) 2 3 2 2 1 1 458 ppm
T09B4.5 O02155 Protein T09B4.5, isoform a 2 2 2 1 1 1 156 ppm
rpl-31 Q9U332 60S ribosomal protein L31 2 1 2 1 1 1 864 ppm
cey-4 Q9XTJ6 Protein Y39A1C.3 2 0 4 2 1 1 927 ppm
F53F4.10 Q20719 Probable NADH dehydrogenase 1 2 2 1 1 1 413 ppm
Y63D3A.7 Q9XWG2 Protein Y63D3A.7 1 1 0 2 1 1 287 ppm
lec-1 O45904 Protein LEC-1, isoform b 0 3 1 0 1 1 1421 ppm
 tag-61 O45865 Protein ANT-1.1, isoform a 5 2 4 4 1 2 1798 ppm
clec-265 Q21471 Protein CLEC-265 4 1 2 3 1 2 13.1 ppm
rpl-33 P49180 60S ribosomal protein L35a 3 1 2 1 1 2 2326 ppm
D1054.10 Q18943 Protein D1054.10 2 2 1 2 1 2 267 ppm
rps-25 P52821 40S ribosomal protein S25 2 1 2 1 1 2 2175 ppm
rpl-41 P48166 60S ribosomal protein L44 (L41) 2 1 2 0 1 2 2062 ppm
T04A8.6 Q22135 Protein T04A8.6 2 0 2 2 1 2 68.0 ppm
C56G2.7 Q09289 Proteasomal ubiquitin receptor ADRM1 homolog 2 0 1 2 1 2 702 ppm
F58F12.1 Q09544 ATP synthase subunit delta 1 2 2 2 1 2 1959 ppm
rps-27 Q9TXP0 40S ribosomal protein S27 1 2 1 3 1 2 191 ppm
Y54F10AM.5 Q9BL03 Protein Y54F10AM.5 1 1 1 1 1 2 367 ppm
aly-1 Q17561 Protein ALY-1 1 0 3 0 1 2 120 ppm
R12E2.13 O61793 Protein R12E2.13 1 0 1 2 1 2 89.4 ppm
his-1 P62784 Histone H4 6 7 3 2 1 3 681 ppm
pqn-53 Q21793 Protein PQN-53, isoform a 4 1 3 0 2 0 69.6 ppm
asp-1 Q9TVS4 Aspartic protease 1 4 1 1 5 2 0 1290 ppm
LLC1.2 O17954 Protein LLC1.2, isoform a 2 3 4 2 2 0 117 ppm
Y34B4A.6 Q95Y29 Protein Y34B4A.6 2 2 2 2 2 0 174 ppm
C08F11.11 O62053 UPF0375 protein C08F11.11 1 1 2 1 2 0 137 ppm
hrpf-1 Q8MQG5 Putative uncharacterized protein W02D3.11 1 0 1 0 2 0 83.0 ppm
sodh-1 Q17334 Alcohol dehydrogenase 1 1 0 0 0 2 0 1763 ppm
ketn-1 A7DT47 Kettin (Drosophila actin-binding) homolog protein 1 0 42 0 0 2 0 134 ppm
flu-2 Q18026 Kynureninase 0 4 0 2 2 0
myo-5 Q21‘000 Protein MYO-5 0 0 0 0 2 0 141 ppm
tba-2 P34690 Tubulin alpha-2 chain 4 2 3 5 2 1 874 ppm
asp-2 Q86NE0 Protein ASP-2, isoform b 3 3 4 2 2 1 202 ppm
ucr-2.1 Q9BI61 Protein VW06B3R.1b 3 1 3 2 2 1 968 ppm
let-2 P17140 Collagen alpha-2(IV) chain 2 6 2 2 2 1 18.6 ppm
htz-1 Q27511 Histone H2A.V (H2A.F/Z) 2 2 2 2 2 1 1163 ppm
Y67D2.3 Q9BKQ9 Protein Y67D2.3 2 1 1 2 2 1 262 ppm
nduf-5 Q9N3D9 Protein NDUF-5 1 2 2 2 2 1 453 ppm
ile-1 P90913 ERGIC-53-like protein 1 1 0 6 2 1 149 ppm
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ZC412.10 A8WHT2 Protein ZC412.10 0 0 0 2 2 1 NA
F45H10.3 O02267 Protein F45H10.3 4 5 1 2 2 2 436 ppm
rps-10 O01869 Protein RPS-10 4 4 3 4 2 2 2017 ppm
rps-17 O01692 40S ribosomal protein S17 4 2 3 3 2 2 3320 ppm
rpl-5 P49405 60S ribosomal protein L5 4 2 1 3 2 2 3694 ppm
rla-1 P91913 60S acidic ribosomal protein P1 3 3 3 2 2 2 4729 ppm
cey-2 P91306 Protein CEY-2 3 1 2 4 2 2 490 ppm
perm-2 O44145 Protein PERM-2 2 2 2 2 2 2
dpy-17 Q20778 Protein DPY-17 2 1 2 1 2 2 15.9 ppm
gln-1 Q95YD1 Protein GLN-1 2 1 0 3 2 2 32.4 ppm
hsp-1 P09446 Heat shock 70 kDa protein A 5 8 7 3 2 3 2550 ppm
rps-6 Q9NEN6 40S ribosomal protein S6 3 4 4 6 2 3 2440 ppm
ubl-1 P37165 Ubiquitin-like protein 1-40S ribosomal protein S27a 3 2 3 4 2 3 592 ppm
hpo-18 O16298 Protein HPO-18 2 4 3 1 2 3
perm-4 O44144 Protein PERM-4 2 3 0 5 2 3
rps-21 P49197 40S ribosomal protein S21 1 1 2 4 2 3 2616 ppm
mdh-2 O02640 Probable malate dehydrogenase, mitochondrial (EC 1.1.1.37) 5 2 3 2 3 0
rps-22 O17218 Protein RPS-22, isoform a 3 2 2 3 3 0 2759 ppm
mig-6 O76840 Papilin (Abnormal cell migration protein 6) 2 13 2 2 3 0 155 ppm
enol-1 Q27527 Enolase 2 1 2 0 3 0 4422 ppm
lec-6 Q9N384 Protein LEC-6 1 1 1 1 3 0 737 ppm
nmy-1 Q20641 Protein NMY-1 0 9 0 0 3 0 114 ppm
lev-11 Q27249 Tropomyosin isoforms c/e 0 6 0 0 3 0 7575 ppm
vig-1 O16646 Vig (Drosophila vasa intronic gene) 3 2 1 3 3 1 1843 ppm
tbb-2 P52275 Tubulin beta-2 chain (Beta-2-tubulin) 10 6 5 8 3 2 1372 ppm
rps-2 P51403 40S ribosomal protein S2 7 6 3 5 3 2 2158 ppm
his-3 P09588 Histone H2A 5 4 4 4 3 2 372 ppm
pab-1 Q9U302 Protein PAB-1, isoform a 5 4 2 5 3 2 840 ppm
rps-7 Q23312 40S ribosomal protein S7 5 2 3 4 3 2 2334 ppm
rpl-23 P48158 60S ribosomal protein L23 4 1 2 3 3 2 2135 ppm
rpl-32 Q22716 Protein RPL-32, isoform a 3 4 2 5 3 2 2363 ppm
F49E2.5 D0VWM5 Protein F49E2.5, isoform k 3 3 2 1 3 2 456 ppm
cey-1 O62213 Protein CEY-1 3 2 3 2 3 2 1132 ppm
rps-5 P49041 40S ribosomal protein S5 3 2 2 2 3 2 1535 ppm
rpl-10 Q09533 60S ribosomal protein L10 (QM protein homolog) 3 1 4 6 3 2 2038 ppm
rps-9 Q20228 40S ribosomal protein S9 3 1 2 3 3 2 2186 ppm
Y66H1A.4 Q9TYK1 Probable H/ACA ribonucleoprotein complex subunit 1-like protein 2 1 3 2 3 2 345 ppm
rpl-7 O01802 60S ribosomal protein L7 6 3 3 4 3 3 2403 ppm
rps-14 P48150 40S ribosomal protein S14 5 5 5 3 3 3 1597 ppm
rpl-30 Q9XWS4 Protein RPL-30, isoform a 4 0 1 3 3 3 1099 ppm
rps-30 Q18231 Protein RPS-30 3 4 3 2 3 3 154 ppm
rpl-25.1 P48162 60S ribosomal protein L23a 1 2 3 2 3 3 3 1316 ppm
rpl-24.1 O01868 60S ribosomal protein L24 6 1 5 5 3 4 3526 ppm
rpl-14 Q9XVE9 Protein RPL-14 3 3 3 3 3 5 3227 ppm
cbd-1 O45599 Protein CBD-1 4 10 2 13 3 14 17.7 ppm
pqn-22 O02143 Prion-like-(Q/n-rich)-domain-bearing protein protein 22 0 19 0 0 4 0 218 ppm
C44B7.10 Q18599 Protein C44B7.10 5 1 2 2 4 1 2154 ppm
rps-18 O18240 Protein RPS-18 3 5 3 4 4 1 4920 ppm
rps-16 Q22054 40S ribosomal protein S16 5 3 5 3 4 2 2456 ppm
rpl-19 O02639 60S ribosomal protein L19 4 2 2 2 4 2 3055 ppm
rpl-20 O44480 60S ribosomal protein L18a 3 3 2 2 4 3 2610 ppm
rps-11 Q20206 Protein RPS-11 7 4 5 5 4 4 1776 ppm
rpl-3 P50880 60S ribosomal protein L3 5 4 3 4 4 4 2393 ppm
rps-26 O45499 40S ribosomal protein S26 5 3 5 3 4 4 1335 ppm
rps-19 O18650 40S ribosomal protein S19 4 5 4 5 4 4 2483 ppm
rpl-35 P34662 60S ribosomal protein L35 4 4 4 4 4 4 4176 ppm
his-24 P10771 Histone H1.1 3 5 4 3 4 4 596 ppm
rps-24 Q1XFY9 Protein RPS-24 3 2 2 4 4 4 2060 ppm
his-11 P04255 Histone H2B 1 3 7 5 5 4 5 426 ppm
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rpl-4 O02056 60S ribosomal protein L4 9 7 3 7 4 7 2708 ppm
vit-6 P18948 Vitellogenin-6 12 5 2 8 5 0 1565 ppm
rps-15 Q9XVP0 40S ribosomal protein S15 6 4 4 5 5 1 2721 ppm
fib-1 Q22053 rRNA 2'-O-methyltransferase fibrillarin 5 3 4 3 5 1 712 ppm
rps-13 P51404 40S ribosomal protein S13 3 4 2 3 5 1 2561 ppm
rpl-13 P91128 60S ribosomal protein L13 5 4 3 6 5 2 2209 ppm
atp-4 O16517 Protein ATP-4 4 5 4 6 5 2 2175 ppm
lys-1 O62415 Protein LYS-1 3 3 3 3 5 2 148 ppm
rpl-27 P91914 60S ribosomal protein L27 2 3 3 5 5 2 2873 ppm
rla-2 Q9U1X9 Protein RLA-2 7 5 6 6 5 3 5637 ppm
rps-3 P48152 40S ribosomal protein S3 6 3 5 6 5 3 2815 ppm
rpl-10 Q9N4I4 60S ribosomal protein L10a 4 4 4 3 5 3 2038 ppm
rpl-12 P61866 60S ribosomal protein L12 4 5 3 4 5 4 3385 ppm
rpl-36 P49181 60S ribosomal protein L36 3 4 4 5 5 5 1493 ppm
unc-15 P10567 Paramyosin (Uncoordinated protein 15) 0 24 1 1 6 1 2391 ppm
rps-23 Q19877 40S ribosomal protein S23 4 5 4 4 6 2 2491 ppm
Y69A2AR.18 Q95XJ0 Protein Y69A2AR.18, isoform a 4 2 6 5 6 2 1322 ppm
rpl-21 P34334 60S ribosomal protein L21 6 5 5 4 6 3 2356 ppm
R09H10.5 Q21884 Protein R09H10.5 5 2 4 5 6 3 70.4 ppm
unc-87 P37806 Protein unc-87 (Uncoordinated protein 87) 1 19 1 2 6 3 626 ppm
rpl-22 P52819 60S ribosomal protein L22 6 4 8 6 6 4 3299 ppm
prdx-2 A8DYR6 Peroxiredoxin protein 2 6 3 4 6 6 4 2916 ppm
mlc-2 P19626 Myosin regulatory light chain 2 3 7 5 5 6 4 2051 ppm
rpl-28 Q21930 60S ribosomal protein L28 8 7 5 6 6 5 2695 ppm
 rpl-37 Q9U2A8 60S ribosomal protein L37a 5 3 4 5 6 5 83.8 ppm
rpl-8 Q9XVF7 60S ribosomal protein L8 7 5 8 5 6 6 1650 ppm
rpl-25.2 Q20647 60S ribosomal protein L23a 2 5 4 7 5 6 7 2133 ppm
ifb-2 Q19286 Intermediate filament protein ifb-2 0 7 0 0 7 0 533 ppm
F40F4.6 Q20219 Protein F40F4.6 11 3 8 0 7 1 223 ppm
T25C12.3 Q22774 Protein T25C12.3 11 6 8 7 7 3 233 ppm
atp-3 P91283 Protein ATP-3, isoform a 8 6 9 6 7 6 1538 ppm
rpa-0 Q93572 60S acidic ribosomal protein P0 9 7 6 8 7 8 2663 ppm
rpl-18 O45946 60S ribosomal protein L18 7 6 5 7 8 4 3797 ppm
rps-4 Q9N3X2 40S ribosomal protein S4 12 8 7 11 8 7 2657 ppm
rpa-2 O01504 60S acidic ribosomal protein P2 7 7 8 8 8 8 138 ppm
rpl-26 Q19869 60S ribosomal protein L26 7 5 6 8 8 8 1712 ppm
atp-5 Q17763 Protein ATP-5 10 5 10 8 8 9 1427 ppm
unc-52 B6VQ97 Protein ZC101.2d 1 27 7 13 9 0 71.9 ppm
lev-11 Q22866 Tropomyosin isoforms a/b/d/f 0 12 0 2 9 2 7575 ppm
eft-3 P53013 Elongation factor 1-alpha (EF-1-alpha) 7 4 5 8 9 3 3510 ppm
dim-1 Q18066 Disorganized muscle protein 1 8 9 6 5 9 4 594 ppm
H27A22.1 O17912 Protein H27A22.1a 13 6 9 5 9 9 8.86 ppm
rps-8 P48156 40S ribosomal protein S8 10 8 7 10 9 10 2237 ppm
H28O16.1 Q9XXK1 ATP synthase subunit alpha 6 7 6 8 10 4 6282 ppm
T25F10.6 Q23050 Protein T25F10.6, isoform a 1 27 4 4 10 4 1392 ppm
rpl-6 P47991 60S ribosomal protein L6 9 6 7 10 10 7 2295 ppm
act-1 P10983 Actin-1 8 15 6 7 10 7 2359 ppm
atp-2 P46561 ATP synthase subunit beta, mitochondrial (EC 3.6.3.14) 10 8 9 8 10 9 6267 ppm
mlc-3 P53014 Myosin, essential light chain (Myosin light chain alkali) 5 11 12 10 12 9 7584 ppm
rpl-7A Q966C6 60S ribosomal protein L7a 14 7 11 11 13 7 2015 ppm
myo-3 P12844 Myosin-3 (Myosin heavy chain A) (MHC A) 0 38 2 3 25 3 489 ppm
let-75 P02567 Myosin-1 0 50 0 4 29 2 603 ppm
myo-2 P12845 Myosin-2 (Myosin heavy chain C) (MHC C) 1 49 1 9 31 4 570 ppm
unc-54 P02566 Myosin-4 15 104 21 53 102 47 2658 ppm
Table 2 Proteins that were identified by LC-MS/MS analyses after DEP-1::HA pull-down experiments.
LC-MS/MS analyses identified 246 proteins. Every pull-down was done in dublicate. The numbers represent the peptides 
that were detected. Min. Protein Probability = 95%; Min. Number of Peptides = 2. Values from „Protein abundance“ corre-
spond to the „C.elegans PaxDB integrated dataset“ (www.pax-db.org).
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Figure 3.8 Comparison of LC-MS/MS results after HA- and GST pull-down experiments.
(A) Number of proteins identified by LC-MS/MS analyses after StrepTactin-HA double purification, HA single purification, 
and GST-purification. (B) Overlap of proteins identified by LC-MS/MS analyses after HA single purification and GST-puri-
fication of DEP-1intraDA. (C) Number of proteins identified by LC-MS/MS analyses after StrepTactin-HA double purifica-
tion, HA single purification, and GST-purification. (D) Average number of peptides corresponding to one protein identified 
by LC-MS/MS analyses after HA single and GST-purification. (E) Influence of amount of protein extract on the number of 
identified proteins by LC-MS/MS analyses of HA-purified proteins. (F) Average abundance of the proteins identified by LC-
MS/MS analyses after HA single- and GST-purification. (G) Relative protein abundance of proteins identified by LC-MS/
MS analyses after HA single purification and (H) GST purification. Protein abundance was calculated from C. elegans PaxDB 
integrated dataset. PMin protein = 95%, #Min peptides = 2; PMin peptide = 95%. 
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3.2.7 Comparison of LC-MS/MS results after HA- and GST pull-down experiments
3.2.8 Production of polyclonal DEP-1 antibodies
LC-MS/MS analyses of HA- and GST-purified DEP-1 led to the identification of total 683 proteins. 
Surprisingly, no proteins were identified which bound to both DEP-1intraDA::HS and GST::DEP-1 
intraDA but not to the controls (Fig 3.8 B), although in both methods the intracellular domain of DEP-1 
was purified. However, the vast majority of identified proteins were found in one or both of the control 
fractions, indicating that the HA-purified DEP-1::HS still contained numerous contaminants that were 
not identified by analyzing the HA-controls.
Further comparison of the LC-MS/MS data of the three different purification methods (SH-double pu-
rification, HA-single purification, and GST-purification) revealed that the amount of purified DEP-1 af-
fects the number of identified proteins significantly (Fig. 3.8 C, D). Moreover, the confidence of proteins 
identified by LC-MS/MS could be enhanced by increasing the yield of purified DEP-1, represented by 
the number of peptides belonging to a protein (Fig. 3.8 E). And in addition, higher amounts of purified 
DEP-1 led to the identification of more proteins that are less abundant (Fig. 3.8 F-H). Thus, our data 
suggest that the yield of purified DEP-1 affects not only the quantity of proteins identified by LC-MS/
MS but also their quality. 
An alternative way to identify novel interaction partners of DEP-1 would be to perform co-immunopre-
cipitation experiments, in which antibodies binding specifically to DEP-1 are used to capture the pro-
tein complex. Since there were no C. elegans DEP-1 antibodies available, we produced polyclonal DEP-1 
antibodies that are directed against the intracellular domain of GST-tagged DEP-1.
Therefore, the GST-tagged intracellular domain of DEP-1 (GST::DEP-1intra, pTB29) was expressed in 
E. coli BL21 and purified using GST-sepharose (Fig. 3.9 B). After elution from the sepharose, the purified 
DEP-1 was used for the immunization of the two rabbits 006-9AB-1D2 and 006-9AC-B07 at the institute 
of laboratory animal sciences, whose sera were received after three months (Fig. 3.9 A step 1). 
The rabbit sera contained a large diversity of antibodies that would affect the quality of immunohisto-
chemical experiments. Thus, we affinity-purified the DEP-1 specific antibodies from the sera by a Hi-
Trap NHS-activated column that was previously packet with GST::DEP-1 (Fig. 3.9 A step 2). Antibodies 
specific for GST::DEP-1 were retained in the column, whereas other antibodies were washed away. After 
washing, the antibodies could be eluted under acidic and basic conditions. A Ponceau-stained dot blot 
enabled the identification of the fractions containing the eluted antibodies (Fig. 3.9 C).
The affinity-purified antibodies contained not only DEP-1, but also GST-specific antibodies. Thus, we 
performed a second affinity-purification with another HiTrap NHS-activated column that was packed 
with GST (Fig. 3.9 A step 3). The eluates from the first affinity-purification were passed through the 
GST column, whereas only the GST but not the DEP-1 specific antibodies were retarded. Finally, the 
affinity-purified antibodies were aliquoted and stored at -80°C. 
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Figure 3.9 Workflow of the production of polyclonal DEP-1 antibodies.
(A) Immunization [1] of rabbits with purified GST::DEP-1intra. After 3 months, the rabbits were bleeded to optain the sera. 
[2] First affinity-purification with NHS activated HiTrap column coupled with purified GST::DEP-1. After flow through of 
the serum, unspecific antibodies were washed off the column, whereas antibodies specific for GST::DEP-1 remained bound 
to the column before they were eluted with 100 mM Glycine (pH=2.5) and 100 mM Triethylamine (pH=11.5). [3] Second 
affinity-purification with NHS activated HiTrap column coupled with purified GST. Flow through of the eluted antibodies 
resulted in the separation of DEP-1 and GST-specific antibodies. (B) Monitoring of the GST::DEP-1 purification by SDS-PA-
GE and Coomassie Blue staining. (C) Ponceau-stained DotBlot allowed the identification of the fractions containing DEP-1 
antibodies after elution with 100 mM Glycine (pH=2.5) and 100 mM Triethylamine (pH=11.5) during affinity-purification.
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Figure 3.10 Polyclonal DEP-1 antibodies.
(A) Total protein extract of 50 worms (wild-type N2, dep-1(lf);lip-1(lf), and Peft-3::dep-1full::HS) boiled in 50 µl of SDS 
loading buffer was analyzed on Western blot using polyclonal antibodies against DEP-1. Arrow indicates the signal corres-
ponding to DEP-1. (B) Same as in (A) with the difference that protein extraction was performed by dounce homogenization. 
(C) Eluates of StrepTactin-purified DEP-1full::HS and DEP-1intra::HS were stained with DEP-1 antibodies. Arrow indicates 
the signal corresponding to DEP-1full and arrowhead indicates DEP-1intra. (D-F) Immunostainings of C. elegans using po-
lyclonal DEP-1 antibodies and (D’-F’) monoclonal AJM-1 antibodies which stain the cell-junctions. (D’’-F’’) Merged images 
of DEP-1 and AJM-1 images with DAPI staining of the nuclei (blue). (D) Head of an adult animal, (E) mid region of a larva 
in the Pn.pxx stage, and (F) vulva of a L4 larva. 
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3.2.9 Examination of polyclonal DEP-1 antibodies
3.2.10 Generation of endogenous DEP-1 reporters by using MosTIC
The specificity of the affinity-purified DEP-1 antibodies was examined by immunoblots in which pro-
tein extracts of N2, dep-1(lf);lip-1(lf), and Peft-3::dep-1full::HS animals were analyzed (3.10 A and B). Our 
results indicated that DEP-1 was weakly stained in N2 animals, not observable in dep-1(lf);lip-1(lf) mu-
tants, and clearly visible in animals that expressed DEP-1 under the ubiquitous promoter eft-3. However, 
only the purified antibodies of the rabbit 006-9AC-B07 but not of 006-9AB-1D2 recognized DEP-1 (Fig. 
3.10 A and B, data not shown). Since StrepTactin-purified DEP-1full::HS and DEP-1intraD1241A::HS 
also were recognized by the produced polyclonal DEP-1 antibodies, we assumed that they were func-
tional and specific for DEP-1 (Fig. 3.10 C).
Additionally, we tested if the polyclonal DEP-1 antibodies also work for C. elegans immunostaining. 
Thereby, fixed and permeabilized worms were incubated with polyclonal DEP-1 as well as αAJM-1 anti-
bodies that stain the cell junctions of the VPCs. After DNA staining with Hoechst dye, the animals were 
mounted on coverslips and analyzed by fluorescence microscopy. A weak and diffuse signal of stained 
DEP-1 could be observed in some neurons of the head (Fig. 3.10 D) and in the vulva of a few animals 
of L4 larval stage (Fig. 3.10 F). However, no DEP-1 expression in the VPCs could be detected in Pn.pxx 
larvae (Fig. 3.10 E). Since we did not further optimize the immunostaining with αDEP-1 antibodies, we 
are not yet able to determine if they would be functional for C. elegans immunostaining.
Until recently, the expression of transgenes in C.elegans was limited to the introduction of extrachromo-
somal repetitive structures, which behave like additional chromosomes in the cells. Since the sequences 
present on these structures are often overexpressed whereas they are silenced in the germline (Kelly et 
al., 1997; Stinchcomb et al., 1985), the translated proteins are usually not expressed in physiological con-
ditions. 
In 2009, a novel transgene-instructed genome engineering technique called MosTIC (Mos1 excision‐in-
duced transgene‐instructed gene conversion) has been reported, allowing the generation of endogenous 
reporters in C. elegans (Robert et al., 2009). MosTIC is initiated by the mobilization of Mos1, a 1.3 kb 
DNA transposon that was isolated from Drosophila mauritiana (Jacobson and Hartl, 1985; Jacobson et 
al., 1986), which was inserted by its controlled mobilization into the genome of C. elegans (Fig. 3.11 A). By 
expressing the Mos transposase in the germline, the Mos1 insertion is re-excised from the genomic loci 
and thereby causing a double-strand break (DSB). This DSB is naturally repaired by recombination using 
homologous chromosome as repair template. However, the recombination machinery can also recognize 
extrachromosomal transgenic repair templates, in which a transgene of interest (e.g. gfp or mCherry) is 
f lanked by two “arms” homologous to the genomic region broken by Mos1 excision (Robert et al., 2009). 
The homologous recombination with such a transgene allows to generate single copy transgenes at a 
defined locus in the genome. 
The strain ttTi25065 contains a Mos1 insertion in the dep-1 3’UTR, enabling the generation of an en-
dogenous dep-1::gfp or dep-1::mCherry reporter. To establish the MosTIC technique in our laboratory, we 
tested three different approaches.
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Fig. 3.11 Creating of endogenous DEP-1 reporters by MosTIC.
(A) Intron exon structure of dep-1 and position of the Mos1 transposon insertion ttTi25067. In presence of the Mos1 trans-
posase (2), the Mos1 transposon is mobilized and generates a double-strand break (DSB) at the excision site. e DSB is 
repaired by homologous recombination (3, 4) using a transgenic repair template, in which gfp (B) or mCherry (C and D) 
is anked by 2 kb of genomic DNA. (C) In the repair template pMW24 an unc-119 rescue construct is anked by FRT sites. 
Aer repair by transgene instructed gene conversion (4), addition of FLPase excises the unc-119 rescue construct (5, 6). 
(D) mCherry is fused to the dep-1 3’UTR, followed by an unc-119 rescue construct. (E) Design of the MosTIC repair tem-
plates pMW23, pMW24, pMW25, pMW28, and pMW29. 
Figure 3.11 Creation of endogenous DEP-1 reporters by MosTIC.
(A) Intron exon structure of dep-1 and position of the Mos1 transposon insertion ttTi25067. In presence of the Mos1 trans-
posase [2], the Mos1 transposon is mobilized and generates a double-strand break (DSB) at the excision site. The DSB is 
repaired by homologous recombination [3, 4] using a transgenic repair template, in which gfp (B) or mCherry (C and D) is 
flanked by 2 kb of genomic DNA. (C) In the repair template pMW24 an unc-119 rescue construct is flanked by FRT sites. 
After repair by transgene instructed gene conversion [4], addition of FLPase excises the unc-119 rescue construct [5, 6]. (D) 
mCherry is fused to the dep-1 3’UTR, followed by an unc-119 rescue construct. (E) Design of the MosTIC repair templates 
pMW23, pMW24, pMW25, pMW28, and pMW29. 
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Strategy A
To insert a GFP tag at the 3’ end of the dep‐1 locus, we generated a repair template (pMW23) in which 
the coding sequence of gfp is f lanked by the last 1.9 kb of the dep‐1 locus and by 2 kb of the dep-1 3’ ge-
nomic region respectively (Fig. 3.11 B). This repair template was micro-injected together with the germ-
line specific transposase (Pglh‐2::MosTase) and the co-injection‐marker Pmyo‐3::mCherry into young 
adult worms homozygous for the Mos1 insertion ttTi25065 to generate extrachromosomal transgenes. 
Thereafter, each P0 animal was transferred to an individual plate and kept at 20°C to give rise to F2-F3 
progeny. 
The identification of transgenic animals in which the GFP has been integrated into the genome occurred 
via a PCR-based screen (Fig. 3.11 B). Thereby, the genomic DNA was extracted form half of a plate con-
taining F2-F3 progeny and tested by PCR for positive integrants. In case of a positive test, the remaining 
half of animals could be sub-pooled and subsequently analyzed by further rounds of PCR-screenings, 
until the animals homozygous for the integrated transgene were identified (for details see Fig. 4 of Robert 
et al., 2009). However, the PCR-screening did not lead to the identification of animals in which the GFP 
-tag was integrated into the dep-1 locus.
Strategy B
As in strategy A, the coding sequence of gfp/mCherry was flanked by the last 1.9 kb of the dep‐1 locus 
and by 2 kb of the dep-1 3’ genomic region, respectively. In addition, the repair constructs pMW24 and 
pMW25 contained the C. briggsae unc-119 rescue sequence that is f lanked by two flippase recognition 
targets (FRT; Fig. 3.11 C, E). These repair templates were micro-injected together with the germline spe-
cific transposase (Pglh‐2::MosTase), and the co-injection‐marker Pmyo‐3::mCherry into ttTi25065;unc-
119(lf) animals. Thereafter, each P0 animal was transferred to an individual plate and kept at 20°C to 
give rise to progeny. The F2-F3 progeny was screened for animals that both lost the extrachromosom-
al repair template and displayed a rescue of the paralyzed Unc phenotype. Thereby, a strain in which 
mCherry::FRT::unc-119(+)::FRT was integrated in the locus of dep-1 could be isolated. 
Next, we tried to excise the unc‐119 rescuing sequence from the obtained transgenic animals by FLP-
FRT site directed recombination. Adding of flippase (FLPase), which recognizes the FRT sites that are 
flanking unc-119(+), catalyzed a recombination between the two identical but oppositely oriented FRT 
repeats (Fig. 3.11 C step 5) to excise unc-119(+) out of the genome and thereby in animals that show the 
Unc phenotype again. 
We first expressed the FLPase under the heat specific promoter Phsp-16-48 and made two heat-shock 
treatments (2x 30min at 33°C with an interval of 16 hours). This led to the identification of ten animals 
that showed an Unc phenotype, indicating that the FRT-flanked unc-119 rescuing construct was excised. 
However, all progeny of these animals exhibited a non-Unc phenotype, why we hypothesized that the 
unc-119 rescuing construct was only excised in the somatic cells but not in the germline. 
For a stronger expression of the FLPase in the germline, we expressed the FLPase under the two promot-
ers Pglh-2 and Peft-3. However, expression of Pglh-2::FLPase (pMW26) or Peft-3::FLPase (pMW27) did 
not result in the identification of animals showing an Unc phenotype.
Strategy C
In the strain received from Strategy B, in which mCherry::FRT::unc-119(+)::FRT was integrated into the 
locus of dep-1, the unc-119 rescue construct disrupted the dep-1 3’UTR. Thus, we made new rescue con-
structs in which the dep-1 3’UTR was cloned in front of the C. briggsae unc-119 rescue sequence without 
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3.2.11 Comparison of DEP-1 reporter lines
In our laboratory, four different reporter lines have been generated to explore the expression pattern of 
DEP-1, namely a transcriptional and an extrachromosomal translational DEP-1::GFP reporter (Berset, 
2005), as well as two MosTic engineered lines in which a GFP or mCherry tag was introduced directly 
into the endogenous dep-1 locus.
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Figure 3.12 Comparison of DEP-1 reporters.
Expression of DEP-1 in Pn.pxx stage (A-A’’), in early L4 stage (B-B’’), in late L4 stage (C-C’’), in the head region (D-D’’), and 
in the tail region (E-E’). (A-E) Extrachromosomal translational dep-1::gfp reporter line zhEx112. (A’-E’) MosTIC engineered 
endogenous dep-1::gfp reporter line zhIs70. (A’’-D’’) MosTIC engineered endogenous dep-1::mCherry reporter line zhIs71. 
Except for (A-E), all images are z-projections (average intensity) of spinning-confocal z-stacks. Scale bar represents 10 µm.
being flanked by FRT sites (Fig. 3.11 D, E). By micro-injecting the repair template pMW28 or pMW29 
together with the germline specific transposase (Pglh‐2::MosTase) and the co-injection‐markers Pmyo-
2::mCherry, Pmyo‐3::mCherry, and Prab-3::mCherry into ttTi25065;unc-119(lf) animals, we were able to 
receive the MosTIC engineered strains zhIs70 (dep-1::gfp) and zhIs71 (dep-1::mCherry). 
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3.2.12 Analysis of vulval morphogenesis in dep-1(lf) mutants
After induction of the vulval cell fates, the VPCs undergo a phase of morphogenetic changes to form the 
adult vulva. Thereby, the vulval cells invaginate and move from the ventral midline toward the dorsal 
uterus (Fig. 3.13 A). At the same time, the cells extend circumferentially toward the vulval midline to 
form a stack of seven toroid-shaped cells surrounding a central lumen (Sharma-Kishore et al., 1999). 
These morphogenetic movements are controlled by LET-502, which induces actomyosin-mediated con-
traction of the apical lumen in the secondary toroids to generate a dorsal pushing force (Farooqui et al., 
2012). 
The role of actin assembly during vulval morphogenesis can be examined by the analysis of filamentous 
actin (F-actin), visualized by the reporter Pdlg-1::LifeAct::gfp (Farooqui et al., 2012). During vulval de-
velopment, LifeAct::GFP is expressed in the VPCs of Pn.pxx stage larvae, already before morphogenic 
movements take place. Particularly, LifeAct::GPF is upregulated in P6.p descendants VulF and VulE as 
well as in the outer descendants VulA and VulB of P5.p and P7.p (Fig. 3.13 B and D). 
The fact that DEP-1::GFP is expressed reciprocally to LifeAct::GFP (downregulation in the primary 
lineage and upregulation in the inner descendants of P5.p and P7.p), led to the hypothesis that DEP-1 is 
involved in controlling actin activity during vulval morphogenesis (Fig. 3.13 B,C). This assumption was 
further supported by the identification of the integrin β-subunit PAT-3 as a substrate of DEP-1, since it 
has been reported that integrins play a crucial role in cell adhesion and migration by providing trans-
membrane links between the extracellular matrix and the actin cytoskeleton (Zaidel-Bar et al., 2007). 
The extrachromosomal translational DEP-1::GFP reporter line zhEx112 indicated that DEP-1 is down-
regulated in the 1° lineage, whereas expression was persistent in the 2° vulval cells until the L4 stage 
(Fig. 3.12 A-C; Berset, 2005). Most of the DEP-1::GFP fusion protein was expressed intracellularly and in 
the endoplasmatic reticulum (ER), but not at the cell membrane as it is expected for a transmembrane 
protein. A similar expression pattern was observed by analysis of a transcriptional Pdep-1::gfp reporter 
(Berset, 2005).
As described in section 3.2.7, we created two DEP-1 reporter lines zhIs70 (DEP-1::GFP) and zhIs71 (DEP-
1::mCherry) by MosTIC. Since APF phenotype of dep-1(lf);lip-1(lf) animals was rescued by DEP-1::GFP 
zhIs70, we assume that the tagged dep-1 is functional. In the Pn.pxx stage of zhIs70 animals, DEP-1::GFP 
is weakly expressed at the apical side of the VPCs and in the cytoplasm of the 2° lineage (Fig. 3.12 A’), 
whereas no cytoplasmic expression could be observed in the 1° lineage. 
In the VPCs of L4 larvae, DEP-1::GFP was expressed at the apical side of the VPCs, but also in intra-
cellular punctae of the 2° lineage (Fig. 3.12 B’ and C’). In addition, DEP-1::GFP expression was found 
in numerous neurons in the head (Fig. 3.12 D’), in the rectal cells, and in the dorso-rectal and lumbar 
ganglions (Fig. 3.12 E’).  
Similar to the expression of DEP-1::GFP in the line zhIs70 was the expression pattern of DEP-1::mCherry 
in zhIs71 animals. However, cytoplasmic expression of DEP-1::mCherry was strongly enhanced in both 
the 1° and 2° VPCs of Pn.pxx larvae (Fig. 3.12 A’’). Furthermore, DEP-1::mCherry expression was more 
dotted in the head region (Fig. 3.12 D’’) compared to DEP-1::GFP (zhIs70). Though, in the vulva of L4 
larvae, the expression patterns of both MosTic engineered reporters looked similarly, namely at the api-
cal membrane with some intracellular punctae in the 2° lineage (Fig. 3.12 B’’ and C’’). 
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3.2.13 Nidogen-1 – another putative substrate of DEP-1 
Among the proteins that were identified by LC-MS/MS after pull-down of N2 protein extract with GST-
purified DEP-1intraDA was Nidogen (NID-1; Fig. 3.1). NID-1 (entactin) is a 174.4 kD glycoprotein that 
consists of two amino (G1 and G2) and one carboxyl (G3) terminal globular domains that are connected 
by a rod domain composed primarily of endothelial growth factor (EGF) repeats (Fox et al., 1991; Kang 
and Kramer, 2000). Being a major constituent of basement membrane, NID-1 forms a complex with col-
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Figure 3.13 Analysis of LifeAct::GFP in dep-1(lf) mutants.
(A) Morphogenetic changes form the vulva. VPCs invaginate and move dorsal from the ventral midline toward the dorsal 
uterus. (B) Schematic intensity of DEP-1::GFP and LifeAct::GFP expression during Pn.pxx stage larvae. Blue arrows repre-
sent schematic intensities of morphogenetic movements taking place during further vulval development. (C) Expression 
of the translational DEP-1::GFP reporter zhEx112 (adapted from Berset et al., 2005). (D) Expression of LifeAct::GFP in a 
wild-type and (E) a dep-1(lf) Pn.pxx stage larva. (F) LifeAct::GFP expression in a wild-type and (G) a dep-1(lf) L4 larva. 
Maximum intensity projections of z-stacks. (F’ and G’) Corresponding Nomarski images.
To investigate if DEP-1 affects the assembly of filamentous actin, we compared the expression of 
LifeAct::GFP in the VPCs of wild-type and dep-1(lf) animals in the Pn.pxx stage and in L4 vulvae (Fig. 
3.13 D-G). Thereby, we analyzed fluorescence images taken by a standard fluorescence microscope and 
a spinning-disc microscope. However, we were not able to observe an alteration in the expression of 
LifeAct::GFP in the VPCs of dep-1(lf) animals, neither in the inner descendants of P5.p and P7.p during 
Pn.pxx stage, nor in the vulva of L4 larvae. Together with the fact that vulval morphogenesis develop-
ment is not obviously altered in dep-1(lf) mutants, we conclude that DEP-1 is not involved in controlling 
morphogenetic movements during vulval development by regulating actin assembly via the integrins. 
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lagen and laminin-1 (Aumailley et al., 1993). Nevertheless, loss of nid-1 results in viable animals that are 
fertile and that display no overt abnormal phenotypes (Kang and Kramer, 2000). 
To examine the role of NID-1 during vulval development, we first created the transcriptional Pnid-
1::gfp reporter line zhEx479. In three-fold staged embryos, Pnid-1::gfp expression could be observed 
predominantly in the body wall muscle cells (Fig. 3.14 B’). In L4 larvae, strong expression of Pnid-1::gfp 
was observed in developing somatic structures of the gonad and in numerous neurons (Fig. 3.14 A’). 
However, significant Pnid-1::gfp expression was neither observed in the VPCs of animals in the Pn.pxx 
stage nor in the vulva of early and late L4 larvae (Fig. 3.14 C’-E’), which is contradictory to the findings 
of Kang and Kramer (2000). By immunostaining of worms with anti-NID-1 antibodies, a strong NID-1 
accumulation was reported to be seen in the vulva of late L3 to L4 stage larvae (Kang and Kramer, 2000). 
Since no further information about VPC specific expression has been reported, the examination of a 
translational NID-1::GFP would be needed. Such a reporter line would also allow verifying the interac-
tion of DEP-1intraDA with NID-1 by performing co-immunoprecipitation experiments. 
We next tested if nid-1 affects RAS/MAPK signaling during vulval development. If so, we would expect 
to see that nid-1(lf) shows the same adjacent primary fate phenotype in the sensitized lip-1(lf) back-
ground as it is observed in dep-1(lf);lip-1(lf) animals. However, no alterations in vulval morphology 
could be observed in nid-1(lf);lip-1(lf) double mutants. 
Since we could neither observe an expression of Pnid-1::gfp in the VPCs, nor had nid-1(lf) an effect on 
vulval development in the sensitized lip-1(lf) background, we did not further analyze this candidate.
Figure 3.14 Expression pattern of NID-1::GFP.
Expression of an extrachromosomal transcriptional Pnid-1::gfp reporter in a L4 larva (A’), in a three-fold-staged embryo 
(B’), in a Pn.pxx staged larva (C’), in an early L4 staged larva (D’), and in a late L4 staged larva (E’). (A-E) Corresponding 
Nomarsky images. 
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A conserved function of C. elegans CASY-1 calsyntenin in associative learning
3.3 A conserved function of C. elegans CASY-1 calsyntenin in associative lear-
ning
   -  ls t i  i  ss i ti   
 learning
Several studies have shown that C. elegans is a convenient model to study genes implicated in associative 
memory (Mohri et al., 2005; Rose and Rankin, 2006; Saeki et al., 2001; Zhang et al., 2005). By using dif-
ferent sensory neurons and integrating interneurons, nematodes can learn about mechanosensory input 
(Rose and Rankin, 2001), chemosensory input (Morrison et al., 1999; Wen et al., 1997), and thermosen-
sory input (Mori, 1999) to approach or avoid tastes, odors or temperatures that predict the presence or 
absence of food.
In collaboration with Andreas Papassotiropoulos, Dominique de Quervain, and Frédéric Hoerndli, we 
analyzed the associative learning behavior of C. elegans mutants lacking genes that were identified in 
a genome-wide screen for gene variants associated with human episodic memory performance (Papas-
sotiropoulos et al., 2006). 
My own contribution to this manuscript
In order to test the associative learning behavior of different mutants in C. elegans, I established the 
“gustatory” NaCl chemotaxis assay (Saeki et al., 2001) in our laboratory. This behavior test is based on 
the observation that wild-type worms display a strong attraction to 25 mM NaCl. However, when worms 
are starved on plates that contain NaCl, the chemotaxis towards NaCl decreases dramatically (Saeki et 
al., 2001). In contrast to wild-type worms, casy-1(tm718) mutants did not show an aversion but only a 
partial decline in their attraction towards NaCl when they were starved in the presence of NaCl (Fig. 3 A 
of the manuscript Hoerndli et al., 2009). Hence, the NaCl chemotaxis assay enables the characterization 
of learning-deficient mutants, and thereby in a further understanding of genes involved in associative 
learning behavior. 
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A Conserved Function of C. elegans CASY-1 Calsyntenin
in Associative Learning
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Abstract
Background: Whole-genome association studies in humans have enabled the unbiased discovery of new genes associated
with human memory performance. However, such studies do not allow for a functional or causal testing of newly identified
candidate genes. Since polymorphisms in Calsyntenin 2 (CLSTN2) showed a significant association with episodic memory
performance in humans, we tested the C. elegans CLSTN2 ortholog CASY-1 for possible functions in the associative behavior
of C. elegans.
Methodology/Principal Findings: Using three different associative learning paradigms and functional rescue experiments,
we show that CASY-1 plays an important role during associative learning in C. elegans. Furthermore, neuronal expression of
human CLSTN2 in C. elegans rescues the learning defects of casy-1 mutants. Finally, genetic interaction studies and neuron-
specific expression experiments suggest that CASY-1 may regulate AMPA-like GLR-1 glutamate receptor signaling.
Conclusion/Significance: Our experiments demonstrate a remarkable conservation of the molecular function of
Calsyntenins between nematodes and humans and point at a role of C. elegans casy-1 in regulating a glutamate receptor
signaling pathway.
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Introduction
The cellular and molecular mechanisms underlying learning
and memory are the focus of intense research. Although many new
components have been described that are conserved across
different animal species, the exact mechanisms by which synaptic
strength is regulated remain elusive [1] . Long-term potentiation
(LTP) and depression (LTD), which are a key mechanisms
underlying memory formation, involve plastic changes in synaptic
strength through modulation of AMPA Glutamate receptor
currents [2]. One frequently used mechanism by which neurons
modulate synaptic strength is through the regulation of the
number of neurotransmitter receptors at the surface of synapses
[3]. Intracellular trafficking, exo- and endocytosis of receptors as
well as surface dynamics also play important roles in regulating the
exact number of receptors at the synapse [2,4]. However, the exact
mechanisms by which this is achieved are not completely
understood.
Studies in both invertebrates and vertebrates have identified
several genes and signaling pathways important for learning and
memory. From this work it appears that many of the memory-
related molecular mechanisms are conserved across different
species. Despite the obvious differences in learning and memory
tasks performed by different species and the anatomical differences
between their nervous systems, recent human genetic studies
suggest that genetic variability in the orthologs of related signaling
molecules known from studies in model organisms contributes to
inter-individual memory differences in humans [5]. Therefore,
genes associated with human episodic memory identified in whole-
genome association studies could provide new insights into the
mechanisms underlying memory formation and storage.
Recently, an unbiased genome-wide screen for human hippo-
campus-dependent, episodic memory, which studied more than
500000 single nucleotide polymorphisms (SNPs), resulted in the
identification of CLSTN2 (encoding calsyntenin 2) as a memory-
related human gene [6]. Specifically, C allele carriers of a common
TRC substitution within CLSTN2 had better episodic memory
performance than TT genotype carriers in a verbal delayed recall
task, which was performed by 341 Swiss young adults (median age
22 years). The better performance of the C allele carriers was
observed 5 min and 24 h after learning, whereas immediate recall
performance was similar between genotype groups, indicating that
CLSTN2 is related to hippocampus-dependent memory perfor-
mance and that the findings were not biased by possible
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4880
87
A conserved function of C. elegans CASY-1 calsyntenin in associative learning
differences in motivation, attention and working memory
performance between groups. This association was not replicated
in a second population of middle-aged participants from the US,
which may be partially attributed to differences in ethnicity, in
mean age between study populations, or in differences between
cognitive tasks used [6]. However, a recent independent study in
Figure 1. Olfactory associative learning defects in casy-1(tm718) mutants. (A) Rooted tree diagram showing the sequence similarities
between the invertebrate and the three classes of vertebrate calsyntenins. The protein sequences of CLSTN1, CLSTN2 and CLSTN3 from Homo sapiens
(Hs), Mus musculus (Mm), Danio rerio (Dr) and the single calsyntenins from Drosophila melanogaster (Dm), Apis mellifera (Am) and Caenorhabditis
elegans (Ce) were aligned using the ClustalX program, and a rooted tree was drawn using PHYLIP. Note that the invertebrate calsyntenins and the
vertebrate CLSTN2 proteins originate from a common branch. (B) Chemotaxis of wild-type and casy-1(tm718) worms towards 1022, 1023 and 1024
fold dilution of Diacetyl in 100% EtOH(V/v) assay in the absence of conditioning. The assays were repeated on three different days using one plate for
each condition and were quantified using the chemotaxis Index CI (CI = (worms in DA - worms at EtOH)/ total number of worms, see methods). Error
bars indicate the standard error of mean. White bars: wild-type N2, Black bars: casy-1(tm718). (C) Swimming assay of casy-1(tm718), wild-type, nicotinic
Acetylcholine-receptor acr-16 knock out (ok789) and levamisole acetylcholine-receptor unc-29 subunit knock-out (x29). Number of body bends per
minute counted manually, and blinded to the respective genotypes (N= 20). (D) Chemotaxis of starvation conditioned wild-type and casy-1(tm718)
animals. The experiment was repeated on three separate days with six replicates per assay. The results of a Student t-test are indicated as * = p,0.05
and ** =p,0.01. (E) Food sensing assay. Locomotion rate of wild-type and casy-1(tm718) worms in body bends/20 seconds of worms transferred
from a food plate to another food plate (FED), or worms allowed to starve on an empty agar plate for 1 hr (STARVED). White bars: wild-type, Black
bars: casy-1(tm718). (F) Adaptation assay. Comparison of the chemotaxis Index CI of wild-type and casy-1(tm718) to 0.1% DA after starving for 1 hour
without DA (White bars), with 100% DA (Black Bars) and on food for 2 hours with 100% DA (Grey bars). Assays were repeated on two different days
using 3 replicates per condition. For the complete dataset of the behavioral assays, see Table S1.
doi:10.1371/journal.pone.0004880.g001
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adolescents replicated the beneficial effect of the CLSTN2 C allele
on verbal recall [7].
Even though there exists no direct equivalent of human episodic
memory in the small nematode C. elegans, several forms of
associative behaviour and long-term memory have been observed
in this model organism [8–11]. For example, C. elegans is capable of
pairing food deprivation sensation with olfactory cues [12],
gustatory cues [9] and the temperature of its environment [11]
by using different sensory neurons and integrating interneurons.
Essentially, this type of learning is akin to some classical
conditioning paradigms such as conditioned taste aversion
(CTA) where an unconditioned stimulus (US) is paired with a
conditioned stimulus (CS) [13]. Moreover, C. elegans is capable of
distinguishing multiple cues based on past experience using a
serotonin dependent mechanism [8]. Together with an easily
modifiable genetic background and many available knock-out
alleles, C. elegans allows a fast and systematic way to analyze genes
implicated in associative memory.
Taking advantage of the fact that the C. elegans genome encodes
only one CLSTN gene (casy-1) homologous to vertebrate CLSTN2
and that a knock-out allele is available, we show that casy-1 plays an
important role in associative learning in both thermotaxis and
chemotaxis conditioning paradigms. While this work was in progress,
an independent study has identified casy-1 in a forward genetic screen
for behavioural mutants [14]. In addition to the reported behavioural
defects of casy-1 mutants, we show here that the pan-neuronal
expression of human CLSTN2 rescues the chemotaxis conditioning
defect of casy-1(tm718), thus demonstrating a strong conservation
between CLSTN2 and casy-1 at the level of their molecular function.
Finally, we describe a putative mechanism for CASY-1 in regulating
associative behaviour via glutamate receptor signalling based on
neuron-specific rescue experiments and on the genetic interaction
between casy-1 and the glutamate receptor subunit glr-1.
Results and Discussion
The C. elegans genome encodes a single CLSTN2
ortholog casy-1
To test a causal relationship between CLSTN2 function and
learning and memory, we searched the genomes of invertebrate
model organisms for CLSTN2 orthologs. While vertebrate
genomes typically encode three Calsyntenin family members, the
genomes of invertebrates like Drosophila melanogaster and C. elegans
contain only a single Calsyntenin gene (Fig. 1A). Protein sequence
alignment of the three vertebrate Calsyntenin family members
with the invertebrate Calsyntenins indicates that the single C.
elegans homolog CASY-1 as well as Drosophila Calsyntenin are most
similar to vertebrate CLSTN2 (Fig. 1A).
CLSTN2 is a type I transmembrane protein with two
extracellular calcium-binding cadherin domains and two intracel-
lular kinesin light chain-binding domains [15,16]. These domains
are conserved in all three Calsyntenin family members including
C. elegans CASY-1 [15]. Similar to mammalian Calsyntenins, a
transcriptional casy-1 reporter is expressed in many head nerve
ring neurons, some of which send processes into the ventral nerve
cord (Fig. 2A and data not shown). Moreover, a GFP-tagged
CASY-1 protein was reported to localize at synapses (Duan and
Hedgecock, personal communication). Given the sequence
similarity between human CLSTN2 and C. elegans CASY-1 and
their neuronal expression in both organisms, we asked whether the
casy-1 gene might function in regulating associative learning in C.
elegans. The casy-1 deletion mutant tm718 (kindly provided by S.
Mitani) contains a 601 bp deletion in exon 4, creating a frameshift
followed by a premature stop codon. The tm718 allele results in the
production of a protein truncated at position 117 that lacks most of
the extracellular and the entire intracellular domain. We observed
no obvious anatomical, behavioral or locomotory defects in naive
casy-1(tm718) animals (Fig. 1B,C). Moreover, casy-1(tm718) animals
appear healthy and are fertile.
Behavioral defects in C. elegans casy-1 mutants
To test associative learning in C. elegans, we used three
established context-dependent behavioral paradigms that are
based on olfactory, gustatory and thermosensory starvation
conditioning, respectively [11,17]. The chemotaxis of naive casy-
1(tm718) animals to three different volatile attractants was
comparable to the response of the wild-type strain (Fig. 1B and
Fig. S1). We thus investigated the olfactory associative learning
capacity of casy-1(tm718) animals by testing their ability to reverse
the attraction to an odorant after associating this odorant with a
Figure 2. Expression pattern of a transcriptional casy-1 reporter. (A) Expression of the casy-1p::RFP transcriptional reporter (red) and (B) a
GLR-1::GFP translational reporter (blue) [22] in the nerve ring of an adult animal. A 3D reconstruction of confocal sections through the left hemisphere
is shown (see methods). The two arrowheads in the bottom right corner point at RMDDL and SMDDL and the arrowhead in the top half points at
SMDVL, which co-express casy-1p::RFP and GLR-1::GFP. Anterior is left and ventral is bottom. Scale bar in (B) is 10 mm.
doi:10.1371/journal.pone.0004880.g002
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negative stimulus such as starvation (see methods). After starvation
conditioning, the chemotaxis index (CI) of unconditioned controls
and conditioned animals was compared in a quantitative
chemotaxis assay [17]. Unconditioned wild-type and casy-
1(tm718) animals both displayed strong chemotaxis to 0.1%
diacetyl (DA, Fig. 1D), indicating that casy-1(tm718) mutants have
no sensory defects in DA olfaction under these conditions. After a
one hour starvation period in the presence of DA, wild-type
animals did not show any attraction to DA, while casy-1(tm718)
mutants were still significantly attracted by DA (CI= 0.3, p,0.01
using a Student t-test, 6 replicates repeated three times), albeit less
efficiently than unconditioned control animals (Fig. 1D). The
behavioral difference between wild-type and casy-1(tm718) animals
is not due to a defect in food detection, since we observed normal
slowing of casy-1(tm718) locomotion compared to wild-type, when
animals were deprived of food and replaced on a new bacterial
lawn (Fig.1E) [18].
To investigate the possibility that the chemotactic association
defect of casy-1(tm718) could be due to adaptation (i.e. a decrement
in response due to sensory fatigue that cannot be dishabituated
[19]) rather than to an associative learning defect, we pre-exposed
both strains to concentrated DA in the presence of abundant food
before measuring their CI to 0.1% DA (gray bars in Fig. 1F). DA-
adapted wild–type and casy-1(tm718) animals showed a similar
partial reduction in their CI to DA , indicating that casy-1(tm718)
mutants can adapt to high concentrations of DA. We thus
conclude that a loss of casy-1 function predominantly reduces
associative learning without significantly impairing olfactory
adaptation.
Next, we tested the performance of casy-1(tm718) mutants in an
‘‘gustatory’’ NaCl chemotaxis conditioning paradigm [9]. Wild-
type worms display a strong attraction to 25 mM NaCl that is
reversed when worms are first starved in the presence of NaCl in
liquid cultures for 1 hour (Fig. 3A) [9]. Unconditioned casy-
1(tm718) worms displayed a chemotaxis index (CI) that was similar
to naive wild-type animals. However, when starved in the presence
of NaCl casy-1(tm718) mutants did not show an aversion but only a
partial decline in their attraction towards NaCl (Fig. 3A).
To test the associative behavior in the context of a third sensory
system, we examined the performance of casy-1(tm718) mutants in
a thermotaxis conditioning paradigm. Wild-type animals typically
migrate towards the temperature at which they had been
previously fed, but they avoid this temperature after a 3 hour
starvation period [11]. We used a modified version of this
conditioning paradigm by training groups of worms at specific
temperatures and placing them on thin agar plates with a steep
temperature gradient to measure their Thermotaxis Index (TTI)
[20]. Wild-type worms grown at 15uC showed a TTI close to zero
after 3 hours of starvation conditioning at 15uC, whereas casy-
1(tm718) animals continued to exhibit significant albeit reduced
thermotaxis to 15uC after starvation conditioning at this
temperature (Fig. 3B).
In conclusion, casy-1(tm718) mutants exhibit strong associative
learning defects in the context of three different sensory stimuli
with no sensory impairment of the naive animals when compared
to wild-type. These results point at a central function of CASY-1 in
promoting associative learning downstream of different sensory
stimuli.
Expression of human CLSTN2 rescues the behavioral
defects of casy-1 mutants
To confirm that the olfactory and thermotaxis association
defects observed in tm718 animals are due to the loss of casy-1
function, we introduced a casy-1 minigene composed of 5 kb of 59
regulatory sequences fused to 3 kb cDNA of the long casy-1
isoform (B0034.3a) and 3 kb of 39 non-coding sequences into casy-
1(tm718) animals. A transgenic line carrying the casy-1 minigene
on an extrachromosomal array (zhE242.1[casy-1 minigene]) was
tested in the olfactory and thermotaxis conditioning paradigms.
We calculated a learning index (%LI) as the difference between the
CI or TTI of unconditioned and conditioned animals divided by
the CI or TTI, respectively, of the unconditioned animals [8] (see
methods). In both paradigms, the transgenic animals showed
Figure 3. NaCl chemotaxis and thermotaxis associative learn-
ing defects in casy-1(tm718) mutants. (A) Chemotaxis of starvation
conditioned wild-type (N2) and casy-1(tm718) worms to 25 mM NaCl.
The chemotaxis index was calculated as CI = (worms at NaCl - worms at
neutral)/ total number of worms. The experiment was repeated on
three separate days with three replicates per assay. Error bars indicate
the standard error of mean. (B) Thermotaxis association experiments
with wild-type and casy-1 (tm718) animals. The thermotaxis index was
calculated as TTI = (worms on the cold side of the plate – worms on the
warm side)/ total worms in the assay. The experiment was repeated on
three separate days. Error bars indicate the standard error of mean. In
(A) and (B), the results of a Student t-test are indicated as * = p,0.05
and ** =p,0.01. For the complete dataset, see Table S1.
doi:10.1371/journal.pone.0004880.g003
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significant rescue of the %LI, while their non-transgenic siblings
(casy-1(tm718) sibs without array) that were simultaneously scored
on the same assay plates exhibited behavioral defects comparable
to the parental casy-1(tm718) strain (Fig. 4A, B).
To test the functional conservation between human CLSTN2
and C. elegans CASY-1 at the molecular level, we expressed human
CLSTN2 cDNA under the control of the pan-neuronal unc-119
promoter and with the C. elegans casy-1 39UTR in place of the
CLSTN2 39UTR in casy-1(tm718) mutants and measured the %LI
of CLSTN2 transgenic animals using the olfactory conditioning
assay. All three transgenic lines that were tested showed a
significant rescue of the behavioral defects (Fig. 4C). Control
transgenic animals carrying the unc-119 promoter-casy-1 39UTR
vector lacking the CLSTN2 cDNA insert exhibited no significant
increase in the %LI when compared to non-transgenic casy-
1(tm718) animals (Fig. S2). Thus, human CLSTN2 can function-
ally replace C. elegans CASY-1 in an associative learning paradigm.
CASY-1 acts in a GLR-1 Glutamate receptor pathway
Human CLSTN1 and CLSTN2 form a complex with the
MINT2/X-11-like neuronal adaptor protein and kinesin light chain
(KLC1), suggesting a function for CLSTNs in the transport or
sorting of synaptic vesicles [15,16,21]. Since mutations in the C.
elegans ortholog of Mint2 (lin-10) cause defects in the clustering of the
AMPA-type glutamate receptor subunit GLR-1 at the synapses of
ventral cord interneurons and LIN-10 can bind to the PDZ binding
motif at the C-terminus of GLR-1 [22], we hypothesized that
CASY-1 might regulate the synaptic function or transport of GLR-
1. Even though we did not observe a significant mislocalization of a
translational GLR-1::GFP reporter in ventral cord motorneurons of
casy-1(tm718) mutants (data not shown), glr-1(n2461) mutants
showed similar association defects in the olfactory conditioning
assays as casy-1(tm718) mutants (Fig. 5A). Notably, GLR-1 has been
previously shown to be important for olfactory assocation and
critical for long-term memory in C. elegans [23,24]. To test a possible
function of CASY-1 in a GLR-1 signaling pathway, we examined
the genetic interaction between casy-1(tm718) and glr-1(n2461). We
found no further reduction in the %LI in the casy-1(tm718); glr-
1(n2461) double loss-of-function mutant compared to either single
mutant, suggesting that casy-1 and glr-1may act in the same pathway
regulating olfactory conditioning (Fig. 5A). We thus tested if
increased levels of GLR-1 could rescue the behavioral defects of
casy-1(tm718) mutants. For this purpose, we introduced a rescuing
multicopy extrachromosomal array containing a 6 kb fragment
spanning the glr-1 locus (zhEx243.1[glr-1(+)]) into the casy-1(tm718)
background. casy-1(tm718); zhEx243.1[glr-1(+)] animals showed a
similar %LI in the olfactory conditioning assay as wild-type animals
Figure 4. Rescue of the casy-1(tm718) behavioral defect with C.
elegans casy-1 and human clstn2 transgenes. (A) Rescue of the
chemotaxis and (B) thermotaxis conditioning defects with a casy-1
minigene. Results obtained with one (zhEx242.1) of four transgenic lines
are shown. To quantify the rescue, we defined a % Learning Index as
%LI = 100 . (CI of naive worms - CI of conditioned worms)/ CI of naive
worms) and analogous for the TTI. As controls, casy-1(tm718) animals
that had lost the GFP-labeled extrachromosomal rescuing array (casy-
1(tm718) sibs without array) were included with the transgenic animals
in the assay, and their %LI was scored in parallel with the %LI of the
transgenic animals. (C) Rescue of the casy-1(tm718) chemotaxis
conditioning defects by expression of human CLSTN2 cDNA under
control of the neuronal unc-119 promoter and the casy-1 39UTR. The
results obtained with three independent lines zhEx282.1 to zhEx282.3
are shown. In (C), Student t-test LIs from casy-1(tm718) were compared
to LIs of the rescue lines. For the complete dataset, see Table S1 and
Fig. S2.
doi:10.1371/journal.pone.0004880.g004
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(Fig. 5A). Thus, increasing the GLR-1 gene dosage can compensate
for the behavioral defects of casy-1(tm718) mutants, suggesting that
CASY-1 positively regulates GLR-1 signaling during olfactory
conditioning.
Some of the head neurons expressing the casy-1 transcriptional
reporter also expressed the glr-1::gfp reporter (Fig. 2B). Strongest
co-expression was seen in the RMDD, SMDD, RMD and SMDV
motor/interneurons that regulate head turning, and weaker casy-
1p::rfp expression was observed in the glr-1-positive AVE command
interneurons (not visible in Fig. 2B). We therefore tested if
expression of casy-1 under control of the glr-1 promoter was
sufficient to rescue the olfactory learning defects of casy-1 (tm718)
mutants. In two out of four lines tested, the DA starvation
conditioning defect was completely and in the remaining two lines
weakly rescued (Fig. 5B and Table S1). Thus, casy-1 acts at least in
part in glr-1 positive neurons during olfactory associative learning.
It is interesting to note that Ikeda et al.[14] found that during salt
chemotaxis conditioning, expression of casy-1 in glr-1 positive
neurons was not sufficient to rescue the associative learning
defects. Accordingly, a recent study by Kano et al. [25] showed
that associative learning as well as short-term memory using the
salt chemotaxis conditioning paradigm are not glr-1 dependent.
Thus, casy-1 may perform another, glr-1 independent function
during gustatory (salt) chemotaxis learning, as casy-1 may act in
multiple, distinct pathways depending on the type of sensory
inputs that need to be associated with the starvation signal.
Conclusions
In summary, our study reveals an important role of C. elegans
casy-1 calsyntenin in associative learning in response to different
environmental stimuli. It should be noted that in all the association
assays shown, the behavior of conditioned casy-1(tm718) mutants
still significantly differed from the naive controls (i.e. the %LI of
casy-1 mutants was always greater than 0), indicating that loss of
casy-1 function does not result in a complete loss of all associative
behavior. Thus, there must exist multiple parallel pathways
controlling associative learning in C. elegans. For example,
components of the insulin signaling pathway have been implicated
in salt chemotaxis learning, and casy-1 was found to act in parallel
to the insulin pathway during salt chemotaxis learning [14].
Finally, we demonstrate that the molecular function of human
CLSTN2 and C. elegans CASY-1 is conserved, as human
Calsyntenin-2 can functionally replace CASY-1 during olfactory
learning. Given the relatively large evolutionary distance between
these two species and the anatomical dissimilarity of their nervous
systems, this degree of conservation at the molecular level is
remarkable. Thus, Calsyntenin might be a key component of
conserved molecular pathways regulating different aspects of
learning and memory in diverse species.
Methods
Strains were maintained and grown according to standard
procedures [26]. Wild-type refers to C. elegans Bristol, variety N2.
casy-1(tm718) mutants were kindly provided by the Mitani Lab and
backcrossed three times before use in all assays. All transgenic
animals were generated by microinjection of the indicated DNAs
into the syncytial gonads as described. Alleles and transgenes used:
LGI: unc-29(x29) (kind gift of A.V. Maricq); LGII: casy-1(tm718);
LGIII: glr-1(n2461); LGV: acr-16(ok789); transgenes: zhEx242.1[-
casy-1 minigene; sur-5::gfp], zhEx243.1[glr-1(+), lin-48 ::gfp],
zhEx282.1 to 282.3[unc-119p::CLSTN2::casy-1 39UTR, sur-5::gfp],
zhEx285.1 to zhEx285.3[unc-119p::no insert::casy-1 39UTR, sur-5::gfp],
zhEx245[casy-1p::rfp], nuIs24[glr-1::gfp], Ex[glr-1p::casy-1].
PCR fusion constructs
All DNA fragments were amplified using proof reading polymerase
from C. elegans genomic DNA or total N2 cDNA. Individual
fragments were fused by PCR fusion [27]. A 6 kb genomic glr-1
fragment was amplified (forward: 59-ccggtcatacgggagataga-39, re-
verse: 59- taaattttcctgggggcttc-39) to generate zhEx243.1. 5 kb of the
59 UTR region of casy-1 (forward outer: 59- ggatattggtcaccttcccta-39,
Figure 5. Genetic interaction between casy-1 and the glr-1
glutamate receptor signaling pathway. (A) Chemotaxis condition-
ing assays with casy-1(tm718) and glr-1(n2461) single and the double
mutants and rescue of casy-1(tm718) conditioning defects by over-
expression of glr-1 using the zhEx243.1 array. (B) Rescue of the casy-
1(tm718) conditioning defects by expression of casy-1 cDNA under
control of the glr-1 promoter. The average %LI of four independent
lines is shown. Two of the lines showed a complete and two lines a
partial rescue of the %LI. For comparison, the data for the casy-1
minigene rescue experiment from fig. 4 A are shown. The scoring and
quantifications were done as described in the legend to [Fig. 4]. For the
complete dataset, see Table S1.
doi:10.1371/journal.pone.0004880.g005
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nested forward: 59- ttctagattattctgacaaccatttg-39, reverse: 59-cgagcag-
catggtgatgtttg-39) were fused to 2995 bp casy-1 cDNA (B0034.3a, 59
fusion primer: 59-actcacgcacacaaaaccaatcatgcgaactgcgtactttatttttgtc-
39, reverse: 59- ggagggagtcatgaatgttga-39) and 1.6 kb of 39UTR
(forward 39UTR: 59-gttcgtttgacaagccgttt-39, nested forward 39UTR:
59- agccgtttggtttttcaatg-39, cDNA fusion primer: 59- aattccttcagg-
catgttgc-39). This PCR construct was used together with the
transformation marker sur-5::gfp to generate zhEx242.1. Details on
the construction of the glr-1p::casy-1, the casy-1p:.rfp and the unc-
119p::CLSTN2::casy-1 39UTR rescue and control (without insert)
constructs are available upon request.
Olfactory conditioning
All assays were conducted with 50–200 well-fed synchronized
young adult worms, using 10 cm Petri CTX agar dishes (2% agar,
5 mM KPO4 pH=6.0, 1 mM CaCl2, 1 mM MgSO4). Except for
agar composition, chemotaxis assays were performed as described
previously [17]. Adaptation and starvation conditioning assays
were performed as previously described [12], except that animals
were washed three times with M9 buffer (22 mM KH2PO4,
22 mM Na2HPO4, 85 mM NaCl, 1 mM MgSO4) for 20 min
each, resulting in 1 hour pre-starvation before the olfactory
conditioning was performed.
NaCl conditioning
Salt chemotaxis and salt chemotaxis learning assays were
assessed as described before with some modifications [28,29],.
Briefly, synchronized and well-fed young adult nematodes were
washed 3 times in CTX buffer. 100–200 worms were placed at the
intersection of a four-quadrant CTX plate to test chemotaxis and
liquid was removed with a tissue paper. Chemotaxis plates were
prepared one day in advance. Pairs of opposite quadrants of four-
quadrant Petri plates (Falcon X plate, Becton Dickinson Labware)
were filled with 16 ml buffered agar (2% agar, 5 mM KPO4 pH 6,
1 mM CaCl2 and 1 mMMgSO4), either containing 25 mM NaCl
or not. Adjacent quadrants were connected with a thin layer of
molten agar 1 h before the assay. The chemotaxis index was
calculated 10 min after the worms were placed on the CTX plates:
(A–C)/ total number of worms), where A is the number of worms
at the quadrants with, and C is the number of worms at the
quadrants without NaCl.
For NaCl chemotaxis learning assays, the collected nematodes
were transferred after the washing procedure into 30 ml CTX
buffer containing 20 mM NaCl for 1 h at room temperature [14],
and chemotaxis was tested immediately afterwards. All experi-
ments were performed in triplicates at least three times.
Thermotaxis conditioning
We created a thermotaxis setup as described previously using a
steep thermal gradient on a thin agar plate [20]. A 2–3 mm thick
CTX agar plate 130 mm long 90 mm wide was rested on heated
and cooled metal blocks, respectively, such that 13uC was
measured at one end and 33u at the other end of the plate.
200–400 worms were spotted along the 22uC isothermic line
measured shortly before applying the worms. The worms were
then left to migrate for 45 min. At the end of the assay, the plate
was separated into a cold region and a warm region along the
22uC isothermic line, and the worms were immediately counted to
determine the TTI as described [20].
Microscopy
For the image shown in Fig. 2, animals were anesthetized with
10 mM NaN3 and mounted in M9 buffer on 3% agarose pads.
Optical sections through the left hemisphere were recorded on a
Leica SP2 confocal microscope using a 636N.A. 1.4 objective and
a z-step size of 0.73 mm. 3D reconstructions were generated using
the volocity 2.3. software package (Improvision) and a lateral view
is shown.
Supporting Information
Figure S1 Naive chemotaxis of wild-type and casy-1(tm718)
mutants. Chemotaxis of naive animals to volatile attractants
(Diacetyl and Isoamyl alcohol) and a repellent (2-Nonanone) was
quantified as described in the methods and the legend to Fig. 1.
The error bars show the SEM.
Found at: doi:10.1371/journal.pone.0004880.s001 (0.39 MB EPS)
Figure S2 Chemotaxis conditioning of casy-1(tm718) negative
control lines. Chemotaxis conditioning transgenic of casy-1(tm718)
carrying the unc-119 promoter-casy-1 39UTR vector without
cDNA insert (zhEx285.1 to zhEx285.3[unc-119p::no insert]). The
average %LI of three independent control lines and their siblings
without array is shown. The LI was calculated as described in the
methods and the legend to Fig. 3 and is expressed as % value.
Found at: doi:10.1371/journal.pone.0004880.s002 (0.38 MB EPS)
Table S1 Supporting document
Found at: doi:10.1371/journal.pone.0004880.s003 (0.52 MB
PDF)
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3.4 PTEN negatively regulates MAPK signaling during C. elegans vulval deve-
lopment
3     
 Caenorhabditis elegans vulval development
The RAS/MAPK, NOTCH, and WNT signaling pathways determine an invariant pattern of cell fates 
during C. elegans vulval development, providing an excellent model to examine the crosstalk between 
different conserved signaling pathways that are deregulated in human cancer. Itay Nakdimon could 
identify in his PhD studies a novel form of crosstalk between components of the insulin pathway and 
the RAS/MAPK pathway during vulval development (Nakdimon et al., 2012). Thereby, the insulin 
receptor DAF-2 stimulates, while DAF-18 PTEN inhibits RAS/MAPK signaling in the VPCs. Genetic 
and biochemical analyses indicated that DAF-18 negatively regulates vulval induction by inhibiting 
MAPK activation.
My own contribution to this manuscript
In collaboration with Anina Schneider (who did her master thesis under my supervision), I was applying 
the previously established mass-spectrometry based approach for the identification of novel interaction 
partners to other GST-tagged fusion proteins such as ERM-1, MADD-2, LET-23, and DAF-18. 
By performing pull-down experiments using the phosphatase domain of DAF-18 containing the sub-
strate trapping mutation D137A, we identified by subsequent LC-MS/MS analyses the MAP kinase 
kinase MEK-2 (see master thesis of Anina Schneider). This led to the idea to investigate the phosphory-
lation level of MEK-2 in let-60(gf) animals and let-60(gf) daf-18(lf) double mutants. However, no further 
increase of pMEK-2 levels could be observed in daf-18(lf) let-60(gf) mutants compared to let-60(lf) ani-
mals (Fig. 2 A of the manuscript Nakdimon et al., 2012). In addition, I made co-immunoprecipitation 
experiments of DAF-18 with MEK-1 and ERK-2, but the results were contradictory and were thus not 
shown in the manuscript.
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Abstract
Vulval development in Caenorhabditis elegans serves as an excellent model to examine the crosstalk between different
conserved signaling pathways that are deregulated in human cancer. The concerted action of the RAS/MAPK, NOTCH, and
WNT pathways determines an invariant pattern of cell fates in three vulval precursor cells. We have discovered a novel form
of crosstalk between components of the Insulin and the RAS/MAPK pathways. The insulin receptor DAF-2 stimulates, while
DAF-18 PTEN inhibits, RAS/MAPK signaling in the vulval precursor cells. Surprisingly, the inhibitory activity of DAF-18 PTEN
on the RAS/MAPK pathway is partially independent of its PIP3 lipid phosphatase activity and does not involve further
downstream components of the insulin pathway, such as AKT and DAF-16 FOXO. Genetic and biochemical analyses indicate
that DAF-18 negatively regulates vulval induction by inhibiting MAPK activation. Thus, mutations in the PTEN tumor
suppressor gene may result in the simultaneous hyper-activation of two oncogenic signaling pathways.
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Introduction
PTEN (Phosphatase and TENsin homologue) is the second-
most frequently somatically mutated tumor suppressor gene in
human cancer. PTEN is often inactivated in glioblastoma,
melanoma, prostate and endometrial neoplasia [1]. Germline
mutations in PTEN are also known to cause a variety of rare
syndromes, collectively known as the PTEN hamartoma tumor
syndromes (PHTS) [2]. Cowden syndrome is the best-described
syndrome within PHTS, with approximately 80% of patients
carrying germline PTEN mutations [3]. The main reported
function of PTEN is as a lipid phosphatase, which dephosphor-
ylates PhosphatidylInositol(3,4,5)-trisphosphate (PIP3) at position
3, thereby inhibiting the insulin pathway [4]. However, PTEN can
also act as a dual-specificity tyrosine and serine/threonine protein
phosphatase [5,6]. The catalytic phosphatase domain of PTEN
(amino acids 123–131) contains several conserved amino acids,
mutations of which affect the efficiency and specificity of the
phosphatase activity [7]. One such mutation is G129E, which
causes PTEN to lose its lipid phosphatase activity while retaining
most of its protein phosphatase activity [4,5]. Using the G129E
mutation, numerous reports have provided evidence for a crucial
role of PTEN protein phosphatase activity in regulating cell
migration, invasion and spreading independently of the canonical
insulin signaling pathway. For example, PTEN G129E regulates
cell migration, spreading, and the formation of focal adhesions [8].
Moreover, PTEN G129E binds and de-phosphorylates the Focal
Adhesion Kinase FAK in vitro [8]. In glioblastoma cells injected
into nude mice, PTEN G129E expression inhibits cell invasion,
accompanied by decreased FAK phosphorylation without chang-
ing the activity of the AKT kinase [6,9]. Additionally, PTEN binds
and dephosphorylates the adaptor protein Shc to modulate cell
motility [10].
The daf-18 gene encodes the single PTEN ortholog in C. elegans
[11]. Under favorable growth conditions, C. elegans larvae pass
through four distinct larval stages termed L1 to L4. However,
under conditions of starvation or overcrowding, the L1 larvae
enter a long-lived, stress resistant alternative developmental stage
called the dauer larva stage. DAF-18 PTEN controls entry into the
larval dauer stage, life span, neurite outgrowth and cell-cycle
progression, mainly by inhibiting the insulin signaling pathway
[12–14]. Human PTEN can functionally replace C. elegans DAF-18
to rescue the daf-18(lf) DAuer Formation defective (DAF-d)
phenotype [15].
In the presence of abundant food, binding of various insulin
ligands to the DAF-2 insulin receptor causes the activation of
AGE-1, the only type I phosphatyidlinositol-3-kinase (PI3K)
encoded by the C. elegans genome [11]. AGE-1 phosphorylates
PI(4,5)P2 to PI(3,4,5)P3, which acts as a second messenger. PIP3
then activates the AKT-1 and AKT-2 kinases that phosphorylate
and thereby inhibit the FOXO transcription factor DAF-16 [16].
In the absence of the insulin signal, non-phosphorylated DAF-16
enters the nucleus and activates genes promoting entry into the
dauer stage [17]. The main reported function of DAF-18 PTEN is
to antagonize the insulin pathway by dephosphorylating PIP3 [14].
Loss of daf-18 thus leads to hyper-activation of the insulin pathway
and a DAF-d phenotype, while loss of daf-2 or age-1 function leads
to a DAuer Formation constitutive (DAF-c) phenotype.
Recent evidence indicates that similar to mammalian PTEN, C.
elegans DAF-18 can also act as a protein phosphatase to regulate
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insulin-independent events. For example, DAF-18 PTEN directly
binds and dephosphorylates the ephrin receptor tyrosine kinase
VAB-1 to regulate oocyte maturation in the hermaphrodite
germline [18]. Moreover, multiple genes causing synthetic lethality
in combination with daf-18(lf) have been identified, pointing to
additional functions of DAF-18 besides its role in insulin signaling
[19].
The development of the C. elegans hermaphrodite vulva, the egg-
laying organ, is one of the best-characterized models for
organogenesis [20]. The interplay between the conserved RAS/
MAPK, NOTCH, and WNT signaling pathways specifies two
distinct vulval cell fates. Beginning in the L2 stage, the gonadal
Anchor Cell (AC) releases the EGF ligand LIN-3, which activates
the EGF receptor homolog LET-23 in the six Vulval Precursor
Cells (VPCs). The VPC located nearest the AC (P6.p) receives
most of the inductive LIN-3 EGF signal and hence exhibits the
strongest activity of the RAS/MAPK pathway, allowing P6.p to
adopt the primary (1u) vulval cell fate. Consequently, P6.p
produces a lateral signal that activates the LIN-12 NOTCH
signal in the neighboring VPCs P5.p and P7.p. Notch signaling in
these two VPCs induces them to adopt the secondary (2u) cell fate
and at the same time blocks transduction of the inductive LIN-3
signal by inhibiting MAPK activation. The 1u VPC P6.p and the
2u VPCs P5.p and P7.p each go through three rounds of cell
division to generate 22 cells that form the vulva. The remaining
three distal VPCs (P3.p, P4.p and P8.p) adopt the non-vulval 3u
fate, which divide once and then fuse with the surrounding
hypodermis (hyp7).
Mutations in genes encoding components of the RAS/MAPK,
NOTCH, and WNT signaling pathways change the patterning of
the VPC fates, which can readily be quantified. For example,
mutations that hyperactivate the RAS/MAPK pathway cause the
induction of more than three VPCs, resulting in a Multivulva
(Muv) phenotype. On the other hand, mutations that cause a
decrease in RAS/MAPK pathway activity, lead to the induction of
fewer than three VPCs, a phenotype called Vulvaless (Vul).
In this work, we have discovered and characterized a new mode of
crosstalk between components of the insulin and the RAS/MAPK
pathways. Using genetic and biochemical epistasis analyses, we found
that the insulin receptor DAF-2 stimulates while DAF-18 PTEN
inhibits RAS/MAPK signaling in the VPCs. Surprisingly, part of the
inhibitory activity of DAF-18 on the RAS/MAPK pathway is
independent of its PIP3 lipid phosphatase activity and does not
involve further downstream components of the insulin pathway. Our
results indicate that DAF-18 negatively regulates vulval induction
most likely by inhibiting MAP kinase MPK-1 signaling.
Results
daf-18 inhibits vulval induction independently of the
canonical insulin signaling pathway
In our previous work, we reported first evidence for a crosstalk
between the DAF-2 insulin receptor and the RAS/MAPK
signaling pathway during vulval development [21]. To further
investigate this interaction, we performed a systematic epistasis
analysis by combining various mutations in the insulin and RAS/
MAPK signaling pathways and quantifying the levels of vulval
induction (Table 1). As reported previously, a reduction-of-
function (rf) mutation in the insulin receptor daf-2 partially
suppressed the Muv phenotype of let-60 ras gain-of-function (gf)
animals (Table 1, rows 1, 2) [21]. Conversely, a loss-of-function (lf)
mutation in the PTEN homolog daf-18 strongly enhanced the let-
60(gf) Muv phenotype (Table 1, row 3). Moreover, daf-18(lf)
suppressed the vulvaless (Vul) phenotype caused by mutations in
the EGF receptor let-23 or in its cofactor lin-2, which activates the
RAS/MAPK signaling pathway in the VPCs (Table 1, rows 4–7).
Since DAF-18 PTEN counteracts the type I phosphatidyl-inositol-
3 kinase (PI3K) AGE-1 that transduces the insulin signal
downstream of DAF-2, we tested if an age-1(lf) mutation could
revert the enhanced vulval induction caused by daf-18(lf).
Surprisingly, age-1(lf) only partially suppressed the increase in
vulval induction caused by daf-18(lf), both in the let-60(gf) and the
lin-2(lf) backgrounds (Table 1, rows 8, 9). Also, the daf-2(rf)
mutation only partially reverted the enhancement of the let-60(gf)
Muv phenotype by daf-18(lf) (Table 1, row 10), suggesting that
DAF-18 inhibits vulval induction to some extent independently of
DAF-2 and AGE-1. However, mutations in further downstream
components of the DAF-2 insulin pathway had no detectable effect
on vulval induction. For example, a gf mutation in akt-1, which
encodes one of the two AKT homologues transducing the insulin
signal downstream of AGE-1 [16], did not suppress the let-23(rf)
Vul phenotype (Table 1, row 11), and a lf mutation in akt-1 did not
suppress the daf-18(lf) let-60(gf) Muv phenotype (Table 1, row 12).
To examine a possible redundancy between the two akt genes, we
performed akt-2 RNAi in daf-18(lf) let-60(gf); akt-1(lf) triple
mutants, but observed no reduction in vulval induction compared
to the RNAi controls (Table 2, rows 1, 2). Also, a lf mutation in
daf-16, which encodes a FOXO transcription factor that is
negatively regulated by the insulin pathway, did not enhance the
let-60(gf) Muv phenotype (Table 1, row 13).
We further tested the role of AGE-1 during vulval development.
Since age-1(lf) leads to a constitutive dauer phenotype (DAF-c) that
is maternally rescued, homozygous age-1(lf) worms could only be
analyzed in the F1 progeny of heterozygous age-1(lf)/+ parents or
when rescued by the daf-16(lf) mutation. Our analysis indicated
that age-1 also exhibits a partial maternal rescue in vulval induction
since the homozygous age-1(lf); let-60(gf) progeny obtained from
heterozygous age-1(lf)/+ parents displayed similar levels of vulval
induction as let-60(gf) single mutants (Table 1, row 14). In contrast,
homozygous age-1(lf); let-60(gf) double mutants maintained in the
daf-16(lf) background exhibited a partially suppressed Muv
phenotype, though age-1(lf) suppressed the let-60(gf) Muv pheno-
type to a lesser extent than daf-2(rf) (Table 1, row 15, p-
value#0.05 compared to row 2).
Author Summary
The human tumor suppressor PTEN is mutated in many
different types of cancer. Using the roundworm C. elegans
as a model to study how cells communicate during animal
development, we discovered a new mechanism by which
PTEN inhibits the activity of the oncogenic RAS/MAPK
signaling pathway. Focusing on the development of the
vulva, the egg-laying organ of the hermaphrodite, as a
model to investigate the regulation of RAS/MAPK signal-
ing, we could distinguish between two distinct inhibitory
activities of PTEN on the RAS/MAPK signaling pathway. On
the one hand, PTEN acts as a lipid phosphatase that
inhibits the production of PIP3, which in turn stimulates
RAS/MAPK signaling. On the other hand, PTEN acts as a
protein phosphatase that negatively regulates RAS/MAPK
signaling by inhibiting signal transduction at the level of
the MAPK, which is a key component in the pathway.
Understanding the detailed molecular mechanism by
which the PTEN tumor suppressor homolog regulates
signal transduction in C. elegans can help predict the
consequences of mutations in human PTEN for cancer
development in humans.
C. elegans PTEN Inhibits MAPK
PLOS Genetics | www.plosgenetics.org 2 August 2012 | Volume 8 | Issue 8 | e1002881
97
PTEN negatively regulates MAPK signaling during C. elegans vulval development
Taken together, the genetic analysis indicates that the DAF-2
insulin receptor promotes and DAF-18 PTEN inhibits vulval
induction. DAF-2 and DAF-18 both regulate vulval induction
through AGE-1-dependent as well as AGE-1-independent path-
ways that do not utilize the canonical insulin pathway downstream
of AGE-1.
DAF-18 inhibits vulval induction independently of other
PI3Ks
AGE-1 is the only C. elegans member of the type I family of
PI3Ks, which convert PI(4,5)P2 into PI(3,4,5)P3. To further
investigate the AGE-1-independent effect of DAF-18 on vulval
induction, we tested the roles of alternative PI3Ks that can
phosphorylate PIs at position 3. vps-34 encodes a type III PI3K,
which catalyzes the production of PI(3)P1, and piki-1 encodes a
type II PI3K involved in the engulfment of apoptotic cell corpses
[22]. In order to examine the role of these alternative PI3Ks
during vulval induction, we performed RNAi against vps-34 and
piki-1 in age-1(lf); daf-18(lf); lin-2(lf) animals and tested for a further
reduction of vulval induction. RNAi to vps-34 and piki-1 has been
previously shown to be effective in different tissues [23,24].
Neither vps-34 nor piki-1 RNAi caused any significant reduction in
the number of induced VPCs when compared to control (gfp)
RNAi animals (Table 2, rows 3–5). Furthermore, vps-34 and piki-1
RNAi in an age-1(lf); daf-18(lf) let-60(gf) background did not cause a
decrease in vulval induction (Table 2, rows 6–8). It thus seems
unlikely that an alternative PI3K acts redundantly with AGE-1
during vulval induction, further supporting our observation that
DAF-18 regulates vulval induction not only by regulating PIP3
levels but also via a lipid phosphatase-independent activity.
daf-18 inhibits 1u vulval cell fate specification
To characterize the nature of the cell fate transformation caused
by daf-18(lf), we quantified the levels of the EGL-17::CFP reporter,
whose expression is induced by RAS/MAPK signaling in the 1u
vulval cell lineage [25] and of the LIP-1::GFP reporter whose
expression is induced by LIN-12 NOTCH signaling in the 2u
vulval cell lineage [26].
daf-18(lf) let-60(gf) double mutants showed an increased
frequency of adjacent VPC descendants expressing high levels of
EGL-17::CFP when compared to let-60(gf) single mutants
(Figure 1A–1D). Specifically, in daf-18(lf); let-60(gf) double mutants
27% of adjacent VPC descendants showed strong EGL-17::CFP
expression (i.e. at least 50% of the signal intensity seen in the P6.p
lineage) versus 16% in let-60(gf) single mutants (Figure 1G).
Furthermore, while the 2u P5.p and P7.p descendants in the wild-
type displayed weak (i.e. less than 50% of the P6.px signal
intensity) EGL-17::CFP expression in 22% of the cases, 52% of
daf-18(lf) single mutants showed EGL-17::CFP expression in the 2u
cells (Figure 1G).
Besides the slight increase in EGL-17::CFP expression, the
morphology of the vulval invagination at the L4 larval stage was
changed in daf-18(lf) let-60(gf) double mutants. The vulval
invagination formed by the P5.p to P7.p descendants of most let-
60(gf) single mutants resembles the single invagination formed in
the wild-type (Figure 1E). In daf-18(lf) let-60(gf) double mutants, on
the other hand, the P5.p to P7.p descendants were often
completely detached from the cuticle, resulting in an abnormal
shape of the vulval invagination (Figure 1F) (37% detached P5.p
and/or P7.p descendants in daf-18(lf) let-60(gf) versus 3% detached
in let-60(gf), n = 54 and n= 35, respectively). A detachment of the
P5.p and P7.p descendants from the cuticle is indicative of a 2u to
1u cell fate transformation as it has been observed in mutants
exhibiting elevated MAPK activity in the 2u lineage [27].
In contrast to the 1u fate marker EGL-17::CFP, expression of
the 2u fate marker LIP-1::GFP was not changed in daf-18(lf)
mutants. In particular, LIP-1::GFP levels in the P5.p and P7.p
Table 1. Epistasis analysis between the insulin and RAS/
MAPK pathways.
genotype Induction±SE % Vul % Muv n
1 let-60(gf) 4.1660.05 0.00 79.1 283
2 daf-2(rf); let-60(gf) 3.2460.11***(1) 0.00 19.3 31
3 daf-18(lf) let-60(gf) 4.9960.05***(1) 0.00 96.4 221
4 let-23(rf) 0.5560.08 93.8 0.00 129
5 let-23(rf); daf-18(lf) 1.9060.10***(4) 63.9 6.8 133
6 lin-2(lf) 1.3460.19 73.8 0.00 42
7 daf-18(lf); lin-2(lf) 2.5060.12***(6) 35.5 1.7 59
8 age-1(lf); daf-18(lf)
let-60(gf)
4.6160.08***(1) 0.00 94.7 113
9 age-1(lf); daf-18(lf);
lin-2(lf)
2.1560.16***(6) 53.1 6.1 49
10 daf-2(rf); daf-18(lf)
let-60(gf)
4.4060.17(1) 0.00 88.0 25
11 let-23(rf); akt-1(gf) 0.3660.13(4) 94.9 0.00 39
12 daf-18(lf) let-60(gf);
akt-1(lf)
4.8060.29(3) 0.00 80 15
13 daf-16(lf); let-60(gf) 4.1860.11(1) 0.00 77.5 80
14 age-1(lf); let-60(gf){ 4.0860.06(1) 0.00 76.2 164
15 age-1(lf); daf-16(lf);
let-60(gf)
3.6260.15**(1) 0.00 54.1 24
SE indicates the standard error of the mean. % Vul indicates the fraction of
animals with less than three induced VPCs. % Muv indicates the fraction of
animals with more than three induced VPCs. Induction indicates the average
number of induced VPCs per animal.
**indicates a p-value#0.005;
***indicates a p-value#0.0005. Numbers in brackets indicate the row against
which a t-test was performed. Alleles used: LG I: daf-16(mu86), LG II: age-
1(mg44), let-23(sy1), LG III: daf-2(e1370), LG IV: let-60(n1046), daf-18(ok480), LG V:
akt-1(ok525lf), akt-1(mg144af), LG X: lin-2(n397).
{F1 progeny of heterozygous age-1(lf)/+ parents.
doi:10.1371/journal.pgen.1002881.t001
Table 2. RNAi against akt-2 and alternative PI3Ks.
genotype RNAi
Induction
±SE
%
Vul
%
Muv n
1 daf-18(lf) let-60(gf); akt-1(lf) gfp 5.4160.12 0.00 100 17
2 daf-18(lf) let-60(gf); akt-1(lf) akt-2 5.5360.18 0.00 94.4 18
3 age-1(lf);daf-18(lf);lin-2(lf) gfp 1.5960.34 71 12 17
4 age-1(lf);daf-18(lf);lin-2(lf) vps-34 1.6060.28 65 0 20
5 age-1(lf);daf-18(lf);lin-2(lf) piki-1 1.6960.31 69 6 16
6 age-1(lf);daf-18(lf);let-60(gf) gfp 5.1460.20 0 94 17
7 age-1(lf);daf-18(lf);let-60(gf) vps-34 5.4060.16 0 100 15
8 age-1(lf);daf-18(lf);let-60(gf) piki-1 5.4460.12 0 100 17
SE indicates the standard error of the mean. % Vul indicates the fraction of
animals with less than three induced VPCs. % Muv indicates the fraction of
animals with more than three induced VPCs. Induction indicates the average
number of induced VPCs per animal. Alleles used: LG II: age-1(mg44), LG IV: daf-
18(ok480), let-60(n1046), LGV: akt-1(ok525lf), LG X: lin-2(n397).
doi:10.1371/journal.pgen.1002881.t002
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descendants were unchanged in daf-18(lf) let-60(gf) double mutants
compared to let-60(gf) single mutants (Figure 1H–1J).
Thus, daf-18(lf) enhances specification of the 1u cell fate and
causes a partial 2u to 1u fate transformation in P5.p and P7.p
without affecting the strength of the lateral LIN-12 NOTCH
signal.
daf-18 negatively regulates vulval induction downstream
of sos-1 and upstream or at the level of mpk-1
Since EGFR/RAS/MAPK signaling induces the 1u vulval cell
fate and daf-18(lf) mutants exhibited an increased expression of the
1u cell fate marker EGL-17::CFP, we sought to determine at what
level DAF-18 inhibits the activity of the EGFR/RAS/MAPK
signaling pathway. For this purpose, we performed further
epistasis analysis combining daf-18(lf) with mutations in different
components of the RAS/MAPK pathway. Even though daf-18(lf)
single mutants showed no obvious changes in the vulval fate
pattern (Table 3, rows 1, 2), daf-18(lf) increased the levels of vulval
induction in most of mutants in the RAS/MAPK pathway tested,
confirming that DAF-18 negatively regulates the RAS/MAPK
signaling during vulval induction. For example, when combined
with mutations in different positive regulators of the RAS/MAPK
pathway such as let-23(rf), lin-2(lf) or lin-45(rf), daf-18(lf) signifi-
cantly suppressed the Vul phenotype of these mutants (Table 3,
rows 5–8 and 11–12). In particular, daf-18(lf) suppressed a lf
mutation in the RAS-GEF sos-1 when assayed in the let-60(gf)
background to rescue the lethality caused by sos-1(lf), placing daf-
18 function downstream of sos-1 (table 3, rows 9–10). However,
since vulval induction in sos-1(lf); let-60(gf) animals is partly
sensitive to the inductive anchor cell signal [28], we cannot
exclude the possibility that DAF-18 might inhibit RAS/MAPK
signaling through a SOS-1 independent branch of the pathway. As
an exception, daf-18(lf) did not suppress the Vul phenotype of lin-
3(rf) mutants (Table 3, rows 3–4), suggesting that daf-18(lf) alone is
not sufficient to activate the RAS/MAPK pathway in the absence
of the inductive AC signal. Furthermore, daf-18(lf) did not affect
the completely penetrant Vul phenotype caused by mpk-1(lf)
(Table 3, rows 13–14). Taken together, our epistasis analysis
indicates that DAF-18 inhibits RAS/MAPK signaling downstream
of or in parallel with the RAS-GEF SOS-1 and upstream or at the
level of the MAP kinase MPK-1.
DAF-18 negatively regulates MPK-1 but not MEK-2
phosphorylation
Activation of the RAS/MAPK pathway results in an increased
phosphorylation and activity of the downstream effectors RAF,
MAPK kinase (MEK) and MAPK. We thus examined if daf-18(lf)
mutants exhibit elevated levels of MEK and MAPK phosphory-
lation. Western blots of extracts from L4 larvae were probed with
antibodies against mono-phosphorylated MEK (pMEK-2) and di-
phosphorylated MAPK (dpMPK-1). Although the C. elegans
genome encodes two MEK genes, MEK-1 and MEK-2, the
Figure 1. DAF-18 inhibits 16 vulval fate specification. (A) Expression of the 1u cell fate marker EGL-17::CFP in let-60(gf) single and (B) daf-18(lf)
let-60(gf) double mutants at the Pn.px stage. (C and D) show the corresponding Nomarski images of the animals shown in (A) and (B), respectively. (E)
Morphology of the vulval invagination in a let-60(gf) mutant at the Pn.pxxx stage. Note that the descendants of P5.p and P7.p remain attached to the
cuticle, which is characteristic of the 2u cell fate. (F) P5.p and P7.p often detach from the cuticle in daf-18(lf) let-60(gf) animals, resulting in a broad
invagination with abnormal morphology. (G) Quantification of the 1u fate marker EGL-17::CFP expression at the Pn.px and Pn.pxx stages in the
indicated genetic backgrounds. Dark blue represents cells with high EGL-17::CFP expression, corresponding to at least 50% of the intensity observed
in the P6.px(x) cells, light blue represents cells with clearly visible but less than 50% of the P6.px(x) signal, and white spaces represent cells with
undetectable levels of EGL-17::CFP. (H) Expression of the 2u fate marker LIP-1::GFP in let-60(gf) and (I) daf-18(lf) let-60(gf) animals. (J) Quantification of
LIP-1::GFP expression in the P5.p through P7.p descendants. Signal intensities are indicated relative to P6.px(x) in let-60(gf).
doi:10.1371/journal.pgen.1002881.g001
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phosphorylation site in human MEK to which the phospho-MEK
antibody was raised (S217/S221) is only conserved in C. elegans
MEK-2. Thus, we were able to specifically detect phosphorylated
MEK-2 in whole animal extracts. Wild-type and daf-18(lf) L4
larvae contained only low levels of pMEK-2 and dpMPK-1 that
could not be reliably quantified. As expected, let-60(gf) single
mutants contained significantly higher levels of pMEK-2 and
dpMPK-1 than wild-type larvae (Figure 2A and 2C). However, we
observed no further increase in pMEK-2 levels in daf-18(lf) let-
60(gf) double compared to let-60(gf) single mutants (Figure 2B). In
contrast, dpMPK-1 levels were around two-fold increased daf-
18(lf) let-60(gf) compared to let-60(gf) mutants (Figure 2D).
Together with the genetic epistasis data presented above, the
increase in MPK-1 phosphorylation in the absence of a significant
change in MEK-2 phosphorylation indicates that DAF-18 most
likely inhibits vulval induction at the level of MPK-1. Finally, the
fact that we observed increased MPK-1 phosphorylation in total
worm lysates suggests a global regulation of the RAS/MAPK
pathway by DAF-18, probably including the germline.
daf-18 expression in the VPCs inhibits vulval induction
To further investigate the role of DAF-18 during vulval
induction, we constructed a translational reporter by inserting a
gfp cassette at the 39 end of the ORF in a genomic daf-18 fragment
(Figure 3). This DAF-18::GFP reporter rescued both the dauer
defective (DAF-d) phenotype (data not shown) as well as the vulval
phenotypes of daf-18(lf) with similar efficiency as a 6.5 kb genomic
fragment spanning the entire daf-18 locus (Figure 4). DAF-18::GFP
expression was observed in many tissues during all larval stages,
including the developing vulva, the uterus, the ventral nerve cord
and the distal tip cells (data not shown). In particular, equal levels
of DAF-18::GFP expression were detected in the six VPCs of L2
larvae, and expression persisted in the descendants of the induced
VPCs until the Pn.pxxx stage (Figure 3). Interestingly, the sub-
cellular localization of DAF-18::GFP changed over the course of
vulval development. In the VPCs of L2 larvae prior to and during
induction (Pn.p stage), DAF-18::GFP was predominantly localized
in the cytoplasm and the nucleus (Figure 3A, 3B and 3B9).
However, at the subsequent stages (Pn.px to Pn.pxx stages), DAF-
18::GFP became increasingly localized to the plasma membrane of
the vulval cells (Figure 2C, 2D and 2D9). Plasma membrane
staining peaked at the ‘‘Christmas tree’’ (Pn.pxxx) stage, when
almost all the protein appeared to be localized to the membranes
and nuclear staining was reduced to very low levels (Figure 3E and
3F). Since the DAF-18::GFP reporter was also expressed in tissues
surrounding the vulval cells, we examined whether tissue-specific
expression of DAF-18 in the VPCs reduces vulval induction. For
this purpose, we expressed daf-18 cDNA fused to gfp under the
control of the Pn.p cell-specific lin-31 promoter, which is active in
the VPCs before and during vulval induction [29] (Plin-31::daf-18
cDNA::gfp::unc-54 39 UTR). Indeed, introduction of the lin-31::daf-
18::gfp transgene into daf-18(lf); let-23(rf) animals repressed vulval
induction with similar efficiency as the daf-18::gfp reporter or a
genomic daf-18 rescue construct (Figure 4).
Besides the vulval cells, the DAF-18::GFP reporter was also
expressed at the L3 to L4 larval stages in several cells of the uterus,
which is part of the somatic gonad (Figure 3). We thus tested if the
daf-18-mediated repression of vulval induction requires the gonad
by ablating the Z1 to Z4 somatic gonad and germline precursor
cells at the L1 stage. In gonad-ablated daf-18(lf) let-60(gf) double
mutants, vulval induction was higher than in gonad-ablated let-
60(gf) single mutants, indicating that DAF-18 represses vulval
induction independently of a signal from the gonad (Table 3, rows
15, 16). Thus, DAF-18 probably acts predominantly in the VPCs
to inhibit MAPK signaling during vulval induction.
Both lipid and protein phosphatase activities of DAF-18
inhibit vulval induction
Mammalian PTEN acts as a lipid phosphatase as well as a dual-
specificity protein phosphatase [5,6]. Moreover, a recent report
has shown that C. elegans DAF-18 can act as a protein phosphatase
inhibiting signaling by the VAB-1 ephrin receptor during oocyte
maturation [18]. The G129E mutation in the catalytic center of
human PTEN eliminates the lipid phosphatase activity, while
retaining the protein phosphatase activity [7]. The corresponding
glycine 174 residue in C. elegans DAF-18 was therefore mutated to
glutamic acid in the daf-18 genomic rescue construct. To quantify
the rescuing activity of the daf-18 wild-type (daf-18 wt) and the
G174E mutated lipid phosphatase mutant (daf-18 G174E), these
constructs were expressed in the daf-18(lf) let-60(gf) and let-23(rf);
daf-18(lf) backgrounds, and vulval induction was quantified. As
expected, expression of daf-18 wt rescued both the DAF-d (data not
shown) and vulval phenotypes of daf-18(lf) (Figure 5). In contrast,
daf-18 G174E did not rescue the DAF-d phenotype ([15] and own
observation), yet exhibited a weaker, though significant rescuing
activity of the vulval induction phenotype (Figure 5). These results
indicate that the DAF-18 protein and lipid phosphatase activities
each play independent roles in negatively regulating the RAS/
MAPK pathway and that both activities are required for the full
inhibition of vulval induction by DAF-18.
Table 3. Epistasis analysis of daf-18 with components of the
RAS/MAPK pathway.
genotype Induction±SE % Vul % Muv n
1 wild-type 3.0060.00 0.0 0.0 many
2 daf-18(lf) 2.9960.01 0.9 0.0 107
3 lin-3(lf) 0.8160.19 95.2 0.0 21
4 daf-18(lf) lin-3(lf) 0.4660.13 94.1 0.0 34
5 let-23(rf) 0.5560.08 93.8 0.0 129
6 let-23(rf); daf-18(lf) 1.9060.10***(5) 63.9 6.8 133
7 lin-2(lf) 1.3460.19 73.7 0.0 42
8 daf-18(lf); lin-2(lf) 2.5060.12***(7) 35.5 1.7 59
9 let-60(gf); sos-1(lf)# 2.6060.17 16.7 0.0 30
10 daf-18(lf) let-60(gf); sos-
1(lf)#
4.1960.12***(9) 0.0 90.3 31
11 lin-45(rf) 1.8160.15 57.3 0.0 68
12 daf-18(lf) lin-45(rf) 2.2960.17*(11) 39.5 2.3 42
13 mpk-1(lf) 0.0060.00 100 0.0 14
14 mpk-1(lf); daf-18(lf) 0.0060.00 100 0.0 17
15 let-60(gf) - gonad 2.4460.27 46 23 13
16 daf-18(lf) let-60(gf) -
gonad
3.3860.38 8 42 12
SE indicates the standard error of the mean. % Vul indicates the fraction of
animals with three or less induced VPCs. % Muv indicates the fraction of animals
with more than three induced VPCs. Induction indicates the average number of
induced VPCs per animal.
*indicates a p-value,0.05.
***indicates a p-value,0.0005, numbers in brackets indicates the row number
against which a t-test was performed. Alleles used: LG II: let-23(sy1), LG III: mpk-
1(ga117), LG IV: daf-18(ok480), let-60(n1046), lin-3(e1417), lin-45(sy96), LG V: sos-
1(s1031), LG X: lin-2(n397).
#sos-1(s1031) is cis-linked to unc-46(e177).
doi:10.1371/journal.pgen.1002881.t003
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Discussion
The Insulin pathway is a key regulator of development,
reproduction, and life span in metazoans. In this study, we have
discovered a new form of cross-talk between the Insulin and RAS/
MAPK pathways during vulval development. Signaling by the
Insulin receptor DAF-2 positively regulates MAPK activation.
Surprisingly, the effect of DAF-2 on vulval development does not
involve activation of the canonical Insulin pathway. DAF-2
signaling regulates vulval induction in at least two distinct
manners, through AGE-1 dependent and independent pathways
(Figure 6). One possible explanation for the AGE-1-independent
branch of DAF-2 signaling is supported by mammalian data,
which suggest that the Insulin receptor can directly stimulate RAS
activation by recruiting GRB2 and the RAS-GEF SOS [30,31].
Also in C. elegans, LET-60 RAS was found to act downstream of
the DAF-2 Insulin receptor to modulate the effects of Insulin
signaling during entry into the Dauer stage [32].
Figure 3. Expression pattern and sub-cellular localization of DAF-18::GFP. (A and B) Nomarski and fluorescence images of animals
expressing the DAF-18::GFP translational reporter at the Pn.p cell stage, (C and D) the Pn.px(x) stage and (E and F) the Pn.pxxx ‘‘Christmas tree’’ stage.
The insets in (B9) and (D9) show higher magnifications of the areas in (B) and (D) marked with dashed boxes.
doi:10.1371/journal.pgen.1002881.g003
Figure 2. DAF-18 inhibits MPK-1 phosphorylation. Total extracts of wild-type, daf-18(lf), let-60(gf) and daf-18(lf) let-60(gf) larvae at the L4 stage
were analyzed on Western blots using antibodies against (A) phosphorylated and total MEK-2 and (C) against di-phosphorylated (dp) and total MPK-1.
Signal intensities were quantified in four (for MEK-2) and three (for MPK-1) independent experiments, and the average ratios of (B) pMEK-2 to total
MEK-2 and (D) dpMPK-1 to total MPK-1 intensities were calculated.
doi:10.1371/journal.pgen.1002881.g002
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Furthermore, we found that the PTEN ortholog DAF-18
strongly inhibits RAS/MAPK signaling. Vulval induction in daf-
18(lf) let-60(gf) double mutants reaches levels similar to those seen
in the strongest Muv mutants such as lin-15AB(lf) [33]. The
increase in RAS/MAPK signaling in daf-18(lf) mutants could be
partially reverted by loss of the PI3K activity, suggesting that
elevated levels of PIP3 do stimulate RAS/MAPK signaling but
cannot explain all the functions DAF-18 exerts during vulval
induction. Accordingly, the inhibitory activity requires both the
lipid and protein phosphatase activities of DAF-18. PIP3 acts as a
second messenger that activates multiple downstream targets. One
major PIP3 target in the Insulin pathway is the AKT kinases,
which phosphorylate and thereby inhibits the FOXO transcription
factor DAF-16. However neither akt-1, akt-2 nor daf-16 mutations
had any detectable effect on vulval induction. Thus, PIP3 must act
via other targets to stimulate RAS/MAPK signaling. Increased
levels of PIP3 in the plasma membrane could, for example,
enhance the recruitment of an alternative GEF that activates RAS
Figure 4. DAF-18 expression in the Pn.p cells inhibits vulval induction. Vulval induction was scored at the L4 stage comparing let-23(rf); daf-
18(lf) animals carrying the different extra-chromosomal arrays (Ex[+]) to their siblings lacking the array (Ex[2]). Three independent lines were scored
per construct and at least 20 Ex[+] and Ex[2] animals were counted per line. For each line, a t-test was performed comparing induction in Ex[+] and
Ex[2] animals on the same plates. * indicates a p-value#0.05, ** a p-value#0.005, and *** a p-value#0.0005.
doi:10.1371/journal.pgen.1002881.g004
Figure 5. A lipid phosphatase deficient mutant of DAF-18 remains partially active. Animals carrying the daf-18 wt and daf-18 G174E extra-
chromosomal arrays were scored at the L4 stage as described in the legend to Figure 4.
doi:10.1371/journal.pgen.1002881.g005
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signaling in parallel to the RAS-GEF SOS-1 [28] (Figure 6).
However, we observed that prior to and at early stages of vulval
induction, DAF-18::GFP was localized predominantly in the
cytoplasm and nucleus of the VPCs, while membrane localization
of DAF-18 only became apparent at later stages. Previous
observations of mammalian PTEN localization suggested that
PTEN performs different functions depending on its sub-cellular
localization [34]. It has been proposed that the lipid phosphatase
activity is important for the cytoplasmic and membrane functions
of mammalian PTEN, while the protein phosphatase activity is
rather required for its nuclear functions [34,35]. The nuclear
localization of PTEN in mammalian cells is often associated with
cell-cycle arrest in G1 and accompanied by decreased levels of
ERK phosphorylation. Prior to vulval induction, the VPCs are
maintained in a long G1 arrest lasting the entire L2 stage [36]. It is
therefore possible that initially DAF-18 acts predominantly in the
nucleus as a protein phosphatase that negatively regulates vulval
induction. Indeed, Western blot analysis revealed elevated levels of
dpMPK-1 in daf-18(lf) mutants, supporting our model that DAF-
18 –directly or indirectly- blocks MAPK activation (Figure 6).
In humans, PTEN is one of the most frequently mutated tumor
suppressor genes. However, not all disease phenotypes associated
with loss of PTEN can be explained by hyper-activation of the
Insulin pathway alone. Thus, PTEN must have other functions
that are independent of its inhibitory activity in the Insulin
pathway. Accordingly, Suzuki and Han [19] observed many
synthetic phenotypes in C. elegans daf-18(lf) mutants, including
embryonic lethality and sterility, which are independent of DAF-
16 FOXO and do not involve DAF-2 InsR signaling. Our work
highlights the importance of C. elegans DAF-18 PTEN in regulating
a range of biological processes and may serve as a basis to better
understand the multiple roles human PTEN plays during cancer
initiation and progression. Thus, single mutations in the PTEN
tumor suppressor may result in the simultaneous hyper-activation
of several oncogenic signaling pathways.
Materials and Methods
General worm methods
Standard methods were used for maintaining and manipulating
Caenorhabditis elegans [37]. Animals were cultured at 20uC and the
wild-type strain is the Bristol N2 strain. Information regarding the
mutants used in this study can be found on WormBase (http://
www.wormbase.org). Mutations used according to their linkage
group:
LG I: daf-16(mu86), LG II: age-1(mg44), let-23(sy1), LG III: daf-
2(e1370), mpk-1(ga117), LG IV: let-60(n1046), daf-18(ok480), lin-
3(e1417), lin-45(sy96), LG V: akt-1(mg144gf), akt-1(ok525lf), LG X:
lin-2(n397), sos-1(s1031), unc-46(e177) to cis link sos-1(s1031), LG
X: lin-2(n397), gap-1(ga133). Transgenes used: syIs59[Pegl-17::cfp],
zhIs4[Plip-1::gfp], zhEx382[daf-18 genomic] zhEx343[daf-18::gfp],
zhEx358[Plin-31::daf-18::gfp], zhEx344[daf-18 G174E].
Plasmids and PCR fusion constructs
pIN05 (daf-18 genomic wt) was made by cloning the whole
genomic fragment of daf-18 starting 1.3 kb upstream of the ATG
and ending 0.5 kb downstream of the STOP and cloning to
pGEM-T. pIN03 (daf-18 genomic G174E) was made by fusion PCR
[38] of two overlapping fragments of the whole genomic daf-18
starting 1.3 kb upstream of the ATG and ending 0.5 kb
Figure 6. Multiple modes of crosstalk between the RAS/MAPK and insulin pathways during vulval development. Activation of LET-60
RAS in the VPCs causes phosphorylated MPK-1 to enter the nucleus where it phosphorylates transcription factors such as LIN-1 ETS, which represses
1u fate-specific gene expression. The insulin signaling pathway interacts with the RAS/MAPK pathway at several levels. Firstly, DAF-2 InsR activation
enhances RAS/MAPK signaling by stimulating the PI3K AGE-1, which positively regulates RAS/MAPK signaling via increased PIP3 production. In
addition, DAF-2 signaling activates the RAS/MAPK signaling independently of AGE-1, possibly by recruiting SEM-5 to the plasma membrane. DAF-18
PTEN inhibits RAS/MAPK signaling in two distinct manners; by dephosphorylating PIP3 and by negatively regulating MAPK activation.
doi:10.1371/journal.pgen.1002881.g006
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downstream of the STOP using primers which contain the
mutation G174E (GGC to GAA) in the overlapping region and
cloning to pGEM-T. pIN17 (Plin-31::daf-18 cDNA::gfp::unc-54
39UTR) was made by amplifying daf-18 cDNA::gfp from a
previously cloned plasmid with primers containing NotI sites on
both ends, digestion with NotI and cloning into the NotI site of the
pB253 plasmid containing the lin-31 enhancer and promoter. The
daf-18 genomic translational GFP reporter was made using fusion
PCR of three parts by inserting a gfp cassette in frame between the
last exon and the 39 UTR into a genomic fragment encompassing
1.3 kb of 59 regulatory sequences and the complete daf-18 coding
sequences. Sequences of the primers used for the different
constructs can be found in Table S1.
Transgenic lines
Worms expressing extra-chromosomal transgenic arrays were
generated by microinjection of DNA into young adult worms [39].
pIN03 (zhEx344), pIN05 (zhEx382) and pIN17(zhEx358) were
injected at a concentration of 50 ng/ml. The fusion PCR daf-18
genomic::gfp (zhEx343) translational reporter was injected at a
concentration of 30 ng/ul. Co-markers used were either pCFJ90
(Pmyo-2::mCherry) at a concentration of 2 ng/ul or pTJ1157
(Plin-48::gfp) at a concentration of 50 ng/ul. Final concentration
of injected DNA was filled up to 150 ng/ul using the empty
plasmid pBluescript-KS.
Fluorescence microscopy
DAF-18::GFP, Plip-1::GFP and Pegl-17::CFP expression were
observed under fluorescent light illumination with either a Leica
DMRA microscope equipped with a cooled CCD camera
(Hamamatsu ORCA-ER) or Olympus BX61 with Q Imaging
Fast 1394 Retiga 2000R camera (Q Imaging Inc., Canada)
controlled by the Openlab 5.x software (Improvision/PerkinEl-
mer). Animals were mounted on 4% agarose pads in M9 solution
with 20 mM tetramisole hydrochloride. Quantification of fluores-
cence levels was performed under the same picture acquisition
settings for all conditions examined.
Vulval induction
Vulval induction was scored by examining worms at the L4
stage under Nomarski optics as described [40]. The number of
VPCs that had adopted a 1u or 2u Vulval fate was counted for
each animal and the induction index was calculated by dividing
the number of 1u or 2u induced cells by the number of animals
scored. Statistical analysis was performed using a t-test for
independent samples.
RNA interference analysis
RNA interference analysis (RNAi) was performed by feeding
animals dsRNA-producing bacteria as described previously [41].
Around 10 to 20 P0 animals at the L1 larval stage were transferred
to plates containing RNAi bacteria grown on 3 mM IPTG. Vulval
induction was scored in the F1 generation (or the P0 for akt-2
RNAi) at the L4 larval stage to count the number of induced
VPCs. gfp, akt-2, piki-1 and vps-34 RNAi clones were all taken from
the Ahringer RNAi library.
Western blot analysis
Forty-five animals at the L4 stage were placed into 15 ml of 16
SDS sample buffer, lysed at 95uC for 5 min, centrifuged at
14,000 rpm for 2 min and the supernatant was loaded on 10%
acrylamide gels, which were analyzed by Western blotting. Anti-
phospho-MEK1/2 (S217/S221) and Anti-MEK1/2 (D1A5) anti-
bodies were purchased from Cell Signaling Technology (Beverly,
MA). Anti-di-phosphorylated ERK-1&2 (M8159) antibody was
purchased from Sigma-Aldrich (St. Louis, MO), and anti-ERK 2
(K-23) antibody was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Quantification of the bands was performed
using the gel quantification plugin in ImageJ software [42]. The
ratios between phosphorylated and total MEK-2 and MPK-1
levels, respectively, were calculated and normalized for each
independent experiment to the ratios measured in the let-60(gf)
single mutants.
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4. General Discussion
4
4.1 Technical aspects
4.1.1 Optimization of protein complex purification from C. elegans extracts
In order to purify DEP-1 together with its physiological interaction partners, we initially used the Strep-
Tactin-HA (SH) double affinity-purification technique that was recently developed at the ETH Zurich 
(Glatter et al., 2009). SH-purified DEP-1 was analyzed by LC-MS/MS, which led to the identification 
of an unexpected low number of proteins: From a total of 42 identified proteins, only three proteins 
are specific for DEP-1intraDA, and only seven for DEP-1full::HS. Further examination of these results 
showed that most of the identified proteins are highly abundant and they seem to be false-positive in-
teractors of DEP-1. However, numerous peptides of DEP-1 were identified by LC-MS/MS analyses, why 
we conclude that the double affinity-purification of both DEP-1full::HS and DEP-1intraDA::HS was 
successful. 
We assume that there are several reasons for these poor results. First, only a low amount of DEP-1 could 
be purified. The StrepTactin-purification led indeed to results as they were described in literature (Glat-
ter et al., 2009), but a large amount of purified DEP-1::HS was lost during the subsequent HA-purifica-
tion. This less efficient HA purification might be due to the fact that we were using an HS-tag in which 
the HA domain is not at the very end of the C-terminus but f lanked by DEP-1 and StrepTactin, and thus 
less accessible to the monoclonal anti-HA-antibodies. Second, the molecular weight of DEP-1full::HS is 
with 158 kD relatively high, which complicated a purification of the intact protein. Third, the yield of 
purified proteins was too low to separate the samples by SDS-PAGE prior to tryptic digestion. Thus, the 
detergent originating form the lysis buffer could not be removed and attained to the mass spectrometer, 
which affected the measurements of LC-MS/MS. And fourth, proteins that have a weak binding affinity 
to DEP-1 might have been lost due to a too vigorous washing procedure.
To increase the yield of purified DEP-1 and thereby the number of interacting proteins which could be 
identified by LC-MS/MS, we performed single HA-purifications of DEP-1full::HS and DEP-1intraDA::HS 
instead of the StrepTactin-HA double affinity-purification. Thereby, the amount of purified DEP-1 was 
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4.1.2 Identification of proteins by LC-MS/MS after GST purification of GST::DEP-1 
We concluded from the previously described purification experiments that the success of the identifica-
tion of interacting proteins by mass spectrometry depends on the yield of purified DEP-1. First, a higher 
amount of protein enables a fractionation by SDS-PAGE, which allows removing all detergent from the 
sample prior to tryptic digestion and analyses by LC-MS/MS. And second, increasing the yield of “bait” 
protein enhances the chance to identify lower abundant proteins because of its higher concentration in 
the sample. 
Thus, we tried to further increase the amount of purified DEP-1 by expressing GST::DEP-1 fusion pro-
teins in E. coli and to purify them with GST sepharose. Purification of GST-tagged proteins is a well-
established method, and allows the purification of milligrams of proteins.
However, there are also a few drawbacks compared to the previously described method. First, the GST 
tag is with 26 kD much bigger than the HS-tag (5 kD) and might also modify DEP-1 and its activity. 
And second, a native expression of C. elegans DEP-1, a transmembrane protein with highly glycosylated 
extracellular domains, is not possible due to the lack of post-translational modification in bacteria. For 
this reason, we expressed not the full-length protein but only the intracellular domain of DEP-1 (DEP-
1intrawt) as well as a version carrying the substrate trapping mutation D1241A (DEP-1intraDA) (Palka, 
2002).
After extensive optimization of the conditions for protein expression and GST purification, we were 
able to receive high yields of purified DEP-1intra. Immobilized on GST-sepharose, DEP-1 was then 
incubated with total protein extract from mixed staged wild-type N2 worms to perform pull-down 
experiments. Since the high yield of DEP-1 allowed a fractionation by SDS-PAGE, we were able to use 
milder washing conditions without the risk of overloading the LC-MS/MS with too complex samples 
containing detergent. 
As one would expect, Colloidal Coomassie Blue staining illustrated that more proteins bound to DEP-
1intraDA rather than to DEP-1intrawt. In total, 585 proteins were identified, of which 97 were not pres-
ent in the control fraction. Most prominent were three protein bands with a molecular weight of 90.1 
kD, 135.9 kD, and 174.4 kD, which correspond to PAT-3, PAT-2, and NID-1 respectively. 
increased dramatically, resulting in a three-fold increase in proteins detected by LC-MS/MS. Among the 
332 proteins identified in two independent LC-MS/MS experiments, 50 proteins were not identified in 
the controls. 
However, these results were still unsatisfactory. First, we had to use an enormous amount of protein 
extract (up to 100 mg) to get an adequate yield of purified DEP-1. This dramatically enhanced the risk 
of pulling-down high abundant proteins that would never interact with DEP-1 under physiological con-
ditions. Second, loss of the second purification step made it even more difficult to remove all detergent 
from the sample. We tried to reduce the amount of detergent by extensive washing procedures, but 
its presence in the final eluate could not be avoided completely, resulting in suboptimal quality of the 
LC-MS/MS data. And third, proteins might have been lost due to this vigorous washing procedure and 
therefore could not be identified as DEP-1 interactors. 
Taken together, both the StrepTactin-HA double and the HA-single purification methods of DEP-1in-
traDA and DEP-1full::HS worked in principle, but the yield of purified protein was not sufficient for a 
successful identification of DEP-1 interactors of by LC-MS/MS.
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4.1.4 Polyclonal DEP-1 antibodies
4.1.3 LET-23 was not identified by LC-MS/MS
As an alternative to purify DEP-1 complexes, we performed co-immunoprecipitation using DEP-1 anti-
bodies. Since there were no C. elegans DEP-1 antibodies available, we produced polyclonal DEP-1 anti-
bodies that are directed against the intracellular domain of GST-tagged DEP-1.
First, immunoblot analyses with protein extracts of N2, dep-1(lf);lip-1(lf), and Peft-3::dep-1full::HS 
worms as well as StrepTactin-purified DEP-1full::HS and DEP-1intraD1241A::HS showed that the affin-
ity-purified antibodies derived from the rabbit 006-9AC-B07 were specific for DEP-1. However, in sub-
sequent immunoblots that were done, the DEP-1 specific signal became weaker whereas other unspe-
cific signals were enhanced (compare Fig. 3.10 A and B). We propose two reasons for these observations. 
First, the unspecific signals seems to correspond to proteins originating from E. coli, since the same 
signals also appear on immunoblots in which E. coli extracts were analyzed (data not shown). Because 
the protein extracts varies in their composition of E. coli, it could be possible that the samples used in 
the first western blot experiments contained less bacteria. To decrease the intensity of unspecific signal 
caused by E. coli proteins, it would be possible to perform pre-absorption with E. coli acetone powder, or 
to use worm protein extract from animals cleaned by sucrose-floating.
Another reason for the decrease in DEP-1 specific signal might be that the purified antibodies degraded 
Although the EGF receptor LET-23 is a known substrate of DEP-1 (Berset, 2005; Jeon and Zinn, 2009; 
Tarcic et al., 2009) it was not identified by our MS-based approaches. This might be due to two reasons. 
First, LET-23 belongs with an abundance of 2.37 ppm to the lower abundant proteins of C. elegans pro-
teome (average protein abundance = 75.62 ppm, PaxDB integrated dataset, pax-db.org). However, the 
average protein abundance of proteins identified in the GST pull-downs had a value of 378.8 ppm, indi-
cating that it is more difficult to pull-down low-abundant proteins rather than high-abundant proteins, 
and especially to identify them by LC-MS/MS. The interaction of LET-23 and DEP-1 was performed 
with the same purified GST::DEP-1intraDA, but LET-23 was detected by a much more sensitive tech-
nique using antibodies (Berset, 2005).
Second, if two proteins with similar physical characteristics are simultaneously analyzed by LC-MS/MS, 
and if one of them exists in a much higher appearance than the other, only the more abundant protein 
is identified. Thus, the absence of a certain protein after LC-MS/MS analysis does not mean that it was 
not present in the sample. 
By using GST- instead of HS-purified DEP-1, not only the quantity of identified proteins could be en-
hanced, but also its quality. On average, 5.07 peptides/protein were identified in the results of HA-puri-
fied DEP-1, whereas 10.93 peptides/protein were recognized in the GST-based approach. Furthermore, 
the average protein abundance decreased from 522.842 ppm (HA-purified DEP-1) to 378.8 ppm (GST-
purified DEP-1), indicating that more low abundant proteins could be identified. We assume that this 
was due to milder washing conditions that were used during the GST-based pull-downs, and that no 
detergent was disturbing LC-MS/MS analyses.
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4.1.5 Generation of endogenous DEP-1 reporters by using MosTIC
A novel transgene-instructed genome engineering technique called MosTIC (Mos1 excision‐induced 
transgene‐instructed gene conversion) has been reported by (Robert et al., 2009), which allows the 
generation of endogenous reporters in C. elegans. Since this technique was not yet established in our 
laboratory, we tested three different approaches to build endogenous DEP-1::GFP and DEP-1::mCherry 
reporter lines. 
In the first strategy A, we tried to identify MosTic engineered animals by a PCR-based screen in which 
the genomic DNA was extracted from half of the F2-F3 progeny and analyzed with primers specific for 
the inserted transgene. Although this approach was already performed in our laboratory to identify spe-
cific animals from a deletion mutant screen, it was not possible to identify MosTic engineered animals 
by this PCR-based screen. We assume that the complexity of genomic DNA increased so dramatically 
until the genomic DNA was extracted from the F2-F3 progeny, that a successful amplification by PCR 
was not possible. 
To facilitate the identification of transgenic animals in our further approaches, we integrated in strat-
egy B additionally to GFP or mCherry a C. briggsae unc-119 rescue sequence as a co-injection marker. 
Screening for transgenic crawling animals under the dissecting scope allows the efficient identification 
of a single rescued worm among many others. Since unc-119 was f lanked by two FRT sites, the rescue 
sequence could be excised by FLP-FRT site directed recombination. Despite expressing FLPase under 
three different promoters, we were not able to identify a strain in which the unc-119 rescue sequence 
was excised. This might be due to several reasons. First, the activity of Phsp-16-48 in the germline might 
have been too low, why FLP-FRT mediated recombination was only promoted in somatic cells. Second, 
we have no evidence that the FLPase under Pglh-2 (pMW26) and Peft-3 (pMW27) was functional. Third, 
germ cells are very efficient in silencing genes present in multi-copy (Kelly et al., 1997). Thus, if the con-
centration of the micro-injected plasmids was too high, they might have been silenced. A strategy that 
might prevent silencing of the FLPase due to multi-copy arrays would be the creation of a transgenic 
line, in which a single-copy of Peft-3::FLPase is integrated into the genome of C. elegans by MosSCI 
(Frøkjær-Jensen et al., 2008). 
over time when they were stored at 4°C. Since other aliquots of affinity-purified DEP-1 antibodies are 
stored at -80°C, it would possible to thaw a new sample. In case the freshly thawed antibodies would as 
well not recognize DEP-1, a large amount of serum from the rabbit 006-9AC-B07 is stored at -80°C and 
could be processed again.
Immunostaining of C. elegans with DEP-1 antibodies led to the observation of a diffuse signal in some 
cells of the head region, in the vulva of a few L4 larvae, but never in the VPCs of Pn.px or Pn.pxx lar-
vae. Since this expression pattern was very different from the expression pattern of DEP-1::GFP that 
was observed in the reporter line zhEx112 (Berset, 2005), we assume that the expression is unspecific 
and stopped a further optimization of DEP-1 immunostainings. However, analyses of the reporter line 
zhIs70 showed that DEP-1::GFP, which is not overexpressed, is also hardly visible in the VPCs prior to 
L4 larval stage, and strongly expressed in the head region. 
Taken together, the polyclonal DEP-1 antibodies derived from the rabbit 006-9AC-B07 seem to work for 
western blot analysis, but it remains to be elucidated if they also work for immunostaining and Co-IPs. 
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4.1.6 Expression patterns of DEP-1 reporter lines
To analyze the expression pattern of DEP-1, four different reporter lines have been built. First, a tran-
scriptional Pdep-1::GFP reporter zhIs10[Pdep-1Δpes::nls::gfp::lacZ, unc-119(+)]. Second, the translational 
DEP-1::GFP reporter line zhEx112 (Berset, 2005), in which the plasmid pTB24 is present as extrachro-
mosomal repetitive structures. Third, the MosTic engineered DEP-1::GFP (zhIs70) reporter line, whereas 
the GFP tag was introduced directly into the endogenous dep-1 locus. And fourth, the DEP-1::mCherry 
(zhIs71) reporter line, which was also made by MosTIC integration. In all three translational reporter 
lines, the GFP/mCherry tag was cloned in front of the stop codon at the 5’ end of dep-1, resulting in a 
functional fusion protein. 
Since DEP-1 is a transmembrane protein tyrosine phosphatase, we expected its expression predomi-
nantly at the cell membrane of the VPCs. However, most of the extrachromosomal DEP-1::GFP reporter 
zhEx112 is expressed intracellularly with accumulations in the endoplasmatic reticulum (ER), but not at 
the cell membrane (Berset, 2005). This might be due to overexpression of DEP-1::GFP, leading to mis-
folding of the protein and therefore in accumulation in the ER. 
In contrast, the endogenous reporter line zhIs70 showed an expression of DEP-1::GFP at the cell mem-
brane of the VPCs, particularly at the apical side as well as in intracellular vesicles. We have to clarify 
that a clear observation of DEP-1::GFP at the apical side was complicated by a strong auto fluorescence 
signal of the cuticle that could not be decreased by optical filters in the spinning-disc microscope that 
was used. However, an apical expression pattern of DEP-1::GFP stands in accordance with immunohis-
tochemistry data performed in human cells, in which DEP-1 tends to be expressed specifically at the 
apical surface of polarized cells (Autschbach et al., 1999), such as in breast epithelia, in which PTPRJ is 
predominantly localized to the apical surface of luminal epithelial cells of alveoli and both small and 
large ducts (Smart et al., 2012). 
In contrast to the apical expression of DEP-1::GFP in the VPCs of zhIs70 animals, DEP-1::mCherry ex-
pression was clearly enhanced in intracellular punctae of both the VPCs and the head of zhIs71 animals. 
Fourth, the efficiency of FLP-FRT site directed recombination in the germline might be in general very 
low. And fifth, we might not have been able to identify the respective animals among the large number 
of crawling siblings. 
As in Strategy B, the repair construct used in strategy C contained a C. briggsae unc-119 rescue sequence. 
However, unc-119(+) was not f lanked by FRT sites and the dep-1 3’UTR was cloned in front of the rescue 
sequence. Micro-injection into ttTi25065;unc-119(lf) animals led immediately to the identification and 
isolation of strains in which a GFP- or mCherry- tag was integrated into the locus of dep-1. However, 
an insertion of the unc-119 rescue construct is only possible if the position of the Mos1 transposon is 
located at the 3’ end of the gene locus of interest. Otherwise the unc-119 rescue sequence is affecting the 
gene of interest and prohibits the translation of a functional protein.
Tagging of DEP-1 with GFP and mCherry using MosTIC was ideal because the Mos1 insertion was 
present at the 3’ end of dep-1. However, for many genes no Mos1 insertions are available, or the position 
of the Mos1 insertion does not allow the creation of a functional reporter line. In these cases a newly 
developed technique called CRISPR-Cas9 can be used, which allows the creation of customized double-
strand breaks (Chen et al., 2013).
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4.2 Role of DEP-1 in integrin regulation
4.2.1 Significance of integrins and EGFR signaling in cancer formation and metastasis 
Since it has been reported that mCherry has the ability to aggregate when it is expressed within some 
fusions (Katayama et al., 2008), we assume that the size of these intracellular punctae are not physiologi-
cal. An aggregation of mCherry enables the observation of very weak expression levels, which would not 
be detectable by analyzing GFP-tagged reporters. However, it is alarming how different mCherry and 
GFP behave, even if the copy number and loci of integration is the same. 
Another difference in the expression of DEP-1 between the extrachromosomal (zhEx112) and endog-
enous (zhIs70) DEP-1::GFP reporter lines could be observed in the head and tail of C. elegans. In animals 
of the line zhEx112, DEP-1 is expressed in a few neuronal cells and in hyp7 cells of the head, but also 
in the B and Y cells of the posterior hindgut. In contrast, the expression of endogenous DEP-1::GFP in 
the line zhEx70 is much more multifaceted, particularly in numerous neurons in the head and the tail. 
Interestingly, expression of DEP-1 in these neuronal cells was clearly cytoplasmic. 
The cause of these different expression patterns of DEP-1::GFP in the extrachromosomal and endog-
enous DEP-1 reporter lines might be the following. Although 4.5 kb of the dep-1 upstream region were 
present in the extrachromosomal DEP-1::GFP reporter, several cis- and trans- regulatory elements as 
well as the native dep-1 3’ UTR were only present and completely functional in the endogenous DEP-
1::GFP reporter lines zhIs70 and zhIs71. Thus, we assume that the expression pattern of DEP-1::GFP in 
the MosTic engineered lines zhIs70 and zhIs71 is closer to the real physiological expression of DEP-1, 
rather than the expression of DEP-1::GFP in zhEx112. 
The ability of metastatic cells to spread throughout the body and to invade other tissues is one of the 
hallmarks of cancer (Hanahan and Weinberg, 2011). Metastasis premises several sequential and obliga-
tory steps that must be completed, such as detachment of the cancer cell from its neighboring cells, deg-
radation of the basement membrane, proliferation in foreign microenvironments, invasion into other 
tissues, and the ability to induce angiogenesis. To obtain these capabilities, cancer cells must degrade 
or remodel all the ECMs that impose barriers to their dissemination. This remodeling of the ECM, but 
also other cellular functions crucial to the initiation, progression and metastasis of solid tumors is con-
trolled among others by integrins (Desgrosellier and Cheresh, 2010; Guo and Giancotti, 2004).
Specific integrin heterodimers are connecting the ECM to the cytoskeleton and mediate thereby the ad-
herence to other cells. Hence, misexpression of integrins can render cancer cells more motile, invasive, 
and resistant to anticancer drugs (Desgrosellier and Cheresh, 2010; Makrilia et al., 2009).
In breast carcinoma, for example, it has been observed that overexpression of β1 integrins causes dis-
ruption of adherens junctions (Gimond et al., 1999). However, the expression levels of β1 and some 
other integrins can also be decreased in tumor cells which potentially increase tumor cell dissemina-
tion (Desgrosellier and Cheresh, 2010; Kren et al., 2007; Mattila et al., 2005; Ramirez et al., 2011).
Thus, expression of integrins is correlated with cancer progression in various tumor types and can be 
used as a molecular marker to improve diagnostic accuracy and to predict the metastatic potential of 
carcinomas (Friedrichs et al., 1995; Hieken et al., 1996; Liu et al., 2013; McCabe et al., 2007; Nip et al., 
1992).
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As discussed previously (see section 3.1.8), integrin trafficking by endosomal pathways influence their 
function and modulates integrin distribution and function (Pellinen, 2006). Several members of the 
Rab family, which regulate integrin and growth factor receptor recycling, are aberrantly expressed in 
various cancer types, resulting in enhanced growth factor signaling (Caswell et al., 2008).Thus, deregu-
lation of integrin trafficking is closely related to cancer development and progression (Mosesson et al., 
2008; Ramsay et al., 2007). 
Another hallmark of cancer is induced angiogenesis, which enables the tumor to be provided with suf-
ficient nutrients and oxygen (Hanahan and Weinberg, 2011). In the past years, some of the key molecu-
lar mechanisms that regulate angiogenesis have been specified. Several data implicate thereby that in-
tegrin signal transduction plays an important regulatory role in angiogenesis (Avraamides et al., 2008). 
These important contributions of integrins to the biology of cancer cells have made integrins appealing 
targets for cancer therapy. One drug that is currently tested in clinical trials is Cilengitide. This cyclic 
pentapeptide that inhibits ligand binding to αv integrins could inhibit tumor growth in patients with 
glioblastoma (Mas-Moruno et al., 2010). However, also other antagonists of several integrins, includ-
ing αvβ3, αvβ5 and α5β1, are currently under investigations for cancer therapeutics (Avraamides et al., 
2008). 
Not only integrins contribute to tumor formation and metastasis, but also members of the epidermal 
growth factor family, including EGFR and ERBB2. In many carcinomas, including breast and pancre-
atic cancer, increased expression and hyperactivation of EGFR have been observed (Normanno et al., 
2006), leading to enhanced activity of oncogenic signaling pathways. Different mechanisms can cause 
an oncogenic behavior of growth factors. For example, expression of a high number of receptors on the 
surface of tumor cells can increase their sensitivity to low concentrations of growth factors (Olayioye et 
al., 2000). Furthermore, mutations in the receptor or in proteins involved in intracellular signal trans-
duction can explain the oncogenic role of growth factor receptors (Voldborg et al., 1997). Since aberrant 
activity of EGFR plays a key role in the development and growth of tumor cells, distinct therapeutic ap-
proaches, such as monoclonal antibodies, are currently employed for targeting EGFR in various human 
cancers (Ennis et al., 1991; Seshacharyulu et al., 2012). 
There is increasing evidence supporting a central role of a crosstalk between integrins and growth fac-
tors, which is essential for many aspects of tumor progression (Desgrosellier and Cheresh, 2010). This 
interplay not only regulates tumor cell adhesion, migration, invasion and survival, but also affects 
many aspects of the host response to cancer (Desgrosellier and Cheresh, 2010). As discussed previously 
(see section 3.1.8), numerous mechanisms revealed a connection between integrins and RTKs playing 
a central role in many aspects of tumor progression in pancreatic, breast, colon, and hepatocellular 
carcinomas (Desgrosellier and Cheresh, 2010; Guo et al., 2006; Pouliot et al., 2001; Ricono et al., 2009; 
Yang et al., 2003). 
For example, studies have shown that integrin ligation can induce EGFR phosphorylation indepen-
dently of EGF, which crucially influences tumor cell susceptibility to treatment (Moro, 2001). 
The receptor protein tyrosine phosphatase DEP-1 plays an essential role in regulating a variety of growth 
factor receptors, such as EGFR, VEGF, HGFR, and PDGFR, and regulates cell proliferation and differen-
tiation (Grazia Lampugnani et al., 2003; Kovalenko et al., 2000; Takahashi et al., 2012; Tarcic et al., 2009). 
DEP-1 is down-regulated in numerous cancer cells in correlation with their malignant phenotype, and 
loss of heterozygosity at DEP-1 has been frequently observed in human cancers (Ruivenkamp et al., 2003; 
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Zhang et al., 1997). Data showing that restoration of DEP-1 expression in culture and in vivo suppresses tu-
mor cell growth (Trapasso et al., 2006) further support  the prominent role  of DEP-1 as a tumor suppressor. 
In conclusion, both integrins, EGFR signaling and DEP-1 play essential roles in the modulation of 
tumorigenesis. By showing that DEP-1 activates PAT-3 by dephosphorylation and that activated inte-
grins negatively regulate RAS/MAPK during vulval development, we could identify a so far unknown 
mechanism that contributes to a further knowledge of how these pathways are regulated. This basic 
research is premise for a further understanding of cancer formation and tumor invasion, but also for 
the development of novel cancer therapeutic drugs. However, our observations also emphasize the need 
for further research focused on the molecular mechanisms connecting DEP-1, the integrins, and RAS/
MAPK signaling.  
In section 3.1 we report the identification of the C. elegans β-integrin subunit PAT-3 in a mass spec-
trometry-based approach as a novel substrate of the tyrosine phosphatase DEP-1. Using biochemical 
and genetic epistasis analyses, we found that PAT-3 acts as a negative regulator of RAS/MAPK signal-
ing during vulval development, and that DEP-1 binds to the highly conserved NPxY motif of the PAT-3 
cytoplasmic tail to regulate its activity. However, there are still several open questions to be answered, 
and further research on the molecular mechanisms connecting DEP-1, the integrins, and RAS/MAPK 
signaling is needed. 
One of the most important questions to be solved is how the integrins PAT-2/PAT-3 are connected to the 
RAS/MAPK signaling pathway. As discussed previously, there are numerous possibilities how integrins 
can be linked to RAS/MAPK signaling (see section 3.1.8). However, the complexity of the two mul-
tifaceted pathways complicates the identification of the connecting molecular mechanism. A central 
question is if integrins do regulate the EGF receptor LET-23 themselves, or if they regulate downstream 
components of the RAS/MAPK pathway affected such as RAS/LET-60. 
One possibility to answer this question is to perform more epistasis analysis, for example by vulva-
specific knock-down of PAT-2 or PAT-3 by RNAi in let-23(gf) animals. If this led to an enhanced vulval 
induction, it would show that integrins act in parallel or downstream of LET-23. 
A similar conclusion could be drawn when dep-1 is knocked-down by RNAi in let-23(gf);pat-3(lf) ani-
mals, in which pat-3 with disrupted NPxY motifs is expressed. If this altered the induction of VPCs 
compared to control RNAi treated mutants, it would suggest that integrins negatively regulate EGFR/
RAS/MAPK signaling via DEP-1 activity. However, if dep-1 RNAi did not change the number of induced 
vulval cells, it would indicate that the integrins negatively regulate more downstream components of the 
RAS/MAPK pathway. 
Another way to test if integrins inhibit the EGF receptor is to analyze the intracellular dynamic of LET-
23. If RNAi against the integrins altered the localization and/or dynamic of LET-23::GFP, it would give 
evidence that PAT-2/PAT-3 regulate the activity of LET-23. As an alternative to RNAi, one could also test 
if pat-3 with disrupted NPxY motifs alters the dynamic of LET-23. 
Talin is one of the most important adaptor proteins of PAT-3 and binds with high affinity to the non-
phosphorylated NPxY motif to trigger integrin activation (Critchley, 2000; Tadokoro et al., 2003). Since 
4.2.2 Outlook: Characterizing the exact role of PAT-2/PAT-3 in RAS/MAPK signaling
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C. elegans talin (TLN-1, UNC-35) co-localizes with PAT-2 and PAT-3 (Moulder et al., 1996), and because 
reduction of talin leads to phenotypes that are also observed with depletion of pat-2 and pat-3 (Cram et 
al., 2003), it would be conceivable that talin is a linker of activated integrin and the RAS/MAPK signal-
ing pathway. 
To test this hypothesis, one could knock-down tln-1/unc-35 specifically in the vulva of let-60(gf) ani-
mals and examine the number of induced vulval cells. If the same increase in vulval induction was ob-
served as when PAT-3 is knocked-down, it would suggest that TLN-1/UNC-35 is downstream of PAT-3 
and a linker of integrins and RAS/MAPK signaling. 
Another important question is if DEP-1 regulates integrin trafficking. As described earlier, we hypoth-
esize that loss off dep-1 causes enhanced apical and intracellular expression of PAT-3::GFP. However, 
due to the limits of optical resolution we have not yet been able to quantify these changes. A method 
that should enable the quantification of putative differences in integrin trafficking caused by DEP-1 is 
f luorescence recovery after photobleaching (FRAP) analysis, which one could perform in pat-3::GFP 
(qyIs43) and pat-3::GFP;dep-1(lf) (AH2916) animals. 
In addition, we plan to analyze animals that express PAT-3::GFP with disrupted NPxY motifs. If mu-
tated NPxY altered the localization of PAT-3::GFP, it would give further evidence that they play a crucial 
role in integrin trafficking. 
Finally, it would be of big interest to determine if the interaction between DEP-1 and PAT-3 is also con-
served in human. To determine this, it first has to be tested in which cell lines DEP-1/CD148 and β1 or 
β3 are expressed. Subsequently, one could perform pull-down experiments to confirm a possible inter-
action of human DEP-1/CD148 with β-integrins. Furthermore, it would be worth to test if reduction of 
β1 or β3 by siRNA affects the level of RAS/MAPK signaling in human cell lines. However, the analyses 
of integrins in cell culture might not be that trivial since 24 distinct α/β heterodimer combinations are 
formed by 18 α-subunits and 8 β-subunits, which all differ in their functionality. 
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5.1.1 PCR
Amplification of PCR fragments was performed with Phusion® High-Fidelity DNA Polymerase (NEB), 
Taq DNA Polymerase (Invitrogen), or LongAmp® Taq DNA Polymerase (NEB) according to the manu-
facturer’s protocol using the following PCR-mixes and cycle programs.
Phusion® High-Fidelity DNA Polymerase (NEB)
Component 20 µl reaction
5X Phusion HF Buffer 4 µl
2 mM dNTPs 2 µl
2 mM forward Primer 2 µl
2 mM reverse Primer 2 µl
Template DNA variable
Phusion DNA Polymerase 0.2 µl
dH2O to 20 µl
Cycles Temperature Time
1x 98° C 30 sec
30x 98° C 10 sec
58° C 30 sec
72° C 30 sec/kb
1x 72° C 5-10 min
12° C ∞
Cycles Temperature Time
1x 94° C 3 min
30x 94° C 45 sec
58° C 30 sec
72° C 1 min/kb
1x 72° C 10 min
12° C ∞
Taq DNA Polymerase (Invitrogen)
Component 20 µl reaction
10X PCR Buffer (minus Mg) 4 µl
2 mM dNTPs 2 µl
50 mM MgCl2 0.8 µl
2 mM forward Primer 2 µl
2 mM reverse Primer 2 µl
Template DNA variable
Taq DNA Polymerase 0.8 µl
dH2O to 20 µl
5.1 DNA Methods
PCRs were run in 0.2 ml Multiply®Pro Tubes (Sarstedt) or sealed 96-well plates on the BioRad MyCycler 
Termocycler. Thereafter, 2-4 μl of the PCR product was loaded together with 4 µl of PCR-loading buffer 
on a 1% agarose gel (containing 50 μl 2 μg/ml Ethidium bromide per 50 ml agarose solution) and was 
run for approximately 20 minutes at 120 V. With a UV-light picture, the quality of the PCR was deter-
mined. 
Cycles Temperature Time
1x 94° C 2 min
30x 94° C 30 sec
58° C 30 sec
65° C 50 sec/kb
1x 65° C 10 min
12° C ∞
LongAmp® Taq DNA Polymerase (NEB)
Component 20 µl reaction
5X LongAmp Taq Reaction Buffer 4 µl
2 mM dNTPs 2 µl
2 mM forward Primer 2 µl
2 mM reverse Primer 2 µl
Template DNA variable
LongAmp Taq Polymerase 0.8 µl
dH2O to 20 µl
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5.1.2 Oligonucleotides
The primers, ordered from Microsynth AG (www.microsynth.ch), were kept in a 100 µM stock solution 
diluted in TE at -20°C. For the PCR reactions, the primers were further diluted with dH2O to a final 
concentration of 2 µM. All primers mentioned below are listed from 5’ to 3’.
bar-1
dep-1
OMW 71 CCTTCTAGGAATAGTCGATTTCCTGCAGGTCGACTCTAGAGGATC
OMW 72 GGAATGTGCAACAAATATCCGACTG
OMW 185 GTAACGCATCCCAGTTTTCTG
OMW 42 TTTGGCCGGCCGATTCACTGACAACATCGGCTGAGC
OMW 43 AAATTAATTAACTATAGCAATGGGATTGCTGGAGTTGC
OMW 44 TTTGGCCGGCCAATCGAACAAAGAAAGCGAGACTCGC
OMW 45 AAATTAATTAATCAAAATCCCGATTCGACAATCAT
OMW 46 GGCGCTTTCGTAAAGCGTTTTCC
OMW 47 CTGATATTCAAGTCGCTGAGCAC
OMW 48 GTTTCAGCTTCGTCCCCTTCCAC
OMW 49 CCCGTATTCGCGAAGAATCTTG
OMW 50 CGCATTACGCAGTTAATGTGAC
OMW 51 CGGAAACCACAGCTGACGAATC
OMW 52 CTGTAGCTGCATCGGAATTGCC
OMW 53 GGAAAACGCTTTACGAAAGCGCC
OMW 54 GTGCTCAGCGACTTGAATATCAG
OMW 55 GTGGAAGGGGACGAAGCTGAAAC
OMW 56 CAAGATTCTTCGCGAATACGGG
OMW 57 GTCACATTAACTGCGTAATGCG
OMW 58 GATTCGTCAGCTGTGGTTTCCG
OMW 59 GGCAATTCCGATGCAGCTACAG
OMW 60 GAGAACGTTTCGATTTTTCGATTTCTTCGATGGCAAATGAG
OMW 61 CATATCAAATTATTGCGACTGTTCAAAAAGGCGGTCAAG
OMW 62 GAAGCATATCAAATTATTGCGACTGTTCAAAAAGGCGGTCAAGTCTCTG
OMW 65 TTTGGCGCGCCAGGATGATACGCTGGAAGTACGAAC
OMW 66 AAAGGCCGGCCAAATCCCGATTCGACAATCATTTG
OMW 67 AAAGAGCTCTCAAAATCCCGATTCGACAATCATTTG
OMW 68 GGTCAAATGATTGTCGAATCGGGATTTGGCCGGCCACCAGCACAGTGGCGGCC
OMW 69 AAAGGCCGGCCTAGCAATGGGATTGCTGGAGTTGC
OMW 70 GGCGCGCCAGGATGAATCGAACAAAGAAAGCGAGACTCGC
OMW 77 GCATTATATGGCATGGCCTGCTTTTGGAGCCCCGTCTCATCC
OMW 78 GCTCCAACGATAGTGCATTCCAGTGCTGGAGTTGGTCGTTC
OTB 94 GTCGACGGATTTTGAACCATTGGGTCG
OMW 121 TTTTTCTACCGGTACCCTCCAAGGG
OMW 128 GAATTCCTAAAACGTGAGTGATCAG
OMW 129 GAGAGCTTAGAACTGGCGAAGTCAC
OMW 130 GCTTACAGACAAGCTGTGACCGTCTC
OMW 131 CATTTTTTCTACCGGTACCCTCCAAGGGTCCTCC
OMW 132 GGAGGACCCTTGGAGGGTACCGGTAGAAAAAATGGTCTCAAAGGGTGAAGAAG
OMW 188 CAAATTGCAGACTCGCAGCGGCAG
OMW 189 GTTGAAGTAGATGTTGGAGACGGAG
OMW 190 CAAAAATGTAGAGAAGGGGTTTCTCTCTATTTGTATAGTTCATCCATGCC
OMW 191 CTCCGTCTCCAACATCTACTTCAAC
OMW 192 GACACTTGTGGCTGGACGACTTGC
OMW 193 GAACCTGACTTACCAGTGTATCGG
OMW 194 AGAGAAACCCCTTCTCTACATTTTTG
OMW 195 CTCCGGATACTTACCTCTTTCTAGTC
OMW 196 CTGTAAGATCCCTAGGTTACCCTC
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OTS 38 TCATTCTCCGTCGTCTTC
OTS 39 CATTTTTTTCAGTTCCAGCC
OMW 73 TTTGGCGCGCCAGGATGAGTAAAGGAGAAGAACTTTTCAC
OMW 74 AAAGGCCGGCCTTTGTATAGTTCATCCATGCCATGTG
OMW 75 GGCATGGATGAACTATACAAAGGCCGGCCACCAGCACAGTGGCGGCCGCTCG
OMW 79 CTACGATATTGCATCAAGACAGCG
OMW 80 CATTTTTTCTACCGGTACCCTCCAAG
OMW 83 CCGCAGTTCGAAAAAGCGGCCGATATGAGTAAAGGAGAAGAACTTTTCAC
OMW 84 GTGGGCAGATCTTCGAATGCATCG
OMW 86 CATTTGGAGTCACATGTTGGGAG
OMW 87 CTAGTTGAACGCTTCCATCTTC
OMW 116 CAATCAGGGACGTCACGGACAAATGATGAGTAAAGGAGAAGAACTTTTCAC
OMW 117 GTAAAGAATAAGGAACAAAAAATGGAAAATACTATTTGTATAGTTCATCCATGCCATGTG
OMW 125 GTTATTGTCTCATGAGCGGATAC
OMW 209 CAGACAACCATTACCTGTCCACAC
OMW 63 TTTGGCCGGCCACCAGCACAGTGGCGGCCGCTCG
OMW 64 AAATTAATTAATCAATCGGCCGCTTTTTCGAACTGCG
OMW 81 CTTGGAGGGTACCGGTAGAAAAAATGGGCCGGCCACCAGCACAGTGGCGGCCGC
OMW 82 ATCGGCCGCTTTTTCGAACTGCGG
let-60
gfp
HA-Strep-III
OMW 223 GCAGTAGAGAATGGAATCAGATCC
OMW 224 CTTGCATTTCTGTACCGCCCATTC
OMW 161 GCTTGCATGCCTGCAGGTCGACG
OMW 162 CCGCTAGCCAAGGGTCCTCCTG
OMW 212 GGTTAGTTCAGCAGCACATAATGC
OMW 213 CAATACCTGATCACTACTTCGCAC
OMW 214 CAGGAGGACCCTTGGCTAGCGGATGCCACAATTTGGTATATTATG
OMW 215 GTGCGAAGTAGTGATCAGGTATTG
dpy-19
eft-3
FLP recombinase
OMW 197 CTCGAAAGAGAAAGAGTCGCAGTGG
OMW 198 GCAGGAAATCCTATAGAGCTTGTGGG
OMW 199 CAAAAATGTAGAGAAGGGGTTTCTCTCTACTTATACAATTCATCCATGCCACCTGTCG
OMW 200 CAAAAATGTAGAGAAGGGGTTTCTCTG
OMW 203 GTATATCAAATTGCAGACTCGCAGCG
OMW 204 CCATGACAGTACTTGCAGCTGATTCG
OMW 205 GATGATGGCAGAGAGAGCCGCTG
OMW 206 GAGGACGACTTCCGACACTTGTGG
OMW 208 GCCTGCAAATGTCTTCGGAACATTC
OMW 210 CTGCCTACCGCTAACTTAATCCTGG
OMW 211 CATCGACGACGAGTTCCAACTCGC
OMW 217 CACATGTTCTTTCCTGCGTTATCCC
OMW 218 CCTTTGAGTGAGCTGATACCGCTC
OMW 219 GGACTTGGATAAATTGGCTCAAAGCTGTAAGATCCCTAGGTTACCCTCC
OMW 222 CTACTTATACAATTCATCCATGCCACCGTAAGATCCCTAGGTTACCCTCCTG
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OJL 115 GCTCAATTCGCGCCAAACTATG
OJL 116 GAACGAGAGGCAGATGGAGAGGC
OIR 4 CTCACCTACCGAGCACATC
OIR 5 CTCGTCTTGTTCACTGTCG
OIR 6 GAGGTGACGCCGAACAGC
OMW 155 CTTCCCAATTACCGTACCAGTGTC
OMW 156 GACACTGGTACGGTAATTGGGAAG
OMW 157 GGGTCCTTTGGCCAATCCCGGG
OMW 158 CTGAGCTCAGAGCGAATTCTGATC
OMW 159 CATTACAATTTCCGATCACATTGC
OMW 160 GCAATGTGATCGGAAATTGTAATGGATTAGGGTGAATGGAGGGTGTTTG
OMW 175 GTCATTCAACGACTGCTTCATCAAG
OMW 176 CTTCTAAGGCTTGGCTTCTCAAAC
OMW 122 CCCTTGGAGGGTACCGGTAGAAAAAATGGTCTCAAAGGGTGAAGAAG
OMW 123 TAGCATTCGTAGAATTCCAACTGAGC
OMW 124 GCTCAGTTGGAATTCTACGAATGCTACTTATACAATTCATCCATGCCACCTGTCG
OMW 201 GGTGGCATGGATGAATTGTATAAGTAGGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCCTTTGAGCCAATTATC-CAAGTCC
OMW 202 CTACTTATACAATTCATCCATGCCACC
mos1
lip-1
lin-31
mCherry
OMW 37 TTCCGGCTCGTATGTTGTGTGG
OMW 38 GGGTGCAGACAGACATACGGACTCTACCGGTACCCTCCAAGGG
myo-3
OMW 139 GGAGCAATATCAGGAAGAGTTCCC
OMW 140 CAGCTACAGCCTGCATTCTTCCG
OMW 141 GCCCTCTCCACTCAATTACCCATC
OMW 142 GTGCAGTTAAGTCAATATTGGGCG
OMW 143 CATTTCACCTGAAATACCAATATTC
OMW 144 CAGAGAATTGCCGCAGATGCTAG
OMW 145 GCATCCCTTCACTTTGACATTGTC
OMW 146 CCTGACACAACCTAAAGTTCAGTC
OMW 147 AGAGCTTTAATTTTCTCCCTCATTTGC
OMW 148 GGACAATGTCAAAGTGAAGGGATGCAGCTTGCATGCCTGCAGGTCGAC
OMW 149 GCAAATGAGGGAGAAAATTAAAGCTCTCTATTTGTATAGTTCATCCATGCC
OMW 150 GCAGCTTTCGATGTAATCGTTAGAG
OMW 151 GATTGTCCGTGTTGGCGACGATCG
OMW 152 GAATATTGGTATTTCAGGTGAAATGAGTAAAGGAGAAGAACTTTTCACTG
nid-1
OMW 88 GGTTACTGTAGCTCCAAAATTCTG
OMW 89 CTGATCAAGTATAGATCAAGACCGG
OMW 90 CATTTGTCCGTGACGTCCCTGATTG
OMW 91 CAATCAGGGACGTCACGGACAAATG
OMW 92 CAATCAGGGACGTCACGGACAAATGCTAATGGTCTCAAAGGGTGAAGAAG
OMW 93 GAATAAGGAACAAAAAATGGAAAATATTACTTATACAATTCATCCATGCCACC
OMW 94 CGAATCATCTCAGCCAATTGCTTG
pat-2
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dnI-F 1 TCCTCTTCATTCGCCGTCCAAGATGCG
dnI-R 1 TCACCTTCCACTGAGCCTCAAACC
OMW 96 CGTTTGACAGCAAGATATAGCCCG
OMW 97 GCAGGTTTTGGTGGAGAATTCTGC
OMW 98 GTTGGCTTTTCCAGCGTATACTGG
OMW 99 CCAGTATACGCTGGAAAAGCCAACATGGTCTCAAAGGGTGAAGAAG
OMW 100 GGGAAAATTATTAAAATATAAGGATAAAAACTATCTTATACAATTCATCCATGCCACC
OMW 101 ATAGTTTTTATCCTTATATTTTAATAATTTTCCC
OMW 102 CATGTCTTCTCAGATAGTTATGGC
OMW 103 GAATGCTTTCTGTGCACTTGGATG
OMW 104 GTTGCCACCTGTTGAAAGCAG
OMW 105 CGACGAGAAGAAGCCATATGCC
OMW 106 GACCGCTGCGACTCGAAAACTTG
OMW 107 GGCGTTGGCTTGTAATGTAAGTGG
OMW 108 CAAATGCTTCAGAAGGACTCAAGC
OMW 109 CTACAATATTGCCCTCGCCGTGC
OMW 110 GACCTGGAATGAGTACTGCTGC
OMW 111 CTAACGAATCAGCAATCTGTGAGG
OMW 112 CCTGTTGAGGAATTACCCAGTAAG
OMW 113 GAGGCCACAGATAATGCAACAGTC
OMW 114 CTTAATTCGGTATCTGCAGGCACAC
OMW 115 CGTTTCGAGTTGTTTGGATGGAG
OMW 126 GAACGAGAACCCAATCGCCAAACAGGCCACGACAAC
OMW 127 CAACATTTAAAAATCCAGTAGCCGCTGGAAAAGCCAAC
OMW 133 CCAGAGCAACAAGAGAAGAATTCCGAGG
OMW 134 CCTCGGAATTCTTCTCTTGTTGCTCTGGGCGGCCGCCATCTTTTACCCATACGATGTTC
OMW 135 CAGTACTTCATGATAGATCCGAAGCCGCTACTTTCAATAACGAAAGGC
OMW 136 GAACCCAATCTACAAACAGGCCGCGGCAGCATTTAAAAATCCAGTATACGCTGG
OMW 137 GCTTGAGTCCTTCTGAAGCATTTG
OMW 138 CTTCATGATAGATCCGAAGCCGCTACTTTCAATAACG
OMW 153 GCACGGCGAGGGCAATATTGTAG
OMW 154 CCCGGGATTGGCCAAAGGACCCTCCTCTTCATTCGCCGTCCAAGATGC
OMW 168 ATGCCACCTTCAACATCATTGCTGC
OMW 169 GTCCTTGATCGGAGAGTTTACTGTC
OMW 170 GTCACGTGACAGACTGTAGCATGG
OMW 171 CCATGCTACAGTCTGTCACGTGACGAGGCCACAGATAATGCAACAGTCTG
OMW 172 CCCATGCTACAGTCTGTCACGTGACTGGAAATTGCTCACAGTACTTCATG
OMW 174 CAGGAGGACCCTTGGCTAGCGGATGCCACCTTCAACATCATTGCTGC
OMW 177 GGAACGTCATATGGATAGGATCC
OMW 178 CCTCTTCATTCGCCGTCCAAGATGCGTTACGCTCTTGCCGCTTGTCTCC
OMW 181 CGTATCCCATTTGGCCATAAGCC
OMW 182 GGCTTATGGCCAAATGGGATACGAACGAGAACCCAATCTACAAACAG
OMW 183 GAGCTCATGCCACCTTCAACATCATTGCTG
pat-3
OMW 95 GATGGTCAGATTCAAGCAATTGGC
OMW 118 TATTTTCCATTTTTTGTTCCTTATTCTTTAC
OMW 119 CTACTGGAAATTTGGAATTCGG
OMW 120 CCGAATTCCAAATTTCCAGTAGATGCGAGAGGGTAGTTTTCCGCG
OMW 163 CAGGAGGACCCTTGGCTAGCGGATGCGAGAGGGTAGTTTTCCGCGAAGG
OMW 164 GGAGCAAGCATAAACTGCTCCAGG
OMW 165 GTTACCAGCCATGTGATGAACCAC
OMW 166 GTGGTTCATCACATGGCTGGTAACGCAATTGCTTCTGAAGAAGGAAGAG
OMW 167 GTGGTTCATCACATGGCTGGTAACAGGTGTGGTTTCTTCAAACGTAATCGTC
OMW 173 CAATCAGGGACGTCACGGACAAATGCTAGCGGCCGCCATCTTTTACCC
OMW 179 GAGCTCATGCGAGAGGGTAGTTTTCCGCG
OMW 180 GGTCGACCATGGAACAGGTAGTTTTCCAG
OMW 187 GGTCAGATTCAAGCAATTGGCTGAG
121
DNA Methods
OLM 6 CCTGGACATTCGATCATCTGAAG
OLM 7 CGTTTCACGATCCAAACAGATTCG
rde-1
OMW 216 GAGGGTAACCTAGGGATCTTACAGCTTTGAGCCAATTTATCCAAGTCCTTG
OMW 220 CAGCTTTGAGCCAATTTATCCAAGTCCTTG
OMW 221 GGTGGCATGGATGAATTGTATAAGTAG
OMW 226 GAACGTCACTTCTTCAAAGATCGCC
OMW 227 GGGATGAATTGGCTCAAAGTTAGG
OMW 228 CCTAACTTTGAGCCAATTCATCCC
unc-119
OMW 184 GGGTACCCATGGAACAGGTAGTTTTCCAG
OMW 229 CATGTCAAAGTGTCCGCTTCACGG
OMW 230 GTCCTCTAGTGAATGGGAATTGACC
OMW 231 GATTTACGCAGCTCGTGTACTCCC
OMW 232 GCATATTCGAACATCCGACAACTGC
5.1.3 PCR purification
5.1.4 Ligation of DNA into pGEM®-T Easy vector
5.1.5 Ligation of DNA into plasmid vector
DNA samples were diluted with 5x Binding solution and purified using the “GenElute™ PCR Clean-Up 
Kit” (Sigma-Aldrich) according to the manufacturer’s protocol.
Depending on the DNA concentration, plasmid backbone and insert were ligated with T4 DNA ligase 
(Roche) for 2 hours at room temperature in:
 2 µl  T4 DNA ligase buffer
 1 µl  T4 DNA ligase
 H2O  to a total volume of 20 µl
PCR fragments were purified using the “GenElute™ PCR Clean-Up Kit” (Sigma-Aldrich) and ligated 
according to the manufacturer’s protocol into pGEM®-T Easy Vectors (Promega). If the PCR fragments 
were amplified with the Phusion® High-Fidelity DNA Polymerase (NEB), a poly-A tailing was performed 
prior to ligation using the GoTaq® DNA Polymerase. Therefore, a mix containing:
 5 µl  PCR (purified)
 2 µl  5x GoTaq PCR Buffer
 0.2 µl  dATPs (10 µM)
 0.2 µl  GoTaq® Polymerase
 2.6 µl  H2O
was incubated at 70° C for 30 min in a PCR machine (BioRad MyCycler). E. coli were transformed with 
the whole mix as described in 6.2.10 with the difference that 40 µl of 1 M IPTG and 40 µl of X-Gal were 
plated on the petri dishes.
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A single bacteria colony was added to 2 ml of 2xTY containing ampicillin and incubated at 37°C over 
night. The next day, the liquid culture was transferred to a 1.5 ml Eppendorf tube and centrifuged for 2 
minutes at 4’000 rpm. The supernatant was discarded and 350 µl of STET were added before vortexing 
to dissolve the pellet. 25 µl of Lysozyme were added and the sample was incubated at 95°C for one min-
ute. Next, the sample was centrifuged at 4°C for 8 minutes at 14’000 rpm, the pellet was removed with a 
forceps and 30 µl of 3 M NaAc pH=5.2 and 300 µl of Isopropanol were added to the supernatant. After 
another centrifugation step using the same conditions, the supernatant was discarded and the pellet was 
resolved in 40 µl of TE. 
MidiPreps were performed using the “QIAfilter Plasmid Midi Kit” (Qiagen) according to the manu-
facturer’s protocol with the following changes. After step 13, the pellet was resolved in 400 µl of TE, 
transferred to a 1.5 ml Eppendorf tube, and the DNA was precipitated with 40 µl of 3M NaAc and 
800 µl of 100% ice-cold EtOH. After incubation at -80° C for 10 minutes, the sample was centrifuged for 
10 minutes at 14’000 rpm at 4° C. The supernatant was discarded and the pellet was resuspended in 100 
µl of TE. 
To mutate one specific site on a plasmid, a ~50 bp long primer was designed with the desired mutation 
in the center. A mix containing: 
  2.5 µl 10x PfuUltra™ HF reaction buffer
  2 µl  dNTPs (10 µM)
  100 ng  Plasmid
  100 ng  Primer (50 bp long)
  0.2 µl  PfuUltra™ HF DNA polymerase
  H2O  to a total volume of 25 µl
Plasmids were digested using restriction enzymes from Roche or NEB according to the manufacturer’s 
protocol. If necessary, digested fragments were dephosphorylated by adding 1/10 of 10X Antarctic Phos-
phatase Reaction Buffer / 1 µl of Antarctic Phosphatase (NEB) and incubated at 37° C for 1 h. The Ant-
arctic Phosphatase was then heat inactivated for 5 min at 70° C. 
Digested DNA fragments that were excised from agarose gels were extracted using the GenElute™ Gel 
Extraction Kit (Sigma-Aldrich) according to the manufacturer’s protocol. 
5.1.6 Restriction enzyme digestion
5.1.7 Transformation of E. coli
5.1.8 Miniprep
5.1.9 Midiprep
5.1.10 Site directed mutagenesis
Competent E. coli were thawed on ice before adding 100 µl to the plasmid of interest. After 10-20 min-
utes incubation on ice, the bacteria were heat shocked for 90 seconds at 42°C. 800 µl of 2xTY buffer were 
added before incubating the sample for 30 minutes at 37°C. After centrifugation for 2 minutes at 4’000 
rpm, the supernatant was discarded, and the pellet was resuspended in 100 µl of 2xTY and the whole 
volume was plated on petri dishes. 
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After incubation, 1 µl of DpnI (NEB) was added to the mix and incubated at 37° C for 1 hour. 10 µl were 
then used for transformation of DH10B competent E. coli.
Cycles Temperature Time
1x 95° C 1 min
35x 95° C 1 min
55° C 1 min
65° C 2 min/kb
12° C ∞
5.1.11 Plasmids
pMW4 Peft-3::dep-1full::HS
Fusion PCR of dep-1minigene (amplified from pTB18 with OMW65/66) with HA-Stre-
pIII (amplified from pTO_HA with OMW68/64) and cloned into the AscI/PacI site of 
pLN022.
pMW5 Peft-3::dep-1intraD1241A::HS
dep-1 intracellular domain with substrate trapping mutation D1241A amplified from 
pTB30 with OMW70 and OMW66 and cloned into the AscI/FseI site of pMW4.
pMW6 Peft-3::gfp::HS
Fusion PCR of gfp (amplified from pPD95.75 with OMW73/76) with HA-StrepIII (am-
plified from pMW4 with OMW75/64) and cloned into the AscI/PacI site of pLN022.
pMW7 let-23::GFP::HS (entry clone)
Fusion PCR of OJE54/OMW80 (amplified from pJE5-02) with OMW81/OMW82 (am-
plified from pMW4) and OMW83/OJE55 (amplified from pJE5-02). PCR construct 
was amplified with adaptor primers OCH40/OCH41 and cloned by BP reaction into 
 pDONR P2r-P3.
pMW8 Peft-3::dep-1fullD1241A::HS
Site directed mutagenesis of pMW4 with OMW77.
pMW10 pat-3::GFP (translational reporter)
Amplification of pat-3::gfp from NK358 worm lysate with OMW96 and OMW102 and 
subcloned into pGEM®-T Easy.
pMW11 pat-3::GFP Y792A (translational reporter)
Site directed mutagenesis of pMW10 with OMW126.
pMW12 pat-3::GFP Y804A (translational reporter)
Site directed mutagenesis of pMW10 with OMW127.
pMW13 pat-3::GFP TTT796-798AAA (translational reporter)
Site directed mutagenesis of pMW10 with OMW136.
was incubated in a PCR machine (BioRad MyCycler) with the following program:
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pMW14 pat-3::GFP Y792A Y804A (translational reporter) 
Site directed mutagenesis of pMW10 with OMW126.
pMW15 pat-3::GFP Y772A (translational reporter)
Site directed mutagenesis of pMW10 with OMW138.
pMW16 pat-3::GFP Y772A Y792A (translational reporter)
Site directed mutagenesis of pMW11 with OMW138.
pMW21 Plin-31::pat-3 HA (B-tail)
Fusion PCR of OMW175-OMW159 (amplified from pPG2) with OMW160-OMW177 
(amplified from genomic DNA from the strain qyIs15)
pMW23 dep-1::gfp::dep-1 (resque construct for MosTic line ttTi25067)
Fusion PCR of OMW197-OMW189 (amplified from genomic DNA) with OMW191-
OMW190 (amplified from pTB24) and OMW194-OMW198 (amplified from genomic 
DNA) and subcloned into pGEM®-T Easy.
pMW24 dep-1::mCherry::FRTunc-119(+)FRT::dep-1 (resque construct for MosTic ttTi25067)
Fusion PCR of OMW211-OMW189 (amplified from genomic DNA) with OMW191-121 
(amplified from pTB24), OMW122-OMW202 (amplified from pWD200), OMW201-
OAH378 (amplified from pCFJ150) and OMW194-OMW210 (amplified from genomic 
DNA). The final PCR product was cloned into pGEM®-T Easy.
pMW25 dep-1::gfp::FRTunc-119(+)FRT::dep-1 (resque construct for MosTic ttTi25067)
Fusion PCR of OMW211-OAH375 (amplified from pMW23) with OAH377-OMW210 
(amplified from pMW24). The final PCR product was cloned into pGEM®-T Easy.
pMW26 Pglh-2::FLPase
FLPase was cut out of pWD79 with MluI/NheI (NEB) and cloned into the MluI/NheI 
site of pJL43.1 (replacement of Transposase with FLPase)
pMW27 Peft-3::FLPase
Fusion PCR of OMW161-OMW162 (amplified from pLN22) with OMW214-M13rev 
(amplified from pMW26) and cloned into pGEM®-T Easy.
pMW28 dep-1::gfp::dep-1 3’UTR::unc-119(+)::dep-1 3’UTR
PCR fragment amplified from pMW24 with OMW216-M13rev was digested with AvrII 
(NEB) and cloned into the AvrII site of pMW23.
pMW29 dep-1::mCherry::dep-1 3’UTR::unc-119(+)::dep-1 3’UTR
Fusion PCR of M13f-OMW199 (amplified from pMW24) with OMW194-OSN63 (am-
plified from pMW28) was digested with SacII (NEB) and cloned into the SacII site of 
pMW28.
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The injection mix (20 µl total volume containing a total amount of 150 ng DNA) was filtered (Coxtar, 
SPIN-X Centrifuge Tube Filter, 0.45 µm Cellulose Acetate) and then injected into young adult her-
maphrodites that were sticked on slides with 2 % agarose pads and Halocarbon oil (700) as described by 
(Mello, Kramer, Stinchcomb, & Ambros, 1991). The injected animals were rescued from the slides with 
M9 buffer, transferred to a fresh plate with OP50 E. coli, and later on screened for transgenic progeny.
Genomic DNA was prepared by lysis of young adult hermaphrodites and served as template for PCR 
assays. 1-10 worms were picked and placed into individual tubes containing 10 µl of lysis mix (see 5.5 
for content) and incubated in a thermocycler. The cycle program on PCR machine (BioRad MyCycler) 
was as follows: 
Temperature Time
60° C 1 hour
95° C 10 min
12° C ∞
Genotyping was performed by 2 primers f lanking the correspondgin mutation or deletion. PCR reac-
tions were done with Invitrogen Taq Polymerase or NEB LongAmp Taq DNA Polymerase in 20 µl of 
reactions. For point-mutations, PCR products were purified prior to sequencing.
Genotyping of 5’ Primer 3’ Primer Size Sequencing Primer
lip-1 OIR4 OIR5 OIR6 920 bp (mut) / 560 bp (wt) -
dep-1(zh34) OMW197 OMW189 1.8 kb OMW52
dep-1(ttTi25067) OMW194 OMW196 500 bp (-Mos) / 1.8 kb (+Mos) -
let-60 OTS38 OTS39 700 bp OTS49
rde-1(ne219) OLM6 OLM7 800 bp (mut) / 2.5 kb (wt) -
pat-3 NPxY motifs OMW112 OMW102 1.3 kb OMW113
pat-3(st564) OMW232 OMW229 12.3 kb OMW111
nid-1(cg119) OMW139 OMW140 2.8 kb (mut) / 5.8 kb (wt) -
5.1.12 DNA sequencing
5.1.13 DNA micro-injection
5.1.14 Lysis of worms
5.1.15 Genotyping PCR assays
DNA samples of interest were first purified using the “GenElute™ PCR Clean-Up Kit” (Sigma-Aldrich). 
The final sample were then sequenced by in-house sequencing service and had a total volume of 10 µl 
containing:
 PCR-Primer:  1 µl (10 µM)
 Plasmid:  500 – 1’000 ng DNA
 PCR:  10-20 ng DNA per 100 bp
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5.1.17 PAT-3::GFP reporter constructs
For the pat-3::GFP translational reporters, a 8.7-kb fragment was PCR-amplified from pat-3::GFP ex-
pressing worms (qyIs43; kindly provided by David Sherwood) with the primers OMW96 and OMW102 
and subcloned into pGEM®-T Easy (Promega) according to the manufacturer’s protocol. The Y-to-A 
mutations were introduced by site directed mutagenesis (see 6.2.7). 
5.1.16 Generation of endogenous dep-1::gfp and dep-1::mCherry reporters
Endogenous single copy reporters of dep-1::GFP and dep-1::mCherry were created by MosTIC insertion 
as reported by (Robert et al., 2009). The repair templates were cloned by PCR fusion of the last 1.8 kb 
of the dep-1 locus to GFP or mCherry, followed by 500 bp of the dep-1 3’ UTR, the C. briggsae unc-119 
rescue construct, and 1.9 kb of the genomic dep-1 downstream region. The final construct was sub-
cloned into pGEM®-T Easy (Promega) and 50 ng/µl of the created plasmid (pMW28 or pMW29) was 
micro-injected together with 50 ng of the Mos1-transposase pJL43.1, 2.5 ng of myo-2::mCherry, 5 ng of 
pCFJ104, and 10 ng of pGH8 into the Mos insertion line ttTi25067; unc-119(e2498). MosTIC engineered 
animals were identified by screening the F2 progeny for crawlers that lost the myo-2::mCherry marker, 
and confirmed by sequencing.
For FLP-FRT site directed recombination of animals in which mCherry::FRT::unc-119(+)::FRT was inte-
grated into the locus of dep-1, 50 ng/µl of Phsp-16-48::f lp (pWD79-2RV) were injected into 30 animals, 
which were incubated directly after micro-injection for 35 minutes at 33°C. Next morning, the animals 
were again heat-shocked again for 20 minutes at 33°C. As further approaches, 50 ng/µl or 100 ng/µl of 
pMW26 (Pglh-2::FLPase), or 100 ng/µl pMW27 (Peft-3::FLPase) were injected. 
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5.2 Protein Methods
5.2.1 SDS-PAGE
5.2.2 Coomassie Blue staining
5.2.3 Colloidal Coomassie Blue staining
Polyacrylamide gels were prepared according to standard protocols (see Molecular Cloning – A Labora-
tory Manual by Maniatis). SDS gels were run at 100 V in fresh SDS running buffer. After running, the 
gel was either stained with Coomassie Blue (see below), or further used for Western blot experiments. 
2x SDS loading buffer: 1 ml 1 M Tris pH=6.8, 2 ml 1 M DTT, 2 ml 20% SDS, 20 ml Bromophenol Blue, 2 ml 
100% Glycerol, 3 ml H2O
5x Laemmli buffer: 60 mM Tris-Cl pH=6.8, 2% SDS, 10% Glycerol, 5% β-mercaptoethanol, 0.01% bromo-
phenol Blue
1x SDS running buffer: 8 l H2O, 30.2 g Tris, 188 g Glycine, 50 ml 20% SDS
Running gel 8%: 2.3 ml H2O, 1.3 ml 30% acrylamide mix, 1.5 ml Tris pH=8.8, 25 µl 20% SDS, 50 µl 10% 
APS, 5 µl TEMED
Running gel 12%: 50 ml 1 M Tris, 150 ml 5 M NaCl, 2.5 ml Tween 20, 5l H2O, 25 µl 20% SDS, 50 µl 10% 
APS, 5 µl TEMED
Stacking gel: 13.6 ml H2O, 3.4 ml 30% acrylamide mix, 2.5 ml 1.5M Tris pH=8.8, 0.1 ml 20% SDS, 0.2 
ml 10% APS, 20 µl TEMED
For Coomassie Blue staining, the SDS-PAGE gel was removed from the glass and transferred to a stain-
ing box. Enough Coomassie stain was added to cover the gel by 1.5 cm. The Coomassie stain was boiled 
in the microwave on high power, before the gel was incubated in the Coomassie stain for 5 to 10 minutes 
on a rocking table. The Coomassie stain was poured off and could be recycled a couple of times when it 
was stored at 4°C. The gel was rinsed twice in dH2O before fresh destain solution is boiled up in the mi-
crowave. A folded Kimwipe is added, and after incubation for 10 minutes, the step with the Coomassie 
destain solution is repeated. The gel can be stored at the end in dH2O. 
For Colloidal Coomassie Blue staining, the SDS-PAGE gel was removed from the glass and transferred 
to a staining box. Enough fixing solution was added to cover the gel and incubated on a rocking table for 
30 minutes before incubation over-night with staining solution. The gel was then transferred to a clean 
staining box and incubated with enough washing solution for not more than 5 minutes. Thereafter the 
gel was again transferred to a clean staining box and stored in dH2O. 
Coomassie Blue Stain: 0.25 g Coomassie Brillant Blue, 45 ml Methanol, 45 ml H2O, 10 ml Glacial acetic acid
Coomassie Blue Destain: 100 ml MetOH, 75 ml Glacial acetic acid, 825 ml H2O
Fixing solution: 20% (v/v) Methanol, 1% (v/v) 85% phosphoric acid, 79% H2O
Staining solution: 20% (v/v) Methanol, 20% (v/v) Roti Blue concentrate, 60% H2O
Washing solution: 25% (v/v) Methanol, 75% H2O
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5.2.5 Antibodies
5.2.6 GST purification of GST::DEP-1
αAJM-1 Monoclonal mouse MH27
αGFP Monocolonal mouse Anti-Green Fluorescent Protein Roche 11 814 460 001
αHA Monocolonal mouse Anti-HA (12CA5) Roche 11 583 816 001
αIgG Goat Anti-Mouse IgG Horseradish Peroxidase (HRP) Jackson Immuno Research 115-035-003
αIgG Goat Anti-Rabbit IgG Horseradish Peroxidase (HRP) Jackson Immuno Research 111-035-003
FITC Fluorescein FITC Donkey Anti-Rabbit IgG (H+L) Jackson Immuno Research 711-096-152
Cy5 Cyanine Cy5 Donkey Anti-Mouse IgG (H+L) Jackson Immuno Research 715-175-151
A single colony of E. coli BL21, previously transformed with pTB29 or pTB30, was grown in a 20 ml 
2xTY liquid culture containing ampicillin at 37°C over-night. The next day, 2x 9 ml were transferred to 
two Erlenmeyer f lasks containing 150 ml 2xTY (without ampicillin) and grown until the OD600=1 was 
reached (measured with a photometer). The culture was cooled down to <18°C, before 0.2 mM IPTG 
(final concentration) was added. After incubation for 4 hours at 18°C, the liquid culture was centrifuged 
at 4’000 rpm for 10 minutes at 4°C. After discarding the supernatant, the pellet was resuspended in 10 
ml of cold PBS (containing 250 µl of 50x complete and 1.2 ml of 10 % Triton-X (endconcentration=1%)), 
and transferred to a 15 ml falcon tube. Keeping the sample on ice, protein extraction was conducted by 
sonication. Sonication was done 5 times for 30 seconds with 20 % intensity, followed by a break of 30 
seconds (Bandelin Sonopuls). The sample was transferred to 2 ml Eppendorf tubes and centrifuged for 
10 minutes at 10’000 rpm at 4°C. 
The supernatant was incubated for 1 hour at 4°C with 200 µl of GST sepharose (Sigma) which has pre-
viously been equilibrated in cold PBS. Thereafter, the sample was washed three times with cold GST 
washing buffer for 15 minutes at 4°C. 
Transfer Buffer: 160 ml Methanol, 640 ml H2O, 2.42 g Tris, 11.528 g Glycine
Blocking Buffer: 5% milk powder (Coop) in TBS-T
5.2.4 Western Blot
Proteins that were previously separated by SDS-PAGE were blotted onto a PVDF membrane by the 
MiniProtean® Electrophoresis System from BioRad. Thereby, the PVDF membrane, which was previ-
ously activated with 100% Methanol, was placed on the SDS gel to form a gel sandwich and placed to the 
Trans-blot cell. The chamber was filled with freshly prepared transfer buffer before the proteins were 
blotted with 100V during 1 hour. Thereafter, the membrane was blocked with 5% milk in TBS-T for 4 
hours to avoid unspecific binding of the antibodies, before the primary antibody, which was diluted in 
the blocking solution, was applied to the membrane over-night at 4°C. Excess antibody was removed by 
three washes of 30 minutes with TBS-T rocking at room temperature. Secondary antibodies conjugated 
with horseradish peroxidase (HRP) were diluted and applied onto the membrane for 1h at room tem-
perature. Afterwards, the same washing conditions were used as to remove the excess primary antibod-
ies. The activation of the HRP was done by applying the Amersham™ ECL™ Wester blotting detection 
reagents (GE Healthcare) onto the membrane for 4 minutes, before the membrane was illuminated on a 
Western blot imaging system. 
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For quality control, 50 µl of the purified GST-bound protein were transferred to a new 1.5 ml Eppendorf 
tube where the whole liquid was taken away with a deformed Pasteur pipette. 30 µl of 2xSDS binding 
buffer were added and the samples were heated up to 95°C for 5 minutes. 15 µl were loaded on a 10 % 
SDS gel and stained with Coomassie Blue.
5.2.7 Preparation of C. elegans protein extract
Strep-III purification
200 µl of StrepTactin® Sepharose® (IBA 2-1201-010) were equilibrated twice with 1 ml of lysis buffer. C. 
elegans protein extract was added to the sepharose and incubated for 30 min at 4° C. After washing six 
times with 1 ml of lysis buffer, the sample was transferred to a Micro Bio-Spin column (Biorad) and 
eluted by gravity f low four times with 250 µl of elution buffer (100 mM Tris pH=8.0, 150 mM NaCl, 1 
mM EDTA, 10 mM Biotin). 
HA-Purification
100 µl of HA-Agarose (Monoclonal Anti-HA-Agarose antibody produced in mouse, A2095, Sigma) was 
equilibrated twice with 1 ml of washing buffer (100 mM Tris pH=8.0, 150 mM NaCl, 1 mM NaCl, 1 mM 
EDTA). Eluate from Strep-III purification was incubated with the HA-Agarose for 4 hours at 4 °C. After 
six washing steps with washing buffer, the sample was transferred to a Micro Bio-Spin column (Biorad) 
and eluted three times with 150 µl of 0.2 M Glycine pH=2.5 into Eppendorf tubes containing 80 µl of 
1M NH4HCO3.
To prepare C. elegans protein extract, mixed-stage liquid cultures were cleaned by sucrose f lotation and 
stored in aliquots at -80°C. After thawing 400 µl of packed worms in 800 µl lysis buffer (100 mM Tris 
pH=8.0, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.5% NP-40, 1x protease inhibitor cocktail; Roche) 
at 4°C, the suspension was dropped into liquid nitrogen. Then, the frozen droplets were transferred 
to a grinding beaker that was previously cooled in liquid nitrogen, and homogenized in a mixer mill 
(MM300; Retsch). The frozen powder was thawed slowly at 4°C before the soluble protein extract was 
optained by centrifugaation the whole mixture for 10 minutes at 4°C and 10,000 g.
5.2.9 HA purification of DEP-1::HS
5.2.8 StrepTactin-HA double purification of DEP-1::HS
180 µl of HA-Agarose (Monoclonal Anti-HA-Agarose antibody produced in mouse, A2095, Sigma) were 
equilibrated twice with 1 ml of washing buffer (100 mM Tris pH=8.0, 150 mM NaCl, 1 mM NaCl, 1 mM 
EDTA). C. elegans protein extract was incubated with the HA-Agarose for 4 hours at 4 °C. After washing 
once with lysis buffer and six times with washing buffer, the sample was transferred to a Micro Bio-Spin col-
umn (Biorad) and eluted three times with 150 µl of 0.2 M Glycine pH=2.5 into Eppendorf tubes containing 
100 µl of 1M NH4HCO3.
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5.2.13 In-gel tryptic digestion
After GST pull-down, separation by SDS-PAGE and Colloidal Coomassie Blue staining, differential 
protein bands were excised with a scalpel into small pieces and prepared for in-gel tryptic digestion. 
Thereby, the gel pieces were washed and dehydrated three times in 50% Acetonitrile and dried in speed-
vac. 10 mM DTT (in 25 mM Ammonium bicarbonate pH=8.0) was added to cover gel pieces and incu-
bated for 45 minutes at 56°C. After DTT was removed, 50 mM IAM (in 25 mM Ammonium bicarbonate 
pH=8.0) was added to cover gel pieces and incubated for 1 hour at room temperature in the dark. IAM 
5.2.10 GST pull-down experiments for Western blot experiments
5.2.11 GST pull-down experiments for LC-MS/MS analyses
Approximately 10 µg of purified GST::DEP-1 (wild-type and D1241A) and 40 µg of GST (negative con-
trol) were incubated with ca. 800 µg total worm extract over night at 4°C for each binding reaction. 
Followed by washing with lysis buffer, bound proteins were eluted by boiling the beads for 5 minutes in 
Laemmli buffer. GFP tagged proteins were detected on Western blots using 10% acrylamide gels with 
monoclonal Anti-GFP antibody (Roche, Cat. No. 11 814 460 001). For phosphatase inhibitor experi-
ments, 5 mM Na3VO4 was added to the lysis buffer.
Approximately 50 µg of purified GST::DEP-1 (wild-type and D1241A) and 100 µg of GST (negative 
control) were used for each binding reaction. To prepare N2 worm extracts, mixed-stage liquid cultures 
were cleaned by sucrose f lotation, resuspended in lysis buffer (100 mM Tris pH=8.0, 150 mM NaCl, 1 
mM EDTA, 1 mM DTT, 0.5% NP-40, 1x protease inhibitor cocktail; Roche), shock frozen in liquid ni-
trogen, and homogenized in a mixer mill (MM300; Retsch). Thawed worm extract was then centrifuged 
for 10 minutes at 4°C and 10’000g to remove insoluble components. About 2.5 mg of total protein extract 
was used for each reaction. Binding was performed at 4°C over night, followed by three washes with lysis 
buffer. Bound proteins were eluted by boiling the beads for 5 minutes in 30 µl of laemmli buffer and 
separated on a 4-15% linear gradient SDS-gel (Biorad Nr. 161-1104), followed by Colloidal Coomassie 
Blue staining according to the manufacturer’s protocol (Roti Blue; Roth).
5.2.12 In-solution tryptic digestion
After HA purification, the volume of the purified proteins was reduced to ~10 µl by speedvac drying 
before 140 µl of 25 mM AmBic pH=8.0 were added. Disulphide bridges were reduced by adding DTT 
with a final concentration of 10 mM (in 25 mM AmBic pH=8.0) and by incubating for 45 minutes at 
50° C. Iodacetamide (IAM) was added with a final contentration of 50 mM (in 25 mM AmBic pH=8.0) 
and the sample was incubated for 1 hour at room temperature in the dark to alkylate cysteines. Tryptic 
digestion was performed by adding 20 ng trypsin and incubation at 37° C over-night. Next morning, the 
samples were speedvac dried, resuspended in 10 µl of 3% acetonitrile, 0.2% of formic acid and desalted 
with C18 ZipTip® (Millipore) before being analyzed on a calibrated LTQ-Orbitrap mass spectrometer 
(Thermo Scientific). 
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5.2.14 ZipTip C18 sample clean-up
5.2.15 Protein identification by LTQ-Orbitrap
Desalted peptides were resovled in 15 µl of 3 % Acetonitrile/0.2 % formic acid and loaded on a 10 cm 
fused silica column packed with 3 µm 200 Å pore size C18 resin. Peptides were eluted from the column 
via an ACN gradient of 5-45% (v/v) over 80 minutes and 40-80% ACN over the subsequent 15 minutes 
in a buffer containing 0.2% formic acid (v/v) at a f low rate of 200 nl/min. 
The range of MS scan was m/z 450-1500. LC-MS/MS spectra were exported to the MASCOT generic 
format (mgf) and proteins were identified by searching the MASCOT database search engine version 
2.2 (Perkins et al., 1999). The MASCOT search parameters were as follows: set-off threshold at 0.05 in 
the expectation value cutoff, peptide tolerance at 5 ppm, MS/MS tolerance at 0.8 Da, peptide charge of 
2+ or 3+, trypsin as enzyme allowing up to one missed cleavage, carbamidomethylation on cysteines 
as a fixed modification and oxidation on methionine as a variable modification. Only peptides with a 
maximum of 2 (3 for semi-tryptic digest) missed cleavage sites were allowed in database searches. Fur-
ther comparisons and analyses of the proteins were performed using Scaffold 3.0 (Proteome Software).
Wetting solution: 100% Acetonitrile (ACN)
Washing solution: 3-5% ACN; 0.1% TFA
Elution solution: 50-60% ACN; 0.1% TFP
Speedvac dried samples were taken up in about 20 µl washing solution. Then, the tip was prewet three 
times by aspirating 10 µl of wetting solution into the tip and subsequent dispension to waste. Thereafter, 
the tip was equilibrated for binding by aspirating 10 µl equlibration solution. The peptides were then 
bound to the ZipTip by aspiration and dispension of the sample during 10 cycles. The tip was washed 
three times by aspirating 10 µl washing solution, before the peptides were eluted twice with 10 µl of elu-
tion solution. The elutions were pooled and speedvac dried before being analyzed by LS-MS/MS.
was removed and gel pieces were washed twice with 50% Acetonitrile before dried in Speed Vac. 25 mM 
Ammonium bicarbonate pH=8.0 containing 50 ng trypsin was added to be absorbed by the gel pieces 
and incubated over night at 37°C. To extract the peptides, gel pieces were incubated three times for 15 
minutes with 50% Acetonitrile /5% TFA and once with 100% Acetonitrile. The peptides were speedvac 
dried before resuspended in 5 µl of 3% Acetonitrile/0.1% formic acid. Samples were desalted with C18 
ZipTip® (Millipore) before being analyzed on a calibrated LTQ-Orbitrap mass spectrometer (Thermo 
Scientific). 
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20101101_01_pTB29_1.mgf
20101101_02_pTB29_2.mgf
20101101_03_pTB29_3.mgf
20101101_04_pTB29_4.mgf
20101101_05_pTB29_5.mgf
20101101_07_pTB30_1.mgf
20101101_08_pTB30_2.mgf
20101101_09_pTB30_3.mgf
20101101_10_pTB30_4.mgf
20101101_11_pTB30_5.mgf
20101101_12_pTB30_6.mgf
20101101_14_pGEX_1.mgf
20101101_15_pGEX_2.mgf
20101101_16_pGEX_3.mgf
20101101_17_pGEX_4.mgf
20101101_18_pGEX_5.mgf
20101117_01_pTB29_1.mgf
20101117_02_pTB29_2.mgf
20101117_03_pTB29_3.mgf
20101117_04_pTB29_4.mgf
20101117_05_pTB29_5.mgf
20101117_07_pTB30_1.mgf
20101117_08_pTB30_2.mgf
20101117_09_pTB30_3.mgf
20101117_10_pTB30_4.mgf
20101117_11_pTB30_5.mgf
20101117_12_pTB30_6.mgf
20101117_13_pTB30_7.mgf
20101117_14_pTB30_8.mgf
20101117_19_pGEX_1.mgf
20101117_20_pGEX_2.mgf
20101117_21_pGEX_3.mgf
20101117_22_pGEX_4.mgf
20101117_23_pGEX_5.mgf
20101220_07_pTB29_1.mgf
20101220_08_pTB29_2.mgf
20101220_09_pTB29_3.mgf
20101220_10_pTB29_4.mgf
20101220_11_pTB29_5.mgf
20101220_12_pTB29_6.mgf
20101220_14_pTB30_1.mgf
20101220_15_pTB30_2.mgf
20101220_16_pTB30_3.mgf
20101220_17_pTB30_4.mgf
20101220_18_pTB30_5.mgf
20101220_19_pTB30_6.mgf
20101220_01_pGEX_1.mgf
20101220_02_pGEX_2.mgf
20101220_03_pGEX_3.mgf
20101220_04_pGEX_4.mgf
20101220_05_pGEX_5.mgf
20100809_03_dep1intra_0727.mgf 20100809_04_dep1fullwt_0727.mgf 20100809_01_gfp_0727.mgf
20100809_08_dep1intra_0720.mgf 20100809_09_dep1fullwt_0720.mgf 20100809_06_gfp_0720.mgf
20100907_04_dep1intra_1.mgf 20100907_05_dep1full_1.mgf 20100907_02_N2_1.mgf
20100907_09_dep1intra_2.mgf 20100907_10_dep1full_2.mgf 20100907_07_N2_2.mgf
20101011_09_dep1intra_1.mgf 20101011_10_dep1full_1.mgf 20101011_07_N2_1.mgf
20101011_14_dep1intra_2.mgf 20101011_15_dep1full_2.mgf 20101011_12_N2_2.mgf
LC-MS/MS data of DEP-1::HS pull-downs
LC-MS/MS data of GST::DEP-1 pull-downs
In-solution tryptic digestioon, in-gel tryptic digestion, ZipTip clean-up, and LC-MS/MS analysis were 
performed in the Functional Genomic Center Zurich, University of Zurich, Switzerland. The project 
run under the name “p726 - A Mass Spectrometry-Based Approach to Identify New Interaction Partners 
of the Tyrosine Phosphatase DEP-1” and was supervised by Dr. Paolo Nanni. The instrument methods 
were saved under the name p726_20101101_95min and the MS data of the DEP-1::GST-pull down ex-
periments as:
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5.2.16 Polyclonal DEP-1 Antibodies
Immunization of rabbits
An adequate amount of the intracellular domain of wild-type DEP-1 (expressed by pTB29) was GST-
purified (see 6.3.1) with the exception that the purified protein was eluted from the GST sepharose at the 
end. This was achieved by washing the beads three times with GST elution buffer (50 mM Glutathion, 
pH=8). The elution fractions were combined and dialyzed with PBS over night. Ca. 200 µg of purified 
DEP-1 protein was aliquoted in six Eppendorf tubes and sent to the “Institute of Laboratory Animal Sci-
ences, UZH” for the immunization of two rabbits. Protein concentration was measured by performing 
Amido Black assay.
Purification of antibodies
The sera of the two rabbits (006-9AB-1D2 and 006-9AC-B07) containing the DEP-1 antibodies were 
affinity-purified by using HiTrap NHS(N-hydroxysuccinimide)-Activated HP columns (Ge Healthcare 
Life Sciences) according to the manufacturer’s protocol. Columns were packed with either 1 mg of puri-
fied GST or with 1 mg of the intracellular domain of wild-type DEP-1 (expressed by pTB29), which were 
previously dialyzed over night in two liters of coupling buffer (0.2 M NaHCO3, 0.5 M NaCl, pH=8.3) 
and concentrated to 1 ml using 10 kD Millipore filters. 1 ml of the sera was diluted 1:10 in 10 mM Tris-
HCl pH=7.5 and firstly f lowed through the DEP-1-column. Washing buffer (10 mM Tris, 500 mM NaCl 
pH=7.5) was used to remove unspecific bound molecules. Elution of antibodies was performed using 100 
mM Glycine pH=2.5 and 100 mM Triethylamine pH=11.5. The eluted fractions were neutralized with 
1 M Tris pH=8 and tested for protein content by performing a dotblot that was stained with Ponceau S. 
The first four fractions of the acidic eluation were pooled and dialyzed with 10 mM Tris pH=7.5 before 
they were f lowed three times through the GST-column. The buffer of the affinity-purified antibodies 
was changed to 1x PBS using 10 kD Millipore filters, aliquoted and stored at -80°C.
Examination of DEP-1 antibodies by Western blot analysis
50 young adult animals from the strains N2, dep-1;lip-1, and zhIs027[Peft-3::dep-1minigene::HA-StrepIII; 
unc-119(+)] were picked to 50 µl of Laemmli buffer, boiled for 5 minutes at 95°C, centrifuged at 14’000 
rpm for 2 minutes and loaded on 12% acrylamide gels. Purified DEP-1 antibodies were diluted 1:500 and 
1:1’000 and incubated for 2 hours at room-temberature. After washing, secondary antibodies conjugated 
with HRP were diluted 1:10’000 and applied onto the membrane for 1 hour at RT.
Immunostaining
The immunostaining method used in this study is based on the protocol established by Finney and 
Ruvkun (1990). Mixed staged worms of a confluent plate were transferred with 1x PBS to an Eppendorf 
tube. The worm suspension was washed with 1x PBS until the remaining OP50 was removed and the 
supernatant was clear. The spinning steps were henceforth performed at 2’000 rpms for 1 minute. The 
volume was adjusted to 450 µl before 500 µl of 2x RFB buffer were added. The tubes were shock frozen 
in liquid nitrogen and stored at -80°C. 
To fix animals, 50 µl of paraformaldehyde (1% end concentration) was added. Afterwards, the tubes 
were subjected to three rounds of freeze-thaw cracking in liquid nitrogen and hand warm tap water to 
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Paraformaldehyde 100 mg Paraformaldehyde, 450 µl dH2O, and 0.5 µl 12 M NaOH was vortexed and 
incubated at 60°C for 10 min (vortexed shortly every 2 minues) before 5 µl 1 M HCl 
and 50 µl 10xPBS were added.
2x RFB  
“Ruvkun Fixation Buffer”
160 mM KCl, 40 mM NaCl, 20 mM Na2EGTA, 10 mM Spermidine HCl,  
30 mM PIPES pH=7.4, 50% Methanol. Store at -20°C.
1x TTB 
“Tris Triton Buffer”
100 mM Tris HCl, pH=7.4, 1 mM EDTA, 0.1% Triton X-100.
100x BO3 Buffer 5 M H3BO3, 2.5 M NaOH. (Crucial: pH should not be lower than 9.5).
4x BO3 Buffer Dilute 100x BO3 Buffer 1:25. Add 0.01% Triton X-100.
1x PBS-T 1x PBS, 0.05% Triton X-100.
ABA-buffer 2% BSA in 1xPBS-T (1.4 ml per sample and staining)
Mowiol 2.4 g Mowiol 4-88, 6 g Glycerol, 6 ml H2O, 12 ml 0.2 M Tris pH=8.5, 2.5% (w/v)
DABCO.
allow the paraformaldehyde to penetrate the cuticle of the worms. After incubation for 30 minutes at 
4°C on a rocker, the fixation reaction was stopped by washing the worms three times with 1x TTB.
The cuticle was permeabilized by reducing the disulfide bonds of the cuticle collagen with 1 ml of 1x 
TTB, 40 µl of Triton X-100 (10%) and 10 µl of β-Mercaptoethanol for 6 h at 37°C. Finally, the worms were 
washed twice with 4x BO3 buffer. The reduced disulfide bonds were modified and sealed by incubating 
the worms in 990 µl of 4x BO3 buffer and 10 µl DTT (1 M) for 15 minutes rocking at RT. The reaction 
was stopped by two washes with 4x BO3 buffer, followed by incubation in 990 µl of 4x BO3 buffer and 10 
µl of H2O2 for 15 minutes. This oxidation step was stopped by two washes with 4x BO3. 
To minimize unspecific binding of the antibodies, permeabilized worms were blocked with 1 ml ABA-
buffer during 15 minutes rocking at RT. Worms were incubated over-night at 4°C with the primary 
antibodes that were diluted in 200 µl of ABA-buffer. After three washing steps (15 minutes rocking at 
RT) with PBS-T, the secondary antibodies were diluted 1:100 in 200 µl of ABA-buffer and incubated 
with the worms for 2 h rocking at RT in the dark. To stain the DNA, worms were incubated with 1 ml of 
PBS-T containing 1 µl of Hoechst dye (10 mg/ml) for 5 minutes rocking at RT, followed by two washes 
with PBS-T for 5 minutes.
The supernatant was removed to an approximate final end volume of 20 µl. 20 µl of Mowiol were added 
and mixed, and then immediately distributed by 2 drops on one slide. The drops were covered with a 
coverslip and dried overnight at RT in the dark. Long-term storage was done at 4°C.
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5.3 Animal methods
The strains used for the experiments and crosses were derivates of Bristol strain N2 of Caenorhabditis 
elegans. The animals were cultivated under standard conditions at 20°C as described in (Brenner, 1974). 
Unless noted otherwise, the mutations used have been described previously and are listed below by their 
linkage group.
LGII:  dep-1(zh34) (Tarcic et al., 2009) 
 unc-4(e120) (Brenner, 1974)
 rrf-3(pk1426) (Simmer et al., 2002)
 ttTi25067 (dep-1 transposon insertion, Université Lyon 1, Villeurbanne, France)
LGIII:  unc-119(ed3) (Maduro & Pilgrim, 1995)
 unc-119(ed4) (Maduro & Pilgrim, 1995)
 unc-119(e2498) (Maduro & Pilgrim, 1995)
 pat-3(st564) (Williams & Waterston, 1994)
 glp-1(q339) (Troemel et al., 1999) 
LGIV:  lip-1(zh15) (Berset et al., 2001)
 let-60(n1046) (Ferguson & Horvitz, 1985)
LGV: rde-1(ne219) (Pavelec et al., 2009)
 nid-1(cg119) (Trzebiatowska et al., 2008)
Integrated transgenic arrays:
LGII:  zhIs70[dep-1::gfp::unc-119(+)]
 zhIs71[dep-1::mCherry::unc-119(+)]
LGIV:  qyIs15[zmp-1 > HA-ßtail] (Hagedorn et al., 2009)
 zhIs038[let-23::GFP; unc-119(+)] (Haag et al., unpublished data), 
LG unknown:  qyIs43 [pat-3::GFP, ina-1(genomic), unc-119(+)] (Hagedorn et al., 2009)
 qyIs110[egl-17>dnPat-3] (Hagedorn et al., 2009)
 zhIs396[Pdlg-1::lifeact::gfp::unc-54 3’UTR,Plin-48::gfp] (Farooqui et al., 2012)
 jeIs2222[pat-2::GFP rol-6(su1006)] (Meighan & Schwarzbauer, 2007)
 zhIs021[Peft-3::taptag::dep-1 intracellular domain(wt)/unc-119(+)] 
 zhIs022[Peft-3::taptag::dep-1 intracellular domain (D1241A) / unc-119(+)]
 zhIs027[Peft-3::dep-1minigene::HA-StrepIII; unc-119(+)]
 zhIs028[Peft-3::dep-1intraD1241A::HA-StrepIII; unc-119(+)]
 zhIs020[Peft-3::taptag::dep-1 extracellular domain / unc-119(+)] 
5.3.1  C. elegans strains and general handling
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Extrachromosomal transgenic lines:
zhEx419[pat-3::gfp Y792A Y804A]
zhEx420[pat-3::gfp Y772A]
zhEx432[pat-3::gfp Y772A Y804A]
zhEx433[pat-3::gfp Δintra]
zhEx456[pat-3::gfp Y792A]
zhEx457[pat-3::gfp Y804A]
zhEx458[pat-3::gfp TTT796-798AAA]
mwEx31[pat-3 Y804F] (Lee et al., 2001)
mwEx32[pat-3 Y792F Y804F] (Lee et al., 2001) 
zhEx477[dep-1::mCherry]
zhEx479[Pnid-1::gfp, myo-2::mCherry]
zhEx524[pat-3::gfp,myo-2::mCherry]
zhEx528[pat-3::gfp Y804A, myo-2::mCherry]
zhEx338[Peft-3::gfp::HA-StrepIII]
zhEx418[Plin-31::rde-1;myo-2::mCherry]
For Nomarski analysis, animals were mounted on 4% agarose pads in M9 solution containing 20 mM 
tetramisole hydrochloride. 
5.3.2 Crosses
Three small agar plates confluent with C. elegans were used to inoculate one liquid culture consistent 
of: 
  100 ml  S-Basal 
  300 µl  1M MgSO4 
  300 µl  1M CaCl2 
  1 ml  K-Citrate pH=6 
  1 ml  100x trace metals 
  1 ml  Pen/Strep 100x  
  100 µl  Nystatin 1’000x 
  100 µl  Cholesterol (5 mg/ml)  
  4 ml  Worm food 
Two to three days later, the worms were cleaned by sucrose f loating.
The worm food media was autoclaved, consisting of: 
  24 g  Bacto tryptone 
  48 g  Yeast extract 
  16 ml  50 % Glycerol 
  2 l  dH2O 
Next, 100 ml autoclaved 1 M KPO4 and 100 µl of E. coli Na22 bacteria were added to the mixture in a 3 
liter Erlenmeyer f lask and grown at 37°C. The following day, the liquid culture was centrifuged at 4’000 
rpm for 10 minutes, the supernatant discarded and the pellet resolved in 15 ml of 2xTY. The worm food 
was then kept at -20°C.
5.3.3 Worm liquid cultures
To generate C. elegans males by heat-shock, four plates containing 20 L4 hermaphrodites were incubated 
at 30° C for 5 hours. 
Twelve males and four hermaphrodites were kept on a NGM plate containing only a small drop of OP50 
food. Two days later, the hermaphrodites were singled out and screened for male F1 offspring. F1 ani-
mals males were either used for further crosses or singled out prior to F2 generation genotyping.
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5.3.6 RNAi
5.3.7 Worm bleaching 
For RNAi, the feeding method described by (Kamath et al., 2001) was used. RNAi plates consisting 
of NGM agar including 3 mM IPTG, 50 µg/ml ampicillin and 50 µg/ml tetracycline were poured and 
dried for 2-4 days at room temperature. RNAi bacterial clones were grown over night at 37° C in 2xTY 
and subsequently spotted on the RNAi plates. Induction of the dsRNA production was performed by 
incubating the RNAi plates for 24 hours at room temperature. The worms were synchronized with hy-
pochloride solution and L1 larvae were placed on growth media plates (P0) and allowed to grow at 20° C. 
Unless noted otherwise, the F2 generation was analyzed.
RNAi NGM plates:
 1.5 g  NaCl 
  1.25 g  Peptone (Tryptone Peptone) 
  9.5 g  Agar (Bacto Agar) 
 0.5 ml  Cholesterol (5 mg/ml) 
 0.5 l  H2O 
  12.5 ml  KPO4 pH=6 
 0.5 ml  1M MgSO4 
 0.5 ml  1M CaCl2 
  1.5 ml  1M IPTG 
 0.5 ml  Ampicillin 
Two plates confluent with adult worms were transferred with H2O to a 15 ml falcon tube. The falcon 
tube was centrifuged for 1 minute at 1’100 rpm and the supernatant was discarded. After adding 2 ml 
of bleaching solution, the worms were vortexed until no floating bodies were detected. The bleach was 
attenuated to 14 ml with H2O and washed four times with H2O. 
5.3.5 Freezing worms
Preferentially L1 worms were frozen and stored at -80° C. Worms of three confluent plates were washed 
with M9 media and centrifuged for 1 minute at 1’100 rpm. The supernatant was discarded until 1 ml 
was left and 1 ml of freezing solution was added. The 2 ml liquid were distributed to four cryotubes, 
labeled with the freezing number and A, B, C or D. The cryotubes were put in freezing boxes, filled with 
Isopropanol and kept on -80°C. Two days later, the D probe was thawed to check if the worms survived 
the freezing.
5.3.4 Cleaning of C. elegans by sucrose floating
Worms from the liquid culture were centrifuged at 2’000 rpm for 1 minute. The supernatant was dis-
carded and the worms were washed twice with 50 ml of cold 0.1 M NaCl. Subsequently, the 0.1 M NaCl 
was removed until 25 ml were left, and 25 ml of ice-cold 60 % Sucrose were added. After centrifugation 
at 1’100 rpm for 5 minutes, the f loating worms were transferred with a Pasteur pipette in another 50 
ml falcon tube and washed twice with 0.1 M NaCl. ~ 400 µl of packed worms were aliquoted in a 1.5 ml 
Eppendorf tube, shock frozen in liquid nitrogen and kept frozen at -80°C. 
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5.4 Instruments
DNA experiments
PCR machine: BioRad MyCycler™
Photometer: Eppendorf Bio Photometer
Nanodrop: NanoDrop® ND-1’000 Spectrophotometer
Protein experiments
Western blot: Mini Trans-Blot® Electrophoretic Transfer Cell
 PowerPac™ Basic Power Supply
Mass Spectrometer: LTQ-Orbitrap Thermo Scientific
HPLC Pump: Eksigent 1D plus
Sonicator: Bandelin Sonopuls
Microscopes
Fluorescent and Nomarski microscope:  Leica DMRA, equipped with a cooled CCD camera  
 (Hamamatsu ORCA-ER)
Dissecting scope:  Leica MS5
Fluorescence dissecting scope:  Leica MZDLIII
Injection scope: Leica DM-IRB
Spinning Disk Confocal scope: Andor Revolution Spinning Disk confocal microscope
 inverted, Zeiss Axio Observer A1. Focus: Piezo Z-Stage.
 Scanner: Yokogawa CSU-X1 Spinning Disk Unit.
 Detector: Andor iXon3 EMCCD-Camera, 512 x 512 pixels,  
 Andor Neo sCMOS-Camera 2560 x 2160 pixels.
Other instruments
Centrifuges: Eppendorf Centrifuge 5804
 Eppendorf Centrifuge 5417 R
SpeedVac: Thermo Savant SpeedVac 121P
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General buffers
Control software for Leica microscope: Openlab 5.0.1
Processing pictures:   Adobe Photoshop CS 5.5 
     Adobe Illustrator CS 5.5,  
     ImageJ 1.47q
     Imaris 7.6.1
DNA analysis:     Sequencher 4.8
     DNA Strider 1.4f6
     CLC Main Workbench 5
     EnzymeX 3.1
Massspectrometry analysis:   Scaffold 3
     Mascot (www.matrixscience.com)
5.5 General buffers
5.6 Kits
5.7 Software used for data analysis
S-Basal: 5.85 g NaCl, 50 ml KPO4, 1 l H2O
STET: 8% Sucrose, 5% Triton-X 100%, 50 mM EDTA, 50 mM Tris pH=8
TE: 2 ml 1 M Tris pH=7.5, 0.4 ml 0.5M EDTA, 197.6 ml H2O
TBS-T: 50 ml 1 M Tris, 150 ml 5 M NaCl, 2.5 ml Tween 20, 5 l H2O
1x TBE: 108 g Tris, 55 g Boric acid, 40 ml 0.5 M EDTA pH=8, 10 l H2O
Bleaching solution: 1 ml 10 M NaOH, 3ml NaClO2 13%, 10 ml H2O
M9: 3 g KH2PO4, 6 g Na2HPO4, 5 g NaCl, 1 ml 1 M MgSO4, 1 l H2O
Worm lysis buffer: 50 mM KCl, 10 mM Tris 8.2, 2.5 mM MgCl2, 0.45% NP-400, 45% 
Tween-200®, 0.01% Gelatine
Electrophoresis Buffer: 0.8 g TrisBase, 55 g Boracid, 40 ml EDTA (0.5 M, pH=8), 10 l H2O
2xTY: 16 g Bacto Tryptone, 10 g Yeast extract, 5 g NaCl, 1 l H2O
PCR Purification: GenElute™ PCR Clean-Up (Sigma)
Gel Extraction: GenElute™ Gel Extraction Kit (Sigma)
MidiPrep: QIAfilter Plasmid Midi Kit (Qiagen)
140
141
6. References
6. References
6
Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., and Mustelin, T. 
(2004). Protein tyrosine phosphatases in the human genome. Cell 117, 699–711.
Ambros, V. (1999). Cell cycle-dependent sequencing of cell fate decisions in Caenorhabditis elegans vulva precursor cells. 
Development 126, 1947–1956.
Arora, D., Stopp, S., Böhmer, S.-A., Schons, J., Godfrey, R., Masson, K., Razumovskaya, E., Rönnstrand, L., Tänzer, S., Bauer, 
R., et al. (2011). Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling. J. Biol. Chem. 286, 
10918–10929.
Aumailley, M., Battaglia, C., Mayer, U., Reinhardt, D., Nischt, R., Timpl, R., and Fox, J.W. (1993). Nidogen mediates the for-
mation of ternary complexes of basement membrane components. Kidney Int. 43, 7–12.
Autschbach, F., Palou, E., Mechtersheimer, G., Rohr, C., Pirotto, F., Gassler, N., Otto, H.F., Schraven, B., and Gayá, A. (1999). 
Expression of the membrane protein tyrosine phosphatase CD148 in human tissues. Tissue Antigens 54, 485–498.
Avraamides, C.J., Garmy-Susini, B., and Varner, J.A. (2008). Integrins in angiogenesis and lymphangiogenesis. Nat Rev Can-
cer 8, 604–617.
Baum, P.D., and Garriga, G. (1997). Neuronal migrations and axon fasciculation are disrupted in ina-1 integrin mutants. 
Neuron 19, 51–62.
Beitel, G.J., Tuck, S., Greenwald, I., and Horvitz, H.R. (1995). The Caenorhabditis elegans gene lin-1 encodes an ETS-domain 
protein and defines a branch of the vulval induction pathway. Genes & Development 9, 3149–3162.
Berset, T.A. (2005). The C. elegans homolog of the mammalian tumor suppressor Dep-1/Scc1 inhibits EGFR signaling to 
regulate binary cell fate decisions. Genes & Development 19, 1328–1340.
Berset, T., Hoier, E.F., Battu, G., Canevascini, S., and Hajnal, A. (2001). Notch inhibition of RAS signaling through MAP 
kinase phosphatase LIP-1 during C. elegans vulval development. Science 291, 1055–1058.
Blanchetot, C., Chagnon, M., Dubé, N., Hallé, M., and Tremblay, M.L. (2005). Substrate-trapping techniques in the identifi-
cation of cellular PTP targets. Methods 35, 44–53.
Borges, L.G., Seifert, R.A., Grant, F.J., Hart, C.E., Disteche, C.M., Edelhoff, S., Solca, F.F., Lieberman, M.A., Lindner, V., 
Fischer, E.H., et al. (1996). Cloning and characterization of rat density-enhanced phosphatase-1, a protein tyrosine phospha-
tase expressed by vascular cells. Circ. Res. 79, 570–580.
Brenner, S. (1974). The genetics of Caenorhabditis elegans. Genetics 77, 71–94.
C. elegans Sequencing Consortium (1998). Genome sequence of the nematode C. elegans: a platform for investigating bio-
logy. Science 282, 2012–2018.
Calderwood, D.A. (2004). Integrin activation. J. Cell. Sci. 117, 657–666.
6. References
142
Calderwood, D.A., Fujioka, Y., de Pereda, J.M., García-Alvarez, B., Nakamoto, T., Margolis, B., McGlade, C.J., Liddington, 
R.C., and Ginsberg, M.H. (2003). Integrin beta cytoplasmic domain interactions with phosphotyrosine-binding domains: a 
structural prototype for diversity in integrin signaling. Proc. Natl. Acad. Sci. U.S.a. 100, 2272–2277.
Calderwood, D.A., Yan, B., de Pereda, J.M., Alvarez, B.G., Fujioka, Y., Liddington, R.C., and Ginsberg, M.H. (2002). The 
phosphotyrosine binding-like domain of talin activates integrins. J. Biol. Chem. 277, 21749–21758.
Caswell, P.T., Chan, M., Lindsay, A.J., McCaffrey, M.W., Boettiger, D., and Norman, J.C. (2008). Rab-coupling protein coor-
dinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J. Cell Biol. 183, 
143–155.
Chabot, C., Spring, K., Gratton, J.-P., Elchebly, M., and Royal, I. (2009). New role for the protein tyrosine phosphatase DEP-1 
in Akt activation and endothelial cell survival. Molecular and Cellular Biology 29, 241–253.
Chen, C., Fenk, L.A., and de Bono, M. (2013). Efficient genome editing in Caenorhabditis elegans by CRISPR-targeted ho-
mologous recombination. Nucleic Acids Res.
Chen, H., Zou, Z., Sarratt, K.L., Zhou, D., Zhang, M., Sebzda, E., Hammer, D.A., and Kahn, M.L. (2006). In vivo beta1 
integrin function requires phosphorylation-independent regulation by cytoplasmic tyrosines. Genes & Development 20, 
927–932.
Chen, N., and Greenwald, I. (2004). The lateral signal for LIN-12/Notch in C. elegans vulval development comprises redun-
dant secreted and transmembrane DSL proteins. Developmental Cell 6, 183–192.
Chen, W.J., Goldstein, J.L., and Brown, M.S. (1990). NPXY, a sequence often found in cytoplasmic tails, is required for coated 
pit-mediated internalization of the low density lipoprotein receptor. J. Biol. Chem. 265, 3116–3123.
Chen, Z., and Han, M. (2001). C. elegans Rb, NuRD, and Ras regulate lin-39-mediated cell fusion during vulval fate specifi-
cation. Curr. Biol. 11, 1874–1879.
Chiu, S.-J., Jiang, S.-T., Wang, Y.-K., and Tang, M.-J. (2002). Hepatocyte growth factor upregulates alpha2beta1 integrin in 
Madin-Darby canine kidney cells: implications in tubulogenesis. J. Biomed. Sci. 9, 261–272.
Chowdhury, S.K., Katta, V., and Chait, B.T. (1990). Electrospray ionization mass spectrometric peptide mapping: a rapid, 
sensitive technique for protein structure analysis. Biochem. Biophys. Res. Commun. 167, 686–692.
Clark, E.A., and Brugge, J.S. (1995). Integrins and signal transduction pathways: the road taken. Science 268, 233–239.
Coller, B.S., and Shattil, S.J. (2008). The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor 
with twists, turns, and even a bend. Blood 112, 3011–3025.
Cox, D., Brennan, M., and Moran, N. (2010). Nat Rev Drug Discov 2010 Cox. 1–17.
Cram, E.J., Clark, S.G., and Schwarzbauer, J.E. (2003). Talin loss-of-function uncovers roles in cell contractility and migrati-
on in C. elegans. J. Cell. Sci. 116, 3871–3878.
Cram, E.J., Shang, H., and Schwarzbauer, J.E. (2006). A systematic RNA interference screen reveals a cell migration gene 
network in C. elegans. J. Cell. Sci. 119, 4811–4818.
Critchley, D.R. (2000). Focal adhesions - the cytoskeletal connection. Curr. Opin. Cell Biol. 12, 133–139.
Crowe, D.T., Chiu, H., Fong, S., and Weissman, I.L. (1994). Regulation of the avidity of integrin alpha 4 beta 7 by the beta 7 
cytoplasmic domain. J. Biol. Chem. 269, 14411–14418.
Cui, M., Chen, J., Myers, T.R., Hwang, B.J., Sternberg, P.W., Greenwald, I., and Han, M. (2006). SynMuv genes redundantly 
inhibit lin-3/EGF expression to prevent inappropriate vulval induction in C. elegans. Developmental Cell 10, 667–672.
Datta, A., Shi, Q., and Boettiger, D.E. (2001). Transformation of chicken embryo fibroblasts by v-src uncouples beta1 integ-
rin-mediated outside-in but not inside-out signaling. Molecular and Cellular Biology 21, 7295–7306.
Datta, A., Huber, F., and Boettiger, D. (2002). Phosphorylation of beta3 integrin controls ligand binding strength. J. Biol. 
Chem. 277, 3943–3949.
Desgrosellier, J.S., and Cheresh, D.A. (2010). nrc2748. Nat Rev Cancer 10, 9–22.
Ennis, B.W., Lippman, M.E., and Dickson, R.B. (1991). The EGF receptor system as a target for antitumor therapy. Cancer 
Invest. 9, 553–562.
Evans, R., Patzak, I., Svensson, L., De Filippo, K., Jones, K., McDowall, A., and Hogg, N. (2009). Integrins in immunity. J. 
Cell. Sci. 122, 215–225.
Fantl, W.J., Johnson, D.E., and Williams, L.T. (1993). Signalling by receptor tyrosine kinases. Annu. Rev. Biochem. 62, 453–
143
6. References
481.
Farooqui, S., Pellegrino, M.W., Rimann, I., Morf, M.K., Müller, L., Fröhli, E., and Hajnal, A. (2012). Coordinated lumen 
contraction and expansion during vulval tube morphogenesis in Caenorhabditis elegans. Developmental Cell 23, 494–506.
Fay, D.S., and Yochem, J. (2007). The SynMuv genes of Caenorhabditis elegans in vulval development and beyond. Develop-
mental Biology 306, 1–9.
Felding-Habermann, B. (2003). Integrin adhesion receptors in tumor metastasis. Clin. Exp. Metastasis 20, 203–213.
Ferguson, E.L., and Horvitz, H.R. (1985). Identification and characterization of 22 genes that affect the vulval cell lineages of 
the nematode Caenorhabditis elegans. Genetics 110, 17–72.
Félix, M.-A. (2012). Caenorhabditis elegans vulval cell fate patterning. Phys Biol 9, 045001.
Finehout, E.J., and Lee, K.H. (2004). An introduction to mass spectrometry applications in biological research. Biochem Mol 
Biol Educ 32, 93–100.
Flint, A.J., Tiganis, T., Barford, D., and Tonks, N.K. (1997). Development of “substrate-trapping” mutants to identify physio-
logical substrates of protein tyrosine phosphatases. Proc. Natl. Acad. Sci. U.S.a. 94, 1680–1685.
Fox, J.W., Mayer, U., Nischt, R., Aumailley, M., Reinhardt, D., Wiedemann, H., Mann, K., Timpl, R., Krieg, T., and Engel, J. 
(1991). Recombinant nidogen consists of three globular domains and mediates binding of laminin to collagen type IV. Embo 
J. 10, 3137–3146.
Friedrichs, K., Ruiz, P., Franke, F., Gille, I., Terpe, H.J., and Imhof, B.A. (1995). High expression level of alpha 6 integrin in 
human breast carcinoma is correlated with reduced survival. Cancer Res. 55, 901–906.
Frøkjær-Jensen, C., Davis, M.W., Hopkins, C.E., Newman, B.J., Thummel, J.M., Olesen, S.-P., Grunnet, M., and Jorgensen, 
E.M. (2008). Single-copy insertion of transgenes in Caenorhabditis elegans. Nat. Genet. 40, 1375–1383.
Gettner, S.N., Kenyon, C., and Reichardt, L.F. (1995). Characterization of beta pat-3 heterodimers, a family of essential inte-
grin receptors in C. elegans. J. Cell Biol. 129, 1127–1141.
Giancotti, F.G., and Tarone, G. (2003). Positional control of cell fate through joint integrin/receptor protein kinase signaling. 
Annu. Rev. Cell Dev. Biol. 19, 173–206.
Gimond, C., van Der Flier, A., van Delft, S., Brakebusch, C., Kuikman, I., Collard, J.G., Fässler, R., and Sonnenberg, A. (1999). 
Induction of cell scattering by expression of beta1 integrins in beta1-deficient epithelial cells requires activation of members 
of the rho family of GTPases and downregulation of cadherin and catenin function. J. Cell Biol. 147, 1325–1340.
Girard, L.R., Fiedler, T.J., Harris, T.W., Carvalho, F., Antoshechkin, I., Han, M., Sternberg, P.W., Stein, L.D., and Chalfie, M. 
(2007). WormBook: the online review of Caenorhabditis elegans biology. Nucleic Acids Res. 35, D472–D475.
Glatter, T., Wepf, A., Aebersold, R., and Gstaiger, M. (2009). An integrated workflow for charting the human interaction 
proteome: insights into the PP2A system. Mol Syst Biol 5.
Golemis, E.A., and Adams, P.D. (2005). Protein-Protein Interactions (CSHL Press).
Grazia Lampugnani, M., Zanetti, A., Corada, M., Takahashi, T., Balconi, G., Breviario, F., Orsenigo, F., Cattelino, A., Kemler, 
R., Daniel, T.O., et al. (2003). Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-
catenin, and the phosphatase DEP-1/CD148. J. Cell Biol. 161, 793–804.
Guo, W., and Giancotti, F.G. (2004). Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 5, 816–826.
Guo, W., Pylayeva, Y., Pepe, A., Yoshioka, T., Muller, W.J., Inghirami, G., and Giancotti, F.G. (2006). Beta 4 integrin amplifies 
ErbB2 signaling to promote mammary tumorigenesis. Cell 126, 489–502.
Hagedorn, E.J., Yashiro, H., Ziel, J.W., Ihara, S., Wang, Z., and Sherwood, D.R. (2009). Integrin Acts Upstream of Netrin 
Signaling to Regulate Formation of the Anchor Cell•s Invasive Membrane in C. elegans. Developmental Cell 17, 187–198.
Haj, F.G., Markova, B., Klaman, L.D., Böhmer, F.-D., and Neel, B.G. (2003). Regulation of receptor tyrosine kinase signaling 
by protein tyrosine phosphatase-1B. J. Biol. Chem. 278, 739–744.
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646–674.
Harroch, S., Palmeri, M., Rosenbluth, J., Custer, A., Okigaki, M., Shrager, P., Blum, M., Buxbaum, J.D., and Schlessinger, J. 
(2000). No obvious abnormality in mice deficient in receptor protein tyrosine phosphatase beta. Molecular and Cellular 
Biology 20, 7706–7715.
Hertog, den, J., Blanchetot, C., Buist, A., Overvoorde, J., van der Sar, A., and Tertoolen, L.G. (1999). Receptor protein-tyro-
sine phosphatase signalling in development. Int. J. Dev. Biol. 43, 723–733.
6. References
144
Hieken, T.J., Ronan, S.G., Farolan, M., Shilkaitis, A.L., and Gupta, Das, T.K. (1996). Beta 1 integrin expression: a marker of 
lymphatic metastases in cutaneous malignant melanoma. Anticancer Res. 16, 2321–2324.
Hirsch, E., Barberis, L., Brancaccio, M., Azzolino, O., Xu, D., Kyriakis, J.M., Silengo, L., Giancotti, F.G., Tarone, G., Fässler, 
R., et al. (2002). Defective Rac-mediated proliferation and survival after targeted mutation of the beta1 integrin cytodomain. 
J. Cell Biol. 157, 481–492.
Hoerndli, F.J., Walser, M., Fröhli Hoier, E., de Quervain, D., Papassotiropoulos, A., and Hajnal, A. (2009). A Conserved 
Function of C. elegans CASY-1 Calsyntenin in Associative Learning. PLoS ONE 4, e4880.
Holsinger, L.J., Ward, K., Duffield, B., Zachwieja, J., and Jallal, B. (2002). The transmembrane receptor protein tyrosine phos-
phatase DEP1 interacts with p120(ctn). Oncogene 21, 7067–7076.
Hood, J.D., and Cheresh, D.A. (2002). Role of integrins in cell invasion and migration. Nat Rev Cancer 2, 91–100.
Horvitz, H.R., and Sternberg, P.W. (1991). Multiple intercellular signalling systems control the development of the Caenor-
habditis elegans vulva. Nature 351, 535–541.
Howe, A., Aplin, A.E., Alahari, S.K., and Juliano, R.L. (1998). Integrin signaling and cell growth control. Curr. Opin. Cell 
Biol. 10, 220–231.
Hughes, P.E., O‘Toole, T.E., Ylänne, J., Shattil, S.J., and Ginsberg, M.H. (1995). The conserved membrane-proximal region of 
an integrin cytoplasmic domain specifies ligand binding affinity. J. Biol. Chem. 270, 12411–12417.
Hunter, T. (1999). 1-s2.0-S0092867400816888-main. Cell 100, 113–127.
Huyer, G., Liu, S., Kelly, J., Moffat, J., Payette, P., Kennedy, B., Tsaprailis, G., Gresser, M.J., and Ramachandran, C. (1997). 
Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J. Biol. Chem. 272, 843–851.
Hynes, R.O. (1992). Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69, 11–25.
Hynes, R.O. (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110, 673–687.
Iuliano, R., Trapasso, F., Le Pera, I., Schepis, F., Samà, I., Clodomiro, A., Dumon, K.R., Santoro, M., Chiariotti, L., Viglietto, 
G., et al. (2003). An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid 
carcinoma cell lines in vitro and in vivo. Cancer Res. 63, 882–886.
Ivaska, J., and Heino, J. (2011). Cooperation between integrins and growth factor receptors in signaling and endocytosis. 
Annu. Rev. Cell Dev. Biol. 27, 291–320.
Jacobson, J.W., and Hartl, D.L. (1985). Coupled instability of two X-linked genes in Drosophila mauritiana: germinal and 
somatic mutability. Genetics 111, 57–65.
Jacobson, J.W., Medhora, M.M., and Hartl, D.L. (1986). Molecular structure of a somatically unstable transposable element 
in Drosophila. Proc. Natl. Acad. Sci. U.S.a. 83, 8684–8688.
Jeon, M., and Zinn, K. (2009). Receptor tyrosine phosphatases control tracheal tube geometries through negative regulation 
of Egfr signaling. Development 136, 3121–3129.
Jeon, M., Scott, M.P., and Zinn, K. (2012). Interactions between Type III receptor tyrosine phosphatases and growth factor 
receptor tyrosine kinases regulate tracheal tube formation in Drosophila. Biol Open 1, 548–558.
Jia, Z., Barford, D., Flint, A.J., and Tonks, N.K. (1995). Structural basis for phosphotyrosine peptide recognition by protein 
tyrosine phosphatase 1B. Science 268, 1754–1758.
Johansson, M.W., Larsson, E., Lüning, B., Pasquale, E.B., and Ruoslahti, E. (1994). Altered localization and cytoplasmic 
domain-binding properties of tyrosine-phosphorylated beta 1 integrin. J. Cell Biol. 126, 1299–1309.
Kamath, R.S., Martinez-Campos, M., Zipperlen, P., Fraser, A.G., and Ahringer, J. (2001). Effectiveness of specific RNA-me-
diated interference through ingested double-stranded RNA in Caenorhabditis elegans. Genome Biol. 2, RESEARCH0002.
Kang, S.H., and Kramer, J.M. (2000). Nidogen Is Nonessential and Not Required for Normal Type IV Collagen Localization 
in Caenorhabditis elegans. Mol. Biol. Cell Vol. 11, 3911–3923.
Kappert, K., Paulsson, J., Sparwel, J., Leppänen, O., Hellberg, C., Östman, A., and Micke, P. (2007). Dynamic changes in the 
expression of DEP-1 and other PDGF receptor-antagonizing PTPs during onset and termination of neointima formation. 
Faseb J. 21, 523–534.
Katayama, H., Yamamoto, A., Mizushima, N., Yoshimori, T., and Miyawaki, A. (2008). GFP-like proteins stably accumulate 
in lysosomes. Cell Struct. Funct. 33, 1–12.
Keane, M.M., Lowrey, G.A., Ettenberg, S.A., Dayton, M.A., and Lipkowitz, S. (1996). The protein tyrosine phosphatase DEP-
145
6. References
1 is induced during differentiation and inhibits growth of breast cancer cells. Cancer Res. 56, 4236–4243.
Kelly, W.G., Xu, S., Montgomery, M.K., and Fire, A. (1997). Distinct requirements for somatic and germline expression of a 
generally expressed Caernorhabditis elegans gene. Genetics 146, 227–238.
Kishihara, K., Penninger, J., Wallace, V.A., Kündig, T.M., Kawai, K., Wakeham, A., Timms, E., Pfeffer, K., Ohashi, P.S., and 
Thomas, M.L. (1993). Normal B lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine 
phosphatase-deficient mice. Cell 74, 143–156.
Kornfeld, K. (1997). Vulval development in Caenorhabditis elegans. Trends Genet. 13, 55–61.
Kovalenko, M., Denner, K., Sandström, J., Persson, C., Gross, S., Jandt, E., Vilella, R., Böhmer, F., and Östman, A. (2000). 
Site-selective dephosphorylation of the platelet-derived growth factor beta-receptor by the receptor-like protein-tyrosine 
phosphatase DEP-1. J. Biol. Chem. 275, 16219–16226.
Kren, A., Baeriswyl, V., Lehembre, F., Wunderlin, C., Strittmatter, K., Antoniadis, H., Fässler, R., Cavallaro, U., and Christo-
fori, G. (2007). Increased tumor cell dissemination and cellular senescence in the absence of beta1-integrin function. Embo 
J. 26, 2832–2842.
Krueger, N.X., Streuli, M., and Saito, H. (1990). Structural diversity and evolution of human receptor-like protein tyrosine 
phosphatases. Embo J. 9, 3241–3252.
la Fuente-García, de, M.A., Nicolás, J.M., Freed, J.H., Palou, E., Thomas, A.P., Vilella, R., Vives, J., and Gayá, A. (1998). 
CD148 is a membrane protein tyrosine phosphatase present in all hematopoietic lineages and is involved in signal transduc-
tion on lymphocytes. Blood 91, 2800–2809.
Law, D.A., DeGuzman, F.R., Heiser, P., Ministri-Madrid, K., Killeen, N., and Phillips, D.R. (1999). Integrin cytoplasmic tyro-
sine motif is required for outside-in alphaIIbbeta3 signalling and platelet function. Nature 401, 808–811.
Lee, H.-J., Kim, S.-Y., Koh, J.-M., Bok, J., Kim, K.-J., Kim, K.-S., Park, M.-H., Shin, H.-D., Park, B.L., Kim, T.-H., et al. (2007). 
Polymorphisms and haplotypes of integrinalpha1 (ITGA1) are associated with bone mineral density and fracture risk in 
postmenopausal Koreans. Bone 41, 979–986.
Lee, M., Cram, E.J., Shen, B., and Schwarzbauer, J.E. (2001). Roles for beta(pat-3) integrins in development and function of 
Caenorhabditis elegans muscles and gonads. J. Biol. Chem. 276, 36404–36410.
Li, L., and Dixon, J.E. (2000). Form, function, and regulation of protein tyrosine phosphatases and their involvement in 
human diseases. Semin. Immunol. 12, 75–84.
Li, M., Wu, X., Wang, J., and Pan, Y. (2012). Towards the identification of protein complexes and functional modules by 
integrating PPI network and gene expression data. BMC Bioinformatics 13, 109.
Liu, S., Calderwood, D.A., and Ginsberg, M.H. (2000). Integrin cytoplasmic domain-binding proteins. J. Cell. Sci. 113 ( Pt 
20), 3563–3571.
Liu, S., Liang, B., Gao, H., Zhang, F., Wang, B., Dong, X., and Niu, J. (2013). Integrin αvβ6 as a novel marker for diagnosis and 
metastatic potential of thyroid carcinoma. Head Neck Oncol 5, 7.
Lu, C.F., and Springer, T.A. (1997). The alpha subunit cytoplasmic domain regulates the assembly and adhesiveness of integ-
rin lymphocyte function-associated antigen-1. J. Immunol. 159, 268–278.
Lu, C., Takagi, J., and Springer, T.A. (2001). Association of the membrane proximal regions of the alpha and beta subunit 
cytoplasmic domains constrains an integrin in the inactive state. J. Biol. Chem. 276, 14642–14648.
Maduro, M., and Pilgrim, D. (1995). Identification and cloning of unc-119, a gene expressed in the Caenorhabditis elegans 
nervous system. Genetics 141, 977–988.
Makrilia, N., Kollias, A., Manolopoulos, L., and Syrigos, K. (2009). Cell adhesion molecules: role and clinical significance in 
cancer. Cancer Invest. 27, 1023–1037.
Mallick, P., and Kuster, B. (2010). Proteomics: a pragmatic perspective. Nat. Biotechnol. 28, 695–709.
Margadant, C., Monsuur, H.N., Norman, J.C., and Sonnenberg, A. (2011). Mechanisms of integrin activation and trafficking. 
Curr. Opin. Cell Biol. 23, 607–614.
Mas-Moruno, C., Rechenmacher, F., and Kessler, H. (2010). Cilengitide: the first anti-angiogenic small molecule drug candi-
date design, synthesis and clinical evaluation. Anticancer Agents Med Chem 10, 753–768.
Matozaki, T., Suzuki, T., Uchida, T., Inazawa, J., Ariyama, T., Matsuda, K., Horita, K., Noguchi, H., Mizuno, H., and Saka-
moto, C. (1994). Molecular cloning of a human transmembrane-type protein tyrosine phosphatase and its expression in 
gastrointestinal cancers. J. Biol. Chem. 269, 2075–2081.
6. References
146
Mattila, E., Auvinen, K., Salmi, M., and Ivaska, J. (2008). The protein tyrosine phosphatase TCPTP controls VEGFR2 signal-
ling. J. Cell. Sci. 121, 3570–3580.
Mattila, E., Marttila, H., Sahlberg, N., Kohonen, P., Tähtinen, S., Halonen, P., Perälä, M., and Ivaska, J. (2010). Inhibition 
of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase. BMC Cancer 10, 7.
Mattila, E., Pellinen, T., Nevo, J., Vuoriluoto, K., Arjonen, A., and Ivaska, J. (2005). Negative regulation of EGFR signalling 
through integrin-alpha1beta1-mediated activation of protein tyrosine phosphatase TCPTP. Nat. Cell Biol. 7, 78–85.
McCabe, N.P., De, S., Vasanji, A., Brainard, J., and Byzova, T.V. (2007). Prostate cancer specific integrin alphavbeta3 modu-
lates bone metastatic growth and tissue remodeling. Oncogene 26, 6238–6243.
Meighan, C.M., and Schwarzbauer, J.E. (2007). Control of C. elegans hermaphrodite gonad size and shape by vab-3/Pax6-
mediated regulation of integrin receptors. Genes & Development 21, 1615–1620.
Mello, C.C., Kramer, J.M., Stinchcomb, D., and Ambros, V. (1991). Efficient gene transfer in C.elegans: extrachromosomal 
maintenance and integration of transforming sequences. Embo J. 10, 3959–3970.
Miller, L.M., Gallegos, M.E., Morisseau, B.A., and Kim, S.K. (1993). lin-31, a Caenorhabditis elegans HNF-3/fork head 
transcription factor homolog, specifies three alternative cell fates in vulval development. Genes & Development 7, 933–947.
Mitra, S.K., and Schlaepfer, D.D. (2006). Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell 
Biol. 18, 516–523.
Mohri, A., Kodama, E., Kimura, K.D., Koike, M., Mizuno, T., and Mori, I. (2005). Genetic control of temperature preference 
in the nematode Caenorhabditis elegans. Genetics 169, 1437–1450.
Mori, I. (1999). Genetics of chemotaxis and thermotaxis in the nematode Caenorhabditis elegans. Annu. Rev. Genet. 33, 
399–422.
Moro, L. (2001). Integrin-induced Epidermal Growth Factor (EGF) Receptor Activation Requires c-Src and p130Cas and 
Leads to Phosphorylation of Specific EGF Receptor Tyrosines. Journal of Biological Chemistry 277, 9405–9414.
Morrison, G.E., Wen, J.Y., Runciman, S., and van der Kooy, D. (1999). Olfactory associative learning in Caenorhabditis ele-
gans is impaired in lrn-1 and lrn-2 mutants. Behav. Neurosci. 113, 358–367.
Mosesson, Y., Mills, G.B., and Yarden, Y. (2008). Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer 8, 
835–850.
Moulder, G.L., Huang, M.M., Waterston, R.H., and Barstead, R.J. (1996). Talin requires beta-integrin, but not vinculin, for its 
assembly into focal adhesion-like structures in the nematode Caenorhabditis elegans. Mol. Biol. Cell 7, 1181–1193.
Murata, Y., Mori, M., Kotani, T., Supriatna, Y., Okazawa, H., Kusakari, S., Saito, Y., Ohnishi, H., and Matozaki, T. (2010). 
Tyrosine phosphorylation of R3 subtype receptor-type protein tyrosine phosphatases and their complex formations with 
Grb2 or Fyn. Genes Cells 15, 513–524.
Nakdimon, I., Walser, M., Fröhli, E., and Hajnal, A. (2012). PTEN negatively regulates MAPK signaling during Caenorhab-
ditis elegans vulval development. PLoS Genet. 8, e1002881.
Nip, J., Shibata, H., Loskutoff, D.J., Cheresh, D.A., and Brodt, P. (1992). Human melanoma cells derived from lymphatic 
metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin. J. Clin. Invest. 90, 1406–1413.
Nooren, I.M.A., and Thornton, J.M. (2003). Diversity of protein-protein interactions. Embo J. 22, 3486–3492.
Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M.R., Carotenuto, A., De Feo, G., Caponigro, F., and 
Salomon, D.S. (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366, 2–16.
O‘Toole, T.E., Ylänne, J., and Culley, B.M. (1995). Regulation of integrin affinity states through an NPXY motif in the beta 
subunit cytoplasmic domain. J. Biol. Chem. 270, 8553–8558.
Ohno, H., Stewart, J., Fournier, M.C., Bosshart, H., Rhee, I., Miyatake, S., Saito, T., Gallusser, A., Kirchhausen, T., and Boni-
facino, J.S. (1995). Interaction of tyrosine-based sorting signals with clathrin-associated proteins. Science 269, 1872–1875.
Olayioye, M.A., Neve, R.M., Lane, H.A., and Hynes, N.E. (2000). The ErbB signaling network: receptor heterodimerization 
in development and cancer. Embo J. 19, 3159–3167.
Oxley, C.L., Anthis, N.J., Lowe, E.D., Vakonakis, I., Campbell, I.D., and Wegener, K.L. (2008). An integrin phosphorylation 
switch: the effect of beta3 integrin tail phosphorylation on Dok1 and talin binding. J. Biol. Chem. 283, 5420–5426.
Ozbabacan, S.E.A., Engin, H.B., Gursoy, A., and Keskin, O. (2011). Transient protein-protein interactions. Protein Eng. Des. 
Sel. 24, 635–648.
147
6. References
Östman, A., Yang, Q., and Tonks, N.K. (1994). Expression of DEP-1, a receptor-like protein-tyrosine-phosphatase, is enhan-
ced with increasing cell density. Proc. Natl. Acad. Sci. U.S.a. 91, 9680–9684.
Page, A.P., and Johnstone, I.L. (2007). The cuticle. WormBook 1–15.
Palka, H.L. (2002). Hepatocyte Growth Factor Receptor Tyrosine Kinase Met Is a Substrate of the Receptor Protein-tyrosine 
Phosphatase DEP-1. Journal of Biological Chemistry 278, 5728–5735.
Papassotiropoulos, A., Stephan, D.A., Huentelman, M.J., Hoerndli, F.J., Craig, D.W., Pearson, J.V., Huynh, K.D., Brunner, 
F., Corneveaux, J., Osborne, D., et al. (2006). Common Kibra Alleles Are Associated with Human Memory Performance. 
Science 314, 475–478.
Pavelec, D.M., Lachowiec, J., Duchaine, T.F., Smith, H.E., and Kennedy, S. (2009). Requirement for the ERI/DICER complex 
in endogenous RNA interference and sperm development in Caenorhabditis elegans. Genetics 183, 1283–1295.
Pellinen, T. (2006). Integrin traffic. J. Cell. Sci. 119, 3723–3731.
Pellinen, T., Tuomi, S., Arjonen, A., Wolf, M., Edgren, H., Meyer, H., Grosse, R., Kitzing, T., Rantala, J.K., Kallioniemi, O., et 
al. (2008). Integrin trafficking regulated by Rab21 is necessary for cytokinesis. Developmental Cell 15, 371–385.
Petermann, A., Haase, D., Wetzel, A., Balavenkatraman, K.K., Tenev, T., Gührs, K.-H., Friedrich, S., Nakamura, M., Mawrin, 
C., and Böhmer, F.-D. (2010). Loss of the Protein-Tyrosine Phosphatase DEP-1/PTPRJ Drives Meningioma Cell Motility. 
Brain Pathology 21, 405–418.
Pouliot, N., Nice, E.C., and Burgess, A.W. (2001). Laminin-10 mediates basal and EGF-stimulated motility of human colon 
carcinoma cells via alpha(3)beta(1) and alpha(6)beta(4) integrins. Exp. Cell Res. 266, 1–10.
Puig, O., Caspary, F., Rigaut, G., Rutz, B., Bouveret, E., Bragado-Nilsson, E., Wilm, M., and Séraphin, B. (2001). The tandem 
affinity purification (TAP) method: a general procedure of protein complex purification. Methods 24, 218–229.
Pytela, R., Pierschbacher, M.D., and Ruoslahti, E. (1985). A 125/115-kDa cell surface receptor specific for vitronectin in-
teracts with the arginine-glycine-aspartic acid adhesion sequence derived from fibronectin. Proc. Natl. Acad. Sci. U.S.a. 82, 
5766–5770.
Ramirez, N.E., Zhang, Z., Madamanchi, A., Boyd, K.L., O‘Rear, L.D., Nashabi, A., Li, Z., Dupont, W.D., Zijlstra, A., and 
Zutter, M.M. (2011). The α₂β₁ integrin is a metastasis suppressor in mouse models and human cancer. J. Clin. Invest. 121, 
226–237.
Ramsay, A.G., Keppler, M.D., Jazayeri, M., Thomas, G.J., Parsons, M., Violette, S., Weinreb, P., Hart, I.R., and Marshall, J.F. 
(2007a). HS1-associated protein X-1 regulates carcinoma cell migration and invasion via clathrin-mediated endocytosis of 
integrin alphavbeta6. Cancer Res. 67, 5275–5284.
Ramsay, A.G., Marshall, J.F., and Hart, I.R. (2007b). Integrin trafficking and its role in cancer metastasis. Cancer Metastasis 
Rev. 26, 567–578.
Ricono, J.M., Huang, M., Barnes, L.A., Lau, S.K., Weis, S.M., Schlaepfer, D.D., Hanks, S.K., and Cheresh, D.A. (2009). Spe-
cific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and 
metastasis. Cancer Res. 69, 1383–1391.
Robert, V.J.P., Katic, I., and Bessereau, J.-L. (2009). Mos1 transposition as a tool to engineer the Caenorhabditis elegans ge-
nome by homologous recombination. Methods 49, 263–269.
Rose, J.K., and Rankin, C.H. (2001). Analyses of habituation in Caenorhabditis elegans. Learn. Mem. 8, 63–69.
Rose, J.K., and Rankin, C.H. (2006). Blocking Memory Reconsolidation Reverses Memory-Associated Changes in Glutama-
te Receptor Expression. Journal of Neuroscience 26, 11582–11587.
Ruivenkamp, C.A.L., van Wezel, T., Zanon, C., Stassen, A.P.M., Vlcek, C., Csikós, T., Klous, A.M., Tripodis, N., Perrakis, A., 
Boerrigter, L., et al. (2002). Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted 
in human cancers. Nat. Genet. 31, 295–300.
Ruivenkamp, C., Hermsen, M., Postma, C., Klous, A., Baak, J., Meijer, G., and Demant, P. (2003). LOH of PTPRJ occurs early 
in colorectal cancer and is associated with chromosomal loss of 18q12–21. Oncogene 22, 3472–3474.
Sacco, F., Tinti, M., Palma, A., Ferrari, E., Nardozza, A.P., van Huijsduijnen, R.H., Takahashi, T., Castagnoli, L., and Cesareni, 
G. (2009). Tumor Suppressor Density-enhanced Phosphatase-1 (DEP-1) Inhibits the RAS Pathway by Direct Dephospho-
rylation ofERK1/2 Kinases. J. Biol. Chem. VOL.284, pp.22048–pp.22058.
Sadiq, M.W., Salehpour, M., Forsgard, N., Possnert, G., and Hammarlund-Udenaes, M. (2011). Morphine brain pharmaco-
kinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass 
spectrometry. Drug Metab. Dispos. 39, 174–179.
6. References
148
Saeki, S., Yamamoto, M., and Iino, Y. (2001). Plasticity of chemotaxis revealed by paired presentation of a chemoattractant 
and starvation in the nematode Caenorhabditis elegans. J. Exp. Biol. 204, 1757–1764.
Sakai, T., Jove, R., Fässler, R., and Mosher, D.F. (2001). Role of the cytoplasmic tyrosines of beta 1A integrins in transforma-
tion by v-src. Proc. Natl. Acad. Sci. U.S.a. 98, 3808–3813.
Sakai, T., Zhang, Q., Fässler, R., and Mosher, D.F. (1998). Modulation of beta1A integrin functions by tyrosine residues in the 
beta1 cytoplasmic domain. J. Cell Biol. 141, 527–538.
Sallee, J.L., and Burridge, K. (2009). Density-enhanced phosphatase 1 regulates phosphorylation of tight junction proteins 
and enhances barrier function of epithelial cells. J. Biol. Chem. 284, 14997–15006.
Schindler, A.J., and Sherwood, D.R. (2013). Morphogenesis of the C. elegans vulva. Wiley Interdiscip Rev Dev Biol 2, 75–95.
Schlaepfer, D.D., and Hunter, T. (1998). Integrin signalling and tyrosine phosphorylation: just the FAKs? Trends Cell Biol. 
8, 151–157.
Schlessinger, J. (2000). Cell signaling by receptor tyrosine kinases. Cell 103, 211–225.
Schwartz, M.A., Schaller, M.D., and Ginsberg, M.H. (1995). Integrins: emerging paradigms of signal transduction. Annu. 
Rev. Cell Dev. Biol. 11, 549–599.
Senis, Y.A., Tomlinson, M.G., Ellison, S., Mazharian, A., Lim, J., Zhao, Y., Kornerup, K.N., Auger, J.M., Thomas, S.G., Dhan-
jal, T., et al. (2009). The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis. 
Blood 113, 4942–4954.
Seshacharyulu, P., Ponnusamy, M.P., Haridas, D., Jain, M., Ganti, A.K., and Batra, S.K. (2012). Targeting the EGFR signaling 
pathway in cancer therapy. Expert Opin. Ther. Targets 16, 15–31.
Sharma-Kishore, R., White, J.G., Southgate, E., and Podbilewicz, B. (1999). Formation of the vulva in Caenorhabditis ele-
gans: a paradigm for organogenesis. Development 126, 691–699.
Shattil, S.J., Kim, C., and Ginsberg, M.H. (2010). The final steps of integrin activation: the end game. Nat. Rev. Mol. Cell Biol. 
11, 288–300.
Shaye, D.D., and Greenwald, I. (2002). Endocytosis-mediated downregulation of LIN-12/Notch upon Ras activation in Cae-
norhabditis elegans. Nature 420, 686–690.
Shultz, L.D., Schweitzer, P.A., Rajan, T.V., Yi, T., Ihle, J.N., Matthews, R.J., Thomas, M.L., and Beier, D.R. (1993). Muta-
tions at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 73, 
1445–1454.
Silva, R., D‘Amico, G., Hodivala-Dilke, K.M., and Reynolds, L.E. (2008). Integrins: the keys to unlocking angiogenesis. Arte-
rioscler. Thromb. Vasc. Biol. 28, 1703–1713.
Simmer, F., Tijsterman, M., Parrish, S., Koushika, S.P., Nonet, M.L., Fire, A., Ahringer, J., and Plasterk, R.H.A. (2002). Loss 
of the putative RNA-directed RNA polymerase RRF-3 makes C. elegans hypersensitive to RNAi. Curr. Biol. 12, 1317–1319.
Sims, P.J., Ginsberg, M.H., Plow, E.F., and Shattil, S.J. (1991). Effect of platelet activation on the conformation of the plasma 
membrane glycoprotein IIb-IIIa complex. J. Biol. Chem. 266, 7345–7352.
Smart, C.E., Askarian Amiri, M.E., Wronski, A., Dinger, M.E., Crawford, J., Ovchinnikov, D.A., Vargas, A.C., Reid, L., Sim-
pson, P.T., Song, S., et al. (2012). Expression and function of the protein tyrosine phosphatase receptor J (PTPRJ) in normal 
mammary epithelial cells and breast tumors. PLoS ONE 7, e40742.
Smith-Garvin, J.E., Koretzky, G.A., and Jordan, M.S. (2009). T cell activation. Annu. Rev. Immunol. 27, 591–619.
Spencer, T.E., Johnson, G.A., Bazer, F.W., and Burghardt, R.C. (2004). Implantation mechanisms: insights from the sheep. 
Reproduction 128, 657–668.
Springer, T.A. (1994). Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 
76, 301–314.
Sternberg, P.W. (1988). Lateral inhibition during vulval induction in Caenorhabditis elegans. Nature 335, 551–554.
Sternberg, P.W., and Han, M. (1998). Genetics of RAS signaling in C. elegans. Trends Genet. 14, 466–472.
Sternberg, P.W., and Horvitz, H.R. (1986). Pattern formation during C. elegans vulval induction. Cell 44, 761–772.
Sternberg, P.W., and Horvitz, H.R. (1989). The combined action of two intercellular signaling pathways specifies three cell 
fates during vulval induction in C. elegans. Cell 58, 679–693.
149
6. References
Sternberg, P.W. (2005). Vulval development. WormBook 1–28.
Stewart, P.L., and Nemerow, G.R. (2007). Cell integrins: commonly used receptors for diverse viral pathogens. Trends Mi-
crobiol. 15, 500–507.
Stinchcomb, D.T., Shaw, J.E., Carr, S.H., and Hirsh, D. (1985). Extrachromosomal DNA transformation of Caenorhabditis 
elegans. Molecular and Cellular Biology 5, 3484–3496.
Sulston, J.E., and Horvitz, H.R. (1977). Post-embryonic cell lineages of the nematode, Caenorhabditis elegans. Developmen-
tal Biology 56, 110–156.
Sulston, J.E., and White, J.G. (1980). Regulation and cell autonomy during postembryonic development of Caenorhabditis 
elegans. Developmental Biology 78, 577–597.
Tadokoro, S., Shattil, S.J., Eto, K., Tai, V., Liddington, R.C., de Pereda, J.M., Ginsberg, M.H., and Calderwood, D.A. (2003). 
Talin binding to integrin beta tails: a final common step in integrin activation. Science 302, 103–106.
Takagi, J., Petre, B.M., Walz, T., and Springer, T.A. (2002). Global conformational rearrangements in integrin extracellular 
domains in outside-in and inside-out signaling. Cell 110, 599–511.
Takahashi, K., Mernaugh, R.L., Friedman, D.B., Weller, R., Tsuboi, N., Yamashita, H., Quaranta, V., and Takahashi, T. (2012). 
Thrombospondin-1 acts as a ligand for CD148 tyrosine phosphatase. Proc. Natl. Acad. Sci. U.S.a. 109, 1985–1990.
Takahashi, T. (2006). A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell 
growth and angiogenesis. Blood 108, 1234–1242.
Tamkun, J.W., DeSimone, D.W., Fonda, D., Patel, R.S., Buck, C., Horwitz, A.F., and Hynes, R.O. (1986). Structure of integrin, 
a glycoprotein involved in the transmembrane linkage between fibronectin and actin. Cell 46, 271–282.
Tan, P.B., Lackner, M.R., and Kim, S.K. (1998). MAP kinase signaling specificity mediated by the LIN-1 Ets/LIN-31 WH 
transcription factor complex during C. elegans vulval induction. Cell 93, 569–580.
Tangye, S.G., Phillips, J.H., Lanier, L.L., de Vries, J.E., and Aversa, G. (1998). CD148: a receptor-type protein tyrosine phos-
phatase involved in the regulation of human T cell activation. J. Immunol. 161, 3249–3255.
Tarcic, G., Boguslavsky, S.K., Wakim, J., Kiuchi, T., Liu, A., Reinitz, F., Nathanson, D., Takahashi, T., Mischel, P.S., Ng, T., et al. 
(2009). An Unbiased Screen Identifies DEP-1 Tumor Suppressor as a Phosphatase Controlling EGFR Endocytosis. Current 
Biology 19, 1788–1798.
Tax, F.E., Thomas, J.H., Ferguson, E.L., and Horvitz, H.R. (1997). Identification and characterization of genes that interact 
with lin-12 in Caenorhabditis elegans. Genetics 147, 1675–1695.
Thomas, P.E., Wharram, B.L., Goyal, M., Wiggins, J.E., Holzman, L.B., and Wiggins, R.C. (1994). GLEPP1, a renal glomeru-
lar epithelial cell (podocyte) membrane protein-tyrosine phosphatase. Identification, molecular cloning, and characterizati-
on in rabbit. J. Biol. Chem. 269, 19953–19962.
Tonks, N.K. (2003). PTP1B: from the sidelines to the front lines! FEBS Letters 546, 140–148.
Tonks, N.K. (2006). Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 7, 833–846.
Trapasso, F., Iuliano, R., Boccia, A., Stella, A., Visconti, R., Bruni, P., Baldassarre, G., Santoro, M., Viglietto, G., and Fusco, A. 
(2000). Rat protein tyrosine phosphatase eta suppresses the neoplastic phenotype of retrovirally transformed thyroid cells 
through the stabilization of p27(Kip1). Molecular and Cellular Biology 20, 9236–9246.
Trapasso, F., Drusco, A., Costinean, S., Alder, H., Aqeilan, R.I., Iuliano, R., Gaudio, E., Raso, C., Zanesi, N., Croce, C.M., et 
al. (2006). Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does 
not predispose to spontaneous tumorigenesis. DNA Cell Biol. 25, 376–382.
Trapasso, F., Yendamuri, S., Dumon, K.R., Iuliano, R., Cesari, R., Feig, B., Seto, R., Infante, L., Ishii, H., Vecchione, A., et al. 
(2004). Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell 
growth in vitro and in vivo. Carcinogenesis 25, 2107–2114.
Troemel, E.R., Sagasti, A., and Bargmann, C.I. (1999). Lateral signaling mediated by axon contact and calcium entry regula-
tes asymmetric odorant receptor expression in C. elegans. Cell 99, 387–398.
Trzebiatowska, A., Topf, U., Sauder, U., Drabikowski, K., and Chiquet-Ehrismann, R. (2008). Caenorhabditis elegans teneu-
rin, ten-1, is required for gonadal and pharyngeal basement membrane integrity and acts redundantly with integrin ina-1 
and dystroglycan dgn-1. Mol. Biol. Cell 19, 3898–3908.
Tsuboi, N., Utsunomiya, T., Roberts, R.L., Ito, H., Takahashi, K., Noda, M., and Takahashi, T. (2008). The tyrosine phospha-
tase CD148 interacts with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem. J. 413, 193.
150
Ulmer, T.S., Yaspan, B., Ginsberg, M.H., and Campbell, I.D. (2001). NMR analysis of structure and dynamics of the cytosolic 
tails of integrin alpha IIb beta 3 in aqueous solution. Biochemistry 40, 7498–7508.
Upla, P., Marjomäki, V., Kankaanpää, P., Ivaska, J., Hyypiä, T., Van Der Goot, F.G., and Heino, J. (2004). Clustering induces a 
lateral redistribution of alpha 2 beta 1 integrin from membrane rafts to caveolae and subsequent protein kinase C-dependent 
internalization. Mol. Biol. Cell 15, 625–636.
Voldborg, B.R., Damstrup, L., Spang-Thomsen, M., and Poulsen, H.S. (1997). Epidermal growth factor receptor (EGFR) and 
EGFR mutations, function and possible role in clinical trials. Ann. Oncol. 8, 1197–1206.
Wang, M., and Sternberg, P.W. (2001). Pattern formation during C. elegans vulval induction. Curr. Top. Dev. Biol. 51, 189–
220.
Wen, J.Y., Kumar, N., Morrison, G., Rambaldini, G., Runciman, S., Rousseau, J., and van der Kooy, D. (1997). Mutations that 
prevent associative learning in C. elegans. Behav. Neurosci. 111, 354–368.
White, D.J., Puranen, S., Johnson, M.S., and Heino, J. (2004). The collagen receptor subfamily of the integrins. Int. J. Bio-
chem. Cell Biol. 36, 1405–1410.
Whiteford, J.R., Xian, X., Chaussade, C., Vanhaesebroeck, B., Nourshargh, S., and Couchman, J.R. (2011). Syndecan-2 is a 
novel ligand for the protein tyrosine phosphatase receptor CD148. Mol. Biol. Cell 22, 3609–3624.
Willard, H.H. (1988). Instrumental Methods of Analysis (Wadsworth Publishing Company).
Williams, B.D., and Waterston, R.H. (1994). Genes critical for muscle development and function in Caenorhabditis elegans 
identified through lethal mutations. J. Cell Biol. 124, 475–490.
Wood, W.B. (1988). The Nematode Caenorhabditis elegans (Cold Spring Harbor Laboratory Pr).
Woodside, D.G., Liu, S., and Ginsberg, M.H. (2001). Integrin activation. Thromb. Haemost. 86, 316–323.
Xiao, T., Takagi, J., Coller, B.S., Wang, J.-H., and Springer, T.A. (2004). Structural basis for allostery in integrins and binding 
to fibrinogen-mimetic therapeutics. Nature 432, 59–67.
Xiong, J.P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D.L., Joachimiak, A., Goodman, S.L., and Arnaout, M.A. 
(2001). Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science 294, 339–345.
Xu, X., Ahn, J.H., Tam, P., Yu, E.J., Batra, S., Cram, E.J., and Lee, M. (2010). Analysis of conserved residues in the betapat-3 
cytoplasmic tail reveals important functions of integrin in multiple tissues. Dev. Dyn. 239, 763–772.
Yamada, K.M., and Even-Ram, S. (2002). Integrin regulation of growth factor receptors. Nat. Cell Biol. 4, E75–E76.
Yang, C., Zeisberg, M., Lively, J.C., Nyberg, P., Afdhal, N., and Kalluri, R. (2003). Integrin alpha1beta1 and alpha2beta1 are 
the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res. 63, 8312–8317.
Ye, F., Hu, G., Taylor, D., Ratnikov, B., Bobkov, A.A., McLean, M.A., Sligar, S.G., Taylor, K.A., and Ginsberg, M.H. (2010). 
Recreation of the terminal events in physiological integrin activation. J. Cell Biol. 188, 157–173.
Ylänne, J., Chen, Y., O‘Toole, T.E., Loftus, J.C., Takada, Y., and Ginsberg, M.H. (1993). Distinct functions of integrin alpha 
and beta subunit cytoplasmic domains in cell spreading and formation of focal adhesions. J. Cell Biol. 122, 223–233.
Yochem, J., Weston, K., and Greenwald, I. (1988). The Caenorhabditis elegans lin-12 gene encodes a transmembrane protein 
with overall similarity to Drosophila Notch. Nature 335, 547–550.
Yoo, A.S., Bais, C., and Greenwald, I. (2004). Crosstalk between the EGFR and LIN-12/Notch pathways in C. elegans vulval 
development. Science 303, 663–666.
Zaidel-Bar, R., Milo, R., Kam, Z., and Geiger, B. (2007). A paxillin tyrosine phosphorylation switch regulates the assembly 
and form of cell-matrix adhesions. J. Cell. Sci. 120, 137–148.
Zhang, L., Martelli, M.L., Battaglia, C., Trapasso, F., Tramontano, D., Viglietto, G., Porcellini, A., Santoro, M., and Fusco, A. 
(1997). Thyroid cell transformation inhibits the expression of a novel rat protein tyrosine phosphatase. Exp. Cell Res. 235, 
62–70.
Zhang, X., and Greenwald, I. (2011). Spatial regulation of lag-2 transcription during vulval precursor cell fate patterning in 
Caenorhabditis elegans. Genetics 188, 847–858.
Zhang, Y., Lu, H., and Bargmann, C.I. (2005). Pathogenic bacteria induce aversive olfactory learning in Caenorhabditis 
elegans. Nature 438, 179–184.
Zhu, J.W., Brdicka, T., Katsumoto, T.R., Lin, J., and Weiss, A. (2008). Structurally distinct phosphatases CD45 and CD148 
both regulate B cell and macrophage immunoreceptor signaling. Immunity 28, 183–196.
151
7. Appendix
7. Appendix
7
7. Appendix
152
1° Primary
2° Secondary
3° Tertiary
A Alanin
AC Anchor cell
APF Adjacent primery fate
C. elegans Caenorhabditis elegans
cDNA complementary DNA
D Aspartic acid
DEP-1 Density enhanced phosphatase 1
DN Dominant-negative
DNA Desoxyribonucleic acid
dNTP Desoxyribonukleosidtriphosphate
Dpy dumpy (shortened body)
DSB Double strand break
DTT Dithiothreitol
ECM Extra eellular matrix 
E. coli Escherichia coli
ETA Ethylendiamine tetraacetic acid
EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
EMS Ethyl methyl sulfonate
ER Endoplasmatic reticulum
EtOH Ethanol
F Phenylalanine
F1 first filial generation
F2 second filial generation
FAK Focal adhesion kinase
FLP Flippase
FRT FLP recognition targets
FRAP Fluorescence recovery after photobleaching
gf gain of function
GFP Green fluorescent protein
GFR Growth factor receptor
GST Gluthatione S-transferase
HA Haemagglutinin
HPLC High performance liquid chromatography
HRP Horse radish peroxidase
HS Haemagglutinin-StrepTactin-III
IPTG Isopropyl-β-D-thiogalactopyranosid
kD kilo dalton
l Liter
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Abbreviations
LC-MS/MS Liquid chromatography-tandem mass spectrometry
LET Lethal
lf loss of function
LIN Lineage defective
L1-4 larval stages 1-4
µl Microliter
µm Micrometer
M Molar
mm Milimeter 
MAPK Mitogen-activated protein kinase
MosTic Mos1 excision‐induced transgene‐instructed gene conversion
MS Mass spectrometry 
Muv Multivulva
N2 C. elegans wild-type strain
ng Nanogramm
NPxY Asp-Pro-X-Tyr
P0 parental generation
PAGE  polyacrylamide gel electrophoresis
PAT Paralysed arrest at two-fold
PCR Polymerase chain reaction
PI3K Phosphoinositide 3-kinase
PTP Phosphotyrosine phosphatase
Pvl Protruding vulva
RAS Rat sarcoma
rf reduction of function
RT Room temperature
RNAi RNA interference
Rol Roller (rolling movement)
Strep StrepTactin
SDS Sodium dodecyl sulfate 
TAP Tandem affinity-purification
TBE Tris-Borat-EDTA
TBS Tris Buffered Saline
TM Transmembrane
Tris Tris[hydroxymethyl]aminomethane
Unc Uncoordinated
UTR Untranslated region
VPC Vulval precursor cell
Vul Vulvaless
wt wild-type
Y Tyrosine
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